CN110526903B - Bisindolylmaleimide derivative and preparation method and application thereof - Google Patents
Bisindolylmaleimide derivative and preparation method and application thereof Download PDFInfo
- Publication number
- CN110526903B CN110526903B CN201910489638.9A CN201910489638A CN110526903B CN 110526903 B CN110526903 B CN 110526903B CN 201910489638 A CN201910489638 A CN 201910489638A CN 110526903 B CN110526903 B CN 110526903B
- Authority
- CN
- China
- Prior art keywords
- compound
- indole
- preparation
- nmr
- dmso
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title abstract description 431
- 150000003924 bisindolylmaleimides Chemical class 0.000 title abstract description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 20
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims abstract description 14
- 108010028144 alpha-Glucosidases Proteins 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims description 465
- -1 amine compounds Chemical class 0.000 claims description 205
- 238000010898 silica gel chromatography Methods 0.000 claims description 138
- 238000000034 method Methods 0.000 claims description 62
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 60
- 239000002994 raw material Substances 0.000 claims description 57
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 45
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 35
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 24
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 23
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 23
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 21
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 15
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 claims description 12
- BIKSKRPHKQWJCW-UHFFFAOYSA-N 3,4-dibromopyrrole-2,5-dione Chemical compound BrC1=C(Br)C(=O)NC1=O BIKSKRPHKQWJCW-UHFFFAOYSA-N 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 208000002249 Diabetes Complications Diseases 0.000 claims description 9
- 239000003472 antidiabetic agent Substances 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 206010012655 Diabetic complications Diseases 0.000 claims description 8
- 230000003178 anti-diabetic effect Effects 0.000 claims description 8
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 claims description 8
- 235000000346 sugar Nutrition 0.000 claims description 8
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000012279 sodium borohydride Substances 0.000 claims description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 5
- 229960004630 chlorambucil Drugs 0.000 claims description 5
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 125000006239 protecting group Chemical group 0.000 claims description 5
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 claims description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 239000007818 Grignard reagent Substances 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims description 4
- 229910052753 mercury Inorganic materials 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 238000006555 catalytic reaction Methods 0.000 claims description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- QTMAZYGAVHCKKX-UHFFFAOYSA-N 2-[(4-amino-5-bromopyrrolo[2,3-d]pyrimidin-7-yl)methoxy]propane-1,3-diol Chemical compound NC1=NC=NC2=C1C(Br)=CN2COC(CO)CO QTMAZYGAVHCKKX-UHFFFAOYSA-N 0.000 claims description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- 238000006751 Mitsunobu reaction Methods 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 230000021736 acetylation Effects 0.000 claims description 2
- 238000006640 acetylation reaction Methods 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 230000031709 bromination Effects 0.000 claims description 2
- 238000005893 bromination reaction Methods 0.000 claims description 2
- 238000010276 construction Methods 0.000 claims description 2
- 230000006196 deacetylation Effects 0.000 claims description 2
- 238000003381 deacetylation reaction Methods 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229960002510 mandelic acid Drugs 0.000 claims description 2
- 230000011987 methylation Effects 0.000 claims description 2
- 238000007069 methylation reaction Methods 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 235000019260 propionic acid Nutrition 0.000 claims description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
- 239000001384 succinic acid Substances 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- AFCAKJKUYFLYFK-UHFFFAOYSA-N tetrabutyltin Chemical compound CCCC[Sn](CCCC)(CCCC)CCCC AFCAKJKUYFLYFK-UHFFFAOYSA-N 0.000 claims description 2
- 229910000083 tin tetrahydride Inorganic materials 0.000 claims description 2
- HOSGXJWQVBHGLT-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical group N1C(=O)CCC2=CC(O)=CC=C21 HOSGXJWQVBHGLT-UHFFFAOYSA-N 0.000 claims 1
- 239000000386 donor Substances 0.000 claims 1
- 239000000348 glycosyl donor Substances 0.000 claims 1
- 238000006772 olefination reaction Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 792
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 384
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 312
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 268
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 247
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 244
- 238000005160 1H NMR spectroscopy Methods 0.000 description 244
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 220
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 179
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 176
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 164
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 160
- 239000007787 solid Substances 0.000 description 129
- 229910052736 halogen Inorganic materials 0.000 description 89
- 125000004093 cyano group Chemical group *C#N 0.000 description 85
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 84
- 150000002367 halogens Chemical group 0.000 description 83
- 239000003208 petroleum Substances 0.000 description 82
- 150000003254 radicals Chemical class 0.000 description 82
- 238000006243 chemical reaction Methods 0.000 description 75
- 238000006467 substitution reaction Methods 0.000 description 69
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 68
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 67
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 67
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 63
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 62
- 239000000843 powder Substances 0.000 description 61
- 125000000217 alkyl group Chemical group 0.000 description 60
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 58
- 239000000243 solution Substances 0.000 description 54
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 50
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 48
- 238000010828 elution Methods 0.000 description 47
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 45
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 42
- LJFIPVIYARKJOQ-UHFFFAOYSA-N carbazole-2,4-dione Chemical compound C1=CC=CC2=NC3=CC(=O)CC(=O)C3=C21 LJFIPVIYARKJOQ-UHFFFAOYSA-N 0.000 description 40
- 239000007858 starting material Substances 0.000 description 38
- 239000000047 product Substances 0.000 description 36
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- 238000000926 separation method Methods 0.000 description 33
- 238000003786 synthesis reaction Methods 0.000 description 33
- 230000002194 synthesizing effect Effects 0.000 description 33
- 125000003118 aryl group Chemical group 0.000 description 31
- 229910001868 water Inorganic materials 0.000 description 31
- 125000003545 alkoxy group Chemical group 0.000 description 29
- 238000004440 column chromatography Methods 0.000 description 29
- 239000011734 sodium Substances 0.000 description 29
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 28
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 28
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 28
- 230000003197 catalytic effect Effects 0.000 description 28
- 229940125961 compound 24 Drugs 0.000 description 28
- 239000000499 gel Substances 0.000 description 28
- 238000001704 evaporation Methods 0.000 description 27
- 125000001072 heteroaryl group Chemical group 0.000 description 27
- 235000002639 sodium chloride Nutrition 0.000 description 27
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 26
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 26
- 229910000104 sodium hydride Inorganic materials 0.000 description 26
- 238000003756 stirring Methods 0.000 description 26
- 230000015572 biosynthetic process Effects 0.000 description 25
- 229940125782 compound 2 Drugs 0.000 description 24
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 24
- 239000012188 paraffin wax Substances 0.000 description 24
- 239000000651 prodrug Substances 0.000 description 24
- 229940002612 prodrug Drugs 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 238000001035 drying Methods 0.000 description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 239000012044 organic layer Substances 0.000 description 21
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
- 125000002883 imidazolyl group Chemical group 0.000 description 20
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
- 239000008098 formaldehyde solution Substances 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- 238000001308 synthesis method Methods 0.000 description 17
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 16
- 125000001931 aliphatic group Chemical group 0.000 description 16
- 125000000623 heterocyclic group Chemical group 0.000 description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 16
- 239000000741 silica gel Substances 0.000 description 16
- 229910002027 silica gel Inorganic materials 0.000 description 16
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 15
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 15
- 125000001309 chloro group Chemical group Cl* 0.000 description 15
- 238000001816 cooling Methods 0.000 description 15
- INQOMBQAUSQDDS-BJUDXGSMSA-N iodomethane Chemical class I[11CH3] INQOMBQAUSQDDS-BJUDXGSMSA-N 0.000 description 15
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 14
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 14
- 229940126543 compound 14 Drugs 0.000 description 14
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 13
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 13
- 238000003818 flash chromatography Methods 0.000 description 13
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- 229940125904 compound 1 Drugs 0.000 description 12
- 239000013078 crystal Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 125000001188 haloalkyl group Chemical group 0.000 description 12
- 150000002772 monosaccharides Chemical group 0.000 description 12
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 11
- 239000007832 Na2SO4 Substances 0.000 description 11
- KZVWEOXAPZXAFB-BQFCYCMXSA-N Temocaprilat Chemical compound C([C@H](N[C@H]1CS[C@@H](CN(C1=O)CC(=O)O)C=1SC=CC=1)C(O)=O)CC1=CC=CC=C1 KZVWEOXAPZXAFB-BQFCYCMXSA-N 0.000 description 11
- 229940126142 compound 16 Drugs 0.000 description 11
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 11
- NFPUARSXIMWASK-GOEBONIOSA-N n-[(5r,7s)-2-(3-chlorophenyl)-1-oxa-3-azaspiro[4.5]dec-2-en-7-yl]acetamide Chemical compound C1[C@@H](NC(=O)C)CCC[C@@]11OC(C=2C=C(Cl)C=CC=2)=NC1 NFPUARSXIMWASK-GOEBONIOSA-N 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- 229910052938 sodium sulfate Inorganic materials 0.000 description 11
- 125000005843 halogen group Chemical group 0.000 description 10
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical class C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 9
- OIIOPWHTJZYKIL-PMACEKPBSA-N (5S)-5-[[[5-[2-chloro-3-[2-chloro-3-[6-methoxy-5-[[[(2S)-5-oxopyrrolidin-2-yl]methylamino]methyl]pyrazin-2-yl]phenyl]phenyl]-3-methoxypyrazin-2-yl]methylamino]methyl]pyrrolidin-2-one Chemical compound C1(=C(N=C(C2=C(C(C3=CC=CC(=C3Cl)C3=NC(OC)=C(N=C3)CNC[C@H]3NC(=O)CC3)=CC=C2)Cl)C=N1)OC)CNC[C@H]1NC(=O)CC1 OIIOPWHTJZYKIL-PMACEKPBSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 125000003342 alkenyl group Chemical group 0.000 description 9
- 125000000304 alkynyl group Chemical group 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 8
- 125000004682 aminothiocarbonyl group Chemical group NC(=S)* 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 8
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 7
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 7
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 7
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 7
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 7
- 229940125936 compound 42 Drugs 0.000 description 7
- 229940127271 compound 49 Drugs 0.000 description 7
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- GXBDUKNALWQPMX-UHFFFAOYSA-N hydron;pyrrole-2,5-dione;chloride Chemical compound Cl.O=C1NC(=O)C=C1 GXBDUKNALWQPMX-UHFFFAOYSA-N 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- CKITYUQKOJMMOI-UHFFFAOYSA-N 3,4-dibromo-1-methylpyrrole-2,5-dione Chemical compound CN1C(=O)C(Br)=C(Br)C1=O CKITYUQKOJMMOI-UHFFFAOYSA-N 0.000 description 6
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 6
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 6
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 description 6
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 6
- 239000011777 magnesium Substances 0.000 description 6
- 125000002757 morpholinyl group Chemical group 0.000 description 6
- RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 6
- 125000004193 piperazinyl group Chemical group 0.000 description 6
- 125000004076 pyridyl group Chemical group 0.000 description 6
- 238000002390 rotary evaporation Methods 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 5
- FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 5
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 125000003282 alkyl amino group Chemical group 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 125000003386 piperidinyl group Chemical group 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- NJZQOCCEDXRQJM-UHFFFAOYSA-N 1-benzylindole Chemical compound C1=CC2=CC=CC=C2N1CC1=CC=CC=C1 NJZQOCCEDXRQJM-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 4
- RQJDUEKERVZLLU-UHFFFAOYSA-N 4-Hydroxybenzylamine Chemical compound NCC1=CC=C(O)C=C1 RQJDUEKERVZLLU-UHFFFAOYSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- KPHYDWCWSJOGAL-QNGCTEGKSA-N [(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-methylcyanamide Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](N(C)C#N)[C@@H](OC)[C@]4(C)O1 KPHYDWCWSJOGAL-QNGCTEGKSA-N 0.000 description 4
- IMUDHTPIFIBORV-UHFFFAOYSA-N aminoethylpiperazine Chemical compound NCCN1CCNCC1 IMUDHTPIFIBORV-UHFFFAOYSA-N 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- 125000001246 bromo group Chemical group Br* 0.000 description 4
- 238000013375 chromatographic separation Methods 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 239000003617 indole-3-acetic acid Chemical class 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 4
- 238000011894 semi-preparative HPLC Methods 0.000 description 4
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- QVHJQCGUWFKTSE-YFKPBYRVSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-YFKPBYRVSA-N 0.000 description 3
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 3
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 3
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 3
- NLHDUFSIMDYGHG-UHFFFAOYSA-N 1-benzyl-4-bromoindole Chemical compound C1=CC=2C(Br)=CC=CC=2N1CC1=CC=CC=C1 NLHDUFSIMDYGHG-UHFFFAOYSA-N 0.000 description 3
- AQXJFUYUNHLBGU-UHFFFAOYSA-N 1-benzyl-5-bromoindole Chemical compound C1=CC2=CC(Br)=CC=C2N1CC1=CC=CC=C1 AQXJFUYUNHLBGU-UHFFFAOYSA-N 0.000 description 3
- MYDJBBMJTSNDOK-UHFFFAOYSA-N 1-benzyl-6-chloroindole Chemical compound C12=CC(Cl)=CC=C2C=CN1CC1=CC=CC=C1 MYDJBBMJTSNDOK-UHFFFAOYSA-N 0.000 description 3
- CTPWWPHZSVXATM-UHFFFAOYSA-N 1-benzyl-7-bromoindole Chemical compound C1=2C(Br)=CC=CC=2C=CN1CC1=CC=CC=C1 CTPWWPHZSVXATM-UHFFFAOYSA-N 0.000 description 3
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 3
- HCHGFRHIBVIAIG-UHFFFAOYSA-N 2-(1H-indol-2-yl)pentanenitrile Chemical compound N1C(=CC2=CC=CC=C12)C(C#N)CCC HCHGFRHIBVIAIG-UHFFFAOYSA-N 0.000 description 3
- NNEMMAAHBKHXLP-UHFFFAOYSA-N 2-(2-chloro-6-fluorophenyl)ethanamine Chemical compound NCCC1=C(F)C=CC=C1Cl NNEMMAAHBKHXLP-UHFFFAOYSA-N 0.000 description 3
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 3
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 3
- HNOQGHCFHGIUHC-UHFFFAOYSA-N 2-indol-1-ylacetonitrile Chemical compound C1=CC=C2N(CC#N)C=CC2=C1 HNOQGHCFHGIUHC-UHFFFAOYSA-N 0.000 description 3
- LFWBXHYTNKEQAI-UHFFFAOYSA-N 2-naphthalen-1-ylethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCC1=CC=CC2=CC=CC=C12 LFWBXHYTNKEQAI-UHFFFAOYSA-N 0.000 description 3
- CVPPUZPZPFOFPK-UHFFFAOYSA-N 2-phenylethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCC1=CC=CC=C1 CVPPUZPZPFOFPK-UHFFFAOYSA-N 0.000 description 3
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 3
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical group [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 description 3
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 3
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- YCNIBOIOWCTRCL-UHFFFAOYSA-N azane;2,2,2-trifluoroacetic acid Chemical compound [NH4+].[O-]C(=O)C(F)(F)F YCNIBOIOWCTRCL-UHFFFAOYSA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- ONOLYWPDPVFTJS-UHFFFAOYSA-N carbazole-2,4-dione;hydrochloride Chemical compound Cl.C1=CC=CC2=NC3=CC(=O)CC(=O)C3=C21 ONOLYWPDPVFTJS-UHFFFAOYSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 229940125844 compound 46 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- KUCDOJMOTMEEOF-UHFFFAOYSA-N gtpl6345 Chemical compound C1=CC(OC)=CC=C1N1C(=O)C(SC=2C3=C4NCCOC4=CN=2)=C3N=C1 KUCDOJMOTMEEOF-UHFFFAOYSA-N 0.000 description 3
- 125000005059 halophenyl group Chemical group 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 238000007243 oxidative cyclization reaction Methods 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 2
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- ZYZCALPXKGUGJI-DDVDASKDSA-M (e,3r,5s)-7-[3-(4-fluorophenyl)-2-phenyl-5-propan-2-ylimidazol-4-yl]-3,5-dihydroxyhept-6-enoate Chemical compound C=1C=C(F)C=CC=1N1C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C(C)C)N=C1C1=CC=CC=C1 ZYZCALPXKGUGJI-DDVDASKDSA-M 0.000 description 2
- WDKQJJGRHSGMEK-UHFFFAOYSA-N 1,3-difluorobenzene methanamine Chemical compound CN.FC1=CC=CC(=C1)F WDKQJJGRHSGMEK-UHFFFAOYSA-N 0.000 description 2
- FZQXMGLQANXZRP-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-3-(3-imidazol-1-ylpropyl)thiourea Chemical compound C1=C(OC)C(OC)=CC=C1NC(=S)NCCCN1C=NC=C1 FZQXMGLQANXZRP-UHFFFAOYSA-N 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- YCGQPIRMLGEWMW-UHFFFAOYSA-N 1-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,8-naphthyridin-3-yl]-3-[4-[(dimethylamino)methyl]-2,6-di(propan-2-yl)phenyl]urea;hydrochloride Chemical compound Cl.CC(C)C=1C=C(CN(C)C)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OC)=C1 YCGQPIRMLGEWMW-UHFFFAOYSA-N 0.000 description 2
- SZCBDIVMCGFVPW-UHFFFAOYSA-N 1-[4-(aminomethyl)-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,8-naphthyridin-3-yl]urea;hydrochloride Chemical compound Cl.CC(C)C=1C=C(CN)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OC)=C1 SZCBDIVMCGFVPW-UHFFFAOYSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- QXOGPTXQGKQSJT-UHFFFAOYSA-N 1-amino-4-[4-(3,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound Cc1ccc(Sc2ccc(Nc3cc(c(N)c4C(=O)c5ccccc5C(=O)c34)S(O)(=O)=O)cc2)cc1C QXOGPTXQGKQSJT-UHFFFAOYSA-N 0.000 description 2
- UQGNSLYYFIRZOM-UHFFFAOYSA-N 1-benzyl-6-bromoindole Chemical compound C12=CC(Br)=CC=C2C=CN1CC1=CC=CC=C1 UQGNSLYYFIRZOM-UHFFFAOYSA-N 0.000 description 2
- XEBXDNXJEJEQFE-UHFFFAOYSA-N 1-benzyl-6-fluoroindole Chemical compound C12=CC(F)=CC=C2C=CN1CC1=CC=CC=C1 XEBXDNXJEJEQFE-UHFFFAOYSA-N 0.000 description 2
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 2
- 125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 description 2
- NCHHYGWGXAVANC-UHFFFAOYSA-N 2-(1-ethylindol-3-yl)acetic acid Chemical compound C1=CC=C2N(CC)C=C(CC(O)=O)C2=C1 NCHHYGWGXAVANC-UHFFFAOYSA-N 0.000 description 2
- XEZVYKDMRRDVHU-UHFFFAOYSA-N 2-(1H-indol-2-yl)butanenitrile Chemical compound C1=CC=C2NC(C(C#N)CC)=CC2=C1 XEZVYKDMRRDVHU-UHFFFAOYSA-N 0.000 description 2
- UGPRHWJHDKGZJI-UHFFFAOYSA-N 2-(1h-indol-2-yl)propanenitrile Chemical compound C1=CC=C2NC(C(C#N)C)=CC2=C1 UGPRHWJHDKGZJI-UHFFFAOYSA-N 0.000 description 2
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 2
- GOWUDHPKGOIDIX-UHFFFAOYSA-N 2-(4-methyl-1-piperazinyl)ethanamine Chemical compound CN1CCN(CCN)CC1 GOWUDHPKGOIDIX-UHFFFAOYSA-N 0.000 description 2
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 2
- XQUVPCCAHOLLDM-UHFFFAOYSA-N 2-[1-(cyanomethyl)indol-3-yl]acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CN(CC#N)C2=C1 XQUVPCCAHOLLDM-UHFFFAOYSA-N 0.000 description 2
- CQZLIDRRAFFXFI-UHFFFAOYSA-N 2-[2-(1-cyanobutyl)-1H-indol-3-yl]acetic acid Chemical compound C(#N)C(CCC)C=1NC2=CC=CC=C2C=1CC(=O)O CQZLIDRRAFFXFI-UHFFFAOYSA-N 0.000 description 2
- HVVJICNAPCNWAB-UHFFFAOYSA-N 2-[2-(1-cyanopropyl)-1H-indol-3-yl]acetic acid Chemical compound C(#N)C(CC)C=1NC2=CC=CC=C2C=1CC(=O)O HVVJICNAPCNWAB-UHFFFAOYSA-N 0.000 description 2
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 2
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- CJNRGSHEMCMUOE-UHFFFAOYSA-N 2-piperidin-1-ylethanamine Chemical compound NCCN1CCCCC1 CJNRGSHEMCMUOE-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- XPQIPUZPSLAZDV-UHFFFAOYSA-N 2-pyridylethylamine Chemical compound NCCC1=CC=CC=N1 XPQIPUZPSLAZDV-UHFFFAOYSA-N 0.000 description 2
- KHSACZVQYSVGDJ-UHFFFAOYSA-N 2h-indole Chemical compound C1=CC=CC2=NCC=C21 KHSACZVQYSVGDJ-UHFFFAOYSA-N 0.000 description 2
- WAZKMRNUYDWWIW-UHFFFAOYSA-N 3,4-bis(6-chloro-1H-indol-3-yl)-1-methylpyrrole-2,5-dione Chemical compound CN1C(C(=C(C1=O)C1=CNC2=CC(=CC=C12)Cl)C1=CNC2=CC(=CC=C12)Cl)=O WAZKMRNUYDWWIW-UHFFFAOYSA-N 0.000 description 2
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 2
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 2
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- GRJZJFUBQYULKL-UHFFFAOYSA-N 4-bromo-1h-indole Chemical compound BrC1=CC=CC2=C1C=CN2 GRJZJFUBQYULKL-UHFFFAOYSA-N 0.000 description 2
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 2
- CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 description 2
- VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 2
- VXWVFZFZYXOBTA-UHFFFAOYSA-N 5-bromo-1h-indole Chemical compound BrC1=CC=C2NC=CC2=C1 VXWVFZFZYXOBTA-UHFFFAOYSA-N 0.000 description 2
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 2
- YTYIMDRWPTUAHP-UHFFFAOYSA-N 6-Chloroindole Chemical compound ClC1=CC=C2C=CNC2=C1 YTYIMDRWPTUAHP-UHFFFAOYSA-N 0.000 description 2
- MAWGHOPSCKCTPA-UHFFFAOYSA-N 6-bromo-1h-indole Chemical compound BrC1=CC=C2C=CNC2=C1 MAWGHOPSCKCTPA-UHFFFAOYSA-N 0.000 description 2
- RDSVSEFWZUWZHW-UHFFFAOYSA-N 7-bromo-1h-indole Chemical compound BrC1=CC=CC2=C1NC=C2 RDSVSEFWZUWZHW-UHFFFAOYSA-N 0.000 description 2
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 2
- QBXVXKRWOVBUDB-GRKNLSHJSA-N ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C Chemical compound ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C QBXVXKRWOVBUDB-GRKNLSHJSA-N 0.000 description 2
- 229940126639 Compound 33 Drugs 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-ZZWDRFIYSA-N L-glucose Chemical compound OC[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-ZZWDRFIYSA-N 0.000 description 2
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 2
- 239000005662 Paraffin oil Substances 0.000 description 2
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 2
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 2
- KMAZLLBHWXHXRY-JWURUJNWSA-N [(2R,3R,4S,5R)-3,4,5-triacetyl-3,4,5,6-tetrahydroxyoxan-2-yl]methyl acetate Chemical compound C(C)(=O)[C@@]1(C(O)O[C@@H]([C@]([C@@]1(O)C(C)=O)(O)C(C)=O)COC(C)=O)O KMAZLLBHWXHXRY-JWURUJNWSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940125807 compound 37 Drugs 0.000 description 2
- 229940126545 compound 53 Drugs 0.000 description 2
- 229940125900 compound 59 Drugs 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine group Chemical group NO AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 150000002475 indoles Chemical class 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229960001110 miglitol Drugs 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000006203 morpholinoethyl group Chemical group [H]C([H])(*)C([H])([H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 2
- NCNJHAHPOUUEQX-LDVROUIZSA-N n-[(2s,3r)-3-hydroxy-1-phenyl-4-[[(1r)-1-phenylethyl]amino]butan-2-yl]-4-(4-methylpiperazine-1-carbonyl)benzamide Chemical compound C([C@@H]([C@H](O)CN[C@H](C)C=1C=CC=CC=1)NC(=O)C=1C=CC(=CC=1)C(=O)N1CCN(C)CC1)C1=CC=CC=C1 NCNJHAHPOUUEQX-LDVROUIZSA-N 0.000 description 2
- 125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 238000006349 photocyclization reaction Methods 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- JUJWROOIHBZHMG-RALIUCGRSA-N pyridine-d5 Chemical compound [2H]C1=NC([2H])=C([2H])C([2H])=C1[2H] JUJWROOIHBZHMG-RALIUCGRSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- 229960001729 voglibose Drugs 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- SLTBMTIRYMGWLX-XMMPIXPASA-N (2r)-2-[(4-chloroanilino)carbamoylamino]-3-(1h-indol-3-yl)-n-(2-phenylethyl)propanamide Chemical compound C1=CC(Cl)=CC=C1NNC(=O)N[C@@H](C(=O)NCCC=1C=CC=CC=1)CC1=CNC2=CC=CC=C12 SLTBMTIRYMGWLX-XMMPIXPASA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- AEVBPXDFDKBGLT-YOUFYPILSA-N (2s,3s,4r,5r)-n-[2-[4-(diethoxyphosphorylmethyl)anilino]-2-oxoethyl]-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolane-2-carboxamide Chemical compound C1=CC(CP(=O)(OCC)OCC)=CC=C1NC(=O)CNC(=O)[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 AEVBPXDFDKBGLT-YOUFYPILSA-N 0.000 description 1
- LQAUXDMGRBWDIU-UHFFFAOYSA-N (3-chloro-4-fluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C(Cl)=C1 LQAUXDMGRBWDIU-UHFFFAOYSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 1
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 1
- RXNPEQZHMGFNAY-GEALJGNFSA-N (5R)-4-[(1S,6R)-5-[(2S)-2-(4-chlorophenyl)-3-(propan-2-ylamino)propanoyl]-2,5-diazabicyclo[4.1.0]heptan-2-yl]-5-methyl-6,8-dihydro-5H-pyrido[2,3-d]pyrimidin-7-one Chemical compound C[C@@H]1CC(=O)NC2=C1C(=NC=N2)N3CCN([C@H]4[C@@H]3C4)C(=O)[C@H](CNC(C)C)C5=CC=C(C=C5)Cl RXNPEQZHMGFNAY-GEALJGNFSA-N 0.000 description 1
- VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 1
- QPAGOTNPJABYCP-FITNPZAZSA-N (E)-N-(oxan-4-yl)-N'-[[(3R)-1,2,3,4-tetrahydroisoquinolin-3-yl]methyl]-N'-[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]but-2-ene-1,4-diamine Chemical compound O1CCC(CC1)NC\C=C\CN([C@H]1CCCC=2C=CC=NC1=2)C[C@@H]1NCC2=CC=CC=C2C1 QPAGOTNPJABYCP-FITNPZAZSA-N 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- FJZNNKJZHQFMCK-LRDDRELGSA-N 1-[(3S,4R)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-phenylurea Chemical compound C1(=CC(=CC(=C1[C@H]1[C@@H](C(=O)NC1)NC(=O)NC1=CC=CC=C1)F)OC)F FJZNNKJZHQFMCK-LRDDRELGSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- YRTFLDFDKPFNCJ-UHFFFAOYSA-N 1-[4-amino-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-2-oxo-4-[3-(3-pyrrolidin-1-ylpropoxy)phenyl]-1,8-naphthyridin-3-yl]urea;dihydrochloride Chemical compound Cl.Cl.CC(C)C=1C=C(N)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C(C=1)=CC=CC=1OCCCN1CCCC1 YRTFLDFDKPFNCJ-UHFFFAOYSA-N 0.000 description 1
- ZFNNBIMQDHBELV-UHFFFAOYSA-N 1-[4-amino-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-[3-(3-cyclohexylpropoxy)phenyl]-2-oxo-1,8-naphthyridin-3-yl]urea;dihydrochloride Chemical compound Cl.Cl.CC(C)C=1C=C(N)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C(C=1)=CC=CC=1OCCCC1CCCCC1 ZFNNBIMQDHBELV-UHFFFAOYSA-N 0.000 description 1
- QRRKZFCXXBFHSV-UHFFFAOYSA-N 1-ethylindole Chemical compound C1=CC=C2N(CC)C=CC2=C1 QRRKZFCXXBFHSV-UHFFFAOYSA-N 0.000 description 1
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 1
- PAYRKGAMXTVMCE-UHFFFAOYSA-N 2-[3-[4-[1-(1-cyanoethyl)indol-3-yl]-2,5-dioxopyrrol-3-yl]indol-1-yl]propanenitrile Chemical compound C(#N)C(C)N1C=C(C2=CC=CC=C12)C=1C(=O)NC(C=1C1=CN(C2=CC=CC=C12)C(C)C#N)=O PAYRKGAMXTVMCE-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- PAYROHWFGZADBR-UHFFFAOYSA-N 2-[[4-amino-5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidin-2-yl]amino]propane-1,3-diol Chemical compound C1=C(I)C(OC)=CC(C(C)C)=C1OC1=CN=C(NC(CO)CO)N=C1N PAYROHWFGZADBR-UHFFFAOYSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- CIBGXJVJPZCMFX-UHFFFAOYSA-N 2-bromobutanenitrile Chemical compound CCC(Br)C#N CIBGXJVJPZCMFX-UHFFFAOYSA-N 0.000 description 1
- OETNUCMBHKNECJ-UHFFFAOYSA-N 2-bromopentanenitrile Chemical compound CCCC(Br)C#N OETNUCMBHKNECJ-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- RXWNCMHRJCOWDK-UHFFFAOYSA-N 2-naphthalen-1-ylethanol Chemical compound C1=CC=C2C(CCO)=CC=CC2=C1 RXWNCMHRJCOWDK-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 1
- HNFMVVHMKGFCMB-UHFFFAOYSA-N 3-[3-[4-(1-aminocyclobutyl)phenyl]-5-phenylimidazo[4,5-b]pyridin-2-yl]pyridin-2-amine Chemical compound NC1=NC=CC=C1C1=NC2=CC=C(C=3C=CC=CC=3)N=C2N1C1=CC=C(C2(N)CCC2)C=C1 HNFMVVHMKGFCMB-UHFFFAOYSA-N 0.000 description 1
- CQZIEDXCLQOOEH-UHFFFAOYSA-N 3-bromopropanenitrile Chemical compound BrCCC#N CQZIEDXCLQOOEH-UHFFFAOYSA-N 0.000 description 1
- OXZYBOLWRXENKT-UHFFFAOYSA-N 4-(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC=C(C(Cl)=O)C=C1 OXZYBOLWRXENKT-UHFFFAOYSA-N 0.000 description 1
- KMMHZIBWCXYAAH-UHFFFAOYSA-N 4-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(Br)C=C1 KMMHZIBWCXYAAH-UHFFFAOYSA-N 0.000 description 1
- DENKGPBHLYFNGK-UHFFFAOYSA-N 4-bromobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Br)C=C1 DENKGPBHLYFNGK-UHFFFAOYSA-N 0.000 description 1
- CQPGDDAKTTWVDD-UHFFFAOYSA-N 4-bromobutanenitrile Chemical compound BrCCCC#N CQPGDDAKTTWVDD-UHFFFAOYSA-N 0.000 description 1
- GSDQYSSLIKJJOG-UHFFFAOYSA-N 4-chloro-2-(3-chloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC1=CC=CC(Cl)=C1 GSDQYSSLIKJJOG-UHFFFAOYSA-N 0.000 description 1
- ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 4-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C=C1 ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 0.000 description 1
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 1
- BFXHJFKKRGVUMU-UHFFFAOYSA-N 4-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=C(S(Cl)(=O)=O)C=C1 BFXHJFKKRGVUMU-UHFFFAOYSA-N 0.000 description 1
- POXFXTSTVWDWIR-UHFFFAOYSA-N 4-iodobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(I)C=C1 POXFXTSTVWDWIR-UHFFFAOYSA-N 0.000 description 1
- NJAKCIUOTIPYED-UHFFFAOYSA-N 4-iodobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(I)C=C1 NJAKCIUOTIPYED-UHFFFAOYSA-N 0.000 description 1
- NWWWGAKVHCSAEU-UHFFFAOYSA-N 5-bromopentanenitrile Chemical compound BrCCCCC#N NWWWGAKVHCSAEU-UHFFFAOYSA-N 0.000 description 1
- IJRKLHTZAIFUTB-UHFFFAOYSA-N 5-nitro-2-(2-phenylethylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCC1=CC=CC=C1 IJRKLHTZAIFUTB-UHFFFAOYSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- YYFFEPUCAKVRJX-UHFFFAOYSA-N 6-fluoro-1h-indole Chemical compound FC1=CC=C2C=CNC2=C1 YYFFEPUCAKVRJX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 1
- BGGALFIXXQOTPY-NRFANRHFSA-N C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC Chemical compound C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC BGGALFIXXQOTPY-NRFANRHFSA-N 0.000 description 1
- QUMCIHKVKQYNPA-RUZDIDTESA-N C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC Chemical compound C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC QUMCIHKVKQYNPA-RUZDIDTESA-N 0.000 description 1
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- LIMFPAAAIVQRRD-BCGVJQADSA-N N-[2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl]-8-[(2R,3S)-2-methyl-3-(methylsulfonylmethyl)azetidin-1-yl]-5-propan-2-ylisoquinolin-3-amine Chemical compound F[C@H]1CN(CC[C@H]1OC)C1=NC=CC(=N1)NC=1N=CC2=C(C=CC(=C2C=1)C(C)C)N1[C@@H]([C@H](C1)CS(=O)(=O)C)C LIMFPAAAIVQRRD-BCGVJQADSA-N 0.000 description 1
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 1
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229910002666 PdCl2 Inorganic materials 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 229940125907 SJ995973 Drugs 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- DRUIESSIVFYOMK-UHFFFAOYSA-N Trichloroacetonitrile Chemical compound ClC(Cl)(Cl)C#N DRUIESSIVFYOMK-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- NPUXORBZRBIOMQ-RUZDIDTESA-N [(2R)-1-[[4-[[3-(benzenesulfonylmethyl)-5-methylphenoxy]methyl]phenyl]methyl]-2-pyrrolidinyl]methanol Chemical compound C=1C(OCC=2C=CC(CN3[C@H](CCC3)CO)=CC=2)=CC(C)=CC=1CS(=O)(=O)C1=CC=CC=C1 NPUXORBZRBIOMQ-RUZDIDTESA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000007098 aminolysis reaction Methods 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000005418 aryl aryl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 238000006480 benzoylation reaction Methods 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- XENVCRGQTABGKY-ZHACJKMWSA-N chlorohydrin Chemical compound CC#CC#CC#CC#C\C=C\C(Cl)CO XENVCRGQTABGKY-ZHACJKMWSA-N 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 210000004913 chyme Anatomy 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940126209 compound 43b Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000006289 hydroxybenzyl group Chemical group 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 125000006301 indolyl methyl group Chemical group 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical group CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000005322 morpholin-1-yl group Chemical group 0.000 description 1
- QDMBFORVKQQLKR-UHFFFAOYSA-N n,n-dimethyl-2-phenylpyridin-4-amine Chemical compound CN(C)C1=CC=NC(C=2C=CC=CC=2)=C1 QDMBFORVKQQLKR-UHFFFAOYSA-N 0.000 description 1
- QAPTWHXHEYAIKG-RCOXNQKVSA-N n-[(1r,2s,5r)-5-(tert-butylamino)-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 QAPTWHXHEYAIKG-RCOXNQKVSA-N 0.000 description 1
- SKEAGJWUKCNICJ-LSDHHAIUSA-N n-[(4-fluoro-3-methoxyphenyl)methyl]-6-[2-[[(2s,5r)-5-(hydroxymethyl)-1,4-dioxan-2-yl]methyl]tetrazol-5-yl]-2-methylpyrimidine-4-carboxamide Chemical compound C1=C(F)C(OC)=CC(CNC(=O)C=2N=C(C)N=C(C=2)C2=NN(C[C@@H]3OC[C@@H](CO)OC3)N=N2)=C1 SKEAGJWUKCNICJ-LSDHHAIUSA-N 0.000 description 1
- PHVXTQIROLEEDB-UHFFFAOYSA-N n-[2-(2-chlorophenyl)ethyl]-4-[[3-(2-methylphenyl)piperidin-1-yl]methyl]-n-pyrrolidin-3-ylbenzamide Chemical compound CC1=CC=CC=C1C1CN(CC=2C=CC(=CC=2)C(=O)N(CCC=2C(=CC=CC=2)Cl)C2CNCC2)CCC1 PHVXTQIROLEEDB-UHFFFAOYSA-N 0.000 description 1
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 1
- LPOIGVZLNWEGJG-UHFFFAOYSA-N n-benzyl-5-(4-methylpiperazin-1-yl)-2-nitroaniline Chemical compound C1CN(C)CCN1C1=CC=C([N+]([O-])=O)C(NCC=2C=CC=CC=2)=C1 LPOIGVZLNWEGJG-UHFFFAOYSA-N 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000032598 susceptibility microvascular complications of diabetes Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- FJXYMVBFBYAWDR-UHFFFAOYSA-N tributyl(prop-1-enyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)\C=C\C FJXYMVBFBYAWDR-UHFFFAOYSA-N 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Provides a bisindolylmaleimide derivative and a preparation method and application thereof. The bisindolylmaleimide derivative has a good alpha-glucosidase inhibition effect, and can be used for preventing and treating diabetes.
Description
The technical field is as follows:
the invention relates to a bisindolylmaleimide derivative and a preparation method and application thereof.
Background art:
with the change of living habits and dietary patterns of people, the incidence of diabetes mellitus is rising year by year. Data published by the WHO in 2011 shows that about 460 million people die of diabetes-related diseases worldwide each year, with medical costs for diabetes as high as $ 4650 million. Currently, there are nearly 1.0 million diabetics and about 3.4 million people with abnormal glucose metabolism in China. Diabetes has become the third leading killer following cancer, cardiovascular disease.
Diabetes is classified into type 1 diabetes (insulin-dependent diabetes mellitus) and type 2 diabetes (non-insulin-dependent diabetes mellitus), and more than 90% of patients belong to type 2 diabetes mellitus. The type 2 diabetes patient does not need insulin treatment, can regulate and control blood sugar by diet, and is treated by medicine only when diet regulation is ineffective. Starch in food is digested into oligosaccharide of glucose molecule by oral saliva and pancreatic amylase, the alpha-glucosidase breaks the alpha-1, 4-glycosidic bond of the oligosaccharide at non-reducing end to release glucose, and the glucose is absorbed by small intestine epithelium and enters blood circulation to become blood sugar. Under physiological state, alpha-glucosidase exists in the upper, middle and lower segments of small intestine, so that the sugar is absorbed rapidly and perfectly by human body. Alpha-glucosidase inhibitors delay or slow postprandial blood glucose elevation by reversibly or competitively inhibiting the activity of alpha-glucosidase at the brush border of the small intestine. In addition, after the alpha-glucosidase inhibitor drugs are taken in the fasting state (when the lower small intestine has no food ingredients), chyme such as carbohydrate, fat, protein and the like in the intestines enters the far end of the ileum; the part is the position with the most abundant storage of the small intestine glucagon-like peptide 21(GLP21), and can stimulate the increase of GLP21 secretion and the release of insulin, thereby reducing the postprandial blood sugar concentration. Therefore, alpha-glucosidase inhibitors (AGIs) are a class of oral hypoglycemic drugs that delay the absorption of carbohydrates in the intestinal tract to achieve the purpose of treating diabetes.
At present, the clinically applied alpha-glucosidase inhibitor drugs are mainly: after the acarbose, the voglibose and the miglitol are taken, the acarbose, the voglibose and the miglitol directly reach the large intestine without decomposing carbohydrate, and adverse reactions such as abdominal discomfort, flatulence, exhaust and the like can occur. Therefore, new alpha-glucosidase inhibitor drugs need to be found.
Diabetic nephropathy (DKD) is one of the most common serious microvascular complications of diabetes, occurs at about 30% -40% of Diabetic patients, has become the first cause of End Stage Renal Disease (ESRD), and is also the leading cause of mortality of diabetes. At present, although some progress is made in the research aspect of anti-DKD medicines, the existing clinical treatment means such as controlling blood pressure, blood sugar, blood fat, anti-inflammation and the like can only delay the progress of DKD to renal failure but can not reverse or prevent the disease development; meanwhile, the problems of uncertain curative effect, large toxic and side effects and the like (Curr Diabetes Rev 2005; 1: 281-.
The invention content is as follows:
the bisindolylmaleimide derivatives are widely concerned due to structural diversity and good biological activity, and the inventor is focused on the drug development of the bisindolylmaleimide derivatives, and unexpectedly finds that the compounds have alpha-glucosidase inhibitory activity and anti-diabetic effect.
Thus, the present inventors provide a compound of formula a, a pharmaceutically acceptable salt or prodrug thereof:
wherein,
the dotted line represents no chemical bond or a single bond;
R1and R2Each independently selected from: -H; alkyl optionally substituted with amino, cyano, hydroxy, carboxy, alkoxy, lipoheterocyclyl, aryl, heteroaryl, -COA; alkenyl optionally substituted with amino, cyano, hydroxy, carboxy, alkoxy, lipoheterocyclyl, aryl, heteroaryl, -COA; a monosaccharide group, the hydroxyl hydrogen of which is optionally substituted by an alkyl group; wherein A is selected from hydrogen, -NR13R14Aryl, arylamino, alkyl optionally substituted with hydroxy, halo, alkoxy optionally substituted with hydroxy, halo;
or, R1And R2Together form- (CH)2)m1-O-(CH2)m2-, wherein H is optionally- (CH)2)0~8-NR13R14Substitution, m1And m2Each independently is an integer of 1 to 6;
or, R1And R2Together form the following group:
wherein R is9、R10independently-H or alkyl; or, R9And R10Together form-C (═ O) -;
R8selected from: -H; a hydroxyl group; an alkyl group optionally substituted with an alkoxy group; an alkenyl group; an alkynyl group; aryl optionally substituted with amino, hydroxy, halogen, alkoxy, alkyl, haloalkyl; a lipoheterocyclyl group optionally substituted with amino, hydroxyl, halogen, alkoxy, alkyl, haloalkyl; heteroaryl, optionally substituted with amino, hydroxy, halogen, alkoxy, alkyl, haloalkyl; -C (═ Y)1)-Y2;-S(=O)2-Y3;
Y1Selected from: o; (ii) S; NH;
Y2selected from: an alkyl group; an alkoxy group; a hydroxyamino group; -NR13R14(ii) a Aryl optionally substituted with amino, hydroxy, halogen, alkoxy, alkyl, haloalkyl; heteroaryl, optionally substituted with amino, hydroxy, halogen, alkoxy, alkyl, haloalkyl; a lipoheterocyclyl group, each of said lipoheterocyclyl groups being optionally substituted with amino, hydroxy, halogen, alkoxy, alkyl, haloalkyl; the aliphatic heterocyclic group is substituted by alkyl, and the aliphatic heterocyclic group is optionally substituted by amino, hydroxyl, halogen, alkoxy, alkyl and halogenated alkyl; alkylamino substituted by at least one of oxygen, hydroxy, heteroaryl, aryl, said heteroaryl, aryl optionally substituted by amino, hydroxy, halogen, alkoxy, alkyl, haloalkyl;
Y3is aryl optionally substituted by halogen, haloalkyl;
R3is selected from-H; a hydroxyl group; halogen; -NR13R14;-(C=O)NR11R12;-(C=O)R15;-O(C=O)R16;-NR17-(C=O)R18;-NR19-(COO)R20;-NR21-(SO2)R22;-O(C=O)NR23R24;-SR25;-(S=O)R26;-(SO2)R27;-(SO2)NR32R33(ii) a Alkyl optionally substituted by hydroxy, cyano, carboxy, monosaccharide, alkoxy, aryl, heteroaryl, lipoheterocyclyl, -NH-CO-alkylene (NH)2)(A1)、-NR13R14(iii) substituted, said aryl, heteroaryl, lipoheterocyclyl being optionally substituted with amino, hydroxy, halogen, alkyl, haloalkyl; alkenyl optionally substituted by hydroxy, cyano, carboxy, monosaccharide, alkoxy, aryl, heteroaryl, lipoheterocyclyl, -NH-CO-alkylene (NH)2)(A1)、-NR13R14Substitution; alkynyl, said alkynyl being optionally substituted by hydroxy, cyano, carboxy, monosaccharide, alkoxy, aryl, heteroaryl, lipoheterocyclyl, -NH-CO-alkylene (NH)2)(A1)、-NR13R14Substitution;
A1selected from-H, alkyl optionally substituted with heteroaryl;
R4and R5Together form ═ O, and/or R6And R7Together form ═ O;
when R is4And R5Or R6And R7Each independently is selected from-H, when not forming ═ O; a hydroxyl group; -NR13R14;-(C=O)R15;-NR17-(C=O)R18;-SR25(ii) a Aryl, said aryl being optionally substituted by a group selected from halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0-2R34Substitution; heteroaryl, said heteroaryl being optionally substituted by a group selected from halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0-2R34Substitution; alkoxy, said alkoxy being optionally substituted by a group selected from halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0-2R34Substitution; aryloxy group ofAryloxy is optionally substituted by a group selected from halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0-2R34Substitution;
G1~G8each independently selected from-H; halogen; a hydroxyl group; a cyano group; a nitro group; a carboxyl group; -NR13R14;-(C=O)NR11R12;-(C=O)R15;-O(C=O)R16;-NR17-(C=O)R18;-NR19-(COO)R20;-NR21-(SO2)R22;-O(C=O)NR23R24;-SR25;-(S=O)R26;-(SO2)R27;-CH=NOR28;-CH=NR29;-CH=NNR30R31;-(SO2)NR32R33(ii) a Alkyl optionally selected from halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0- 2R34Substitution; alkenyl, said alkenyl being optionally selected from halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0-2R34Substitution; alkynyl, said alkynyl being optionally selected from halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0-2R34Substitution; aryl, said aryl being optionally substituted by a group selected from halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0-2R34Substitution; heteroaryl, said heteroaryl being optionally substituted by a group selected from halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0-2R34Substitution; alkoxy, said alkoxy being optionally substituted by a group selected from halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0-2R34Substitution; aryloxy optionally selected from halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0-2R34Substitution;
R13、R14each independently selected from-H; an amino group; a monosaccharide group, the hydroxyl hydrogen of which is optionally substituted by an alkyl group; alkyl optionally selected from halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0-2R34Substitution; aryl optionally substituted with amino, hydroxy, halogen, alkyl optionally selected from halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0-2R34Substitution; an aliphatic heterocyclic group optionally substituted with amino, hydroxy, halogen, alkyl optionally substituted with a group selected from halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0-2R34Substitution;
R11、R12、R15、R16、R17、R18、R19、R20、R21、R22、R23、R24、R25、R26、R27、R28、R29、R30、R31、R32、R33、R34each independently selected from: -H; an alkyl group; an aryl group;
the aliphatic heterocyclic group and the heteroaryl group each independently contain 1 to 4 heteroatoms selected from N, O, S.
Alternatively, in a compound of formula a, a pharmaceutically acceptable salt or prodrug thereof, as described above: the alkyl in the alkyl, the halogenated alkyl, the alkoxy and the alkylamino is C1~C20Alkyl or is C1~C18Alkyl or is C1~C6Alkyl or is C1~C4An alkyl group; the alkenyl is C2~C20Alkenyl or is C2~C18Alkenyl or is C2~C6Alkenyl or is C2~C4An alkenyl group; the alkynyl is C2~C20Alkynyl, or is C2~C18Alkynyl, or is C2~C6Alkynyl, or is C2~C4An alkynyl group; the aliphatic heterocyclic group is a 4-14-membered monocyclic or polycyclic aliphatic heterocyclic group, and the number of ring hetero atoms is 1-3, or the number of ring hetero atoms is 1-2; the aryl group in the aryl group and the aryloxy group is C6~C14Monocyclic or polycyclic aryl; the heteroaryl is a 5-14-membered monocyclic or polycyclic heteroaryl, and the number of the ring-hetero atoms is 1-3 or 1-2.
Alternatively, in a compound of formula a, a pharmaceutically acceptable salt or prodrug thereof, as described above:
R1and R2Each independently selected from: -H; c1~C6Alkyl radical, said C1~C6Alkyl is optionally substituted by amino, cyano, hydroxy, carboxy, C1~C6Alkoxy, 5-or 6-membered lipoheterocyclyl, C6~C10Aryl, 5-to 10-membered heteroaryl, -COA substitution; c2~C6Alkenyl radical, said C2~C6Alkenyl is optionally substituted by amino, cyano, hydroxy, carboxy, C1~C6Alkoxy, 5-or 6-membered lipoheterocyclyl, C6~C10Aryl, 5-to 10-membered heteroaryl, -COA substitution; a monosaccharide radical, the hydroxyl hydrogen of which is optionally substituted by C1~C6Alkyl substitution; wherein A is selected from hydrogen, -NR13R14,C6~C10Aryl radical, C6~C10Arylamino, C optionally substituted by hydroxy, halogen1~C6Alkyl, C optionally substituted by hydroxy, halogen1~C6An alkoxy group;
or, R1And R2Together form the following group:
wherein R is9、R10Independently is-H or C1~C6An alkyl group; or, R9And R10Together form-C (═ O) -;
R8selected from: -H; hydroxyl radicalA group; c1~C18Alkyl radical, said C1~C18Alkyl is optionally substituted by C1~C6Alkoxy substitution; c2~C18An alkenyl group; c2~C18An alkynyl group; c6~C10Aryl radical, said C6~C10Aryl being optionally substituted by amino, hydroxy, halogen, C1~C6Alkoxy radical, C1~C6Alkyl radical, C1~C6Haloalkyl substitution; 5-or 6-membered lipoheterocyclyl, said lipoheterocyclyl being optionally substituted by amino, hydroxy, halogen, C1~C6Alkoxy radical, C1~C6Alkyl radical, C1~C6Haloalkyl substitution; 5-10 membered heteroaryl, said heteroaryl optionally substituted with amino, hydroxy, halogen, C1~C6Alkoxy radical, C1~C6Alkyl radical, C1~C6Haloalkyl substitution; -C (═ Y)1)-Y2;-S(=O)2-Y3;
Y1Selected from: o; (ii) S; NH;
Y2selected from: c1~C18An alkyl group; c1~C18An alkoxy group; a hydroxyamino group; -NR13R14;C6~C10Aryl radical, said C6~C10Aryl being optionally substituted by amino, hydroxy, halogen, C1~C6Alkoxy radical, C1~C6Alkyl radical, C1~C6Haloalkyl substitution; 5-10 membered heteroaryl, said heteroaryl optionally substituted with amino, hydroxy, halogen, C1~C6Alkoxy radical, C1~C6Alkyl radical, C1~C6Haloalkyl substitution; 5-or 6-membered lipoheterocyclyl, said lipoheterocyclyl being optionally substituted by amino, hydroxy, halogen, C1~C6Alkoxy radical, C1~C6Alkyl radical, C1~C6Haloalkyl substitution; 5-or 6-membered aliphatic heterocyclic group substituted C1~C6Alkyl-substituted 5-or 6-membered lipoheterocyclyl, each of which is optionally substituted by amino, hydroxy, halogen, C1~C6Alkoxy radical, C1~C6Alkyl radical, C1~C6Haloalkyl substitution; c1~C6Alkylamino radical, said C1~C6Alkylamino is substituted by oxygen, hydroxy, 5-10 membered heteroaryl, C6~C10At least one of aryl, 5-to 10-membered heteroaryl, C6~C10Aryl being optionally substituted by amino, hydroxy, halogen, C1~C6Alkoxy radical, C1~C6Alkyl radical, C1~C6Haloalkyl substitution;
Y3is optionally halogen, halogeno C1~C6Alkyl substituted C6~C10An aryl group;
R3is selected from-H; a hydroxyl group; halogen; -NR13R14;-(C=O)NR11R12;-(C=O)R15;-O(C=O)R16;-NR17-(C=O)R18;-NR19-(COO)R20;-NR21-(SO2)R22;-O(C=O)NR23R24;-SR25;-(S=O)R26;-(SO2)R27;-(SO2)NR32R33;C1~C6Alkyl radical, said C1~C6Alkyl being optionally substituted by hydroxy, cyano, carboxy, monosaccharide, C1~C6Alkoxy radical, C6~C10Aryl, 5-to 10-membered heteroaryl, 5-or 6-membered lipoheterocyclyl, -NH-CO-C1~C6Alkylene (NH)2)(A1)、-NR13R14Substituted, said C6~C10Aryl, 5-to 10-membered heteroaryl, 5-or 6-membered lipoheterocyclyl optionally substituted by amino, hydroxy, halogen, C1~C6Alkyl radical, C1~C6Haloalkyl substitution; c2~C6Alkenyl radical, said C2~C6Alkenyl optionally substituted by hydroxy, cyano, carboxy, monosaccharide, C1~C6Alkoxy radical, C6~C10Aryl, 5-to 10-membered heteroaryl, 5-or 6-membered lipoheterocyclyl, -NH-CO-C1~C6Alkylene oxideRadical (NH)2)(A1)、-NR13R14Substitution; c2~C6Alkynyl radical, said C2~C6Alkynyl is optionally substituted by hydroxy, cyano, carboxy, monosaccharide, C1~C6Alkoxy radical, C6~C10Aryl, 5-to 10-membered heteroaryl, 5-or 6-membered lipoheterocyclyl, -NH-CO-C1~C6Alkylene (NH)2)(A1)、-NR13R14Substitution;
A1selected from-H, C optionally substituted with 5-to 10-membered heteroaryl1~C6An alkyl group;
R4and R5Together form ═ O, and/or R6And R7Together form ═ O;
when R is4And R5Or R6And R7Each independently is selected from-H, when not forming ═ O; a hydroxyl group; -NR13R14;-(C=O)R15;-NR17-(C=O)R18;-SR25;C6~C10Aryl radical, said C6~C10Aryl is optionally substituted by halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0-2R34Substitution; 5-10 membered heteroaryl, said heteroaryl optionally selected from halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0-2R34Substitution; c1~C6Alkoxy radical, said C1~C6Alkoxy is optionally selected from halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0-2R34Substitution; c6~C10Aryloxy radical, said C6~C10Aryloxy is optionally substituted by a group selected from halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0-2R34Substitution;
G1~G8each independently selected from-H; halogen; a hydroxyl group; a cyano group; a nitro group; a carboxyl group; -NR13R14;-(C=O)NR11R12;-(C=O)R15;-O(C=O)R16;-NR17-(C=O)R18;-NR19-(COO)R20;-NR21-(SO2)R22;-O(C=O)NR23R24;-SR25;-(S=O)R26;-(SO2)R27;-CH=NOR28;-CH=NR29;-CH=NNR30R31;-(SO2)NR32R33;C1~C6Alkyl radical, said C1~C6Alkyl is optionally selected from halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0-2R34Substitution; c2~C6Alkenyl radical, said C2~C6Alkenyl is optionally selected from halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0-2R34Substitution; c2~C6Alkynyl radical, said C2~C6Alkynyl is optionally selected from halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0-2R34Substitution; c6~C10Aryl radical, said C6~C10Aryl is optionally substituted by halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0-2R34Substitution; 5-10 membered heteroaryl, said heteroaryl optionally selected from halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0-2R34Substitution; c1~C6Alkoxy radical, said C1~C6Alkoxy is optionally selected from halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0-2R34Substitution; c6~C10Aryloxy radical, said C6~C10Aryloxy is optionally substituted by a group selected from halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0-2R34Substitution;
R13、R14each independently selected from-H; an amino group; a monosaccharide radical, the hydroxyl hydrogen of which is optionally substituted by C1~C6Alkyl substitution; c1~C6Alkyl radical, said C1~C6Alkyl is optionally selected from halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0-2R34Substitution; c6~C10Aryl radical, said C6~C10Aryl being optionally substituted by amino, hydroxy, halogen, C1~C6Alkyl substitution, said C1~C6Alkyl is optionally selected from halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0-2R34Substitution; 5-or 6-membered lipoheterocyclyl, said lipoheterocyclyl being optionally substituted by amino, hydroxy, halogen, C1~C6Alkyl substitution, said C1~C6Alkyl is optionally selected from halogen, hydroxy, cyano, nitro, carboxy, azido, -NR13R14,-S(O)0-2R34Substitution;
R11、R12、R15、R16、R17、R18、R19、R20、R21、R22、R23、R24、R25、R26、R27、R28、R29、R30、R31、R32、R33、R34each independently selected from: -H; c1~C6An alkyl group; c6~C10An aryl group;
the aliphatic heterocyclic group and the heteroaryl group each independently contain 1 to 4 heteroatoms selected from N, O, S.
Alternatively, the compound of formula a, a pharmaceutically acceptable salt or prodrug thereof, described above is: a compound of formula I, a compound of formula II, or a pharmaceutically acceptable salt or prodrug thereof,
wherein, in the formula I,
the dotted line represents no chemical bond or a single bond;
G1~G8each independently selected from-H; halogen; c1~C6Alkyl groups of (a); c2~C6An alkenyl group; c2~C6An alkynyl group;
R3is selected from-H; -NR13R14;C1~C6Alkyl radical, said C1~C6Alkyl being optionally substituted by hydroxy, cyano, carboxy, monosaccharide, C1~C6Alkoxy radical, C6~C10Aryl, 5-to 10-membered heteroaryl, 5-or 6-membered lipoheterocyclyl, -NH-CO-C1~C6Alkylene (NH)2)(A1)、-NR13R14Substituted, the 5-or 6-membered aliphatic heterocyclic group, 5-to 10-membered heteroaryl group, C6~C10Aryl being optionally substituted by amino, hydroxy, halogen, C1~C6Alkyl radical, C1~C6Haloalkyl substitution;
wherein A is1Selected from: -H; c1~C6Alkyl radical, said C1~C6The alkyl is optionally substituted by 5-10 membered heteroaryl, the 5-10 membered heteroaryl is optionally substituted by amino, hydroxy, halogen, C1~C6Alkyl radical, C1~C6Haloalkyl substitution; r13、R14Each independently selected from: -H; c1~C6An alkyl group;
R1and R2Each independently selected from: -H; c1~C6Alkyl radical, said C1~C6Alkyl being optionally substituted by cyano, hydroxy, carboxy, C6~C10Aryl, 5-to 10-membered heteroaryl, C6~C10Aryl and 5-to 10-membered heteroaryl are optionally substituted by amino, hydroxyl, halogen, C1~C6Alkyl radical, C1~C6Haloalkyl substitution;
in the formula II, the reaction mixture is shown in the specification,
G1~G8each independently selected from-H; halogen;
R3is selected from-H; c1~C6Alkyl radical, said C1~C6Alkyl being optionally substituted by hydroxy, cyano, carboxy, monosaccharide, C1~C6Alkoxy radical, C6~C10Aryl, 5-to 10-membered heteroaryl, 5-or 6-membered lipoheterocyclyl, -NH-CO-C1~C6Alkylene (NH)2)(A1)、-NR13R14Substituted, the 5-or 6-membered aliphatic heterocyclic group, 5-to 10-membered heteroaryl group, C6~C10Aryl being optionally substituted by amino, hydroxy, halogen, C1~C6Alkyl radical, C1~C6Haloalkyl substitution;
wherein A is1Selected from: -H; c1~C6Alkyl radical, said C1~C6The alkyl is optionally substituted by 5-10 membered heteroaryl, the 5-10 membered heteroaryl is optionally substituted by amino, hydroxy, halogen, C1~C6Alkyl radical, C1~C6Haloalkyl substitution; r13、R14Each independently selected from: -H; c1~C6An alkyl group;
R4and R5Together form ═ O, and/or R6And R7Together form ═ O;
when R is4And R5Or R6And R7Each independently is selected from-H OR-OR when not forming ═ O35,R35is-H or C1~C6An alkyl group;
R9、R10independently is-H or C1~C6An alkyl group; r8Is selected from-C (═ Y)1)-Y2,-S(=O)2-Y3;
Wherein, Y1Selected from ═ O; (ii) S; NH;
Y2selected from hydroxylamine groups; c6~C10Aryl radical, said C6~C10Aryl being optionally substituted by amino, hydroxy, halogen, C1~C6Alkoxy radical, C1~C6Alkyl radical, C1~C6Haloalkyl substitution; 5-10 membered heteroaryl, said 5-10 membered heteroaryl optionally substituted with amino, hydroxy, halogen, C1~C6Alkoxy radical, C1~C6Alkyl radical, C1~C6Haloalkyl substitution; a5 or 6 membered lipoheterocyclyl, said 5 or 6 membered lipoheterocyclyl being optionally substituted by amino, hydroxy, halogen, C1~C6Alkoxy radical, C1~C6Alkyl radical, C1~C6Haloalkyl substitution; 5-or 6-membered aliphatic heterocyclic group substituted C1~C6Alkyl-substituted 5-or 6-membered lipoheterocyclyl, each of said 5-or 6-membered lipoheterocyclyl being optionally substituted by amino, hydroxy, halogen, C1~C6Alkoxy radical, C1~C6Alkyl radical, C1~C6Haloalkyl substitution; c1~C6Alkylamino radical, said C1~C6Alkylamino is substituted by oxygen, hydroxy, 5-10 membered heteroaryl, C6~C10At least one of aryl, 5-to 10-membered heteroaryl, C6~C10Aryl being optionally substituted by amino, hydroxy, halogen, C1~C6Alkoxy radical, C1~C6Alkyl radical, C1~C6Haloalkyl substitution;
Y3is optionally halogen, halogeno C1~C6Alkyl substituted C6~C10An aryl group;
or, R9And R10Together form-C (═ O) -, R8Is selected from-H; c1~C18An alkyl group; c1~C6Alkoxy-substituted C1~C18An alkyl group.
In the above compound of formula a, a pharmaceutically acceptable salt or prodrug thereof:
alternatively, the compound of formula I,
the dotted line represents no chemical bond or a single bond;
G1~G8as defined for compounds of formula I as described in claim 4;
R3is selected from-H; -NR13R14;C1~C6Alkyl radical, said C1~C6Alkyl being optionally substituted by hydroxy, cyano, carboxy, monosaccharide, C1~C6Alkoxy, morpholinyl, piperidinyl, piperazinyl, pyridinyl, phenyl or-NH-CO-C1~C6Alkylene (NH)2)(A1)、-NR13R14Substituted, the morpholinyl, piperidinyl, piperazinyl, pyridinyl, phenyl being optionally substituted by amino, hydroxy, halogen, C1~C6Alkyl radical, C1~C6Haloalkyl substitution;
wherein A is1Selected from: -H; c1~C6Alkyl radical, said C1~C6The alkyl is optionally substituted by imidazolyl and indolyl which are optionally substituted by amino, hydroxy, halogen, C1~C6Alkyl radical, C1~C6Haloalkyl substitution; r13、R14Each independently selected from: -H; c1~C6An alkyl group;
R1and R2Each independently selected from-H; c1~C6Alkyl radical, said C1~C6Alkyl is optionally substituted by cyano, hydroxy, carboxy, phenyl, naphthyl, pyridyl, said phenyl, naphthyl, pyridyl being optionally substituted by amino, hydroxy, halogen, C1~C6Alkyl radical, C1~C6Haloalkyl substitution;
alternatively, the reaction mixture of formula II,
G1~G8as defined for compounds of formula II as defined in claim 4;
R3is selected from-H; c1~C6Alkyl radical, said C1~C6Alkyl is optionally substituted by amino, hydroxy, phenyl, morpholinyl, piperidinyl, piperazinyl, said phenyl, morpholinyl, piperidinyl, piperazinyl being optionally substituted by amino, hydroxy, halogen, C1~C6Alkyl radical, C1~C6Haloalkyl substitution;
R4and R5Together form ═ O, and/or R6And R7Together form ═ O;
when R is4And R5Or R6And R7Each independently is selected from-H or-OH, when not forming ═ O;
R9、R10is methyl;
R8is selected from-C (═ Y)1)-Y2;-S(=O)2-Y3;
Wherein, Y1Selected from ═ O; (ii) S; NH;
Y2selected from: a hydroxyamino group; phenyl optionally substituted by amino, hydroxy, halogen, C1~C6Alkoxy radical, C1~C6Alkyl radical, C1~C6Haloalkyl substitution; an imidazolyl group; piperazinyl optionally substituted with morpholinyl; alkylamino substituted by at least one of oxygen, hydroxyl, indolyl and phenyl;
Y3is optionally halogen, C1~C6Haloalkyl-substituted phenyl;
or, R9And R10Together form-C (═ O) -, R8Is selected from-H; c1~C18An alkyl group; c1~C6Alkoxy-substituted C1~C18An alkyl group.
In the above compound of formula a, a pharmaceutically acceptable salt or prodrug thereof:
alternatively, the compound of formula I,
the dotted line represents no chemical bond or a single bond;
G1~G8as defined for compounds of formula I as described in claim 4;
R3selected from: c1~C6Alkyl radical, said C1~C6Alkyl is morpholinyl, piperidinyl, piperazinyl, pyridinyl, phenyl or-NH-CO-C1~C6Alkylene (NH)2)(A1) Is optionally substituted by at least one of amino, hydroxy, halogen, C1~C6Alkyl radical, C1~C6Haloalkyl substitution; c2~C6Alkyl radical, said C2~C6Alkyl is substituted by hydroxy; c3~C6Alkyl radical, said C3~C6Alkyl is-NR13R14Substitution;
wherein A is1Selected from: -H; c1~C6Alkyl radical, said C1~C6The alkyl is optionally substituted by imidazolyl and indolyl which are optionally substituted by amino, hydroxy, halogen, C1~C6Alkyl radical, C1~C6Haloalkyl substitution; r13、R14Each independently selected from: -H; c1~C6An alkyl group;
R1and R2Each independently selected from C1~C6Alkyl radical, said C1~C6The alkyl is substituted by at least one of phenyl, naphthyl and pyridyl;
alternatively,
in the formula I, the compound is shown in the specification,
the dotted line represents no chemical bond or a single bond;
G1~G8each independently selected from-H, halogen, allyl, isopentenyl;
R3is selected from-H; -Me; - (CH)2)1~6OH;-(CH2)0~6NH2;-(CH2)1~4NMe2;-(CH2)1~4CN;-(CH2)1~ 4CO2H;-(CH2)1~4C6H5OH;-(CH2)1~4C6H5OMe;-(CH2)1~4C6H5NH2;-(CH2)1~4M; morpholinoethyl; piperidine ethyl group; piperazine ethyl; methylpiperazinoethyl; a pyridylethyl group; a halogenated phenethyl group; - (CH)2)1~6-NH-CO-CH(NH2)(A1) (ii) a Wherein A is1、R13、R14The method of claim 4, wherein M is a monosaccharide;
or, said R3Selected from the group consisting of morpholinoethyl; piperidine ethyl group; piperazine ethyl; methylpiperazinoethyl; a pyridylethyl group; an aminobenzyl group; an aminophenylethyl group; a hydroxybenzyl group; a halogenated phenethyl group; - (CH)2)1~6-NH-CO-CH(NH2)(A1);-(CH2)2~ 4OH;-(CH2)3~6NH2;-(CH2)1~4NMe2(ii) a Wherein A is1Is selected from-H; an imidazolylmethyl group; indolylmethyl;
or, said R3Selected from 2- (4-morpholinyl) ethyl; 2- (piperidin-1-yl) ethyl; 2- (piperazin-1-yl) ethyl; 2- (4-methylpiperazin-1-yl) ethyl; 2- (pyridin-2-yl) ethyl; p-aminobenzyl; p-aminophenyl ethyl; p-hydroxyphenylmethyl; 2- (2-chloro-6-fluorophenyl) ethyl; - (CH)2)1~6-NH-CO-CH(NH2)(A1);-(CH2)2~4OH;-(CH2)3~6NH2;-(CH2)1~4NMe2(ii) a Wherein A is1Is selected from-H; (imidazol-4-yl) methyl; (indol-3-yl) methyl;
R1and R2Each independently selected from-H; -Et; - (CH)2)1~4CN;-(CH2)1~4CO2H;-(CH2)1~4OH; a phenethyl group; a naphthylethyl group; a pyridylethyl group;
or, said R1And R2Each independently selected from phenethyl; a naphthylethyl group; a pyridylethyl group;
alternatively, the reaction mixture of formula II,
G1~G8each independently selected from-H; halogen;
R3is-H;
R4and R5Together form ═ O, and/or R6And R7Together form ═ O;
when R is4And R5Or R6And R7Each independently is selected from-H OR-OR when not forming ═ O35,R35is-H or C1~C6An alkyl group;
R9、R10are both methyl;
R8is selected from-C (═ Y)1)-Y2;-S(=O)2-Y3;
Wherein, Y1Selected from ═ O; (ii) S; NH;
Y2selected from: a hydroxyamino group; phenyl, said phenyl being optionally substituted by halogen, C1~C6Haloalkyl substitution; an imidazolyl group; oxoindolylethylamino; an oxophenylethylamino group; (morpholinoethyl) piperazinyl; (halophenyl) methylamino; (halophenyl) ethylamino; (halomethylphenyl) ethylamino; a phenylmethylamino group; (methoxyphenyl) methylamino; hydroxypropylamino; 4- (N, N-bis (2-chloroethyl) amino) phenylpropyl;
or, Y2Selected from: a hydroxyamino group; a phenyl group; a halogenated phenyl group; trifluoromethyl substituted phenyl; 2-oxidenin-2- (1H-indol-3-yl) -1-ethylamino; imidazol-1-yl; 2-oxidenin-2-phenyl-1-ethylamino; 4- (2 (morpholin-1-yl) ethyl) piperazin-1-yl; (2, 6-difluorophenyl) methylamino; (3-chloro-4-fluorophenyl) methylamino; 2- (2-chloro-6-fluorophenyl) -1-ethylamino; 2- (4-trifluoromethylphenyl) -1-ethylamino; a phenylmethylamino group; (4-methoxyphenyl) methylamino; (S) -2-hydroxy-1-propylamino; 4- (N, N-bis (2-chloroethyl) amino) phenylpropyl;
Y3is optionally halogen, C1~C6Haloalkyl-substituted phenyl;
or, Y3Selected from the group consisting of halophenyl; trifluoromethyl substituted phenyl;
or,
R9and R10Together form-C (═ O) -;
R8is selected from-H; c1~C18An alkyl group; c1~C6Alkoxy-substituted C1~C18An alkyl group; or, R8Is methyl.
Alternatively, a compound of formula a, a pharmaceutically acceptable salt or prodrug thereof, as described above, selected from the following compounds, pharmaceutically acceptable salts or prodrugs thereof:
alternatively, in the above compound of formula a, a pharmaceutically acceptable salt or prodrug thereof, the pharmaceutically acceptable salt comprises a salt of an organic or inorganic acid; alternatively, the pharmaceutically acceptable salt is selected from salts of the compound of formula a with: hydrochloric acid; sulfuric acid; phosphoric acid; formic acid; acetic acid; propionic acid; lactic acid; citric acid; tartaric acid; succinic acid; fumaric acid; maleic acid; mandelic acid; malic acid; camphorsulfonic acid;
optionally, the pharmaceutically acceptable prodrug comprises a phosphate prodrug or a carbamate prodrug of the compound of formula a.
The present invention also provides a process for preparing a compound of formula a, as described above, a pharmaceutically acceptable salt or prodrug thereof, characterized in that: comprising the step of preparing a compound of formula I-1, a compound of formula I-2, a compound of formula I-3, a compound of formula II-1, or a compound of formula II-2,
in the compound of the formula I-1, G1~G8、R1、R2As mentioned above, the preparation of the compound of formula I-1 comprises the steps of:
1) a process for the preparation of a compound of formula a3, selected from the following Process (1) or Process (2),
method (1): preparing a compound of a formula a3 by a Perkin condensation reaction of a compound of a formula a1 and a compound of a formula a 2;
method (2): subjecting a compound of formula a2, a compound of formula a6 and a compound of formula a7 to Grignard reaction and reaction with iodoethane to obtain a compound of formula a8, and subjecting a compound of formula a8 to hydrolysis under alkaline conditions and then acidification to obtain a compound of formula a 3;
and 2) a step of preparing a compound of formula I-1,
preparing a compound shown in the formula I-1 from a compound shown in the formula a3 through reaction;
in the compound of the formula I-2, G1~G8、R1、R2、R3As described above, but R3Instead of H, the preparation of the compound of formula I-2 comprises: preparing a compound of formula I-2 from the compound of formula I-1;
g in the compound of the formula I-31~G8、R1、R2、R3As described above, the preparation of the compound of formula I-3 comprises:
1): subjecting the compound of formula I-1 to cyclization reaction or oxidative cyclization reaction of dichlorodicyan p-benzoquinone (DDQ) to obtain a compound of formula a5, and further subjecting the compound of formula a5 to obtain a compound of formula I-3, wherein R in the compound of formula I-33Is H;
or 2): the compound of the formula I-2 is subjected to photocyclization reaction or oxidative cyclization reaction of dichloro dicyan p-benzoquinone (DDQ) to prepare the compound of the formula I-3, wherein R in the compound of the formula I-33Is not H;
wherein when R is1、R2Optionally adopting a protecting group for protection when the active group is an active group;
in the compound of the formula II-1, R9、R10is-H or alkyl; g1~G8、R3、R4、R5、R6、R7、R8As mentioned above, the preparation of the compound of formula II-1 comprises the steps of: II-1-A compound, II-1-B compound, II-1-C compound, II-1-D compound or II-1-a step of preparing a compound of type E,
the class II-1-A compound is a compound of formula II-1 defined as follows: r in the Compound of formula II-18is-C (═ Y)1)-Y2,Y1Selected from ═ O or ═ S; y is2Is aryl, optionally substituted with amino, hydroxy, halogen, alkoxy, alkyl, haloalkyl;
the preparation steps of the II-1-A compounds comprise: prepared by acylation of a compound of formula b1 with an arylformyl or arylsulfonyl reagent wherein the aryl group has a substituent with Y2The substituents on the aryl groups are the same; in the compounds of the formula b1, G1~G8、R3、R4、R5、R6、R7、R9、R10As described in class II-1-A;
the class II-1-B compounds are compounds of formula II-1 defined as follows: r in the Compound of formula II-18is-C (═ Y)1)-Y2,Y1Selected from ═ O or ═ S; y is2Is imidazolyl; the preparation steps of the II-1-B compounds comprise: reacting the compound of the formula b1 with 1, 1' -thiocarbonyldiimidazole or triphosgene with imidazole to obtain a compound of a formula b 2; wherein Y in said compound of formula b21Is ═ O or ═ S;
the class II-1-C compounds are compounds of formula II-1 defined as follows: r in the Compound of formula II-18is-C (═ Y)1)-Y2,Y1Selected from ═ O or ═ S; y is2Selected from hydroxylamine groups; -NR13R14(ii) a The aliphatic heterocyclic group is substituted by alkyl, and the aliphatic heterocyclic group is optionally substituted by amino, hydroxyl, halogen, alkoxy, alkyl and halogenated alkyl; alkylamino substituted by at least one of oxygen, hydroxy, heteroaryl, aryl optionally substituted by amino, hydroxy, halogen, alkoxy, alkyl, alkoxy, heteroaryl, aryl, or heteroaryl,Haloalkyl substitution; wherein R is13、R14As described above; the preparation steps of the II-1-C compounds comprise: the compound of the formula b2 reacts with methyl iodide to generate a compound of the formula b3, and the compound of the formula b3 reacts with the compound R to obtain the compound; wherein the compound R is selected from alkyl-substituted aliphatic heterocyclic ring substituted by aliphatic heterocyclic group, and the aliphatic heterocyclic group and the aliphatic heterocyclic ring are both optionally substituted by amino, hydroxyl, halogen, alkoxy, alkyl and halogenated alkyl; alkylamino substituted by at least one of oxygen, hydroxy, heteroaryl, aryl, said heteroaryl, aryl optionally substituted by amino, hydroxy, halogen, alkoxy, alkyl, haloalkyl;
the class II-1-D compounds are compounds of formula II-1 defined as follows: r in the Compound of formula II-18is-C (═ NH) -NHOH; the preparation steps of the II-1-D compounds comprise: from the compound of formula b1 to the compound of formula b4, the compound of formula b4 is reacted with hydroxylamine hydrochloride;
the class II-1-E compounds are compounds of formula II-1 defined as follows: r in the Compound of formula II-18is-C (═ Y)1)-Y2,Y1Is ═ O, Y2Is 4- (N, N-bis (2-chloroethyl) amino) phenylpropyl; the preparation steps of the II-1-E compounds comprise: a compound of formula b1 with chlorambucil;
in the compound of the formula II-2, R9And R10Together form-C (═ O) -; g1~G8、R3、R4、R5、R6、R7、R8As described above; the preparation steps of the compound of the formula II-2 comprise: reacting a compound of a formula c1 with a compound of a formula c2 to obtain a compound of a formula c3, reacting to obtain a compound of a formula c4, reacting to obtain a compound of a formula c5, reacting to obtain a compound of a formula c6, reacting to obtain a compound of a formula c7, reacting to obtain a compound of a formula c8, reacting to obtain a compound of a formula c9, and reacting to obtain a compound of a formula II-2;
R3optionally protecting with a protecting group when the reactive group is an active group;
alternatively, the Perkin condensation reaction is carried out in oxalyl chloride, triethylamine (Et)3N), in the presence of dichloromethane;
optionally, the aminolysis reaction is carried out in the presence of Hexamethyldisilazane (HMDS), N-dimethylformamide, and methanol;
optionally, in the photocyclization reaction, acetone is used as a solvent, an iodine simple substance is used as a catalyst, and the reaction is performed under the illumination of a high-pressure mercury lamp;
optionally, the oxidative cyclization reaction of dichlorodicyan p-benzoquinone (DDQ) is carried out in a benzene solvent under the catalysis of p-toluenesulfonic acid to generate an oxidative ring closure reaction with DDQ;
alternatively, the compound of formula a6 is prepared by reacting dibromomaleimide with methyl iodide;
alternatively, the compound of formula a8 is hydrolyzed in an alkaline solution such as KOH or NaOH, and then acidified by hydrochloric acid or the like to obtain a compound of formula a 3;
alternatively, when R1、R2Or R3When active, the protecting group is selected from (Boc)2O;
Alternatively, R in the II-1-A compound3is-H; r6And R7Together form ═ O; r8The preparation method of the II-1-A compound is methyl, and comprises the following steps: dissolving staurosporine in dichloromethane, adding triethylamine, and performing acylation reaction with a halogenated benzoylation reagent; halogenating reaction, namely halogenating the product obtained in the step I with halogenated succinimide in methanol at room temperature; oxidizing the product obtained in the step (c) with an oxidizing agent to obtain a product containing R4 and R5 which are independently selected from-H; -OH; or R4 and R5 together form ═ O; the acylation, halogenation and oxidation are optionally carried outThe sequence of (a); optionally, the oxidation reaction is carried out with the following reagents: o is2DMSO, t-BuOK and optionally NaOH;
alternatively, R in the compound of formula B2 in the II-1-B compounds3is-H; r4、R5Is independently selected from-H; r6And R7Together form ═ O; r8Is methyl; the preparation of the II-1-B compounds is carried out by the following method: the method comprises the following steps: dissolving staurosporine in dichloromethane, adding triethylamine, and reacting with 1, 1' -thiocarbonyl diimidazole to obtain the product; or the method II: dissolving staurosporine in tetrahydrofuran, adding diisopropylethylamine and triphosgene for reaction, dissolving a reaction crude product in tetrahydrofuran, and adding diisopropylethylamine, imidazole and p-dimethylaminopyridine to obtain the product;
alternatively, R in the II-1-C compounds3is-H; r4、R5Are all-H; r6And R7Together form ═ O; r8Is methyl; the preparation steps of the II-1-C compounds comprise: the compound of the formula b2 is salified with methyl iodide in an acetonitrile solvent, then dissolved in dichloromethane, and added with triethylamine and a compound R to react to substitute imidazole salt to obtain the compound;
alternatively, R in the II-1-D compounds3is-H; r4、R5Are all-H; r6And R7Together form ═ O; r8Is methyl; the preparation method of the compound of the classification (4) comprises the following steps: the Fradcarbazole C is prepared by the reaction of hydroxylamine hydrochloride;
alternatively, R in the II-1-E compounds3is-H, R4、R5Are all-H; r6And R7Together form ═ O; r8Is methyl; the preparation steps of the II-1-E compounds comprise: the staurosporine is prepared by reacting staurosporine with chlorambucil;
alternatively, in the compound of formula II-2, R3is-H; r4And R5Together form ═ O; r6And R7Together form ═ O; r8Is methyl; the preparation steps of the compound of the formula II-2 comprise: taking glucose asRaw materials are subjected to full acetylation, 1-position bromination, 1, 2-position alkene formation reaction, deacetylation, TIPS protection of 6-position hydroxyl, 3, 4-position construction of oxazole cyclic ketone, methylation, and reduction of sodium hydroxymercuric borohydride to introduce hydroxyl at the 1-position, so that a sugar donor is obtained; using 2, 3-dibromomaleimide as a raw material, reacting with an indole Grignard reagent to introduce a molecule of indole through BOM protection, protecting the nitrogen and hydrogen of the indole with Boc, and reacting with the indole Grignard reagent to obtain a parent nucleus; using Mitsunobu reaction to carry out glycosylation on the sugar donor in the step I and the mother nucleus in the step II to form a first glycosidic bond, separating isomers of the glycosidic bond through silica gel column chromatography, then removing Boc and TIPS protecting groups, irradiating by a high-pressure mercury lamp to carry out cyclization, replacing 6-hydroxy with iodine, deiodinating 5, 6-into double bonds, forming a second glycosidic bond under the catalysis of iodine, deiodinating by tetrabutyl tin hydride, and removing BOM by 20% palladium hydroxide carbon to obtain the product;
alternatively, in the compound of formula II-2, R3is-H; r8Is methyl; r4And R5Together form ═ O, R6、R7Are all-H; or, R4、R5Are all-H, R6And R7Together form ═ O; the preparation steps of the compound of the formula II-2 comprise: the R is3is-H, R4And R5Together form ═ O, R6And R7Together form ═ O, R8The compound of formula II-2, which is methyl, is prepared by sodium borohydride reduction and zinc powder acetic acid reduction;
alternatively, the compound of formula II-2 is prepared from isomers with different glycosidic bonds and oxazolone configurations using D-glucose or L-glucose.
In the invention, the compounds 1-81, 158-166 and the important intermediate products 24c, 26c, 43c, 46c, 49c, 52c and 58c can be prepared from indole or halogen substituted indole and indole acetic acid by the following chemical synthesis methods:
in the formulae A-I and A-II, G1~G8Each independently is-H, -F, -Cl, -Br, allyl, or isopentenyl; x is-H, -Me, -NH22- (4-morpholinyl) ethyl, 2- (piperidin-1-yl) ethyl, - (CH)2)nNH2、-(CH2)nNMe2、-(CH2)nCN、-(CH2)nCO2H、-(CH2)nOY、-(CH2)nC6H5R3(Y is-H, glucosyl or amino acid group, n is 1-4, R3=-OH、-OMe);R1,R2represents-H, -Et, - (CH)2)mCN、-(CH2)mCO2H、-(CH2)mOH(m=1~4)、-CH2Ph。
The compound 82-101 can be prepared from halogen substituted indole and dibromomaleimide by the following chemical synthesis method:
in the above formulae A to III, G5~G8Each independently is-H, -F, -Cl or-Br; x is-H, -Me or-CH2OH,R1,R2Each independently is-H, -Et or-CH2OH。
The compounds 102-129 and intermediates 102f and 116c thereof can be prepared from indole and dibromomaleimide by the following chemical synthesis methods:
in the above formulae A to IV, G5~G8Are all-H; x represents-H, -Me, 2- (piperazin-1-yl) ethyl, 2- (2-chloro-6-fluoro-phen-1-yl) ethyl, 2- (4-morpholinyl) ethyl, 2- (piperidin-1-yl) ethyl, 2- (4-methylpiperazin-1-yl) ethyl, - (CH)2)nOH、-(CH2)nNH2、(n=1,2);R1Is phenylethyl or 2- (naphthalen-1-yl) ethyl.
The compounds 130-157 can be prepared from staurosporine (staurosporine), halogen-containing benzoyl reagent and benzenesulfonyl reagent by the following chemical synthesis method:
in the above formulae A-V and A-VI, R1is-H, -F, -Cl, -Br, -I or-CF3;R2、R3Each independently is ═ O, -H, or-OH; x is-H or-Br.
The compounds 167-184 can be prepared from staurosporine, thiocarbonyl diimidazole or triphosgene, imidazole, methyl iodide and amine compounds; or the staurosporine and chlorambucil are prepared by the following chemical synthesis method:
in the above formulae A to VII, R4Represents ═ O, ═ S or ═ NH, R5Represents 2-oxylidene-2- (1H-indol-3-yl) -1-ethylamino, imidazol-1-yl, hydroxylamino, 2-oxylidene-2-phenyl-1-ethylamino, 4- (2- (4-morpholinyl) ethyl) piperazin-1-yl, (2, 6-difluorophenyl) methylamino, (3-chloro-4-fluorophenyl) methylamino, 2- (2-chloro-6-fluorophenyl) -1-ethylamino, 2- (3-trifluoromethylphenyl) -1-ethylamino, phenylmethylamino, (4-methoxyphenyl) methylamino, (S) -2-hydroxy-1-propylamino, amino, 4- (N, N-bis (2-chloroethyl) aminophenyl) propyl.
185-196 parts of a compound in a formula A-VIII, wherein 185-187 parts of the compound can be prepared from D-glucose and dibromomaleimide by the following chemical synthesis method, and 188-190 parts of the compound in the formula A-VIII can be prepared from 26b by the same method; 191 to 195 can be prepared by the same method by replacing D-glucose with L-glucose.
In the above formulae A to VIII, R1a、R1bEach independently is-H or-OH, or R1a、R1bTogether form ═ O, R2a、R2bEach independently is-H or-OH, or R2a、R2bTogether form ═ O, R3is-H, -Me, 2- (piperazin-1-yl) ethyl, 2- (2-chloro-6-fluorophenyl) ethyl, 2- (4-morpholinyl) ethyl, 2- (piperidin-1-yl) ethyl, 2- (4-methylpiperazin-1-yl) ethyl, - (CH)2)nOH or- (CH)2)nNH2(n ═ 1 or 2); r3Represents H, - (CH)2)nCH3(n is 0 to 17) or- (CH)2)nOY,(n=1,2、Y=Me,Et)。
The invention also provides an alpha-glucosidase inhibition composition, which comprises at least one of the compound shown in the formula A, pharmaceutically acceptable salt or prodrug thereof and pharmaceutically acceptable auxiliary materials.
The invention also provides an antidiabetic pharmaceutical composition, which comprises at least one of the compound shown in the formula A, the pharmaceutically acceptable salt or the prodrug thereof and pharmaceutically acceptable auxiliary materials. Optionally, the anti-diabetic drug is a drug against alpha-glucosidase mediated diabetes.
The invention also provides a pharmaceutical composition for resisting diabetic complications, which comprises at least one of the compound shown in the formula A, pharmaceutically acceptable salt or prodrug thereof and pharmaceutically acceptable auxiliary materials. Optionally, the diabetic complication is diabetic nephropathy.
The compound of formula A, the pharmaceutically acceptable salt or prodrug thereof, the alpha-glucosidase inhibiting composition, or the antidiabetic pharmaceutical composition of the present invention can be administered orally and by injection, and are also suitable for other administration modes, such as transdermal administration and the like. The antidiabetic pharmaceutical composition of the present invention may be in the form of tablets, capsules, powders, granules, lozenges, suppositories, oral liquids or sterile parenteral suspensions and the like. Also comprises injection preparations with various volumes, freeze-dried powder and other injection forms. The medicaments of the dosage forms can be prepared according to the conventional method in the field of pharmacy. In the anti-diabetic pharmaceutical composition of the present invention, the excipients used include those conventional in the art, such as diluents, fillers, binders, wetting agents, absorption enhancers, surfactants, adsorption carriers, lubricants, etc.
The invention also provides application of the compound of the formula A and pharmaceutically acceptable salts or prodrugs thereof in preparing alpha-glucosidase inhibitors.
The invention also provides application of the compound shown in the formula A, the pharmaceutically acceptable salt or the prodrug thereof in preparing an antidiabetic medicament, and optionally the antidiabetic medicament is a medicament for resisting the diabetes mediated by the alpha-glucosidase.
The invention also provides application of the compound of the formula A, the pharmaceutically acceptable salt or the prodrug thereof in preparing medicines for treating diabetic complications, wherein the diabetes is optionally diabetes mediated by alpha-glucosidase. Optionally, the diabetic complication is diabetic nephropathy.
The invention also provides the use of the compound of formula a, or a pharmaceutically acceptable salt or prodrug thereof, as an alpha-glucosidase inhibitor.
The present invention also provides the use of a compound of formula a, as described above, a pharmaceutically acceptable salt or prodrug thereof, for treating diabetes. Optionally, the diabetes is alpha-glucosidase mediated diabetes.
The present invention also provides the use of a compound of formula a, as described above, a pharmaceutically acceptable salt or prodrug thereof, for treating an diabetic complication, optionally diabetic nephropathy.
Advantageous effects
The compound has stronger alpha-glucosidase inhibition effect and good activity for resisting diabetes and diabetic complications such as diabetic nephropathy.
Drawings
FIG. 1: h & E stained photomicrographs of renal cortex tissue sections showing therapeutic effect of compound 49 on diabetic nephropathy mice: x 400.
A is the normal group, B is the db/db model group, C is the model group + losartan group (positive drug), D is the model group + Compound 49(0.5mg/kg/day), E is the model group + Compound 49(1.0mg/kg/day), and F is the model group + Compound 49(2.0 mg/kg/day).
The specific implementation mode is as follows:
the present invention is illustrated below by examples, but the scope of the present invention is not limited to these examples.
[ example 1 ] preparation of Compounds 1 to 196
Preparation of Compound 1
i) Preparation of 1-ethyl-3-indoleacetic acid (1a)
Under the protection of argon, 4g of sodium hydride (with the mass fraction of 60 percent and dispersed in paraffin) and 80mL of tetrahydrofuran are added into a 250mL three-necked bottle, the mixture is stirred and suspended at the temperature of 0 ℃,30mL of indole-3-acetic acid (with the mass fraction of 3.5g and 20mmol) dissolved in tetrahydrofuran is added, after stirring for half an hour, 30mL of iodoethane (with the mass fraction of 5mL and 60mmol) dissolved in tetrahydrofuran is added dropwise, the mixture is slowly heated to the room temperature, after reaction is carried out overnight, the temperature is reduced to be below 0 ℃,10 drops of methanol are added dropwise, a proper amount of water is added to obtain a bright yellow solution, ethyl acetate is used for extraction, a water layer is extracted again after being added with concentrated hydrochloric acid, organic layers are combined, and anhydrous Na is used for extracting2SO4Drying, evaporating to dryness in vacuum, separating by silica gel column chromatography, eluting with petroleum ether and ethyl acetate (8: 1) (v/v) to obtain 3.87g of product (1a), with yield of 95.4%.1H NMR(600MHz,CDCl3)δ7.59(d,1H,J=8.2Hz,Ar-H),7.30(d,1H,J=8.2Hz,Ar-H),7.20(dt,1H,J=8.2Hz,0.9Hz,Ar-H),7.10(dt,1H,J=8.2Hz,1.0Hz,Ar-H),7.07(s,1H,Ar-H),4.10(q,2H,J=7.3Hz,CH3-CH 2-),3.77(s,2H,-CH 2-CO2H),1.41(t,3H,J=7.3Hz,-CH2-CH 3).13C NMR(150MHz,CDCl3)δ178.6,135.9,127.6,126.1,121.7,119.2,119.0,109.4,106.0,40.8,31.1,15.4.ESI-MS m/z 202.1[M-H]–.
ii) preparation of 1-cyanomethylindole (1b)
Under the protection of argon, 180mg of sodium hydride (mass fraction: 60%, min.) was added into a 100mL three-necked flaskDispersed in paraffin) and 30mL of acetonitrile, stirring and suspending at-5 ℃, dropwise adding indole (351mg,3.0mmol) dissolved in 10mL of acetonitrile, stirring and reacting for 30min, slowly dropwise adding 2-bromoacetonitrile (300 mu L,4.5mmol) dissolved in 10mL of acetonitrile, slowly heating to room temperature, reacting for 24h, and then adding saturated NH4The reaction was terminated with aqueous Cl solution, extracted with ethyl acetate (100 mL. times.3), and the organic layers were combined and washed with anhydrous Na2SO4Drying, vacuum evaporating, separating with silica gel column chromatography, eluting with petroleum ether and ethyl acetate 15:1(v/v) to obtain colorless oily product (1b)299mg, with yield of 64%.1H NMR(600MHz,CDCl3)δ7.64(d,1H,J=8.2Hz,Ar-H),7.33-7.28(m,2H,Ar-H),7.19(d,1H,J=6.9Hz,Ar-H),7.02(d,1H,J=3.2Hz,Ar-H),6.58(d,1H,J=3.2Hz,Ar-H),4.87(s,2H,-CH 2-CN).13C NMR(150MHz,CDCl3)δ135.6,128.9,127.1,122.8,121.5,120.8,114.4,108.7,104.1,34.1.ESI-MS m/z 157.1[M+H]+.
iii) preparation of 2- (1-ethyl-3-indole) -3- (1-cyanomethyl-3-indole) maleic anhydride (1c)
Compound 1a (299mg,1.92mmol) was reacted with 25mL CH2Cl2Dissolving, and dripping 5mL of CH at-5 DEG C2Cl2After the completion of the dropwise addition of the dissolved oxalyl chloride (366mg,2.88mmol), the mixture was reacted at-5 ℃ for 2 hours, followed by addition of 0.5mL of oxalyl chloride, the reaction was continued for 2.5 hours, the temperature was raised to room temperature, and the solvent was vacuum-dried to obtain yellow crystals. Using 30mL CH2Cl2Redissolved and added dropwise to 15mL CH2Cl2The dissolved compound 1b (390mg,1.92mmol) and triethylamine (388mg,3.84mmol) were separated by silica gel column chromatography and eluted with ethyl acetate (3: 1) (v/v) as petroleum ether to give 270mg of red powder (1c) with a yield of 36%.1H NMR(600MHz,DMSO-d6)δ7.97(s,1H,Ar-H),7.95(s,1H,Ar-H),7.64(d,1H,J=8.2Hz,Ar-H),7.54(d,1H,J=8.2Hz,Ar-H),7.22(t,1H,J=7.3Hz,Ar-H),7.12(t,1H,J=7.8Hz,Ar-H),6.90(d,1H,J=7.7Hz,Ar-H),6.87(d,1H,J=7.8Hz,Ar-H),6.85(t,1H,J=7.7Hz,Ar-H),6.77(t,1H,J=7.8Hz,Ar-H),5.67(s,2H,-CH 2-CN),4.28(q,2H,J=7.3Hz,-CH 2-CH3),1.33(t,3H,J=7.3Hz,-CH2-CH 3).13C NMR(150MHz,DMSO-d6)δ166.2,166.1,135.7,135.6,133.2,132.5,129.9,126.1,125.5,125.3,123.1,122.3,121.7,121.6,120.9,120.3,116.0,110.6,110.4,106.0,104.0,40.9,34.1,15.2.ESI-MS m/z 396.2[M+H]+.
iv) preparation of 2- (1-ethyl-3-indole) -3- (1-cyanomethyl-3-indole) maleimide (1)
Compound 1c (126mg,0.32mmol) was dissolved in 4mL of DMF in a single vial, sealed and mixed with HMDS (6.7mL,32mmol) and MeOH (0.64mL,16mmol) under stirring, and then poured into a single vial to change the reaction solution from red to a pale yellow turbidity which gradually changed to a clear solution as the reaction proceeded to orange-red. After overnight reaction, poured into 25mL cold water, extracted with ethyl acetate (50 mL. times.3), the organic layers were combined and washed with anhydrous Na2SO4Drying and vacuum evaporating. Separating with silica gel column chromatography, eluting with chloroform to obtain orange red powder (1)118mg with yield of 94%.1H NMR(600MHz,DMSO-d6)δ11.00(s,1H,imide-NH),7.87(s,1H,Ar-H),7.82(s,1H,Ar-H),7.57(d,1H,J=8.2Hz,Ar-H),7.48(d,1H,J=8.2Hz,Ar-H),7.15(t,1H,J=8.3Hz,Ar-H),7.05(t,1H,J=7.4Hz,Ar-H),6.83(d,1H,J=8.3Hz,Ar-H),6.80(d,1H,J=8.2Hz,Ar-H),6.75(t,1H,J=7.8Hz,Ar-H),6.68(t,1H,J=7.8Hz,Ar-H),5.64(s,2H,N-CH 2-CN),4.26(q,2H,J=7.3Hz,-CH 2-CH3),1.32(t,3H,J=7.3Hz,-CH2-CH 3).13C NMR(150MHz,DMSO-d6)δ172.7,172.6,135.5,135.4,131.8,131.4,129.1,126.0,125.8,122.6,121.8,121.5,121.2,121.0,120.4,119.6,116.1,110.1,110.0,106.8,104.6,40.7,34.0,15.2.ESI-MS m/z 395.2[M+H]+.
Preparation of Compound 2
i) Preparation of 1-cyanoethylindole (2b)
According to the preparation method of the compound 1b, sodium hydride (360mg,9.0mmol, dispersed in paraffin wax, mass fraction 60%), indole (702mg, 6.0mmol) and 3-bromopropionitrile (744 μ L,9.0mmol) were used as raw materials, and separation was performed by silica gel column chromatography and elution was performed with petroleum ether and ethyl acetate 15:1(v/v) to obtain 949mg of a colorless oily product (2b), yield 94%.1H NMR(600MHz,CDCl3)δ7.65(d,1H,J=7.8Hz,Ar-H),7.30(d,1H,J=7.8Hz,Ar-H),7.25(t,1H,J=7.8Hz,Ar-H),7.15(t,1H,J=6.8Hz,Ar-H),7.13(d,1H,J=3.2Hz,Ar-H),6.55(d,1H,J=3.2,Ar-H),4.42(t,2H,J=6.9Hz,N-CH 2-CH2CN),2.78(t,2H,J=J=6.9Hz,NCH2-C 2H-CN).13C NMR(150MHz,CDCl3)δ135.4,129.1,127.5,122.3,121.6,120.2,117.4,108.7,103.0,42.2,19.2.
ii) preparation of 2- (1-ethyl-3-indole) -3- (1-cyanoethyl-3-indole) maleic anhydride (2c)
According to the preparation method of the compound 1c, the compound was prepared from the compound 2b (988mg,5.81mmol), oxalyl chloride (1107mg,8.72mmol), 1a (1180mg,5.81mmol) and triethylamine (1176mg,11.64mmol), and subjected to silica gel column chromatography and eluted with ethyl acetate ═ 2:1(v/v) to give 530mg of red powder (2c) in 23% yield.1H NMR(600MHz,CDCl3)δ7.84(s,1H,Ar-H),7.66(s,1H,Ar-H),7.35(d,1H,J=8.3Hz,Ar-H),7.34(d,1H,J=8.3Hz,Ar-H),7.22(dt,1H,J=7.3Hz,1.0Hz,Ar-H),7.16(dt,1H,J=7.5Hz,1.4Hz,Ar-H),7.11(d,1H,J=7.8Hz,Ar-H),6.90(dt,1H,J=7.8Hz,1.0Hz,Ar-H),6.89(d,1H,J=8.2Hz,Ar-H),6.82(dt,1H,J=7.3Hz,1.0Hz,Ar-H),4.47(t,2H,J=6.9Hz,N-CH 2-CH2-CN),4.23(q,2H,J=7.3Hz,-CH 2-CH3),2.85(t,2H,J=6.9Hz,-NCH2-CH 2-CN),1.51(t,3H,J=7.3Hz,-CH2-CH 3).13C NMR(150MHz,CDCl3)δ166.7,166.6,136.2,135.5,132.8,131.5,129.6,126.2,126.0,125.6,123.4,122.9,122.8,122.5,121.3,120.8,116.5,110.0,109.1,106.7,105.0,42.4,41.7,19.0,15.1.ESI-MS m/z 410.2[M+H]+.
iii) preparation of 2- (1-ethyl-3-indole) -3- (1-cyanoethyl-3-indole) maleimide (2d)
According to the preparation of compound 1, from compound 2c (230mg,0.56mmol), HMDS (12mL,57mmol) and MeOH (1.2mL,28.5mmol), separation by silica gel column chromatography and elution with chloroform gave 219mg of orange-red powder (2d) in 95% yield.1H NMR(600MHz,CDCl3)δ7.75(s,1H,Ar-H),7.58(s,1H,Ar-H),7.51(s,1H,-NH),7.31(d,1H,J=8.2Hz,Ar-H),7.29(d,1H,J=8.2Hz,Ar-H),7.16(t,1H,J=7.3Hz,Ar-H),7.11(t,1H,J=8.2Hz,Ar-H),7.09(d,1H,J=8.2Hz,Ar-H),6.88(d,1H,J=8.2Hz,Ar-H),6.85(t,1H,J=7.4Hz,Ar-H),6.77(t,1H,J=7.3Hz,Ar-H),4.45(t,2H,J=6.9Hz,N-CH 2-CH2CN),4.20(q,2H,J=7.3Hz,-CH 2-CH3),2.80(t,2H,J=6.9Hz,-NCH2-CH 2-CN),1.48(t,3H,J=7.3Hz,-CH2CH 3).13C NMR(150MHz,CDCl3)δ171.8,171.7,136.0,135.4,131.7,130.6,129.5,126.6,126.3,125.9,123.0,122.7,122.3,122.2,120.8,120.2,116.7,109.6,108.8,107.3,105.4,42.3,41.5,18.9,15.2.ESIMS:m/z 407.1[M–H]–.
iv) preparation of N-hydroxymethyl-2- (1-ethyl-3-indole) -3- (1-cyanoethyl-3-indole) maleimide (2)
In a 15mL reaction flask was added compound 2d (16.2mg, 39.7. mu. mol) and NaHCO3(6.7mg, 79.4. mu. mol), a formaldehyde solution (3mL, 37% by mass) was added, and the mixture was stirred at 85 ℃ for 10 hours and poured into cold water. Extracting with ethyl acetate, combining the organic layers, and adding anhydrous Na2SO4Drying, vacuum evaporating, separating with silica gel column chromatography, and eluting with petroleum ether and ethyl acetate 3:1(v/v) to obtain red powder (2)17.1mg with yield of 98%.1H NMR(600MHz,DMSO-d6)δ7.93(s,1H,Ar-H),7.85(s,1H,Ar-H),7.59(d,1H,J=8.2Hz,Ar-H),7.47(d,1H,J=8.3Hz,Ar-H),7.06(dt,1H,J=7.8Hz,0.9Hz,Ar-H),7.04(dt,1H,J=7.3Hz,1.0Hz,Ar-H),6.83(d,1H,J=8.3Hz,Ar-H),6.78(d,1H,J=8.3Hz,Ar-H),6.69(dt,1H,J=7.3Hz,1.0Hz,Ar-H),6.68(dt,1H,J=7.8Hz,0.9Hz,Ar-H),6.31(t,1H,J=7.0Hz,-OH),4.98(d,2H,J=6.9Hz,N-CH 2-OH),4.59(t,2H,J=6.4Hz,N-CH 2-CH2CN),4.26(q,2H,J=7.3Hz,CH 2-CH3),3.03(t,2H,J=6.4Hz,N-CH2-CH 2-CN),1.34(t,3H,J=7.3Hz,-CH2CH 3).13C NMR(150MHz,DMSO-d6)δ171.5,171.4,136.2,136.1,132.3,132.2,128.4,126.7,126.5,126.4,122.6,122.3,121.9,121.7,120.5,120.3,119.0,110.9,110.7,106.2,105.3,60.8,42.0,41.3,19.1,15.8.ESI-MS m/z 439.2[M+H]+.
Preparation of Compound 3
i) Preparation of 1-cyanopropylindole (3b)
According to the preparation method of compound 1b, the compound was prepared from indole (1170mg,10mmol), NaH (600mg,15mmol, mass fraction 60%, dispersed in paraffin) and 4-bromobutyronitrile (1.6mL,15mmol), and subjected to silica gel column chromatography and elution with petroleum ether and ethyl acetate 20:1(v/v) to give 1042mg of colorless oily product (3b) in 57% yield.1H NMR(600MHz,CDCl3)δ7.70(d,1H,J=7.7Hz,Ar-H),7.38(d,1H,J=8.3Hz,Ar-H),7.29(t,1H,J=7.7Hz,Ar-H),7.19(t,1H,J=7.4Hz,Ar-H),7.12(d,1H,J=3.3Hz,Ar-H),6.58(d,1H,J=3.3Hz,Ar-H),4.28(t,2H,J=6.6Hz,N-CH 2-(CH2)2CN),2.19(t,2H,J=5.5Hz,N(CH2)2-C 2H-CN),2.16-2.14(m,2H,-NCH2-C 2H-CH2CN)。13C NMR(150MHz,CDCl3)δ135.9,128.9,127.8,122.1,121.4,119.9,119.0,109.3,102.2,44.5,26.1,14.7.ESI-MS m/z 185.1[M+H]+Ii) preparation of 2- (1-ethyl-3-indole) -3- (1-cyanopropyl-3-indole) maleic anhydride (3c)
According to the preparation method of the compound 1c, the compound was prepared from 3b (407mg,2.21mmol), oxalyl chloride (421mg,3.32mmol), the compound 1a (449mg,2.21mmol) and triethylamine (447mg,4.42mmol), and subjected to silica gel column chromatography and chloroform elution to obtain 415mg of red powder (3c) with a yield of 45%.1H NMR(600MHz,DMSO-d6)δ7.89(s,1H,Ar-H),7.88(s,1H,Ar-H),7.57(d,1H,J=8.8Hz,Ar-H),7.54(d,1H,J=8.2Hz,Ar-H),7.14(t,1H,J=8.2Hz,Ar-H),7.12(t,1H,J=7.7Hz,Ar-H),6.94(d,1H,J=8.3Hz,Ar-H),6.91(d,1H,J=8.3Hz,Ar-H),6.80(t,1H,J=7.1Hz,Ar-H),6.79(t,1H,J=7.1Hz,Ar-H),4.33(t,2H,J=7.1Hz,N-CH 2-(CH2)2CN),4.26(q,2H,J=7.1Hz,-CH 2-CH3),2.44(t,2H,J=7.4Hz,N(CH2)2-CH 2-CN),2.06-2.04(m,2H,-NCH2-CH 2-CH2CN),1.32(t,3H,J=7.1Hz,-CH2-CH 3)。13C NMR(150MHz,DMSO-d6)δ166.9×2,136.6,136.3,133.6,133.5,128.8,127.8,125.8,125.7,122.9,122.8,122.3,122.2,120.8,120.7,120.4,111.1,111.0,105.2,104.7,55.5,40.4,26.1,15.7,14.3.ESI-MS m/z424.2[M+H]+.
Iii) preparation of 2- (1-ethyl-3-indole) -3- (1-cyanopropyl-3-indole) maleimide (3)
According to the preparation of compound 1, from 3c (205mg,0.49mmol), HMDS (10.2mL,48.5mmol) and MeOH (0.97mL,24.3mmol), separation by silica gel column chromatography and elution with chloroform gave 203mg of orange-red powder (3) in 98% yield.1H NMR(600MHz,DMSO-d6)δ10.94(s,1H,imide-NH),7.78(s,1H,Ar-H),7.74(s,1H,Ar-H),7.50(d,1H,J=8.3Hz,Ar-H),7.47(d,1H,J=8.3Hz,Ar-H),7.07(dt,1H,J=7.1Hz,1.1Hz,Ar-H),7.05(dt,1H,J=7.1Hz,1.1Hz,Ar-H),6.86(d,1H,J=7.7Hz,Ar-H),6.85(d,1H,J=7.7Hz,Ar-H),6.71(t,1H,J=7.7Hz,Ar-H),6.69(t,1H,J=7.1Hz,Ar-H),4.29(t,2H,J=6.6Hz,N-CH 2-(CH2)2CN),4.24(q,2H,J=7.2Hz,-CH 2-CH3),2.40(t,2H,J=7.1Hz,N(CH2)2-CH 2-CN),2.05-2.03(m,2H,NCH2-CH 2-CH2CN),1.32(t,3H,J=7.2Hz,-CH2-CH 3).13C NMR(150MHz,DMSO-d6)δ173.4×2,136.4,136.1,132.4,132.2,128.5,127.6,126.3,126.2,122.4,122.3,122.0,121.9,120.5,120.3,120.0,110.7,110.6,105.9,105.3,45.0,41.2,26.2,15.8,14.3.HR-ESIMS m/z 421.1645[M–H]–(calcd.for C26H21N4O2,421.1665).
Preparation of Compound 4
According to the preparation of Compound 2, starting from Compound 3(6.3mg, 13.9. mu. mol), NaHCO3(2.3mg, 27.9. mu. mol) and a formaldehyde solution (3mL, mass fraction 37%) were subjected to silica gel column chromatography and eluted with petroleum ether (ethyl acetate: 3:1 (v/v)) to give 6.8mg of N-hydroxymethyl-2- (1-ethyl-3-indole) -3- (1-cyanopropyl-3-indole) maleimide (4) as a red powder in 99% yield.1H NMR(600MHz,CDCl3)δ7.74(s,1H,Ar-H),7.50(s,1H,Ar-H),7.33(d,1H,J=5.5Hz,Ar-H),7.32(d,1H,J=5.5Hz,Ar-H),7.17-7.15(m,2H,Ar-H),7.11(t,1H,J=7.3Hz,Ar-H),6.88(d,2H,J=7.3Hz,Ar-H),6.74(t,1H,J=7.3Hz,Ar-H),5.25(d,2H,J=7.8Hz,N-CH 2-OH),4.27(t,2H,J=6.4Hz,N-CH 2-(CH2)2CN),4.20(q,2H,J=7.3Hz,N-CH 2-CH3),3.15(brs,1H,-OH),2.17(t,2H,J=5.9Hz,N(CH2)2-CH 2-CN),2.13-2.11(m,2H,NCH2-CH 2-CH2CN),1.48(t,3H,J=7.3Hz,-CH2-CH 3).13C NMR(150MHz,CDCl3)δ171.8,171.7,136.2,136.1,131.7,131.2,128.5,126.4,126.3,125.9,122.9,122.8,122.4,122.3,120.7,120.2,118.6,109.9,109.3,106.7,105.5,61.9,44.8,41.6,25.9,15.3,14.6.ESI-MS m/z 475.1[M+Na]+.
Preparation of Compound 5
i) Preparation of 1-cyanobutylindole (5b)
According to the preparation method of the compound 1b, the compound is prepared from indole (585mg,5mmol), NaH (300mg,7.5mmol, mass fraction 60%, dispersed in paraffin) and 5-bromovaleronitrile (880. mu.L, 7.5mmol), and the colorless oily product (5b) is obtained by silica gel column chromatography and elution with petroleum ether, ethyl acetate: 10:1(v/v), 627mg with the yield of 83%.1H NMR(600MHz,DMSO-d6)δ7.68(d,1H,J=8.0Hz,Ar-H),7.35(d,1H,J=8.4Hz,Ar-H),7.26(t,1H,J=7.7Hz,Ar-H),7.16(t,1H,J=7.3Hz,Ar-H),7.12(d,1H,J=2.7Hz,Ar-H),6.58(d,1H,J=2.7Hz,Ar-H),4.17(t,2H,J=6.8Hz,N-CH 2-(CH2)3CN),2.26(t,2H,J=7.3Hz,N(CH2)3-CH 2-CN),1.98-1.93(m,2H,NCH2-CH 2-(CH2)2CN),1.61-1.54(m,2H,N(CH2)2-CH 2-CH2CN).13C NMR(150MHz,DMSO-d6)δ136.0,128.8,127.7,121.8,121.3,119.6,119.4,109.3,101.7,45.5,29.4,23.0,17.0.
ii) preparation of 2- (1-ethyl-3-indole) -3- (1-cyanobutyl-3-indole) maleic anhydride (5c)
According to the preparation of compound 1c from 5b (627mg,3.17mmol), oxalyl chloride (604mg,4.76mmol), compound 1a (644mg,3.17mmol) and triethylamine (640mg,6.34mmol), column on silica gelChromatography and elution with petroleum ether and ethyl acetate 2:1(v/v) gave 712mg of red powder (5c) in 51% yield.1H NMR(600MHz,DMSO-d6)δ7.91(s,1H,Ar-H),7.90(s,1H,Ar-H),7.56(d,1H,J=8.3Hz,Ar-H),7.53(d,1H,J=8.3Hz,Ar-H),7.11(dt,1H,J=7.5Hz,1.0Hz,Ar-H),7.10(dt,1H,J=7.8Hz,0.9Hz,Ar-H),6.88(d,1H,J=8.3Hz,Ar-H),6.86(d,1H,J=8.7Hz,Ar-H),6.76(dt,1H,J=7.8Hz,1.0Hz,Ar-H),6.75(dt,1H,J=7.4Hz,0.9Hz,Ar-H),4.30(t,2H,J=6.9Hz,N-CH 2-(CH2)3CN),4.28(q,2H,J=7.3Hz,N-CH 2-CH3),2.51(t,2H,J=7.3Hz,N(CH2)3-CH 2-CN),1.84-1.81(m,2H,NCH2-CH 2-(CH2)2CN),1.50-1.48(m,2H,N(CH2)2-CH 2-CH2CN),1.34(t,3H,J=7.3Hz,-CH2-CH 3).13C NMR(150MHz,DMSO-d6)δ166.9×2,136.5,136.3,133.7,133.3,128.5,127.9,125.9×2,122.8,122.7,122.1×2,121.0,120.7,120.6,111.2,111.1,104.9,104.8,45.7,41.5,29.3,22.7,16.4,15.7.ESI-MS m/z 438.1[M+H]+.
Iii) preparation of 2- (1-ethyl-3-indole) -3- (1-cyanobutyl-3-indole) maleimide (5)
Prepared from 5c (616mg,1.14mmol), HMDS (12mL,57mmol) and MeOH (1.14mL,28.5mmol) by the method for preparing compound 1, and subjected to silica gel column chromatography and chloroform elution to give orange-red powder (5)585mg, with a yield of 95%.1H NMR(600MHz,DMSO-d6)δ10.92(s,1H,imide-NH),7.80(s,1H,Ar-H),7.77(s,1H,Ar-H),7.50(d,1H,J=8.2Hz,Ar-H),7.47(d,1H,J=8.2Hz,Ar-H),7.04(dt,1H,J=7.4Hz,0.9Hz,Ar-H),7.03(dt,1H,J=7.8Hz,1.0Hz,Ar-H),6.81(d,1H,J=8.2Hz,Ar-H),6.79(d,1H,J=7.8Hz,Ar-H),6.67(dt,1H,J=7.4Hz,0.9Hz,Ar-H),6.65(dt,1H,J=7.8Hz,1.0Hz,Ar-H),4.28(t,2H,J=6.8Hz,N-CH 2-(CH2)3CN),4.26(q,2H,J=7.3Hz,N-CH 2-CH3),2.52(t,2H,J=7.3Hz,N(CH2)3-CH 2-CN),1.82-1.79(m,2H,NCH2-CH 2-(CH2)2CN),1.50-1.47(m,2H,N(CH2)2-CH 2-CH2CN),1.34(t,3H,J=7.3Hz,-CH2CH 3).13C NMR(150MHz,DMSO-d6)δ173.4×2,136.3,136.0,132.4,132.0,128.8,128.2×2,127.7,126.4,122.3,122.2 121.8,121.0×2,120.0,110.8,110.7,105.6,105.4,45.5,41.3,29.3,22.7,16.4,15.8.ESI-MS m/z 437.1[M+H]+.
Preparation of Compound 6
According to the preparation of Compound 2, starting from Compound 5(6.7mg, 14.4. mu. mol), NaHCO3(2.4mg, 28.8. mu. mol) and formaldehyde solution (3mL, mass fraction 37%) were subjected to silica gel column chromatography and eluted with petroleum ether and ethyl acetate (5: 2) (v/v) to give 6.9mg of N-hydroxymethyl-2- (1-ethyl-3-indole) -3- (1-cyanobutyl-3-indole) maleimide (6) as a red powder in 96% yield.1H NMR(600MHz,CDCl3)δ7.70(s,1H,Ar-H),7.55(s,1H,Ar-H),7.32(d,1H,J=8.2Hz,Ar-H),7.27(d,1H,J=8.3Hz,Ar-H),7.13(dt,1H,J=7.8Hz,1.0Hz,Ar-H),7.11(dt,1H,J=7.8Hz,1.0Hz,Ar-H),7.06(d,1H,J=7.8Hz,Ar-H),6.91(d,1H,J=7.8Hz,Ar-H),6.81(d,1H,J=7.8Hz,Ar-H),6.74(d,1H,J=7.8Hz,Ar-H),5.25(d,2H,J=7.8Hz,N-CH 2-OH),4.19(q,2H,J=7.3Hz,N-CH 2-CH3),4.15(t,2H,J=6.4Hz,N-CH 2-(CH2)3CN),3.34(t,1H,J=7.8Hz,-OH),2.27(t,2H,J=6.8Hz,N(CH2)3-CH 2-CN),1.90-1.94(m,2H,NCH2-CH 2-(CH2)2CN),1.57-1.51(m,2H,N(CH2)2-CH 2-CH2CN),1.47(t,3H,J=7.3Hz,-CH2-CH 3).13C NMR(150MHz,CDCl3)δ171.9×2,136.1×2,131.5×2,127.9,126.7,126.3,126.0,122.7,122.6,122.5,122.3,120.5,120.2,119.2,109.7,109.5,106.2,105.6,61.8,45.8,41.6,29.0,22.8,17.0,15.2.ESI-MS m/z489.1[M+Na]+.
Preparation of Compound 7
i) Preparation of 1-cyanomethyl-3-indoleacetic acid (7a)
Adding hydrogen in a 100mL three-neck bottle under the protection of argonDissolving sodium chloride (1028mg,25.7mmol, 60% by mass, dispersed in paraffin) in 40mL of DMF, stirring and suspending at-5 deg.C, adding 10mL of 3-indoleacetic acid (900mg,5.14mmol) dissolved in DMF, stirring for 30min, adding dropwise bromoacetonitrile (1.03mL,15.4mmol) dissolved in 10mL of DMF, slowly heating to room temperature, reacting overnight, cooling to below 0 deg.C, adding 10mL of methanol dropwise, adding appropriate amount of water to obtain bright yellow solution, extracting with 30mL of diethyl ether to remove paraffin oil, acidifying water layer with 6N hydrochloric acid to weak acidity, extracting with ethyl acetate (100mL × 3 times), combining ethyl acetate layers, and anhydrous Na2SO4Drying, vacuum evaporating, separating with Sephadex LH-20 gel column chromatography, and eluting with methanol to obtain white crystal (7a)314mg with yield of 29%.1H NMR(600MHz,DMSO-d6)δ12.33(s,1H,-CO2 H),7.58(d,1H,J=8.3Hz,Ar-H),7.56(d,1H,J=8.2Hz,Ar-H),7.36(s,1H,Ar-H),7.26(dt,1H,J=7.8Hz,1.0Hz,Ar-H),7.13(dt,1H,J=7.4Hz,0.9Hz,Ar-H),5.52(s,2H,-C 2H-CN),3.69(s,2H,-C 2H-CO2H).13C NMR(150MHz,DMSO-d6)δ173.4,136.3,128.7,127.6,122.8,120.4,119.9,117.2,110.3,110.2,34.2,31.1.
ii) preparation of 2, 3-bis (1-cyanomethyl-3-indole) maleic anhydride (7b)
According to the preparation method of the compound 1c, the compound was prepared from the compound 1b (226mg,1.45mmol), oxalyl chloride (274mg,2.18mmol), the compound 7a (310mg,1.45mmol) and triethylamine (293mg,2.9mmol) as starting materials, and the product was separated by silica gel column chromatography and eluted with ethyl acetate 3:1(v/v) as petroleum ether to give 235mg of red powder (7b) with a yield of 40%.1H NMR(600MHz,DMSO-d6)δ8.05(s,2H,Ar-H),7.64(d,2H,J=8.3Hz,Ar-H),7.22(dt,2H,J=7.6Hz,1.2Hz,Ar-H),6.89(d,2H,J=7.9Hz,Ar-H),6.84(dt,2H,J=7.9Hz,0.8Hz,Ar-H),5.69(s,4H,-C 2H-CN).13C NMR(150MHz,DMSO-d6)δ166.0×2,135.6×2,132.9×2,128.6×2,125.5×2,123.2×2,121.6×2,121.1×2,115.9×2,110.4×2,105.8×2,34.2×2.ESI-MS m/z 407.2[M+H]+.
iii) preparation of 2, 3-bis (1-cyanomethyl-3-indole) maleimide (7)
According to the preparation of Compound 1, starting from Compound 7b (200mg, 0.49)mmol), HMDS (4.1mL,19.6mmol) and MeOH (0.39mL,9.8mmol) were prepared and chromatographed on silica gel with petroleum ether, ethyl acetate ═ 2:1(v/v) to give 183mg of orange-red powder (7), 92% yield.1H NMR(600MHz,DMSO-d6)δ11.10(s,1H,imide-NH),7.94(s,2H,Ar-H),7.58(d,2H,J=8.3Hz,Ar-H),7.15(dt,2H,J=7.4Hz,1.1Hz,Ar-H),6.82(d,2H,J=8.0Hz,Ar-H),6.75(dt,2H,J=7.0Hz,0.8Hz,Ar-H),5.65(s,4H,-C 2H-CN).13C NMR(150MHz,DMSO-d6)δ172.4×2,135.5×2,131.8×2,127.8×2,126.1×2,122.7×2,121.3×2,120.6×2,116.1×2,110.1×2,106.5×2,34.1×2.ESI-MS m/z406.1[M+H]+.
Preparation of Compound 8
i) Preparation of 1-cyanopropyl-3-indoleacetic acid (8a)
According to the preparation method of the compound 7a, indole acetic acid (1.4g,8mmol), NaH (1.6g,40mmol, mass fraction 60%, dispersed in paraffin) and bromobutyronitrile (2.4mL,24mmol) were used as raw materials, and separated by silica gel column chromatography and eluted with ethyl acetate ═ 3:1(v/v) to obtain 541mg of white crystals (8a) with a yield of 30%.1H NMR(600MHz,DMSO-d6)δ7.54(d,1H,J=7.3Hz,Ar-H),7.42(d,1H,J=7.7Hz,Ar-H),7.22(s,1H,Ar-H),7.12(t,1H,J=7.3Hz,Ar-H),7.00(1H,t,J=7.3Hz,Ar-H),4.17(t,2H,J=6.9Hz,N-C 2H-(CH2)2CN),3.53(s,2H,-C 2H-CO2H),2.43(t,2H,J=6.9Hz,N(CH2)2-C 2H-CN),2.03-2.01(2H,m,NCH2-C 2H-CH2CN).13C NMR(150MHz,DMSO-d6)δ175.0,136.3,128.6,127.2,121.6,120.7,119.9,119.0,110.4,109.8,44.5,33.2,26.4,14.4.ESI-MS m/z 241.1[M–H]–.
ii) preparation of 2, 3-bis (1-cyanopropyl-3-indole) maleic anhydride (8b)
According to the method for producing compound 1c, compound 3b (452mg,2.46mmol), oxalyl chloride (469mg,3.69mmol), compound 8a (595mg,2.46mmol) and triethylamine (497mg,4.92mmol) were prepared as starting materials, and separated by silica gel column chromatography and eluted with ethyl acetate 1:1(v/v) as petroleum ether to give 500mg of red powder (8b) in 44% yield1H NMR(600MHz,DMSO-d6)δ7.88(s,2H,Ar-H),7.57(d,2H,J=8.4Hz,Ar-H),7.14(dt,2H,J=7.8Hz,0.9Hz,Ar-H),6.95(d,2H,J=8.4Hz,Ar-H),6.81(dt,2H,J=7.8Hz,0.9Hz,Ar-H),4.30(t,4H,J=6.9Hz,N-C 2H-(CH2)2CN),2.42(t,4H,J=7.3Hz,N(CH2)2-C 2H-CN),2.05-2.02(m,4H,NCH2-C 2H-CH2CN).13C NMR(150MHz,DMSO-d6)δ166.8×2,136.6×2,133.7×2,128.5×2,125.7×2,123.0×2,122.2×2,120.8×2,120.4×2,111.1×2,105.1×2,45.3×2,26.1×2,14.3×2.ESI-MS m/z 463.2[M+H]+.
iii) preparation of 2, 3-bis (1-cyanopropyl-3-indole) maleimide (8)
According to the preparation of compound 1, from compound 8b (375mg,0.81mmol), HMDS (6.8mL,32.5mmol) and MeOH (0.66mL,16.2mmol), separation was performed by silica gel column chromatography eluting with petroleum ether, ethyl acetate ═ 2:1(v/v) to give 341mg of orange-red powder (8), 91% yield.1H NMR(600MHz,DMSO-d6)δ10.98(s,1H,imide-NH),7.76(s,2H,Ar-H),7.50(d,2H,J=8.2Hz,Ar-H),7.08(dt,2H,J=7.8Hz,0.9Hz,Ar-H),6.90(d,2H,J=8.2Hz,Ar-H),6.73(dt,2H,J=7.4Hz,0.9Hz,Ar-H),4.28(t,4H,J=6.9Hz,N-C 2H-(CH2)2CN),2.38(4H,t,J=7.3Hz,N(CH2)2-C 2H-CN),2.04-2.02(m,4H,NCH2-C 2H-CH2CN).13C NMR(150MHz,DMSO-d6)δ173.3×2,136.4×2,132.5×2,128.2×2,126.2×2,122.5×2,121.9×2,120.5×2,120.2×2,110.7×2,105.8×2,45.0×2,26.1×2,14.3×2.HR-ESIMS m/z 460.1769[M–H]–(calcd.for C28H22N5O2,460.1774).
Preparation of Compound 9
i) Preparation of 1-cyanobutylindole-3-acetic acid (9a)
According to the preparation method of the compound 7a, indole acetic acid (1.4g,8mmol), NaH (1.6g,40mmol, 60% dispersed in paraffin) and bromovaleronitrile (2mL,16mmol) are used as raw materials, and white ether is obtained by silica gel column chromatography separation and elution of ethyl acetate ═ 3:1(v/v)1.69g of colored crystal (9a) was obtained, yield 83%.1H NMR(600MHz,DMSO-d6)δ12.30(s,1H,-CO2 H),7.59(d,1H,J=7.8Hz,Ar-H),7.45(d,1H,J=8.2Hz,Ar-H),7.27(s,1H,Ar-H),7.18(dt,1H,J=7.8Hz,0.9Hz,Ar-H),7.08(dt,1H,J=7.8Hz,0.9Hz,Ar-H),4.13(t,2H,J=6.9Hz,N-C 2H-(CH2)3CN),3.72(s,2H,-C 2H-CO2H),2.44(t,2H,J=6.9Hz,N(CH2)3-C 2H-CN),1.81-1.79(m,2H,NCH2-C 2H-(CH2)2CN),1.51-1.48(m,2H,N(CH2)2-C 2H-CH2CN).13C NMR(150MHz,DMSO-d6)δ173.7,136.4,128.2,127.7,121.8,121.0,119.6,119.2,110.2,107.9,45.1,31.4,29.6,22.8,16.3.ESI-MS m/z 255.1[M–H]–.
ii) preparation of 2, 3-bis (1-cyanobutyl-3-indole) maleic anhydride (9b)
According to the preparation method of the compound 1c, the compound 5b (1140mg,5.76mmol), oxalyl chloride (1097mg,8.64mmol), the compound 9a (1470mg,5.76mmol) and triethylamine (1163mg,11.5mmol) were used as raw materials, and the raw materials were separated by silica gel column chromatography and eluted with ethyl acetate 2:1(v/v) to obtain the product, i.e., 900mg of red powder (9b), with a yield of 32%.1H NMR(600MHz,DMSO-d6)δ7.93(s,2H,Ar-H),7.55(d,2H,J=8.3Hz,Ar-H),7.09(t,2H,J=7.3Hz,Ar-H),6.83(d,2H,J=8.3Hz,Ar-H),6.73(2H,t,J=7.4Hz,Ar-H),4.32(t,4H,J=6.9Hz,N-C 2H-(CH2)3CN),2.52(t,4H,J=7.3Hz,N(CH2)3-C 2H-CN),1.85-1.83(m,4H,NCH2-CH 2-(CH2)2CN),1.51-1.48(m,4H,N(CH2)2-C 2H-CH2CN).13C NMR(150MHz,DMSO-d6)δ166.9×2,136.4×2,133.6×2,128.3×2,126.0×2,122.8×2,121.9×2,121.0×2,120.6×2,111.2×2,104.9×2,45.7×2,29.3×2,22.7×2,16.4×2.ESI-MS m/z 491.2[M+H]+.
iii) preparation of 2, 3-bis (1-cyanobutyl-3-indole) maleimide (9)
According to chemical combinationThe preparation of substance 1 was carried out using compound 9b (470mg,0.96mmol), HMDS (8.1mL,38.4mmol) and MeOH (0.77mL,19.2mmol) as starting materials, and separation by silica gel column chromatography eluting with petroleum ether and ethyl acetate 3:2(v/v) gave 426mg of orange-red powder (9) in 90% yield.1H NMR(600MHz,DMSO-d6)δ10.93(s,1H,imide-NH),7.80(s,2H,Ar-H),7.48(d,2H,J=8.2Hz,Ar-H),7.02(dt,2H,J=7.8Hz,1.0Hz,Ar-H),6.77(d,2H,J=8.2Hz,Ar-H),6.63(dt,2H,J=7.4Hz,0.9Hz,Ar-H),4.29(t,4H,J=6.9Hz,N-CH 2-(CH2)3CN),2.51(t,4H,J=7.3Hz,N(CH2)3-C 2H-CN),1.83-1.81(m,4H,NCH2-CH 2-(CH2)2CN),1.50-1.48(m,4H,N(CH2)2-C 2H-CH2CN).13C NMR(150MHz,DMSO-d6)δ173.4×2,136.3×2,132.4×2,128.0×2,126.5×2,122.3×2,121.6×2,121.0×2,120.0×2,110.8×2,105.6×2,45.5×2,29.3×2,22.7×2,16.3×2.ESI-MS m/z 488.2[M–H]–.
Preparation of Compound 10
In a 25mL single-neck flask, compound 1(50mg,0.127mmol) was dissolved in a mixture of 10mL acetic acid and concentrated hydrochloric acid ═ 3:1(v/v), refluxed at 120 ℃ for 30min, cooled to room temperature, extracted with water and ethyl acetate, the organic layer was evaporated to dryness, separated by silica gel column chromatography, and eluted with dichloromethane to give 50mg of 2- (1-ethyl-3-indole) -3- (1-carboxymethyl-3-indole) maleimide (10) as a red solid in 95% yield.1H NMR(600MHz,DMSO-d6)δ10.97(brs,1H,imide-NH),7.88(s,1H,Ar-H),7.66(s,1H,Ar-H),7.45(d,1H,J=8.2Hz,Ar-H),7.32(d,1H,J=8.2Hz,Ar-H),7.04(t,1H,J=7.1Hz,Ar-H),7.02(d,1H,J=8.2Hz,Ar-H),6.97(t,1H,J=8.2Hz,Ar-H),6.72(t,1H,J=7.1Hz,Ar-H),6.60(d,1H,J=7.7Hz,Ar-H),6.58(t,1H,J=7.7Hz,Ar-H),4.86(s,2H,-C 2H-CO2H),4.21(q,2H,J=7.2Hz,-C 2H-CH3),1.27(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ173.6,173.5,172.2,137.2,135.9,134.2,131.7,128.1,127.2,126.9,126.0,122.2,122.1,122.0,121.7,120.1,119.9,111.0,110.5,105.6,105.2,49.9,41.1,15.8.ESI-MS m/z 412.0[M–H]–.
Preparation of Compound 11
Suspending NaH (68mg,1.7mmol, 60% by mass in paraffin) in 10mL of DMF in a 50mL two-necked flask, adding 10mL of DMF-dissolved compound 1(200mg,0.56mmol) at 5 ℃ under stirring, reacting at low temperature for 30min, slowly adding bromoacetonitrile (114. mu.L, 1.7mmol) dropwise, and reacting at low temperature for 30 min. Saturated NH is added dropwise4The reaction was terminated with Cl solution, extracted with ethyl acetate, the organic layer was concentrated, chromatographed on a gel column, eluted with methanol to give N-cyanomethyl-2- (1-ethyl-3-indole) -3- (1-cyanomethyl-3-indole) maleimide (11) as a red solid powder in 161mg, 66% yield.1H NMR(600MHz,DMSO-d6)δ7.93(s,1H,Ar-H),7.89(s,1H,Ar-H),7.60(d,1H,J=8.2Hz,Ar-H),7.50(d,1H,J=8.2Hz,Ar-H),7.18(t,1H,J=7.1Hz,Ar-H),7.08(t,1H,J=7.2Hz,Ar-H),6.86(d,1H,J=8.2Hz,Ar-H),6.85(d,1H,J=8.3Hz,Ar-H),6.79(t,1H,J=7.1Hz,Ar-H),6.72(t,1H,J=7.7Hz,Ar-H),5.66(s,2H,N-C 2H-CN),4.75(s,2H,N-C 2H-CN),4.27(q,2H,J=7.1Hz,-C 2H-CH3),1.33(t,3H,J=7.1Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ170.3,170.2,136.2×2,133.0,132.3,129.5,126.4,126.3,125.9,123.4,122.6,122.1,121.9,121.2,120.5,116.7,116.3,110.9,110.8,107.1,105.1,41.4,34.7,26.4,15.7.ESI-MS m/z 434.1[M+H]+.
Preparation of Compound 12
According to the preparation method of the compound 10, using the compound 11(50mg,0.12mmol) as a starting material, separation by silica gel column chromatography and elution with dichloromethane and methanol at a ratio of 5:1(v/v) gave 48mg of N-carboxymethyl-2- (1-ethyl-3-indole) -3- (1-carboxymethyl-3-indole) maleimide (12) as a red solid in 85% yield.1H NMR(600MHz,DMSO-d6)δ7.93(s,1H,Ar-H),7.80(s,1H,Ar-H),7.47(d,1H,J=8.3Hz,Ar-H),7.38(d,1H,J=8.2Hz,Ar-H),7.05(t,1H,J=7.7Hz,Ar-H),7.02(t,1H,J=7.1Hz,Ar-H),6.96(d,1H,J=7.7Hz,Ar-H),6.72(t,1H,J=7.7Hz,Ar-H),6.70(d,1H,J=8.2Hz,Ar-H),6.65(t,1H,J=7.1Hz,Ar-H),5.13(s,2H,N-C 2H-CO2H),4.29(s,2H,-C 2H-CO2H),4.25(q,2H,J=7.1Hz,-C 2H-CH3),1.32(t,3H,J=7.1Hz,-CH2-CH 3).13C NMR(150MHz,DMSO-d6)δ171.6,171.5,170.5,170.0,137.2,136.0,134.0,132.2,127.6,126.9,126.6,126.1,122.5,122.4,122.1,121.7,120.4,120.3,110.9,110.7,105.8,105.4,48.1,41.3,39.9,15.7.ESI-MS m/z 470.0[M–H]–.
Preparation of Compound 13
i) Preparation of 1,2,3,4, 6-D-glucopyranose pentaacetate (13a)
Glucose (2g,11.1mmol), anhydrous sodium acetate (2.5g,30.5mmol) and acetic anhydride (12.5 mL) are added into a 100mL single-neck bottle, reflux is carried out at 110 ℃, the reaction solution is poured into 100g of crushed ice while the solution is hot, a large amount of white solid is generated by stirring, suction filtration is carried out after the ice is melted, and the filter cake is recrystallized by absolute ethyl alcohol to obtain 4.1g of white powder (13a), wherein the yield is 95%. ESI-MS M/z 391.1[ M + H ]]+.
ii) preparation of 2,3,4, 6-O-tetraacetyl-D-glucopyranose (13b)
In N2Under protection, 13a (525mg,1.35mmol) is dissolved in 10mL of anhydrous THF in a 50mL two-mouth bottle, benzylamine (0.22mL,2.02mmol) is added dropwise at 5 ℃, the temperature is slowly raised to room temperature, the reaction is carried out overnight, the TLC detection shows that the reaction is complete, the vacuum evaporation is carried out, silica gel column chromatography is carried out, and the white solid (13b)441mg is obtained by eluting petroleum ether and ethyl acetate which are 3:1(v/v), and the yield is 94%. ESI-MS M/z 349.2[ M + H ]]+.
iii) preparation of 2,3,4, 6-O-tetraacetyl-D-glucopyranosyl trichloroacetic acid imino ester (13c)
In a two-necked bottle, N2Under protection, use 5mL CH2Cl2Dissolving 13b (390mg,1.12mmol), dropwise adding trichloroacetonitrile (1.35mL,13.45mmol) at the temperature of 5 ℃, dropwise adding a catalytic amount of DBU, changing the reaction solution from light yellow to light yellow, reacting for 30min, evaporating to dryness in vacuum, separating by silica gel column chromatography, and eluting with petroleum ether and ethyl acetate (4: 1 (v/v)) to obtain 381mg of milky white solid (13c) with the yield of 70%. ESI-MS M/z 492.0[ M + H ]]+.
iv) O-2- (1-ethyl-3-indole) -3- (1-cyanoethyl-3-indole) maleimide-2, 3,4, 6-O-tetraacetyl-alpha-D-glucopyranoside (13D)
After pumping compound 13c (10mg, 22.8. mu. mol) and compound 4(7.5mg, 16.5. mu. mol) to dryness with an air pump, they were put into a 15mL two-necked bottle and pumped out in a desiccator for 3 hours. Drying molecular sieve with muffle furnace, pulverizing, burning the powder with alcohol burner for 30min, cooling with air pump, adding about 200mg into reaction flask, adding 5mL dry CH2Cl2Air pump for exchanging N2Three times, cooling to-20 deg.C, reacting for 20min, and dripping 2 μ L BF3·Et2And O, immediately changing the color from red to purple, then returning to red, raising the temperature to room temperature and reacting for 10 hours, wherein the reaction is complete. Cooling to-5 deg.C, adding 10mg NaHCO3The reaction was terminated, suction filtered, the solvent evaporated and separated by gel column chromatography eluting with dichloromethane to methanol 1:1(v/v) to give 16.7mg of red solid (13d) in 95% yield.1H NMR(600MHz,CDCl3)δ7.79(s,1H,Ar-H),7.61(s,1H,Ar-H),7.31(d,1H,J=8.2Hz,Ar-H),7.30(d,1H,J=8.2Hz,Ar-H),7.17(t,1H,J=8.3Hz,Ar-H),7.11(t,1H,J=8.2Hz,Ar-H),7.08(d,1H,J=8.2Hz,Ar-H),6.86(d,1H,J=7.3Hz,Ar-H),6.85(t,1H,J=7.3Hz,Ar-H),6.77(t,1H,J=7.3Hz,Ar-H),5.36/5.28(d,2H,J=11.5Hz,N-C 2H-O),5.19(t,1H,J=10.0Hz,Glc-C3-H),5.10(t,1H,J=10.0Hz,Glc-C2-H),5.00(t,1H,J=10.0Hz,Glc-C4-H),4.86(d,1H,J=8.2Hz,Glc-C1-H),4.46(t,2H,J=7.3Hz,N-C 2H-CH2CN),4.21(q,2H,J=7.3Hz,N-C 2H-CH3),4.18/4.03(dd,2H,J=12.4Hz,2.8Hz,Glc-C6- 2H),3.70(dt,1H,J=10.1Hz,3.7Hz,Glc-C5-H),2.82(t,2H,J=7.3Hz,NCH2-C 2H-CN),1.94(s,12H,4-COC 3H),1.49(t,3H,J=7.3Hz,-CH2-C 3H).13C NMR(150MHz,CDCl3)δ171.4,171.3,170.8,170.4,169.5,169.4,136.2,135.5,131.9,130.9,129.0,126.5,125.9,125.8,123.2,122.8,122.5,122.4,121.0,120.5,116.8,109.8,109.0,107.3,105.5,100.0,73.0,72.1,71.2,68.1,66.2,61.6,42.4,41.6,20.8,20.7,20.6,20.6,19.0,15.3.ESI-MS m/z 791.4[M+Na]+.
v) preparation of O-2- (1-ethyl-3-indole) -3- (1-cyanoethyl-3-indole) maleimide-alpha-D-glucopyranoside (13)
In a single-neck flask, sample 13d was treated with 1mL CH2Cl2Dissolving, adding 4mL of anhydrous methanol, dropwise adding NaOMe/MeOH while stirring at 0 ℃ until the pH is 9-10, heating to room temperature for reaction for 30min, detecting by TLC that no raw material remains, and adding saturated NH at 0 DEG4The reaction was stopped with Cl solution. Extracting with ethyl acetate, evaporating to dryness, separating with gel column chromatography, and eluting with methanol to obtain red solid (13)13mg with yield of 100%.1H NMR(600MHz,DMSO-d6)δ7.94(s,1H,Ar-H),7.87(s,1H,Ar-H),7.60(d,1H,J=8.2Hz,Ar-H),7.48(d,1H,J=8.2Hz,Ar-H),7.06(t,1H,J=7.8Hz,Ar-H),7.04(t,1H,J=7.3Hz,Ar-H),6.82(d,1H,J=7.8Hz,Ar-H),6.78(d,1H,J=8.3Hz,Ar-H),6.68(t,2H,J=7.8Hz,Ar-H),5.20/5.14(d,2H,J=11.0Hz,N-C 2H-O),5.10(d,1H,J=5.5Hz,Glc-C1-H),4.99(d,1H,J=3.7Hz,Glc-C2-OH),4.92(d,1H,J=3.7Hz,Glc-C3-OH),4.60(t,2H,J=6.7Hz,N-C 2H-CH2CN),4.47(t,1H,J=6.0Hz,Glc-C6-OH),4.41(d,1H,J=8.2Hz,Glc-C4-OH),4.27(q,2H,J=7.3Hz,N-C 2H-CH3),3.62(m,1H,Glc-C2-H),3.48(m,1H,Glc-C3-H),3.11(m,2H,Glc-C6- 2H),3.09(m,1H,Glc-C4-H),3.04(t,2H,J=6.7Hz,NCH2-C 2H-CN),2.95(m,1H,Glc-C5-H),1.34(t,3H,J=7.3Hz,N-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ171.5,171.4,136.1,136.0,132.5,132.4,128.4,126.7,126.4,126.3,122.6,122.4,122.0,121.8,120.5,120.4,119.0,110.9,110.7,106.2,105.3,103.0,77.6,77.3,73.8,70.2,66.2,61.4,41.9,41.3,19.1,15.8.HR-ESIMS m/z 623.2139[M+Na]+(C33H35N4O8Na,623.2118).
Preparation of Compound 14
Dissolving 1c (20mg,50.6 μmol) in 2mL of DMF, adding 0.5mL of ethylenediamine while stirring, reacting at room temperature overnight, adding an appropriate amount of water, extracting with ethyl acetate, evaporating the organic layer to dryness, separating by silica gel column chromatography, and eluting with dichloromethane and methanol at a ratio of 10:1(v/v) to obtain 22mg of N- (2-aminoethyl) -2- (1-ethyl-3-indole) -3- (1-cyanomethyl-3-indole) maleimide (14) as an orange red powder in a yield of 99%.1H NMR(600MHz,DMSO-d6)δ7.89(s,1H,Ar-H),7.84(s,1H,Ar-H),7.60(d,1H,J=8.2Hz,Ar-H),7.49(d,1H,J=8.2Hz,Ar-H),7.17(t,1H,J=7.8Hz,Ar-H),7.07(t,1H,J=7.4Hz,Ar-H),6.88(d,1H,J=7.8Hz,Ar-H),6.86(d,1H,J=7.6Hz,Ar-H),6.78(t,1H,J=7.4Hz,Ar-H),6.71(t,1H,J=7.6Hz,Ar-H),5.67(s,2H,-C 2H-CN),4.26(q,2H,J=7.3Hz,N-C 2H-CH3),3.71(t,2H,J=6.2Hz,N-C 2H-CH2-NH2),2.94(t,2H,J=6.2Hz,N-CH2-C 2H-NH2),1.32(t,3H,J=7.3Hz,N-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ171.9×2,136.0,135.9,132.4,132.0,129.0,126.4,126.2,125.7,123.1,122.4,122.1,121.9,121.0,120.2,116.7,110.7,110.6,107.3,105.2,41.2,40.0,39.0,34.6,15.7.ESI-MS m/z 438.1[M+H]+.
Preparation of Compound 15
According to the preparation method of compound 14, compound 2c (60mg,146.7 μmol) was used as a starting material, and subjected to silica gel column chromatography and eluted with dichloromethane methanol 10:1(v/v) to give N- (2-aminoethyl) -2- (1-ethyl-3-indole) -3- (1-cyanoethyl-3-indole) maleimide (15) as a red crystal in a yield of 100% 74.5 mg.1H NMR(600MHz,DMSO-d6)δ7.89(s,1H,Ar-H),7.82(s,1H,Ar-H),7.60(d,1H,J=8.3Hz,Ar-H),7.48(d,1H,J=8.3Hz,Ar-H),7.07(t,1H,J=7.8Hz,Ar-H),7.05(t,1H,J=7.3Hz,Ar-H),6.87(d,1H,J=8.0Hz,Ar-H),6.83(d,1H,J=8.0Hz,Ar-H),6.70(t,1H,J=7.3Hz,Ar-H),6.69(t,1H,J=7.8Hz,Ar-H),4.59(t,2H,J=6.4Hz-C 2H-CH2-CN),4.27(q,2H,J=7.2Hz,N-C 2H-CH3),3.76(t,2H,J=6.1Hz,N-C 2H-CH2-NH2),3.03(t,2H,J=6.1Hz,N-CH2-C 2H-NH2),3.00(t,2H,J=6.4Hz,-C 2H-CN),1.33(t,3H,J=7.2Hz,N-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ171.4,171.3,135.5,135.4,131.5,131.4,127.7,126.4,125.9,125.8,121.9,121.7,121.5,121.2,119.7,119.6,118.3,110.2,110.0,105.7,104.9,41.3,40.6,38.5,37.4,18.4,15.1.ESI-MS m/z 452.3[M+H]+.
Preparation of Compound 16
Dissolving the compound 15(20mg,0.044mmol) in a 4N hydrochloric acid/ethyl acetate solution, stirring at room temperature for 6h, evaporating the solvent to dryness, freeze-drying for 5h, and recrystallizing with anhydrous ethanol/petroleum ether (v/v,5:1) to obtain a deep red crystal N- (2-aminoethyl) -2- (1-ethyl-3-indole) -3- (1-cyanoethyl-3-indole) maleimide hydrochloride (16)17mg, with a yield of 79.2%.1H NMR(600MHz,DMSO-d6)δ8.15(brs,3H,-NH3 +),7.92(s,1H,Ar-H),7.85(s,1H,Ar-H),7.65(d,1H,J=8.0Hz,Ar-H),7.52(d,1H,J=8.0Hz,Ar-H),7.07(t,1H,J=7.8Hz,Ar-H),7.15(t,1H,J=7.6Hz,Ar-H),6.89(d,1H,J=8.0Hz,Ar-H),6.81(d,1H,J=8.0Hz,Ar-H),6.72(t,1H,J=7.3Hz,Ar-H),6.70(t,1H,J=7.8Hz,Ar-H),4.58(t,2H,J=6.4Hz N-C 2H-CH2CN),4.27(q,2H,J=7.2Hz,N-C 2H-CH3),3.96(t,2H,J=6.2Hz,N-C 2H-CH2-NH3 +),3.73(t,2H,J=6.2Hz,N-CH2-C 2H-NH3 +),3.01(t,2H,J=6.4Hz,NCH2-C 2H-CN),1.32(t,3H,J=7.2Hz,N-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ171.4,171.2,135.6,135.4,131.5,131.3,127.7,127.4,125.9,125.8,121.9,121.6,121.5,121.2,119.7,119.5,118.3,110.2,110.1,105.7,104.7,45.3,42.6,38.5,37.4,18.4,15.1.ESI-MS m/z 452.2[M–Cl]+.
Preparation of Compound 17
According to the preparation method of compound 14, using compound 3c (24mg,56.7 μmol) and ethylenediamine as starting materials, silica gel column chromatography and dichloromethane/methanol 10:1(v/v) as eluent, 26mg of N- (2-aminoethyl) -2- (1-ethyl-3-indole) -3- (1-cyanopropyl-3-indole) maleimide (17) was obtained as a deep red solid, with a yield of 98%.1H NMR(600MHz,DMSO-d6)δ7.79(s,1H,Ar-H),7.76(s,1H,Ar-H),7.53(d,1H,J=8.3Hz,Ar-H),7.50(d,1H,J=8.3Hz,Ar-H),7.09(t,1H,J=8.5Hz,Ar-H),7.07(t,1H,J=8.5Hz,Ar-H),6.90(t,2H,J=7.9Hz,Ar-H),6.75(d,1H,J=7.4Hz,Ar-H),6.72(d,1H,J=7.4Hz,Ar-H),4.31(t,2H,J=6.7Hz,N-C 2H-(CH2)2CN),4.25(q,2H,J=7.2Hz,N-C 2H-CH3),3.76(t,2H,J=5.7Hz,N-C 2H-CH2-NH2),3.01(t,2H,J=5.7Hz,NCH2-C 2H-NH2),2.41(t,2H,J=7.2Hz,N(CH2)2-C 2H-CN),2.02(m,2H,NCH2-C 2H-CH2CN),1.31(t,3H,J=7.2Hz,N-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ171.5×2,135.9,135.6,131.9,131.8,127.4,126.4,125.6×2,122.0,121.8,121.6×2,120.0,119.8,119.6,110.3,110.2,105.4,104.9,44.5,40.7,38.5,37.2,25.6,15.2,13.7.HR-ESIMS m/z 466.2266[M+H]+(calcd.for C28H28N5O2,466.2243).
Preparation of Compound 18
According to the preparation method of compound 14, compound 4c (24mg,54.9 μmol) was used as a starting material, and subjected to silica gel column chromatography and eluted with dichloromethane and methanol at a ratio of 10:1(v/v) to give N- (2-aminoethyl) -2- (1-ethyl-3-indole) -3- (1-cyanobutyl-3-indole) maleimide (18) as a red solid in a yield of 30mg (100%).1H NMR(600MHz,DMSO-d6)δ7.82(s,1H,Ar-H),7.80(s,1H,Ar-H),7.51(d,1H,J=8.4Hz,Ar-H),7.47(d,1H,J=8.4Hz,Ar-H),7.05(t,1H,J=7.5Hz,Ar-H),7.04(t,1H,J=7.4Hz,Ar-H),6.83(d,1H,J=8.5Hz,Ar-H),6.82(d,1H,J=8.7Hz,Ar-H),6.68(t,1H,J=7.5Hz,Ar-H),6.66(t,1H,J=7.4Hz,Ar-H),4.30(t,2H,J=6.8Hz,N-C 2H-(CH2)3CN),4.26(q,2H,J=7.2Hz,N-C 2H-CH3),3.60(t,2H,J=6.4Hz,N-C 2H-CH2-NH2),2.82(t,2H,J=6.4Hz,N-CH2-C 2H-NH2),2.51(t,2H,J=7.2Hz,N(CH2)3-C 2H-CN),1.82(m,2H,NCH2-C 2H-(CH2)2CN),1.46(m,2H,N(CH2)2-C 2H-CH2CN),1.33(t,3H,J=7.2Hz,N-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ172.2×2,136.2,136.0,132.4,132.0,127.9,127.3,126.8,126.3,122.3,122.2,121.8,121.0,120.0,119.9,114.3,110.7,110.6,105.6,105.4,45.4,41.2,40.8,40.0,29.2,22.6,16.3,15.7.ESI-MS m/z 480.2[M+H]+.
Preparation of Compound 19
i) Preparation of N-t-butyloxycarbonylglycine (19a)
In a 15mL single-necked flask, add 4mL of 10% Na2CO3Dissolving glycine (1.0g,13mmol) in an aqueous solution, dripping Boc anhydride (2.84g,13mmol) dissolved in 2mL acetonitrile at 5 ℃, heating to room temperature after dripping, stirring overnight, filtering, extracting the filtrate with petroleum ether, discarding a petroleum ether layer, adjusting the water layer to acidity with hydrochloric acid, extracting with ethyl ester, drying, evaporating to dryness in vacuum, separating by silica gel column chromatography, and eluting with dichloromethane and methanol at 30:1(v/v) to obtain white needle crystals (19a)0.8g with the yield of 35%. ESI-MS M/z 389.3[2M + K ]]+.
ii) preparation of N- (N-tert-Butyloxycarbonylglycylethyl) -2- (1-ethyl-3-indole) -3- (1-cyanomethyl-3-indole) maleimide (19b)
In a 25mL two-necked flask with 2mL CH2Cl2Compound 19a (26mg,0.15mmol), compound 14(50mg,0.11mmol) and DMAP (4mg,0.03mmol) were dissolved, and 0.5mL of CH was added2Cl2The dissolved DCC (35mg,0.17mmol) was reacted overnight at room temperature, the reaction was completed by TLC detection, suction filtration was performed, the filtrate was evaporated to dryness, silica gel column chromatography was performed, and petroleum ether and ethyl acetate were eluted at 1:3(v/v) to give 47mg of orange-red solid (19b) with a yield of 69%.1H NMR(600MHz,DMSO-d6)δ8.05(t,1H,J=5.5Hz,-NH),7.87(s,1H,,Ar-H),7.86(s,1H,Ar-H),7.59(d,1H,J=8.2Hz,Ar-H),7.50(d,1H,J=8.2Hz,Ar-H),7.17(dt,1H,J=7.2Hz,1.1Hz,Ar-H),7.07(dt,1H,J=7.2Hz,1.1Hz,Ar-H),6.90(t,1H,J=5.9Hz,-NH),6.86(d,1H,J=8.2Hz,Ar-H),6.85(d,1H,J=8.2Hz,Ar-H),6.79(t,1H,J=7.7Hz,Ar-H),6.70(t,1H,J=7.7Hz,Ar-H),5.64(s,2H,-C 2H-CN),4.27(q,2H,J=7.1Hz,N-C 2H-CH3),3.65(t,2H,J=6.1Hz,N-C 2H-CH2-NH),3.51(m,2H,N-CH2-C 2H-NH),3.35('q'like,J=5.5Hz,6.1Hz,-CO-C 2H-NH-),1.35(s,9H,-C(C 3 3H)),1.33(t,3H,J=7.1Hz,N-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ171.9,171.8,171.0,169.0,136.1×2,132.5,132.0,129.1,126.6,126.3,125.6,123.3,122.5,122.2,121.9,121.1,120.3,116.7,110.8,110.6,107.5,105.3,78.6,60.4,41.3,38.1,37.8,34.6,28.7,15.8.ESI-MS m/z 495.3[M+H]+.
iii) preparation of N-glycylethyl-2- (1-ethyl-3-indole) -3- (1-cyanomethyl-3-indole) maleimide (19)
Dissolving the compound 19b (30mg,0.05mmol) in 8mL of toluene, adding a proper amount of 100-200 mesh silica gel, and adding N2Refluxing with 110 deg.C condensed water under protection for 3.5h, cooling to room temperature, vacuum filtering under reduced pressure column, evaporating organic layer to dryness, separating with silica gel column chromatography, and eluting with dichloromethane and methanol at ratio of 50:1(v/v) to obtain red solid (19)23.5mg with yield of 95%.1H NMR(600MHz,DMSO-d6)δ7.87(s,1H,Ar-H),7.82(s,1H,Ar-H),7.59(d,1H,J=8.3Hz,Ar-H),7.49(d,1H,J=8.3Hz,Ar-H),7.17(dt,1H,J=7.7Hz,1.1Hz,Ar-H),7.07(dt,1H,J=7.7Hz,1.1Hz,Ar-H),6.86(d,1H,J=7.7Hz,Ar-H),6.84(d,1H,J=7.1Hz,Ar-H),6.79(t,1H,J=7.7Hz,Ar-H),6.71(t,1H,J=7.7Hz,Ar-H),5.65(s,2H,-C 2H-CN),4.25(q,2H,J=7.1Hz,N-C 2H-CH3),3.66(t,2H,J=5.5Hz,N-C 2H-CH2NH),3.50-3.60(brs.2H,-NH2),3.49(t,2H,J=5.5Hz,NCH2-C 2H-NH),3.23(s,2H,-CO-C 2H-NH2),3.15(s,1H,NCH2-CH2-NH),1.31(t,3H,J=7.1Hz,N-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ171.9×2,170.7,136.1×2,132.5,132.0,129.1,126.5,126.3,125.7,123.3,122.5,122.2,122.0,121.1,120.3,116.7,110.8,110.7,107.4,105.3,63.2,43.1,38.1,37.8,34.6,15.8.ESI-MS m/z 495.3[M+H]+.
Preparation of Compound 20
i) Preparation of N-t-butyloxycarbonyl-L-alanine (20a)
According to the method for producing compound 19a, starting from L-alanine (1.3g,15mmol), 0.66g of white needle-like crystals (20a) was obtained with a yield of 23%. ESI-MS M/z 212.2[ M + Na ]]+.)
ii) preparation of N- (N-t-butyloxycarbonyl-L-alanylethyl) -2- (1-ethyl-3-indole) -3- (1-cyanomethyl-3-indole) maleimide (20b)
According to the method for producing compound 19b, 45mg of an orange-red solid (20b) was obtained in 65% yield from compound 20a (30mg,0.16mmol), compound 14(50mg,0.11mmol), DMAP (4mg,0.03mmol) and DCC (35mg,0.17 mmol).1H NMR(600MHz,DMSO-d6)δ8.05(t,1H,J=5.5Hz,-NH),7.85(s,1H,Ar-H),7.82(s,1H,Ar-H),7.58(d,1H,J=8.2Hz,Ar-H),7.48(d,1H,J=8.2Hz,Ar-H),7.16(dt,1H,J=7.1Hz,1.1Hz,Ar-H),7.06(dt,1H,J=7.1Hz,1.1Hz,Ar-H),6.85(d,2H,J=7.7Hz,Ar-H),6.77(t,1H,J=7.2Hz,Ar-H),6.70(t,1H,J=7.7Hz,Ar-H),5.64(s,2H,-C 2H-CN),4.24(q,2H,J=7.1Hz,N-C 2H-CH3),3.87(q,1H,J=8.3Hz,CH3-CH-NH-),3.62(m,2H,N-C 2H-CH2NH),3.47(m,1H,J=6.1Hz,NCH2-C 2H-NH-),3.26(m,1H,J=6.1Hz,NCH2-C 2H-NH-),1.32(s,9H,-C(CH3)3),1.30(t,3H,J=7.1Hz,N-CH2-C 3H),1.13(d,3H,J=6.6Hz,-NH-CH-C 3H).13C NMR(150MHz,DMSO-d6)δ171.9,171.8,171.0,169.0,136.1×2,132.5,132.0,129.1,126.6,126.3,125.6,123.3,122.5,122.2,121.9,121.1,120.3,116.7,110.8,110.6,107.5,105.3,78.6,60.4,41.3,38.1,37.8,34.6,28.7,15.8.ESI-MS m/z 1219.2[2M+H]+.
iii) preparation of N- (L-alanylethyl) -2- (1-ethyl-3-indole) -3- (1-cyanomethyl-3-indole) maleimide (20)
According to the preparation method of compound 19, 23.4mg of product (20) was obtained in 94% yield from compound 20b (30mg,0.049 mmol).1H NMR(600MHz,DMSO-d6)δ8.41(t,1H,J=5.5Hz,-NH),7.84(s,1H,Ar-H),7.67(s,1H,Ar-H),7.46(d,1H,J=8.3Hz,Ar-H),7.33(d,1H,J=8.3Hz,Ar-H),7.06(t,2H,J=7.1Hz,Ar-H),7.03(d,1H,J=8.3Hz,Ar-H),6.74(t,1H,J=7.1Hz,Ar-H),6.65(dd,2H,J=7.1Hz,8.3Hz,Ar-H),4.90(s,2H,-C 2H-CN),4.21(q,2H,J=7.1Hz,N-C 2H-CH3),3.66(m,2H,N-C 2H-CH2NH),3.49(m,2H,NCH2-C 2H-NH-),3.53(m,1H,J=6.6Hz,-CO-CH-NH2),1.28(t,3H,J=7.1Hz,-NCH2-C 3H),1.18(d,3H,J=7.1Hz,H2NCH-C 3H).13C NMR(150MHz,DMSO-d6)δ173.4,172.1,169.4,137.1,136.0,134.1,131.9,127.2×2,126.7,126.0,122.4,122.3×2,122.2,121.9,120.2×2,110.8,110.6,105.6×2,49.7,49.1,41.2,38.0,37.4,19.7,15.7.ESI-MS m/z 509.2[M+H]+.
Preparation of Compound 21
i) Preparation of N, N-di-tert-butyloxycarbonyl-L-histidine (21a)
According to the method for producing compound 18a, starting from histidine (1.0g,7mmol), 0.92g of white needle-like crystals (21a) was obtained in 37% yield. ESI-MS M/z 356.4[ M + H ]]+.
ii) preparation of N- (N, N-di-tert-butyloxycarbonyl-L-histidylethyl) -2- (1-ethyl-3-indole) -3- (1-cyanomethyl-3-indole) maleimide (21b)
According to the method for producing compound 18b, 35mg of product (21b) was obtained in 45% yield from compound 21a (80.9mg,0.16mmol), compound 14(50mg,0.11mmol), DMAP (4.2mg,0.03mmol) and DCC (35mg,0.17 mmol). ESI-MS M/z 775.5[ M + H ]]+.
iii) preparation of N- (L-histidylethyl) -2- (1-ethyl-3-indole) -3- (1-cyanomethyl-3-indole) maleimide (21)
According to the preparation method of compound 18, compound 21b (30mg,0.039mmol) was used as a starting material to give 20.2mg of product (21) with a yield of 90%.1H NMR(600MHz,DMSO-d6)δ7.85(s,1H,Ar-H),7.80(s,1H,Ar-H),7.58(d,1H,J=8.2Hz,Ar-H),7.54(s,1H,imidazole-H),7.48(d,1H,J=8.2Hz,Ar-H),7.16(t,1H,J=7.1Hz,Ar-H),7.05(t,1H,J=7.1Hz,Ar-H),6.84(d,2H,J=8.2Hz,Ar-H),6.77(t,1H,J=6.6Hz,Ar-H),6.76(s,1H,imidazole-H),6.68(t,1H,J=7.7Hz,Ar-H),5.63(s,2H,-C 2H-CN),4.23(q,2H,J=7.1Hz,N-C 2H-CH3),3.65(m,2H,N-C 2H-CH2-NH),3.59(m,1H,NCH2-C 2H-NH-),3.53(m,1H,J=4.4Hz,-CO-CH-NH2),3.4(m,2H,imidazole-C 2H-CHNH2),1.29(t,3H,J=7.1Hz,NCH2-C 3H).13C NMR(150MHz,DMSO-d6)δ173.6,172.0,171.9,136.1,135.4,135.3,132.7,132.5,131.9,129.2,126.6,126.3,123.3,122.5,122.2,122.0,121.1,120.3,116.7,110.8,110.7,107.5,105.3,70.3,60.4,55.4,42.3,38.2,34.6,29.5,22.6,15.7.ESI-MS m/z575.3[M+H]+.
Preparation of Compound 22
i) Preparation of N-t-butyloxycarbonyl-L-tryptophan (22a)
According to the method for producing compound 18a, 1.3g of white needle-like crystals (22a) was obtained in 63.3% yield from tryptophan (1.0g,5 mmol). ESI-MS M/z 305.3[ M + H ]]+.
ii) preparation of N- (N-tert-butyloxycarbonyl-L-tryptophyl-ethyl) -2- (1-ethyl-3-indole) -3- (1-cyanomethyl-3-indole) maleimide (22b)
According to the method for producing compound 18b, compound 22a (72mg,0.17mmol), compound 13(50mg,0.11mmol), DMAP (4.2mg,0.03mmol) and DCC (35mg,0.17mmol) were used as starting materials to give compound (22b)80mg, with a yield of 89%. ESI-MS M/z 724.2[ M + H ]]+,746.2[M+Na]+.
iii) preparation of N- (L-tryptophyl-ethyl) -2- (1-ethyl-3-indole) -3- (1-cyanomethyl-3-indole) maleimide (22)
According to the preparation method of compound 18, compound 22b (30mg,0.041mmol) was used as a starting material to give 23.2mg of product (22) with a yield of 90%.1H NMR(600MHz,DMSO-d6)δ10.81(brs,1H,-NH),8.22(t,1H,J=6.1Hz,-NH),7.86(s,1H,Ar-H),7.81(s,1H,Ar-H),7.58(d,1H,J=8.3Hz,Ar-H),7.46(dd,2H,J=8.2Hz,7.7Hz,Ar-H),7.32(d,2H,J=8.2Hz,Ar-H),7.16(t,1H,J=8.8Hz,Ar-H),7.04–7.02(m,2H,Ar-H),6.88–6.86(m,3H,Ar-H),6.74(t,1H,J=7.7Hz,Ar-H),6.67(t,1H,J=7.2Hz,Ar-H),5.61(s,2H,-C 2H-CN),4.21(q,2H,J=7.1Hz,N-C 2H-CH3),3.67(m,2H,-N-C 2H-CH2-NH),3.43(m,2H,-CH-C 2H-indole),3.1(d,2H,J=3.8Hz,-CH-C 2H-indole),2.68–2.65(m,2H,NCH2-C 2H-NH-),1.26(t,3H,J=7.1Hz,NCH2-C 3H).13C NMR(150MHz,DMSO-d6)δ175.2,172.0,171.9,136.8,136.6,136.1,132.4,132.0,129.2,127.9,126.6,126.3,125.7,124.1,123.2,122.4,122.2,122.0,121.4,121.1,120.3,119.0,118.7,116.7,111.8,111.1,110.8,110.6,107.5,105.3,60.3,55.8,41.3,38.2,34.6,31.3,15.7.ESI-MS m/z 624.4[M+H]+.
Preparation of Compound 23
According to the preparation method of compound 16, starting from compound N- (2-aminoethyl) -2- (1-ethyl-3-indole) -3- (3-indole) maleimide (930mg,2.34mmol), hydrochloride 23(893mg, yield 88%) was obtained.1H NMR(500MHz,DMSO-d6)δ11.84(s,1H,indole-NH),8.19(brs,3H,-NH3 +),7.77(d,1H,J=2.5Hz,Ar-H),7.70(s,1H,Ar-H),7.48(d,1H,J=8.2Hz,Ar-H),7.39(d,1H,J=8.1Hz,Ar-H),7.05(t,1H,J=7.6Hz,Ar-H),6.99(dd,2H,J=7.1Hz,5.0Hz,Ar-H),6.74(t,1H,J=8.7Hz,Ar-H),6.73(t,1H,J=7.9Hz,Ar-H),6.63(t,1H,J=7.5Hz,Ar-H),4.25(q,2H,J=7.2Hz,-NC 2H-CH3),3.84(t,2H,J=5.7Hz,N-CH 2-CH2NH3 +),3.10(t,2H,J=5.7Hz,NCH2-C 2H-NH3 +),1.29(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ172.2,172.1,136.5,135.9,131.8,129.8,127.6,126.9,126.4,125.4,122.2,122.1,121.9,121.5,120.0,119.8,112.3,110.5,106.0,105.5,41.1,40.2,39.4,15.7.HR-ESIMS m/z 399.1826[M–Cl]+(calcd.for C24H23N4O2,399.1815).
Preparation of Compound 24
i) Preparation of 1-benzylindole (24a)
In a 100mL three-necked flask, NaH (300mg,7.5mmol, 60% by mass in paraffin) was suspended in 30mL of DMF, 10mL of DMF-dissolved indole (585mg,5mmol) was slowly added dropwise at-5 deg.C, allowed to warm to room temperature for 30min and then allowed to cool to-5 deg.C. Benzyl bromide (0.89mL,7.5mmol) was added dropwise, and after the addition was completed, the mixture was addedStirring at 5 deg.C for 30min, adding 10mL methanol, adding 100mL saturated ammonium chloride solution, and adding CH2Cl2Extraction (100mL × 3), combination of organic layers, drying over anhydrous sodium sulfate, evaporation to dryness in vacuo, separation by silica gel column chromatography, and elution with petroleum ether and ethyl acetate (100: 1 (v/v)) gave 1.02g of a cream solid (24a) in 99% yield.1H NMR(600MHz,CDCl3)δ7.76(d,1H,J=7.7Hz,Ar-H),7.38–7.33(m,4H,Ar-H),7.27(dt,1H,J=6.8Hz,0.9Hz,Ar-H),7.22(dt,1H,J=6.9Hz,0.9Hz,Ar-H),7.20(t,1H,J=3.2Hz,Ar-H),7.18(d,2H,J=6.8Hz,Ar-H),6.65(dd,1H,J=3.2Hz,0.9Hz,Ar-H),5.37(s,2H,Ph-CH2-).13C NMR(150MHz,CDCl3)δ137.7,136.5,128.9,128.9,128.4,127.8,127.0,126.9,121.9,121.2,119.7×2,109.9,101.9,50.2.ESI-MS m/z 208.2[M+H]+.
ii) preparation of 2- (1-ethyl-3-indole) -3- (1-benzyl-3-indole) maleic anhydride (24b)
Following the preparation of compound 1c, compound 24a (356mg,1.72mmol), oxalyl chloride (328mg,2.58mmol), compound 1a (349mg,1.72mmol) and Et3N (347mg,3.44mmol) was used as the starting material to give 299mg of red solid (24b) in 39% yield.1H NMR(600MHz,DMSO-d6)δ8.02(s,1H,Ar-H),7.94(s.1H,Ar-H),7.53(d,1H,J=7.3Hz,Ar-H),7.44(d,1H,J=7.8Hz,Ar-H),7.33(t,2H,J=6.4Hz,Ar-H),7.27(t,1H,J=6.8Hz,Ar-H),7.20(d,2H,J=5.9Hz,Ar-H),7.11(t,1H,J=7.3Hz,Ar-H),7.05(t,1H,J=6.8Hz,Ar-H),6.91(d,1H,J=7.3Hz,Ar-H),6.88(d,1H,J=7.3Hz,Ar-H),6.75(t,1H,J=7.3Hz,Ar-H),6.73(t,1H,J=7.3Hz,Ar-H),5.52(s,2H,Ph-CH2-),4.29(q,2H,J=6.8Hz,-C 2H-CH3),1.34(t,3H,J=6.8Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ167.0,166.9,137.9,136.6,136.3,133.9,133.3,129.2×2,128.8,128.1,127.8,127.6×2,126.2,125.9,122.9,122.8,122.2,122.0,120.8,120.7,111.5,111.1,105.3,104.7,50.0,40.5,15.7.ESI-MS m/z447.2[M+H]+.
iii) preparation of 2- (1-ethyl-3-indole) -3- (1-benzyl-3-indole) maleimide (24c)
According to the preparation of compound 1, from compoundsObject 24b (260mg,0.58mmol), HMDS (2.44mL,11.7mmol) and MeOH (0.23mL,5.8mmol) was prepared as a red powdered solid (24c)248mg with 96% yield.1H NMR(600MHz,DMSO-d6)δ10.95(s,1H,imide-NH),7.90(s,1H,Ar-H),7.83(s,1H,Ar-H),7.46(d,1H,J=8.2Hz,Ar-H),7.36(d,1H,J=8.2Hz,Ar-H),7.32(t,2H,J=7.6Hz,Ar-H),7.26(t,1H,J=7.3Hz,Ar-H),7.17(d,2H,J=7.3Hz,Ar-H),7.04(t,1H,J=7.8Hz,Ar-H),6.97(t,1H,J=7.3Hz,Ar-H),6.84(d,1H,J=8.2Hz,Ar-H),6.82(d,1H,J=7.7Hz,Ar-H),6.65(t,1H,J=7.8Hz,Ar-H),6.64(t,1H,J=7.4Hz,Ar-H),5.49(s,2H,Ph-CH2-),4.26(q,2H,J=7.3Hz,-C 2H-CH3),1.34(t,3H,J=7.3Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ173.4×2,138.2,136.4,136.0,132.8,132.0,129.1×2,128.5,128.0,127.5,127.4×2,126.7,126.4,122.4,122.2,121.8,121.7,120.2,120.1,111.1,110.7,106.0,105.4,49.9,41.3,15.8.ESI-MS m/z446.2[M+H]+.
iv) preparation of 2- (1-ethyl-3-indole) -3- (3-indole) maleimide (24d)
Compound 24c (100mg,0.225mmol) was dissolved in DMSO (0.85mL), and a 1M t-BuOK/THF solution (8.4mL,8.4mmol) was added dropwise with stirring, and O was introduced into the reaction mixture after completion of the addition2About 30min, the reaction was quenched with saturated ammonium chloride solution, extracted with ethyl acetate (100 mL. times.3), combined with the organic layers, and dried over anhydrous Na2SO4Drying and vacuum evaporating. Silica gel column chromatography, dichloromethane and ethyl acetate 6:1(v/v) to give 70.5mg of red powder (24d), 89% yield.1H NMR(600MHz,DMSO-d6)δ11.66(s,1H,indole-NH),10.90(s,1H,imido-NH),7.76(s,1H,Ar-H),7.72(s,1H,Ar-H),7.46(d,1H,J=8.2Hz,Ar-H),7.37(d,1H,J=8.1Hz,Ar-H),7.04(t,1H,J=7.6Hz,Ar-H),6.98(t,1H,J=7.5Hz,Ar-H),6.90(d,1H,J=8.0Hz,Ar-H),6.74(d,1H,J=8.1Hz,Ar-H),6.69(t,1H,J=7.5Hz,Ar-H),6.62(t,1H,J=7.5Hz,Ar-H),4.24(q,2H,J=7.2Hz,-C 2H-CH3),1.31(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ173.6,173.5,136.6,136.0,131.9,129.8,128.4,127.7,126.6,125.7,122.2,122.1,121.9,121.6,120.1,119.9,112.3,110.6,106.1,105.5,41.2,15.8.ESI-MS m/z 356.1[M+H]+.
v) preparation of 2- (1-ethylindole) -3- (3-indole) maleic anhydride (24e)
Compound 24d (50mg,0.14mmol) was suspended in 20mL 10% aqueous KOH in a 50mL single neck flask, refluxed at 110 ℃ for 40min, cooled to room temperature, acidified by dropwise addition of 2N hydrochloric acid, extracted with ethyl acetate, combined with organic layers, dried over anhydrous sodium sulfate, concentrated under vacuum, chromatographed on silica gel column, eluted with dichloromethane to give 43mg of red solid (24e) in 86% yield.1H NMR(600MHz,DMSO-d6)δ11.96(s,1H,indole-NH),7.89(d,1H,J=2.8Hz,Ar-H),7.83(s,1H,Ar-H),7.52(d,1H,J=8.3Hz,Ar-H),7.44(d,1H,J=8.3Hz,Ar-H),7.10(t,1H,J=7.4Hz,Ar-H),7.05(t,1H,J=7.7Hz,Ar-H),6.98(d,1H,J=7.7Hz,Ar-H),6.78(t,1H,J=7.6Hz,Ar-H),6.77(d,1H,J=7.6Hz,Ar-H),6.70(t,1H,J=7.1Hz,Ar-H),4.25(q,2H,J=7.3Hz,-C 2H-CH3),1.30(t,3H,J=7.3Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ167.1,167.0,136.8,136.2,133.1,131.3,128.7,127.9,126.1,125.2,122.7×2,122.2,121.9,120.7,120.5,112.8,111.0,105.5,104.8,41.4,15.7.ESI-MS m/z 357.1[M+H]+.
vi) preparation of N- (N, N-dimethylaminoethyl) -2- (1-ethyl-3-indole) -3- (3-indole) maleimide (24)
Compound 24d (55mg,0.154mmol), N-dimethylethylenediamine (84.4. mu.L, 0.772mmol) and a catalytic amount of Et were dissolved in 30mL of toluene3After dissolving N and toluene, the mixture was refluxed for 17 hours at 110 ℃ with condensed water under nitrogen protection, the solvent was evaporated to dryness, and the resulting solution was subjected to pressure column chromatography and eluted with dichloromethane and methanol at a ratio of 10:1(v/v) to give 52mg of a red solid (24) with a yield of 79%.1H NMR(600MHz,DMSO-d6)δ11.73(s,1H,indole-NH),7.80(d,1H,J=2.7Hz,Ar-H),7.77(s,1H,Ar-H),7.47(d,1H,J=8.3Hz,Ar-H),7.39(d,1H,J=8.1Hz,Ar-H),7.05(t,1H,J=7.7Hz,Ar-H),6.99(t,1H,J=7.6Hz,Ar-H),6.89(d,1H,J=7.9Hz,),6.74(d,1H,J=8.1Hz,Ar-H),6.70(d,1H,J=7.4Hz,Ar-H),6.62(d,1H,J=7.8Hz,Ar-H),4.24(q,2H,J=7.2Hz,-C 2H-CH3),3.66(t,2H,J=6.4Hz,N-C 2H-CH2N(CH3)2),2.49(t,J=6.4Hz,2H,NCH2-C 2H-N(CH3)2),2.18(s,6H,-N(CH3)2),1.31(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ172.1×2,136.6,136.0,132.1,130.0,127.4,126.8,126.5,125.6,122.3,122.2,121.9,121.6,120.2,120.0,112.4,110.7,106.1,105.5,57.3,45.7×2,41.3,36.3,15.8.HR-ESIMS m/z 427.2140[M+H]+(calcd.for C26H27N4O2,427.2134).
Preparation of Compound 25
According to the preparation method of the compound 16, the hydrochloride salt is obtained by taking the compound 24(50mg,0.117mmol) as a raw material: n- (N, N-dimethylaminoethyl) -2- (1-ethyl-3-indole) -3- (3-indole) maleimide hydrochloride (25) (48mg, yield 90%).1H NMR(500MHz,DMSO-d6)δ11.94(s,1H,indole-NH),10.61(brs,1H,(CH3)2NH +),7.77(d,1H,J=2.4Hz,Ar-H),7.69(s,1H,Ar-H),7.47(d,1H,J=8.2Hz,Ar-H),7.40(d,1H,J=8.1Hz,Ar-H),7.05(t,1H,J=7.6Hz,Ar-H),6.99(d,1H,J=7.8Hz,Ar-H),6.98(t,1H,J=7.8Hz,Ar-H),6.76(d,1H,J=8.0Hz,Ar-H),6.72(t,1H,J=7.5Hz,Ar-H),6.62(t,1H,J=7.5Hz,Ar-H),4.23(q,2H,J=7.0Hz,-C 2H-CH3),3.93(t,2H,J=5.7Hz,N-CH 2-CH2(CH3)2NH+),3.36(t,2H,J=6.0Hz,NCH2-C 2H-(CH3)2NH+),2.84(s,6H,(C 3 2H)NH+),1.28(t,3H,J=7.1Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ171.9×2,136.5,135.9,131.8,129.9,128.0,127.1,126.4,125.3,122.2,122.1×2,121.7,120.0,119.8,112.4,110.9,105.9,105.5,54.8,42.6×2,41.1,33.9,15.7.HR-ESIMS m/z 427.2141[M–Cl]+(calcd.for C26H26N4O2,426.2056).
Preparation of Compound 26
i) Preparation of 1-benzyl-6-bromoindole (26a)
According to the method for synthesizing compound 24a, the compound was prepared from 6-bromoindole (980mg,5mmol), NaH (300mg,7.5mmol, 60% by mass in paraffin) and benzyl bromide (1283mg,7.5mmol) as starting materials, and the compound was separated by silica gel column chromatography, and 1.14g of white powdery solid (26a) was eluted with petroleum ether, ethyl acetate 60:1(v/v), with the yield being 80%.1H NMR(600MHz,CDCl3)δ7.54(d,1H,J=8.8Hz,Ar-H),7.47(s,1H,Ar-H),7.35–7.31(m,3H,Ar-H),7.25(dd,1H,J=8.8Hz,1.9Hz,Ar-H),7.10–7.12(m,3H,Ar-H),6.56(d,1H,J=3.8Hz,Ar-H),5.27(s,2H,Ph-C 2H-).13C NMR(150MHz,CDCl3)δ137.3,137.1,129.0×2,127.9,127.7,126.8×2,123.0,122.3,115.5,112.8,102.1,50.2.ESI-MS m/z286.0/288.0[M+H]+.
ii) preparation of 2- (1-ethyl-3-indole) -3- (1-benzyl-6-bromo-3-indole) maleic anhydride (26b)
According to the preparation method of the compound 24b, the compound 24a (1100mg,3.86mmol), (COCl)2(500. mu.L, 5.79mmol), Compound 1c (783mg,3.86mmol) and Et3N (1070 μ L,7.72mmol) was prepared as a starting material, and methanol was recrystallized to obtain 652mg of red powder (26b), with a yield of 32.2%.1H NMR(600MHz,DMSO-d6)δ8.02(s,1H,Ar-H),7.99(s,1H,Ar-H),7.73(s,1H,Ar-H),7.54(d,1H,J=8.2Hz,Ar-H),7.35(t,2H,J=7.7Hz,Ar-H),7.29(t,1H,J=6.6Hz,Ar-H),7.19(d,2H,J=7.1Hz,Ar-H),7.12(t,1H,J=7.7Hz,Ar-H),6.90(d,1H,J=8.2Hz,Ar-H),6.88(d,1H,J=7.7Hz,Ar-H),6.76(d,1H,J=7.7Hz,Ar-H),6.71(t,1H,J=7.7Hz,Ar-H),5.53(s,2H,Ph-CH2-),4.32(q,2H,J=7.2Hz,-C 2H-CH3),1.37(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ166.9,166.8,137.6,137.3,136.3,134.4,133.6,130.0,129.2×2,128.2,127.5×2,126.8,125.7,125.4,123.6,123.5,122.9,122.0,120.8,115.8,114.3,111.2,105.5,104.5,50.0,41.6,15.8.ESI-MS m/z 525.1/527.1[M+H]+.
iii) preparation of 2- (1-ethyl-3-indole) -3- (1-benzyl-6-bromo-3-indole) maleimide (26c)
According to the preparation of compound 24c, as compound 26b (600mg,1.14mmol), HMDS (12mL,57.3mmol) and MeOH (1.2mL,28.7mmol) were prepared as starting materials and chromatographed on a silica gel column with dichloromethane to give 218mg of red powdered solid (26c) in 95% yield.1H NMR(600MHz,DMSO-d6)δ10.99(s,1H,imide-NH),7.90(s,1H,Ar-H),7.89(s,1H,Ar-H),7.65(s,1H,Ar-H),7.48(d,1H,J=8.3Hz,Ar-H),7.34(t,2H,J=7.7Hz,Ar-H),7.28(t,1H,J=7.1Hz,Ar-H),7.17(d,2H,J=7.1Hz,Ar-H),7.05(t,1H,J=7.7Hz,Ar-H),6.82(d,1H,J=8.8Hz,Ar-H),6.79(d,1H,J=7.1Hz,Ar-H),6.72(d,1H,J=8.3Hz,Ar-H),6.63(t,1H,J=7.1Hz,Ar-H),5.51(s,2H,Ph-CH2-),4.29(q,2H,J=7.1Hz,-C 2H-CH3),1.37(t,3H,J=7.1Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ173.3,173.1,137.9,137.2,136.1,133.4,132.3,129.3,129.2×2,128.1,127.4,127.4,126.5,126.2,125.9,123.3,123.0,122.3,121.7,120.2,115.3,113.9,110.8,106.3,105.1,49.8,41.3,15.8.ESI-MS m/z 524.1/526.1[M+H]+.
iv) preparation of 2- (1-ethyl-3-indole) -3- (6-bromo-3-indole) maleimide (26d)
According to the preparation of compound 24d, compound 26c (538mg,1.03mmol), DMSO (1.7mL), 1M solution of t-BuOK/THF (16.8mL,16.8mmol) and O2Is prepared by taking the raw materials as raw materials. Silica gel column chromatography, petroleum ether and ethyl acetate 3:1(v/v) to give 366mg of red powder (26d), 82% yield.1H NMR(600MHz,DMSO-d6)δ7.81(s,1H,Ar-H),7.76(d,1H,J=2.8Hz,Ar-H),7.57(s,1H,Ar-H),7.46(d,1H,J=8.3Hz,Ar-H),7.04(dt,1H,J=8.2Hz,1.1Hz,Ar-H),6.78(d,1H,J=8.0Hz,Ar-H),6.75(dd,1H,J=8.6Hz,1.8Hz,Ar-H),6.71(d,1H,J=8.8Hz,Ar-H),6.69(dt,1H,J=7.3Hz,0.9Hz,Ar-H),4.26(q,2H,J=7.1Hz,-C 2H-CH3),1.34(t,3H,J=7.1Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ173.4×2,137.4,136.0,132.2,130.6,128.6,127.4,126.4,125.0,123.1,122.6,122.3,121.7,120.2,115.0,114.9,110.7,106.3,105.3,41.3,15.8.ESI-MS m/z434.0/436.0[M+H]+,HR-ESIMS m/z 434.0506[M+H]+(calcd.for C22H17N3O2Br,434.0504).
v) preparation of 2- (1-ethyl-3-indole) -3- (6-bromo-3-indole) maleic anhydride (26e)
According to the preparation method of the compound 24e, starting from the compound 26d (80mg,0.185mmol), 60mg of an orange-red solid (26e) was obtained with a yield of 75%.1H NMR(600MHz,DMSO-d6)δ11.99(s,1H,indole-NH),7.88(d,1H,J=2.7Hz,Ar-H),7.84(s,1H,Ar-H),7.62(s,1H,Ar-H),7.49(d,1H,J=8.0Hz,Ar-H),7.08(t,1H,J=7.6Hz,Ar-H),6.80(t,2H,J=7.1Hz,Ar-H),6.73(t,2H,J=7.5Hz,Ar-H),4.26(q,2H,J=8.2Hz,-C 2H-CH3),1.32(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ166.8×2,137.4,136.1,133.2,131.7,128.9,127.5,125.8,124.4,123.2,123.0,122.7,121.9,120.7,115.7,115.2,111.0,105.5,104.5,41.4,15.8.ESI-MS m/z 435.0/437.0[M+H]+.
vi) preparation of N- (N, N-dimethylaminoethyl) -2- (1-ethyl-3-indole) -3- (6-bromo-3-indole) maleimide (26)
According to the preparation method of compound 24, compound 26e (50mg,0.115mmol), N-dimethylethylenediamine (81. mu.L, 0.575mmol) and a catalytic amount of Et3N was prepared as the starting material to give 46.4mg of a red solid (26) in 80% yield.1H NMR(500MHz,DMSO-d6)δ11.79(s,1H,indole-NH),7.84(s,1H,Ar-H),7.77(s,1H,Ar-H),7.56(d,1H,J=1.4Hz,Ar-H),7.47(d,1H,J=8.2Hz,Ar-H),7.03(t,1H,J=7.6Hz,Ar-H),6.74(d,2H,J=8.5Hz,Ar-H),6.69(d,1H,J=6.5Hz,Ar-H),6.68(t,1H,J=62Hz,Ar-H),4.26(q,2H,J=7.2Hz,-C 2H-CH3),3.64(t,2H,J=6.4Hz,-NC 2HCH2-N(CH3)2),2.46(t,2H,J=6.5Hz,-NCH2C 2H-N(CH3)2),2.16(s,6H,-N(CH3)2),1.33(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ171.8×2,137.3,136.0,132.2,130.5,127.6,126.3,126.2,124.8,122.9,122.6,122.3,121.6,120.1,114.9,114.8,110.7,106.2,105.1,57.2,45.6,41.2,36.2,15.7.HR-ESIMS m/z 505.1250[M+H]+(calcd.for C26H26N4O2Br,505.1239).
Preparation of Compound 27
According to the preparation method of compound 16, compound 26(100mg,0.198mmol) is used as a raw material to obtain hydrochloride thereof: n- (N, N-dimethylaminoethyl) -2- (1-ethyl-3-indole) -3- (6-bromo-3-indole) maleimide hydrochloride (27) (91mg, yield 85%).1H NMR(500MHz,DMSO-d6)δ12.08(s,1H,indole-NH),10.63(brs,1H,-(CH3)2NH +),7.79(s,1H,Ar-H),7.74(s,1H,Ar-H),7.60(s,1H,Ar-H),7.48(d,1H,J=8.2Hz,Ar-H),7.05(t,1H,J=7.5Hz,Ar-H),6.84(d,1H,J=8.0Hz,Ar-H),6.76(d,1H,J=7.2Hz,Ar-H),6.74(s,1H,Ar-H),6.70(d,1H,J=7.4Hz,Ar-H),4.26(q,2H,J=6.9Hz,-C 2H-CH3),3.92(t,2H,J=4.9Hz,N-CH 2-CH2N(CH3)2H+),3.04(t,2H,J=4.9Hz,NCH2-C 2H-N(CH3)2H+),2.83(s,6H,-(C 3 2H)NH+),1.32(t,3,J=6.9Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ171.8,171.6,137.4,136.0,132.1,130.5,128.0,126.9,126.1,124.7,123.1,122.5,122.3,121.8,120.1,115.0,114.8,110.7,106.2,105.2,54.8,45.6,42.6×2,41.2,33.5,15.7.HR-ESIMS m/z 505.1246[M–Cl]+(calcd.for C26H27N4O2Br,505.1250).
Preparation of Compound 28
According to the preparation method of compound 14, using compound 26e (49mg,0.114mmol) and ethylenediamine as starting materials, 49mg of N- (2-aminoethyl) -2- (1-ethyl-3-indole) -3- (6-bromo-3-indole) maleimide (28) was obtained as a red solid in a yield of 90%.1H NMR(500MHz,DMSO-d6)δ7.81(s,1H,Ar-H),7.76(s,1H,Ar-H),7.56(s,1H,Ar-H),7.46(d,1H,J=8.3Hz,Ar-H),7.03(t,1H,J=7.6Hz,Ar-H),6.77(d,1H,J=8.0Hz,Ar-H),6.74(dd,1H,J=8.6Hz,1.4Hz,Ar-H),6.70(d,1H,J=8.6Hz,Ar-H),6.67(t,1H,J=7.5Hz,Ar-H),4.25(q,2H,J=7.2Hz,-C 2H-CH3),3.56(t,2H,J=6.5Hz,N-C 2H-CH2NH2),2.77(t,2H,J=6.5Hz,NCH2-C 2H-NH2),1.32(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ172.1×2,137.3,135.9,132.0,130.4,127.7,126.4,126.2,124.8,123.0,122.5,122.2,121.6,120.1,114.9,114.8,110.7,106.3,105.2,41.3,41.2,40.6,15.7.HR-ESIMS m/z 477.0934[M+H]+(calcd.for C24H22N4O2Br,477.0926).
Preparation of Compound 29
According to the preparation method of the compound 16, the hydrochloride of the compound 28(200mg,0.42mmol) is used as a raw material: n- (2-aminoethyl) -2- (1-ethyl-3-indole) -3- (6-bromo-3-indole) maleimide hydrochloride (29)172mg, yield 80%.1H NMR(500MHz,DMSO-d6)δ12.03(s,1H,indole-NH),8.20(brs,3H,-NH3 +),7.80(s,1H,Ar-H),7.75(s,1H,Ar-H),7.60(s,1H,Ar-H),7.48(d,1H,J=8.1Hz,Ar-H),7.05(t,1H,J=7.4Hz,Ar-H),6.83(d,1H,J=7.9Hz,Ar-H),6.76(d,1H,J=8.5Hz,Ar-H),6.73(d,1H,J=8.8Hz,Ar-H),6.72(t,1H,J=7.8Hz,Ar-H),4.26(q,2H,J=6.9Hz,-C 2H-CH3),3.83(t,2H,J=6.4Hz,N-C 2H-CH2NH3 +),3.08(t,2H,J=6.5Hz,NCH2-C 2H-NH3 +),1.32(t,3H,J=6.9Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ171.9,171.8,137.4,136.9,132.0,130.5,127.9,126.8,126.1,124.7,123.1,122.5,122.3,121.8,120.1,115.0,114.8,110.7,106.2,105.2,41.2,38.1,36.1,15.7.HR-ESIMS m/z 477.0932[M–Cl]+(calcd.for C24H22N4O2Br,477.0934).
Preparation of Compounds 30, 31, 32
NaH (13.5mg,0.563mmol, 60% by mass in paraffin) was suspended in DMF at 0 ℃, DMF dissolved compound 24d (40mg,0.113mmol) was added dropwise, NaH (338mg,14.1mmol, 60% by mass in paraffin) was suspended in DMF, chlorohydrin (38. mu.L, 0.563mmol) was added dropwise, the reaction was carried out at low temperature for 20min, the mixture was introduced into the suspension of compound 24d with a catheter, the reaction was carried out for 20min, the temperature was raised to room temperature, and the condensate was refluxed for 4.5 h. Cooling to-5 deg.C, adding MeOH dropwise, adding appropriate amount of saturated ammonium chloride solution, extracting with ethyl acetate, mixing organic layers, drying with anhydrous sodium sulfate, evaporating solvent under vacuum, and separating by pressure column chromatography, eluting with dichloromethane (methanol: 100:1 (v/v)) to obtain red solid N- (2-hydroxyethyl) -2- (1-ethyl-3-indole) -3- (3-indole) maleimide (30), 2- (1-ethyl-3-indole) -3- (1- (2-hydroxyethyl) -3-indole) maleimide (31) and N- (2-hydroxyethyl) -2- (1-ethyl-3-indole) -3- (1- (2-hydroxyethyl) -3-indole) maleimide (32) of 23mg, 5mg and 4mg, yields 51%, 11% and 8%, respectively.
Compound 30:1H NMR(600MHz,DMSO-d6)δ11.67(s,1H,indole-NH),7.78(d,1H,J=2.1Hz,Ar-H),7.73(s,1H,Ar-H),7.45(d,1H,J=8.2Hz,Ar-H),7.37(d,1H,J=8.1Hz,Ar-H),7.03(t,1H,J=7.6Hz,Ar-H),6.97(t,1H,J=7.6Hz,Ar-H),6.91(d,1H,J=8.0Hz,Ar-H),6.73(d,1H,J=8.0Hz,Ar-H),6.68(t,1H,J=7.5Hz,Ar-H),6.61(t,1H,J=7.6Hz,Ar-H),4.89(t,1H,J=5.5Hz,imide-NCH2CH2OH),4.22(q,2H,J=7.2Hz,-C 2H-CH3),3.62-3.59(m,4H,imide-N(CH2)2-),1.29(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ172.1×2,136.5,135.9,131.8,129.7,127.5,126.8,126.4,125.5,122.1×2,121.8,121.5,120.0,119.8,112.2,110.5,106.0,105.5,58.7,41.1,40.9,15.6.HR-ESIMS m/z 400.1666[M+H]+(calcd.for C24H22N3O3,400.1661).
compound 31:1H NMR(600MHz,DMSO-d6)δ10.92(s,1H,imide-NH),7.82(s,1H,Ar-H),7.70(s,1H,Ar-H),7.48(d,1H,J=8.2Hz,Ar-H),7.46(d,1H,J=8.2Hz,Ar-H),7.05(t,1H,J=7.6Hz,Ar-H),7.02(t,1H,J=7.1Hz,Ar-H),6.92(d,1H,J=8.0Hz,Ar-H),6.72(d,1H,J=7.3Hz,Ar-H),6.71(t,1H,J=6.9Hz,Ar-H),6.64(t,1H,J=7.7Hz,Ar-H),4.95(t,1H,J=5.2Hz,indole-NCH2CH2OH),4.26(t,2H,J=5.6Hz,indole-NC 2HCH2-),4.23(q,2H,J=7.2Hz,-C 2H-CH3)3.71-3.69(m,2H,indole-NCH2C 2H-),1.30(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ173.5×2,136.7,136.0,133.4,131.9,128.0,127.5,126.9,126.1,122.2,122.1,122.0,121.9,120.1,120.0,111.0,110.6,105.5,105.2,60.6,49.1,41.2,15.8.HR-ESIMS m/z 400.1668[M+H]+(calcd.for C24H22N3O3).
compound 32:1H NMR(500MHz,DMSO-d6)δ7.84(s,1H,Ar-H),7.72(s,1H,Ar-H),7.48(d,1H,J=7.8Hz,Ar-H),7.46(d,1H,J=7.8Hz,Ar-H),7.05(t,1H,J=7.2Hz,Ar-H),7.02(t,1H,J=7.4Hz,Ar-H),6.93(d,1H,J=8.0Hz,Ar-H),6.73(d,1H,J=7.8Hz,Ar-H),6.71(t,1H,J=7.5Hz,Ar-H),6.65(t,1H,J=7.3Hz,Ar-H),4.93(t,1H,J=4.7Hz,indole-NCH2CH2OH),4.88(t,1H,J=4.8Hz,imide-NCH2CH2OH),4.26(t,2H,J=5.3Hz,indole-NC 2HCH2-),4.22(q,2H,J=7.1Hz,-C 2H-CH3),3.70(t,2H,J=5.3Hz,indole-NCH2C 2H-),3.65-3.57(m,4H,imide-N(CH2)2-),1.29(t,3H,J=7.1Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ172.0×2,136.6,135.9,133.3,131.8,127.1,126.7,126.4,125.9,122.1,122.0×2,121.8,120.0,119.9,110.9,110.5,105.9,105.2,60.5,58.6,49.0,41.1,40.9,15.6.HR-ESIMS m/z 444.1934(calcd.for C26H26N3O4,444.1923[M+H]+).
preparation of Compound 33
According to the preparation method of the compound 24, using 4-methoxybenzylamine (185. mu.L, 1.4mmol) and the compound 24e (50mg,0.14mmol) as starting materials, 48mg of N- (4-methoxybenzyl) -2- (1-ethyl-3-indole) -3- (3-indole) maleimide (33) was obtained in a yield of 72%.1H NMR(600MHz,DMSO-d6)δ11.75(s,1H,indole-NH),7.82(d,1H,J=2.7Hz,Ar-H),7.77(s,1H,Ar-H),7.45(d,1H,J=8.3Hz,Ar-H),7.39(d,1H,J=8.1Hz,Ar-H),7.29(d,2H,J=8.7Hz,Ar-H),7.04(t,1H,J=7.6Hz,Ar-H),6.98(t,1H,J=7.6Hz,Ar-H),6.90(d,2H,J=6.7Hz,Ar-H),6.89(d,1H,J=2.1Hz,Ar-H),6.74(d,1H,J=8.1Hz,Ar-H),6.69(t,1H,J=7.5Hz,Ar-H),6.62(t,1H,J=7.5Hz,Ar-H),4.68(s,2H,-C 2H-),4.24(q,2H,J=7.2Hz,-C 2H-CH3),3.70(s,3H,-OCH3),1.29(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ172.0,171.9,159.1,136.6,136.0,132.2,130.1,129.9,129.6×2,127.5,127.3,126.9,126.5,125.6,122.3×2,121.9,121.6,120.2,112.0,114.5,112.4,110.7,106.1,105.5,55.6,41.2,41.1,15.7.ESI-MS m/z 498.2[M+Na]+.
Preparation of Compound 34
According to the preparation method of compound 2, compound 33(60mg,0.126mmol) and NaHCO3(42mg,0.5mmol) and HCHO (3mL, mass fraction 37%) solution as raw materials, separating by gel column chromatography, eluting with methanol to obtain dark red solid N- (4-methoxybenzyl) -2- (1-ethyl-3-indole) -3- (1-hydroxymethyl-3-indole) maleimide (34)51mg, yield 78%.1H NMR(600MHz,DMSO-d6)δ7.99(s,1H,Ar-H),7.74(s,1H,Ar-H),7.55(d,1H,J=8.3Hz,Ar-H),7.47(d,1H,J=8.2Hz,Ar-H),7.39(t,1H,J=8.1Hz,Ar-H),7.29(d,2H,J=8.8Hz,Ar-H),7.05(m,2H,Ar-H),6.99(d,1H,J=8.1Hz,Ar-H),6.91(d,2H,J=8.8Hz,Ar-H),6.72(d,1H,J=7.2Hz,Ar-H),6.69(t,1H,J=8.1Hz,-CH2OH),6.63(d,1H,J=7.0Hz,Ar-H),5.60(d,2H,J=7.2Hz,-C 2HOH),4.70(s,2H,-CH2-),4.23(q,2H,J=7.2Hz,-C 2H-CH3),3.71(s,3H,-OCH3),1.30(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ171.9,171.8,159.2,136.1,136.0,132.6×2,132.2,129.8,129.6,127.4,126.9,126.8,126.4,122.4×2,121.9,121.8,120.5,120.3,114.6,111.4,110.7,105.9,105.5,100.0,69.7,60.3,41.7,41.3,15.7.ESI-MS m/z 528.1[M+Na]+.
Preparation of Compound 35
According to the preparation method of the compound 24, N- (4-hydroxybenzyl) -2- (1-ethyl-3-indole) -3- (3-indole) is prepared by using 4-hydroxybenzylamine (86mg, 0.7mmol) and the compound 24e (50mg,0.14mmol) as raw materialsIndole) maleimide (35)35mg, yield 60%.1H NMR(600MHz,DMSO-d6)δ11.72(s,1H,indole-NH),9.26(s,1H,Ar-OH),7.80(d,1H,J=2.3Hz,Ar-H),7.77(s,1H,Ar-H),7.45(d,1H,J=8.3Hz,Ar-H),7.38(d,1H,J=8.1Hz,Ar-H),7.17(d,1H,J=8.5Hz,Ar-H),7.11(d,2H,J=8.3Hz,Ar-H),7.03(t,1H,J=7.4Hz,Ar-H),6.97(d,1H,J=7.5Hz,Ar-H),6.89(d,1H,J=8.0Hz,Ar-H),6.71(d,2H,J=8.4Hz,Ar-H),6.68(d,1H,J=7.4Hz,Ar-H),6.61(t,1H,J=7.4Hz,Ar-H),4.64(s,2H,-NCH2Ar),4.22(q,2H,J=7.2Hz,-C 2H-CH3),1.30(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ172.0×2,156.7,136.6,136.0,134.1,132.1,132.0,130.1,129.9,129.7,129.2,128.1,127.9,127.5,126.9,126.5,125.6,115.8×2,115.5×2,112.4,110.7,106.1,105.5,56.6,41.2,15.7.ESI-MS m/z 462.3[M+H]+.
Preparation of Compound 36
According to the preparation method of compound 2, compound 35(59mg,0.128mmol) and NaHCO3(53.7mg,0.64mmol) was used as a starting material to obtain N- (4-hydroxybenzyl) -2- (1-ethyl-3-indole) -3- (1-hydroxymethyl-3-indole) maleimide (36) as a deep red solid in a yield of 50 mg.1H NMR(600MHz,DMSO-d6)δ9.44(s,1H,Ar-OH),8.00(s,1H,Ar-H),7.75(s,1H,Ar-H),7.56(d,1H,J=8.3Hz,Ar-H),7.47(d,1H,J=8.3Hz,Ar-H),7.19(d,2H,J=8.5Hz,Ar-H),7.05(m,2H,Ar-H),7.00(d,1H,J=8.1Hz,Ar-H),6.74(d,2H,J=8.6Hz,Ar-H),6.72(d,1H,J=7.4Hz,Ar-H),6.69(t,1H,J=7.4Hz,-CH2OH),6.63(d,1H,J=3.3Hz,Ar-H),5.61(d,2H,J=7.4Hz,-C 2HOH),4.65(s,2H,-NCH2Ar),4.03(q,2H,J=7.1Hz,-C 2H-CH3),1.17(t,3H,J=7.1Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ171.9×2,157.3,136.1,136.0,132.7,132.6,132.2,129.7,128.1,127.3,126.8×2,126.4,122.4×2,121.9,121.8,120.5,120.3,115.8,111.4,110.7,105.9,105.5,100.0,69.7,60.3,41.3,15.7.ESI-MS m/z 514.1[M+Na]+.
Preparation of Compound 37
According to the preparation of Compound 24Preparation method using 4- (2-aminoethyl) morpholine (771 uL, 0.59mmol) and compound 24e (50mg,0.14mmol) as starting materials gave 41mg, 61% yield of N- (2- (4-morpholine) ethyl) -2- (1-ethyl-3-indole) -3- (3-indole) maleimide (37).1H NMR(500MHz,DMSO-d6)δ11.68(s,1H,indole-NH),7.78(s,1H,Ar-H),7.73(s,1H,Ar-H),7.46(d,1H,J=8.3Hz,Ar-H),7.37(d,1H,J=8.1Hz,Ar-H),7.04(t,1H,J=7.6Hz,Ar-H),6.98(t,1H,J=7.5Hz,Ar-H),6.90(d,1H,J=8.0Hz,Ar-H),6.71(d,1H,J=8.3Hz,Ar-H),6.70(t,1H,J=7.5Hz,Ar-H),6.62(t,1H,J=7.5Hz,Ar-H),4.23(q,2H,J=7.2Hz,-C 2H-CH3),3.68(t,2H,J=6.4Hz,imide-NC 2HCH2-),3.53(t,4H,J=4.4Hz,morpholine-N(CH2-CH 2)2O),2.53(t,2H,J=6.4Hz,imide-NCH2C 2H-),2.44(t,4H,J=4.4Hz,morpholine-N(CH 2-CH2)2O),1.30(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ172.0×2,136.5,135.9,131.9,129.8,127.4,126.8,126.4,125.4,122.2,122.1,121.7,121.4,120.0,119.8,112.3,110.5,106.0,105.3,66.7×2,56.3,53.6×2,41.1,35.2,15.6.HR-ESIMS m/z 469.2247[M+H]+(calcd.for C28H29N4O3,469.2240[M+H]+).
Preparation of Compound 38
According to the preparation method of compound 2, compound 37(33mg,0.071mmol) and NaHCO3(30mg,0.35mmol) was used as a starting material to obtain N- (2- (4-morpholine) ethyl) -2- (1-ethyl-3-indole) -3- (1-hydroxymethyl-3-indole) maleimide (38) as a deep red solid in a yield of 29mg (82%).1H NMR(500MHz,DMSO-d6)δ7.96(s,1H,Ar-H),7.70(s,1H,Ar-H),7.55(d,1H,J=8.2Hz,Ar-H),7.47(d,1H,J=8.2Hz,Ar-H),7.05(t,1H,J=8.1Hz,Ar-H),7.02(t,1H,J=8.4Hz,Ar-H),6.73(t,1H,J=7.5Hz,Ar-H),6.67(t,1H,J=7.3Hz,Ar-H),6.62(d,1H,J=8.5Hz,Ar-H),6.60(d,1H,J=8.0Hz,Ar-H),5.59(d,2H,J=7.3Hz,indole-C 2H-OH),4.22(q,2H,J=7.2Hz,-C 2H-CH3),3.72(t,2H,J=6.4Hz,imide-NC 2HCH2-),3.56(t,4H,J=4.5Hz,morpholine-N(CH2-C 2H)2O),2.57(t,2H,J=6.4Hz,imide-NCH2C 2H-),2.47(t,4H,J=4.5Hz,morpholine-N(C 2H-CH2)2O),1.29(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ171.9×2,136.0,135.9,132.4,131.9,127.3,126.9,126.6,126.2,122.3,122.2,121.8,121.6,120.3,120.1,111.9,110.6,105.7,105.4,69.5,66.6×2,56.3,53.5×2,41.1,35.3,15.6.HR-ESIMS m/z 499.2352[M+H]+(calcd.for C29H31N4O4,499.2345).
Preparation of Compound 39
According to the preparation method of compound 24, using 2- (2-aminoethyl) pyridine (50. mu.L, 0.421mmol) and compound 24e (30mg,0.084mmol) as starting materials, 25mg of N- (2- (2-pyridine) ethyl) -2- (1-ethyl-3-indole) -3- (3-indole) maleimide (39) was prepared in 64% yield.1H NMR(600MHz,DMSO-d6)δ11.71(s,1H,indole-NH),8.48(d,1H,J=4.7Hz,Ar-H),7.75(d,1H,J=2.7Hz,Ar-H),7.73–7.70(m,2H,Ar-H),7.48(d,1H,J=8.2Hz,Ar-H),7.38(d,1H,J=8.1Hz,Ar-H),7.31(d,1H,J=7.7Hz,Ar-H),7.23(dd,1H,J=7.4,4.9Hz,Ar-H),7.05(t,1H,J=7.6Hz,Ar-H),6.99(t,1H,J=7.5Hz,Ar-H),6.88(d,1H,J=8.1Hz,Ar-H),6.71(t,2H,J=8.0Hz,Ar-H),6.64(d,1H,J=7.7Hz,Ar-H),4.24(q,2H,J=7.2Hz,-C 2H-CH3),3.93(t,2H,J=7.1Hz,imide-NC 2HCH2-),3.09(t,2H,J=7.1Hz,imide-NCH2C 2H-),1.30(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ172.0,171.9,158.9,149.7,137.2,136.6,136.0,132.0,129.9,127.6,126.9,126.5,125.6,123.8,122.3,122.2,121.9,121.6,120.1,119.9,112.4,110.7,106.0,105.5,100.0,41.2,38.2,36.7,15.8.HR-ESIMS m/z 461.1981[M+H]+(calcd.for C29H25N4O2,461.1978).
Preparation of Compound 40
According to the preparation method of compound 16, compound 39(200mg, 0.435)mmol) as a starting material to prepare its hydrochloride salt: n- (2- (2-pyridine) ethyl) -2- (1-ethyl-3-indole) -3- (3-indole) maleimide hydrochloride (40)173mg, yield 80%.1H NMR(500MHz,DMSO-d6)δ11.88(s,1H,indole-NH),10.60(brs,1H,-pryidine-H+),8.82(s,1H,Ar-H),8.45(t,1H,J=7.2Hz,Ar-H),7.99(d,1H,J=6.4Hz,Ar-H),7.87(t,1H,J=7.0Hz,Ar-H),7.68(d,1H,J=7.1Hz,Ar-H),7.61(d,1H,J=7.6Hz,Ar-H),7.45(d,1H,J=7.7Hz,Ar-H),7.37(d,1H,J=7.4Hz,Ar-H),7.04(t,1H,J=6.8Hz,Ar-H),6.97(t,1H,J=7.1Hz,Ar-H),6.87(d,1H,J=7.5Hz,Ar-H),6.70(t,1H,J=6.6Hz,Ar-H),6.65(d,1H,J=7.1Hz,Ar-H),6.61(d,1H,J=6.6Hz,Ar-H),4.20(q,2H,J=7.1Hz,-C 2H-CH3),4.02(t,2H,J=7.1Hz,imide-NC 2HCH2-),3.39(t,2H,J=7.1Hz,imide-NCH2C 2H-),1.26(t,3H,J=7.1Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ171.7×2,155.0,145.7,142.4,136.5,135.9,131.8,129.9,127.9,127.6,126.7,126.3,125.4,125.9,122.2,122.1,121.9,121.6,120.0,119.8,112.3,110.6,105.8,105.3,45.7,41.1,37.6,15.6.HR-ESIMS m/z 461.1989[M-Cl]+(calcd.for C29H25N4O2,461.1978).
Preparation of Compound 41
Compound 24e (52mg,0.146mmol) was dissolved in 10mL of THF, and hydrazine hydrate (73. mu.L, 1.46mmol) was added dropwise. The reaction mixture was heated to 45 ℃ and reacted for 15min, the solvent was evaporated in vacuo, water and ethyl acetate were added to extract, the organic layer was evaporated to dryness, and the mixture was subjected to silica gel column chromatography and eluted with dichloromethane and methanol at a ratio of 100:1(v/v) to give N-amino-2- (1-ethyl-3-indole) -3- (3-indole) maleimide (41) as a red solid in a yield of 83.3%.1H NMR(600MHz,DMSO-d6)δ11.71(d,1H,J=2.2Hz,indole-NH),7.81(d,1H,J=2.2Hz,Ar-H),7.73(s,1H,Ar-H),7.46(d,1H,J=8.3Hz,Ar-H),7.40(d,1H,J=8.3Hz,Ar-H),7.05(t,1H,J=7.1Hz,Ar-H),6.99(t,1H,J=7.1Hz,Ar-H),6.93(d,1H,J=7.7Hz,Ar-H),6.74(d,1H,J=8.2Hz,Ar-H),6.71(t,1H,J=7.7Hz,Ar-H),6.63(t,1H,J=7.7Hz,Ar-H),4.85(s,2H,-NH2),4.22(q,2H,J=7.7Hz,-C 2H-CH3),1.30(t,3H,J=7.7Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ171.5,171.4,136.6,136.0,131.9,129.9,126.6,126.1,125.6,125.4,122.3,122.2,121.9,121.5,120.1,119.9,112.4,110.7,106.2,105.6,41.2,15.8.HR-ESIMS m/z 371.1511[M+H]+(calcd.for C22H19N4O2,371.1508).
Preparation of Compound 42
Compound 24d (22mg,0.05mmol) was suspended in HCHO (4mL, 37% by mass) in a 10mL single-necked flask and reacted at room temperature overnight. TLC detection completed, poured into ice water (30mL), extracted with ethyl acetate (2 × 50mL), saturated brine (2 × 50mL), combined organic phases, dried over anhydrous sodium sulfate, evaporated in vacuo to remove the solvent, and chromatographed on silica gel column with dichloromethane and methanol 80:1(v/v) to give N-hydroxymethyl-2- (1-ethyl-3-indole) -3- (3-indole) maleimide (42) as a red solid in 60mg yield.1H NMR(500MHz,DMSO-d6)δ11.71(s,1H,indole-NH),7.81(d,1H,J=2.7Hz,Ar-H),7.76(s,1H,Ar-H),7.48(d,1H,J=8.2Hz,Ar-H),7.39(d,1H,J=8.1Hz,Ar-H),7.06(t,1H,J=7.0Hz,Ar-H),6.99(t,1H,J=7.4Hz,Ar-H),6.92(d,1H,J=8.0Hz,Ar-H),6.73(dd,2H,J=7.7Hz,4.6Hz,Ar-H),6.64(d,1H,J=7.4Hz,Ar-H),6.30(t,1H,J=7.0Hz,-CH2-OH),4.97(d,2H,J=7.0Hz,-C 2H-OH),4.25(q,2H,J=7.2Hz,-C 2H-CH3),1.32(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ171.7×2,136.6,136.1,132.1,130.1,128.0,127.3,126.6,125.6,122.3×2,121.9,121.5,120.2,120.0,112.4,110.7,106.0,105.4,60.8,41.6,15.7.HR-ESIMS m/z 386.1490[M+H]+(calcd.for C23H20N3O3,386.1499[M+H]+).
Preparation of Compound 43
i) Preparation of 1-benzyl-6-fluoroindole (43a)
According to the synthesis method of compound 24a, 6-fluoroindole (675mg,5mmol), NaH (300mg,7.5mmol, 60% by mass, dispersed in paraffin) and benzyl bromide (1283mg,7.5mmol) are used as raw materials to obtain white crystalline powder (43a)1.01g, yield 90%.1H NMR(600MHz,CDCl3)δ7.53(dd,1H,J=8.7Hz,5.5Hz,Ar-H),7.29-7.24(m,3H,Ar-H),7.06-7.09(m,3H,Ar-H),6.92(dd,1H,J=9.6Hz,2.3Hz,Ar-H),6.86(dt,1H,J=9.6Hz,2.3Hz,Ar-H),6.51(d,1H,J=3.2Hz,Ar-H),5.21(s,2H,-CH2-Ph).13C NMR(150MHz,CDCl3)δ159.9(d,1JCF=240Hz),137.2,136.5(d,3JCF=12Hz),129.0,128.9×2,127.9,126.9×2,125.3,121.7(d,3JCF=10Hz),108.5(d,2JCF=25Hz),102.0,96.3(d,2JCF=26Hz),50.4.ESI-MS m/z 225.1[M+H]+.
ii) preparation of 2- (1-ethyl-3-indole) -3- (1-benzyl-6-fluoro-3-indole) maleic anhydride (43b)
According to the method for synthesizing compound 24b, compound 43a (600mg,2.67mmol), (COCl)2(345. mu.L, 4.00mmol), Compound 1a (541mg,2.67mmol) and Et3N (738. mu.L, 5.33mmol) was used as a starting material to obtain 400mg of a red solid (43b) in a yield of 32%.1H NMR(600MHz,DMSO-d6)δ8.00(s,1H,Ar-H),7.99(s,1H,Ar-H),7.53(d,1H,J=8.3Hz,Ar-H),7.36(dd,1H,J=8.7Hz,2.3Hz,Ar-H),7.34(t,2H,J=7.3Hz,Ar-H),7.28(t,1H,J=7.3Hz,Ar-H),7.22(d,2H,J=7.3Hz,Ar-H),7.11(t,1H,J=6.9Hz,Ar-H),6.89(dd,1H,J=8.7Hz,5.5Hz,Ar-H),6.78(d,1H,J=7.8Hz,Ar-H),6.69(t,1H,J=7.8Hz,Ar-H),6.63(dt,1H,J=9.2Hz,2.3Hz,Ar-H),5.49(s,2H,-CH2-Ph),4.32(q,2H,J=7.3Hz,-C 2H-CH3),1.36(t,3H,J=7.3Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ166.9,166.8,155.9(d,1JCF=235Hz),137.6,136.6(d,3JCF=12Hz),136.3,134.3,133.5,129.6,129.2×2,128.2,127.6×2,127.1,125.8,123.1(d,3JCF=13Hz),123.0,122.8,122.1,120.7,111.2,109.2(d,2JCF=23Hz),105.5,104.6,98.0(d,2JCF=26Hz),50.0,41.5,15.8.ESI-MS m/z 465.2[M+H]+.
iii) preparation of 2- (1-ethyl-3-indole) -3- (1-benzyl-6-fluoro-3-indole) maleimide (43c)
According to the preparation of compound 24c, starting from compound 43b (317mg,0.68mmol), HMDS (7.2mL,34.3mmol) and MeOH (0.68mL,17.2mmol), 287mg of a red powdery solid (43c) was prepared in 91% yield.1H NMR(600MHz,DMSO-d6)δ11.00(s,1H,imide-NH),7.89(s,1H,Ar-H),7.88(s,1H,Ar-H),7.46(d,1H,J=8.3Hz,Ar-H),7.33(t,2H,J=7.3Hz,Ar-H),7.28(dd,1H,J=8.7Hz,2.3Hz,Ar-H),7.27(t,1H,J=7.8Hz,Ar-H),7.19(d,2H,J=7.3Hz,Ar-H),7.04(t,1H,J=8.2Hz,Ar-H),6.83(dd,1H,J=8.7Hz,5.5Hz,Ar-H),6.76(d,1H,J=8.2Hz,Ar-H),6.63(t,1H,J=7.8Hz,Ar-H),6.53(dt,1H,J=9.2Hz,2.3Hz,Ar-H),5.47(s,2H,-CH2-Ph),4.26(q,2H,J=7.3Hz,-C 2H-CH3),1.34(t,3H,J=7.3Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ173.3×2,159.4(d,1JCF=235Hz),137.9,136.5(d,3JCF=12Hz),136.0,133.2,132.2,129.2,129.0×2,128.1,127.5×2,126.8,126.3,123.5,122.7(d,3JCF=11Hz),122.3,121.8,120.1,110.8,108.6(d,2JCF=24Hz),106.3,105.2,97.6(d,2JCF=26Hz),49.9,41.3,15.8.ESI-MS m/z 464.2[M+H]+.
iv) preparation of 2- (1-ethyl-3-indole) -3- (6-fluoro-3-indole) maleimide (43)
According to the preparation of compound 24d, compound 43c (247mg,0.53mmol), DMSO (0.85mL), 1M solution of t-BuOK/THF (8.4mL,8.4mmol) and O2The starting material was prepared by column chromatography on silica gel eluting with petroleum ether ethyl acetate 3:1(v/v) to give 118mg of red powdered solid (43) in 60% yield.1H NMR(500MHz,DMSO-d6)δ11.69(s,1H,indole-NH),10.92(s,1H,imide-NH),7.76(s,1H,Ar-H),7.72(s,1H,Ar-H),7.45(d,1H,J=8.2Hz,Ar-H),7.14(d,1H,J=8.6Hz,Ar-H),7.04(t,1H,J=7.9Hz,Ar-H),6.81(d,1H,J=8.1Hz,Ar-H),6.71(dd,1H,J=8.5Hz,5.9Hz,Ar-H),6.67(d,1H,J=7.3Hz,Ar-H),6.47(t,1H,J=8.6Hz,Ar-H),4.24(q,2H,J=7.1Hz,-C 2H-CH3),1.32(t,3H,J=7.1Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ173.4×2,159.3(d,1JCF=235Hz),136.5(d,3JCF=12Hz),136.0,132.1,130.4,128.2,127.7,126.4,122.6,122.4(d,3JCF=11Hz),122.3,121.8,120.1,110.7,108.2(d,2JCF=24Hz),106.2,105.3,98.4(d,2JCF=27Hz),41.3,15.8.HR-ESIMS m/z 374.1314[M+H]+(calcd.for C22H17N3O2F,374.1305).
Preparation of Compound 44
According to the method for synthesizing compound 42, compound 43(20mg,0.05mmol) and HCHO (5mL, mass fraction 37%) were synthesized, and subjected to silica gel column chromatography and eluted with dichloromethane methanol 70:1(v/v) to give N-hydroxymethyl-2- (1-ethyl-3-indole) -3- (6-fluoro-3-indole) maleimide (44) as a red solid in a yield of 60 mg.1H NMR(500MHz,DMSO-d6)δ11.74(s,1H,indole-NH),7.81(s,1H,Ar-H),7.79(d,1H,J=2.7Hz,Ar-H),7.49(d,1H,J=8.3Hz,Ar-H),7.17(dd,1H,J=8.7Hz,2.3Hz,Ar-H),7.06(s,1H,Ar-H),6.84(d,1H,J=8.0Hz,Ar-H),6.73-6.69(m,2H,Ar-H),6.50(td,J=8.4Hz,2.4Hz,1H,Ar-H),6.30(t,1H,J=7.0Hz,-CH2-OH),4.97(d,2H,J=7.0Hz,-C 2H-OH),4.27(q,2H,J=7.2Hz,-C 2H-CH3),1.34(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ171.6,171.5,159.4(d,1JCF=235Hz),136.62(d,3JCF=12Hz),136.1,132.2×2,130.6,128.2,127.9,127.3,126.4,122.5(d,3JCF=11Hz),121.8,120.3,110.8,108.3(d,2JCF=25Hz),106.1,105.2,98.5(d,2JCF=27Hz),60.8,41.3,15.6.HR-ESIMS m/z 404.1393[M+H]+(calcd.for C23H19N3O3F,404.1405).
Preparation of Compound 45
According to the preparation method of the compound 2, 43(30mg,0.08mmol), formaldehyde solution (3mL, 37 percent by mass) and NaHCO are adopted3(13.5mg,0.16mmol) as a starting material, silica gel column chromatography, petroleum ether: ethyl acetate ═ 2:1(v/v) to obtain 35mg of N-hydroxymethyl-2- (1-ethyl-3-indole) -3- (1-hydroxymethyl-6-fluoro-3-indole) maleimide (45) as a red solid in a yield of 99%.1H NMR(600MHz,DMSO-d6)δ7.95(s,1H,Ar-H),7.78(s,1H,Ar-H),7.48(d,1H,J=8.3Hz,Ar-H),7.41(dd,1H,J=9.0Hz,1.5Hz,Ar-H),7.06(t,1H,J=7.7Hz,Ar-H),6.91(d,1H,J=8.1Hz,Ar-H),6.73(t,1H,J=7.9Hz,Ar-H),6.61(dd,J=8.8Hz,5.4Hz,Ar-H),6.51(dd,1H,J=8.8Hz,2.0Hz),5.57(s,2H,-C 2H-OH),4.95(s,2H,-C 2H-OH),4.25(q,2H,J=7.3Hz,-C 2H-CH3),1.31(t,3H,J=7.3Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ171.5×2,159.4(d,1JCF=235Hz),136.2(d,3JCF=12Hz),136.1,133.0,132.2,128.3,126.7,126.6,123.2,122.6(d,3JCF=11Hz),122.5,121.8,120.4,110.8,108.8(d,2JCF=25Hz),106.0,105.3,98.0(d,2JCF=26Hz),69.8,60.8,41.3,15.8.HR-ESIMS m/z 456.1342[M+Na]+(calcd.for C24H20N3O4FNa,456.1336).
Preparation of Compound 46
i) Preparation of 1-benzyl-6-chloroindole (46a)
According to the synthesis method of the compound 24a, the compound is prepared by taking 6-chloroindole (303mg,2mmol), NaH (120mg,3mmol, mass fraction of 60%, dispersed in paraffin) and benzyl bromide (513mg,3mmol) as raw materials, and the raw materials are separated by silica gel column chromatography and eluted by petroleum ether and ethyl acetate 60:1(v/v) to obtain white powdery solid (46a)483mg with the yield of 100%.1H NMR(600MHz,CDCl3)δ7.55(d,1H,J=8.22Hz,Ar-H),7.26-7.33(m,4H,Ar-H),7.12(d,1H,J=3.2Hz,Ar-H),7.09(d,2H,J=7.7Hz,Ar-H),7.08(d,1H,J=1.8Hz,Ar-H),6.53(dd,1H,J=3.4Hz,0.9Hz,Ar-H),5.28(s,2H,Ph-CH2-).13C NMR(150MHz,CDCl3)δ137.1,136.8,129.1,129.0,127.9,127.8,127.3,126.8×2,121.9,120.4,109.8,102.0×2,50.2.ESI-MS m/z 242.1/244.1[M+H]+.
ii) preparation of 2- (1-ethyl-3-indole) -3- (1-benzyl-6-chloro-3-indole) maleic anhydride (46b)
Following the synthesis of compound 24b, compound 46a (419mg,1.73mmol), (COCl)2(446. mu.L, 5.20mmol), Compound 1a (352mg,1.73mmol) and Et3N (480. mu.L, 3.47mmol) was prepared as a starting material, and methanol was recrystallized to yield 278mg of red powder (46b), 33.4% yield.1H NMR(600MHz,DMSO-d6)δ8.01(s,2H,Ar-H),7.59(s,1H,Ar-H),7.54(d,1H,J=8.2Hz,Ar-H),7.34(t,2H,J=7.8Hz,Ar-H),7.29(t,1H,J=7.3Hz,Ar-H),7.19(d,2H,J=7.8Hz,Ar-H),7.11(t,1H,J=7.7Hz,Ar-H),6.92(d,1H,J=8.7Hz,Ar-H),6.77(d,1H,J=8.7Hz,Ar-H),6.75(d,1H,J=7.3Hz,Ar-H),6.69(t,1H,J=7.3Hz,Ar-H),5.53(s,2H,Ph-CH2-),4.32(q,2H,J=7.3Hz,-C 2H-CH3),1.37(t,3H,J=7.3Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ166.9,166.8,137.6,136.9,136.3,134.5,133.6,129.9,129.3×2,128.2,127.7,127.5×2,126.8,125.7,125.2,123.2,122.9,122.0,121.0,120.8,111.4,111.2,105.5,104.5,50.0,41.5,15.8.ESI-MS m/z 481.2/483.2[M+H]+.
iii) preparation of 2- (1-ethyl-3-indole) -3- (1-benzyl-6-chloro-3-indole) maleimide (46c)
According to the preparation of compound 24c, starting from compound 46b (240mg,0.5mmol), HMDS (4.2mL,20mmol) and MeOH (0.4mL,10mmol), silica gel column chromatography and dichloromethane elution gave 218mg of red powdered solid (46c) in 91% yield.1H NMR(600MHz,DMSO-d6)δ11.00(s,1H,imide-NH),7.91(s,1H,Ar-H),7.90(s,1H,Ar-H),7.51(d,1H,J=1.9Hz,Ar-H),7.47(d,1H,J=8.2Hz,Ar-H),7.34(t,2H,J=7.4Hz,Ar-H),7.28(t,1H,J=7.3Hz,Ar-H),7.17(d,2H,J=7.3Hz,Ar-H),7.05(t,1H,J=7.7Hz,Ar-H),6.84(d,1H,J=8.2Hz,Ar-H),6.72(d,1H,J=7.8Hz,Ar-H),6.67(dd,1H,J=8.7Hz,1.9Hz,Ar-H),6.62(t,1H,J=7.3Hz,Ar-H),5.50(s,2H,Ph-CH2-),4.28(q,2H,J=7.3Hz,-C 2H-CH3),1.36(t,3H,J=7.3Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ173.3×2,137.9,136.8,136.1,133.5,132.3,129.3,129.2×2,128.1,127.4×2,127.2,126.5,126.2,125.6,122.9,122.3,121.7,120.5,120.2,111.0,110.8,106.3,105.1,49.8,41.3,15.8.ESI-MS m/z 480.1/482.2[M+H]+.
iv) preparation of 2- (1-ethyl-3-indole) -3- (6-chloro-3-indole) maleimide (46)
According to the preparation of compound 23d, compound 46c (160mg,0.33mmol), DMSO (0.85mL), 1M solution of t-BuOK/THF (8.4mL,8.4mmol) and O2The raw material was prepared by silica gel column chromatography and eluted with petroleum ether ethyl acetate 3:1(v/v) to give 128mg of red powder (46) in 99% yield.1H NMR(500MHz,DMSO-d6)δ11.75(s,1H,indole-NH),10.94(s,1H,imide-NH),7.79(s,1H,Ar-H),7.76(s,1H,Ar-H),7.45(d,1H,J=8.3Hz,Ar-H),7.41(s,1H,Ar-H),7.02(t,1H,J=7.6Hz,Ar-H),6.77(d,1H,J=7.7Hz,Ar-H),6.73(d,1H,J=8.2Hz,Ar-H),6.66(t,1H,J=7.5Hz,Ar-H),6.61(dd,1H,J=8.5Hz,1.1Hz,Ar-H),4.24(q,2H,J=7.2Hz,-C 2H-CH3),1.32(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ173.3×2,136.8,135.9,132.0,130.5,128.4,127.2,126.6,126.2,124.6,122.5,122.2,121.6,120.0,119.9,111.8,110.6,106.1,105.1,41.1,15.7.HR-ESIMS m/z390.1014[M+H]+(calcd.for C22H17N3O2Cl,390.1009).
Preparation of Compound 47
According to the method for synthesizing compound 42, compound 46(19mg,0.05mmol) and HCHO (5mL, mass fraction 37%) were synthesized, and the mixture was separated by silica gel column chromatography and eluted with dichloromethane methanol 80:1(v/v) to give N-hydroxymethyl-2- (1-ethyl-3-indole) -3- (6-chloro-3-indole) maleimide (47) as a red solid in a yield of 50 mg.1H NMR(500MHz,DMSO-d6)δ11.78(s,1H,indole-NH),7.83(s,1H,Ar-H),7.79(s,1H,Ar-H),7.48(d,1H,J=8.3Hz,Ar-H),7.42(d,1H,J=1.3Hz,Ar-H),7.04(t,1H,J=7.5Hz,Ar-H),6.77(d,1H,J=8.0Hz,Ar-H),6.71(d,1H,J=8.6Hz,Ar-H),6.68(t,1H,J=7.5Hz,Ar-H),6.62(dd,1H,J=8.6Hz,1.5Hz,Ar-H),6.30(t,1H,J=6.9Hz,imide-CH2-OH),4.94(d,2H,J=6.9Hz,imide-C 2H-OH),4.28(q,2H,J=7.2Hz,-C 2H-CH3),1.33(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ171.5×2,137.0,136.1,132.3,130.9,128.2,127.0,126.9,126.4,124.6,122.6,122.4,121.7,120.3,120.2,112.1,110.9,106.2,105.2,60.8,41.3,15.8.HR-ESIMS m/z 420.1107[M+H]+(calcd.for C23H19N3O3Cl,420.1109).
Preparation of Compound 48
According to the preparation method of compound 2, compound 46(14mg, 36.0. mu. mol), formaldehyde solution (3mL, mass fraction 37%) and NaHCO3(7mg,0.083mmol) was prepared by silica gel column chromatography and eluted with petroleum ether ethyl acetate 3:1(v/v) to give N-hydroxymethyl-2- (1-ethyl-3-indole) -3- (1-hydroxymethyl-6-chloro-3-indole) maleimide (48) as a red solid in 99% yield.1H NMR(600MHz,DMSO-d6)δ7.99(s,1H,Ar-H),7.83(s,1H,Ar-H),7.69(d,1H,J=1.8Hz,Ar-H),7.50(d,1H,J=8.2Hz,Ar-H),7.06(t,1H,J=7.8Hz,Ar-H),6.89(d,1H,J=8.2Hz,Ar-H),6.75(t,1H,J=7.3Hz,-CH2-OH),6.72(t,1H,J=7.7Hz,Ar-H),6.66(dd,1H,J=8.2Hz,1.8Hz,Ar-H),6.62(d,1H,J=8.2Hz,Ar-H),6.35(t,1H,J=6.8Hz,-CH2-OH),5.61(d,2H,J=7.3Hz,-N-C 2H-OH),4.97(d,2H,J=6.8Hz,-N-C 2H-OH),4.28(q,2H,J=6.8Hz,-C 2H-CH3),1.32(t,3H,J=6.8Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ171.4×2,136.5,136.0,133.3,132.4,128.6,127.2,126.6,126.3,125.4,122.7,122.5,121.7,120.6,120.4,111.5,110.9,105.9,105.2,69.8,60.9,41.3,15.8.HR-ESIMS m/z 472.1046[M+Na]+(calcd.for C24H20N3O4ClNa,472.1040).
Preparation of Compound 49
i) Preparation of 1-benzyl-4-bromoindole (49a)
According to the preparation method of the compound 24a, the compound 4-bromoindole (700mg,3.59mmol), NaH (129mg,5.38mmol, 60 mass percent and dispersed in paraffin) and benzyl bromide (0.64mL,5.38mmol) are used as raw materials, silica gel column chromatography separation is carried out, and the white product is obtained by eluting petroleum ether and ethyl acetate which are 100:1(v/v)0.88g of crystal (49a) was obtained, the yield was 86%.1H NMR(600MHz,DMSO-d6)δ7.64(d,1H,J=3.3Hz,Ar-H),7.49(d,1H,J=8.3Hz,Ar-H),7.29-7.27(m,2H,Ar-H),7.25-7.23(m,2H,Ar-H),7.19-7.18(m,2H,Ar-H),7.03(t,1H,J=7.7Hz,Ar-H),6.45(d,1H,J=2.8Hz,Ar-H),5.43(s,2H,Ph-CH2-).13C NMR(150MHz,DMSO-d6)δ138.4,136.7,130.9,129.2,129.1,128.0,127.6,127.4,123.0×2,122.4,114.2,110.5,101.4,50.0.ESI-MS m/z 286.0/288.0[M+H]+.
ii) preparation of 2- (1-ethyl-3-indole) -3- (1-benzyl-4-bromo-3-indole) maleic anhydride (49b)
According to the preparation of compound 24b, compound 49a (400mg,1.4mmol), (COCl)2(214. mu.L, 2.25mmol), Compound 1a (548mg,2.7mmol) and Et3N (626 μ L,4.5mmol) was prepared as the starting material, which was chromatographed on silica gel and eluted with petroleum ether ethyl acetate 7:1(v/v) to give 220mg of red powder (49b) in 30.0% yield.1H NMR(600MHz,pyridine-d5)δ8.37(s,1H,Ar-H),7.63(s,1H,Ar-H),7.41(d,1H,J=3.8Hz,Ar-H),7.42(m,3H,Ar-H),7.24-7,22(m,4H,Ar-H),7.06-7.04(m,4H,Ar-H),6.77(t,1H,J=7.2Hz,Ar-H),5.3(d,1H,J=15.9Hz,Ph-C 2H-),5.24(d,1H,J=15.9Hz,Ph-CH2-),4.05(q,2H,J=8.2Hz,-C 2H-CH3),1.37(t,3H,J=8.2Hz,-CH2-C 3H).13C NMR(150MHz,pyridine–d5)δ166.0,165.6,148.5×2,136.4,135.5,135.4,133.2,130.6,127.5,126.4,125.5,125.4,124.5,124.1,123.8,122.5,122.1,121.5,121.2,119.9,113.4,109.3,109.2,104.4,103.8,48.8,40.1,13.5.ESI-MS m/z 525.1/527.1[M+H]+.
iii) preparation of 2- (1-ethyl-3-indole) -3- (1-benzyl-4-bromo-3-indole) maleimide (49c)
According to the preparation method of compound 24c, using compound 49c (110mg,0.21mmol), HMDS (4.5mL,21mmol) and MeOH (0.4mL,10.5mmol) as raw materials, silica gel column chromatography separation and elution with petroleum ether and dichloromethane ═ 1:4(v/v) gave 100mg of red powder (49c) with a yield of 91%.1H NMR(600MHz,DMSO-d6)δ11.02(s,1H,imide-NH),8.05(s,1H,Ar-H),7.53(s,1H,Ar-H),7.47(t,2H,J=8.7Hz,Ar-H),7.27(d,1H,J=7.6Hz,Ar-H),7.19(dd,3H,J=5.0Hz,1.8Hz,Ar-H),7.09(dt,2H,J=8.2Hz,2.0Hz,Ar-H),6.99-6.95(m,2H,Ar-H),6.68(d,1H,J=8.1Hz,Ar-H),6.58(t,1H,J=7.6Hz,Ar-H),5.42(d,1H,J=15.9Hz)/5.38(d,1H,J=15.9Hz)(Ph-CH2-),4.25(q,2H,J=7.2Hz,-C 2H-CH3),1.35(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ173.9,173.2,137.9,137.6,136.5,134.3,133.3,132.0,129.0,127.9,127.1,126.9,126.7,125.7,124.6,123.7,122.5,121.9,120.6,114.4,111.0×2,110.9,106.2,105.0,49.8,49.2,41.4,15.8.ESI-MS m/z 524.1/526.1[M+H]+.
iv) preparation of 2- (1-ethyl-3-indole) -3- (4-bromo-3-indole) maleimide (49)
According to the preparation method of compound 24d, compound 49c (110mg,0.21mmol), DMSO (1.24mL), 1M t-BuOK/THF solution (0.97mL,0.97mmol) and O2The starting material was prepared by column chromatography on silica gel eluting with petroleum ether ethyl acetate 3:1(v/v) to give 63mg of red powder (49) in 70% yield.1H NMR(600MHz,DMSO-d6)δ11.65(s,1H,indole-NH),10.93(s,1H,imide-NH),8.00(s,1H,Ar-H),7.48(d,1H,J=8.3Hz,Ar-H),7.45(d,1H,J=8.3Hz,Ar-H),7.30(d,1H,J=2.8Hz,Ar-H),7.24(d,1H,J=7.7Hz,Ar-H),7.09(t,1H,J=7.7Hz,Ar-H),7.01(t,1H,J=6.6Hz,Ar-H),6.58(d,1H,J=7.9Hz,Ar-H),6.53(t,1H,J=7.3Hz,Ar-H),4.24(q,2H,J=7.2Hz,-C 2H-CH3),1.34(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ174.0,173.4,137.9,136.4,134.3,133.3,128.6,127.4,126.4,125.8,124.1,123.5,122.4,121.8,120.4,114.1,112.2,110.8,106.5,105.1,41.3,15.8.HR-ESIMS m/z 434.0514[M+H]+(calcd.for C22H17N3O2Br,434.0504).
Preparation of Compound 50
According to the method for synthesizing compound 42, compound 49(20mg,0.05mmol) and HCHO (5mL, mass fraction 37%) were synthesized, and separated by silica gel column chromatography and eluted with dichloromethane methanol 70:1(v/v) to obtain N-hydroxymethyl-2- (1-ethyl-3-indole) as a red solid)11mg of (E) -3- (4-bromo-3-indolyl) maleimide (50), yield 50%.1H NMR(500MHz,DMSO-d6)δ11.70(s,1H,indole-NH),8.03(s,1H,Ar-H),7.48(d,1H,J=8.1Hz,Ar-H),7.45(d,1H,J=8.2Hz,Ar-H),7.34(d,1H,J=2.5Hz,Ar-H),7.22(d,1H,J=7.5Hz,Ar-H),7.07(t,1H,J=7.9Hz,Ar-H),7.02(t,1H,J=7.3Hz,Ar-H),6.56(d,2H,J=7.5Hz,Ar-H),6.34(t,1H,J=7.0Hz,-CH2-OH),4.95(d,2H,J=7.0Hz,-C 2H-OH),4.27(q,2H,J=7.2Hz,-C 2H-CH3),1.33(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ171.9,171.4,137.8,136.4,133.9,133.3,128.6,126.7,126.2,125.6,124.0,123.4,122.4,121.6,120.4,113.8,112.1,110.8,106.1,105.0,60.7,41.2,15.6.HR-ESIMS m/z 464.0602[M+H]+(calcd.for C23H19N3O3Br,464.0604).
Preparation of Compound 51
According to the preparation method of the compound 2, the compound 49(100mg,0.23mmol), formaldehyde solution (3mL, 37 percent by mass) and NaHCO are used3(97mg,1.15mmol) was used as a starting material, and the crude product was subjected to silica gel column chromatography and eluted with petroleum ether and ethyl acetate 4:1(v/v) to give 67mg of N-hydroxymethyl-2- (1-ethyl-3-indole) -3- (1-hydroxymethyl-4-bromo-3-indole) maleimide (51) as a red solid in 59% yield.1H NMR(500MHz,DMSO-d6)δ8.02(s,1H,Ar-H),7.68(d,1H,J=8.1Hz,Ar-H),7.48(s,1H,Ar-H),7.45(d,1H,J=8.3Hz,Ar-H),7.28(d,1H,J=7.5Hz,Ar-H),7.15(d,1H,J=7.9Hz,Ar-H),7.06(t,1H,J=7.4Hz,Ar-H),6.73(d,1H,J=8.2Hz,Ar-H),6.62(t,1H,J=6.8Hz,Ar-H),6.60(t,1H,J=7.2Hz,indole-CH2-OH),6.37(t,1H,J=6.5Hz,imide-CH2-OH),5.53(d,2H,J=7.2Hz,indole-C 2H-OH),4.97(d,2H,J=6.5Hz,imide-C 2H-OH),4.24(q,2H,J=7.1Hz,-C 2H-CH3),1.33(t,3H,J=7.1Hz,-CH2-C 3H).13CNMR(125MHz,DMSO-d6)δ172.0,171.5,137.4,136.5,134.6,133.5,131.3,127.2,126.2,125.9,124.8,123.8,122.6,121.9,120.7,114.1,111.2,110.9,106.0,105.1,69.6,60.8,41.4,15.7.HR-ESIMS m/z516.0540[M+Na]+(calcd.for C24H20N3O4BrNa,516.0535).
Preparation of Compound 52
i) Preparation of 1-benzyl-5-bromoindole (52a)
According to the preparation method of the compound 24a, the compound 5-bromoindole (700mg,3.59mmol), NaH (129mg,5.38mmol, 60% by mass in paraffin) and benzyl bromide (0.64mL,5.38mmol) are used as raw materials, and silica gel column chromatography separation and elution with petroleum ether and ethyl acetate 60:1(v/v) are carried out to obtain 0.88g of white crystalline powder (52a), the yield of which is 86%.1H NMR(600MHz,DMSO-d6)δ7.75(d,1H,J=1.6Hz,Ar-H),δ7.56(d,1H,J=3.3Hz,Ar-H),7.42(d,2H,J=8.8Hz,Ar-H),7.30(t,2H,J=7.7Hz,Ar-H),7.24-7.16(m,3H,Ar-H),6.48(d,1H,J=2.2Hz,Ar-H),5.41(s,2H,-CH2-).13C NMR(150MHz,DMSO-d6)δ138.5,135.0,131.3,130.7×2,129.1,128.0,127.6,127.5,124.2,123.2,112.8,112.4,101.3,49.8.ESI-MS m/z 286.0/288.0[M+H]+.
ii) preparation of 2- (1-ethyl-3-indole) -3- (1-benzyl-5-bromo-3-indole) maleic anhydride (52b)
According to the preparation method of the compound 24b, the compound 52a (1100mg,3.86mmol), (COCl)2(500. mu.L, 5.79mmol), Compound 1a (783mg,3.86mmol) and Et3N (1.07mL,7.72mmol) was used as the starting material, and pure methanol was recrystallized to yield 652mg of red powder (52b), 32.2% yield.1H NMR(600MHz,DMSO-d6)δ8.06(s,1H,Ar-H),7.99(s,1H,Ar-H),7.55(d,1H,J=8.1Hz,Ar-H),7.39(d,1H,J=8.7Hz,Ar-H),7.33(t,2H,J=7.5Hz,Ar-H),7.28(d,1H,J=6.7Hz,Ar-H),7.17(d,2H,J=7.4Hz,Ar-H),7.14(d,1H,J=8.8Hz,Ar-H),7.10(t,1H,J=7.7Hz,Ar-H),6.98(s,1H,Ar-H),6.76(d,1H,J=8.1Hz,Ar-H),6.69(d,1H,J=8.2Hz,Ar-H),5.52(s,2H,-CH2-Ph),4.33(q,2H,J=6.6Hz,-C 2H-CH3),1.39(t,3H,J=6.6Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ166.8×2,137.6,136.2,135.2,134.8,133.2,129.5,129.2,128.2,128.0,127.6,127.5,127.4,125.8,125.3,124.4,122.9,121.7,120.7,113.5,113.4,111.2,104.8,104.6,99.9,50.2,41.5,16.1.ESI-MS m/z 525.1/527.0[M+H]+.
iii) preparation of 2- (1-ethyl-3-indole) -3- (1-benzyl-5-bromo-3-indole) maleimide (52c)
According to the preparation of compound 24c, starting from compound 52b (110mg,0.21mmol), HMDS (4.5mL,21mmol) and MeOH (0.4mL,11mmol), separation by silica gel column chromatography and elution with dichloromethane afforded 100mg of a red powdered solid (52c) in 91% yield.1H NMR(600MHz,DMSO-d6)δ10.98(s,1H,imide-NH),7.96(s,1H,Ar-H),7.86(s,1H,Ar-H),7.48(d,1H,J=8.3Hz,Ar-H),7.34(dt,3H,J=7.2Hz,1.7Hz,Ar-H),7.27(t,1H,J=7.3Hz,Ar-H),7.14(d,2H,J=7.1Hz,2H,Ar-H),7.06(dd,1H,J=6.8Hz,2.0Hz,Ar-H),6.90(d,1H,J=1.9Hz,Ar-H),6.72(d,1H,J=8.0Hz,Ar-H),6.62(t,1H,J=7.2Hz,Ar-H),5.49(s,2H,-CH2-Ph),4.30(q,2H,J=7.2Hz,-C 2H-CH3),1.38(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ173.2×2,137.9,136.0,135.0,133.9,132.0,129.2,128.8,128.4,128.19,127.4,127.0×2,126.7,124.8,124.2×2,122.4,121.4,120.1,113.1,112.9,110.8,105.6,105.1,50.0,41.3,16.1.ESI-MS m/z 524.1/526.1[M+H]+.
iv) preparation of 2- (1-ethyl-3-indole) -3- (5-bromo-3-indole) maleimide (52)
According to the preparation of compound 24d, compound 52c (90mg,0.172mmol), DMSO (0.85mL) and a 1M solution of t-BuOK/THF (7mL,7mmol) and O2Is prepared by taking the raw materials as raw materials. Silica gel column chromatography, dichloromethane and ethyl acetate 4:1(v/v) gave 54mg of red powder (52) in 73% yield.1H NMR(600MHz,DMSO-d6)δ11.82(s,1H,indole-NH),10.92(s,1H,imide-NH),7.80(s,1H,Ar-H),7.77(s,1H,Ar-H),7.49(d,1H,J=8.3Hz,Ar-H),7.31(d,1H,J=8.6Hz,Ar-H),7.05(d,1H,J=8.0Hz,Ar-H),7.03(d,1H,J=8.0Hz,Ar-H),6.79(s,1H,Ar-H),6.77(d,1H,J=8.0Hz,Ar-H),6.67(t,1H,J=7.2Hz,Ar-H),4.28(q,2H,J=7.2Hz,-C 2H-CH3),1.36(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ173.4,173.3,136.0,135.2,131.9,131.0,128.1,127.8,127.5,126.5,124.6,124.0,122.4,121.4,120.1,114.2,112.4,110.7,105.8,105.3,41.3,16.1.HR-ESIMS m/z434.0514[M+H]+(calcd.for C22H17N3O2Br,434.0504).
Preparation of Compound 53
According to the method for synthesizing compound 42, compound 52(21mg,0.05mmol) and HCHO (5mL, mass fraction 37%) were synthesized, and subjected to silica gel column chromatography and eluted with dichloromethane methanol 70:1(v/v) to give N-hydroxymethyl-2- (1-ethyl-3-indole) -3- (5-bromo-3-indole) maleimide (53) as a red solid in 12mg with a yield of 55%.1H NMR(500MHz,DMSO-d6)δ11.86(s,1H,indole-NH),7.83(s,1H,Ar-H),7.80(s,1H,Ar-H),7.49(d,1H,J=8.4Hz,Ar-H),7.32(d,1H,J=8.7Hz,Ar-H),7.06(d,1H,J=8.3Hz,Ar-H),7.03(d,1H,J=7.7Hz,Ar-H),6.81(s,1H,Ar-H),6.77(t,1H,J=8.2Hz,Ar-H),6.67(t,1H,J=7.7Hz,Ar-H),6.31(t,1H,J=6.7Hz,-CH2-OH),4.95(d,2H,J=6.4Hz,-C 2H-OH),4.28(q,2H,J=7.0Hz,-C 2H-CH3),1.36(t,3H,J=6.8Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ171.4,171.3,136.0,135.1,131.9,131.1,127.6,127.3,127.2,126.2,124.6,123.9,122.3,121.3,120.1,114.1,112.4,110.7,105.5,105.0,60.7,41.2,15.9.HR-ESIMS m/z 464.0600[M+H]+(calcd.for C23H19N3O3Br,464.0604).
Preparation of Compound 54
According to the preparation method of compound 2, compound 53(53mg,0.122mmol) and NaHCO are used3(51mg,0.62mmol) and formaldehyde solution (3mL, mass fraction 37%) as raw materials, separating by silica gel column chromatography, eluting with petroleum ether and ethyl acetate (4: 1 (v/v)) to obtain red solid N-hydroxymethyl-2- (1-ethyl-3-indole) -3- (1-hydroxymethyl-5-bromo-3-indole) maleimide (54)60mg, yield 99%.1H NMR(500MHz,DMSO-d6)δ8.04(s,1H,Ar-H),7.78(s,1H,Ar-H),7.50(d,2H,J=8.6Hz,Ar-H),7.13(d,1H,J=8.6Hz,Ar-H),7.06(t,1H,J=7.5Hz,Ar-H),6.87(d,1H,J=7.9Hz,Ar-H),6.75(t,1H,J=6.8Hz,indole-CH2-OH),6.71(d,1H,J=7.6Hz,Ar-H),6.68(s,1H,Ar-H),6.34(t,1H,J=6.4Hz,imide-CH2-OH),5.58(d,2H,J=6.8Hz,indole-C 2H-OH),4.96(d,2H,J=6.4Hz,imide-C 2H-OH),4.28(q,2H,J=6.9Hz,-C 2H-CH3),1.35(t,3H,J=6.9Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ171.4×2,136.0,134.8,133.6,132.0,128.2,128.1,126.9,126.6,124.8,124.3,122.5,121.4,120.4,113.3,113.2,110.8,105.4,105.2,69.9,60.8,41.4,16.1.HR-ESIMS m/z 516.0547[M+Na]+(calcd.for C24H20N3O4BrNa,516.0535),.
Preparation of Compound 55 (Compound 26d)
See preparation of compound 26 d.
Preparation of Compound 56
According to the method for synthesizing compound 42, compound 55(21mg,0.05mmol) and HCHO (5mL, mass fraction 37%) were synthesized, and subjected to silica gel column chromatography and eluted with dichloromethane methanol 70:1(v/v) to give N-hydroxymethyl-2- (1-ethyl-3-indole) -3- (6-bromo-3-indole) maleimide (56) as a red solid in 12mg (yield 53%).1H NMR(600MHz,DMSO-d6)δ11.81(s,1H,indole-NH),7.85(s,1H,Ar-H),7.80(s,1H,Ar-H),7.58(d,1H,J=1.8Hz,Ar-H),7.50(d,1H,J=8.3Hz,Ar-H),7.38(dd,1H,J=7.6Hz,1.5Hz,Ar-H),7.06(t,1H,J=7.6Hz,Ar-H),6.79(d,1H,J=8.0Hz,Ar-H),6.76(dd,1H,J=8.6Hz,1.8Hz,Ar-H),6.71(d,1H,J=3.9Hz,Ar-H),6.69(t,1H,J=3.9Hz,Ar-H),6.32(t,1H,J=7.0Hz,-CH2-OH),4.96(d,2H,J=7.0Hz,-C 2H-OH),4.29(q,2H,J=7.2Hz,-C 2H-CH3),1.35(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ171.5×2,137.5,136.1,132.3,130.7,128.2,127.0,126.3,124.9,123.0,122.8,122.4,121.7,120.3,115.1,115.0,110.9,106.2,105.1,60.8,41.3,15.8.HR-ESIMS m/z464.0591[M+H]+(calcd.for C23H19N3O3Br,464.0604).
Preparation of Compound 57
According to the process for the preparation of the compound 2,with compound 56(50mg,0.115mmol), NaHCO3(29mg,0.345mmol) and formaldehyde solution (3mL, mass fraction 37%) as raw materials, separating by silica gel column chromatography, eluting with petroleum ether and ethyl acetate (4: 1) (v/v) to obtain red solid N-hydroxymethyl-2- (1-ethyl-3-indole) -3- (1-hydroxymethyl-6-bromo-3-indole) maleimide (57)48mg, yield 85%.1H NMR(500MHz,DMSO-d6)δ7.98(s,1H,Ar-H),7.83(s,2H,Ar-H),7.49(d,1H,J=8.2Hz,Ar-H),7.07(t,1H,J=7.7Hz,Ar-H),6.89(d,1H,J=7.7Hz,Ar-H),6.78(d,1H,J=8.2Hz,Ar-H),6.76(t,1H,J=6.8Hz,-CH2-OH),6.72(t,1H,J=7.7Hz,Ar-H),6.60(d,1H,J=8.2Hz,Ar-H),6.35(t,1H,J=6.6Hz,-CH2-OH),5.61(d,2H,J=6.6Hz,-N-C 2H-OH),4.98(d,2H,J=6.6Hz,-C 2H-OH),4.27(q,2H,J=6.6Hz,-C 2H-CH3),1.34(t,3H,J=6.6Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ171.4×2,136.9,136.1,133.1,132.3,128.7,126.6,126.3,125.7,123.2,123.1,122.5,121.7,120.4,115.3,114.4,110.9,106.0,105.2,69.8,60.9,41.4,15.8.HR-ESIMS m/z 516.0544[M+Na]+(calcd.for C24H20N3O4BrNa,516.0535).
Preparation of Compound 58
i) Preparation of 1-benzyl-7-bromoindole (58a)
According to the preparation method of the compound 24a, the compound 7-bromoindole (700mg,3.59mmol), NaH (129mg,5.38mmol, 60% by mass in paraffin) and benzyl bromide (0.64mL,5.38mmol) are used as raw materials, and silica gel column chromatography separation and elution with petroleum ether and ethyl acetate 60:1(v/v) yield of 1.0g of white crystalline powder (58a) is obtained.1H NMR(600MHz,DMSO-d6)δ7.61(d,1H,J=7.8Hz,Ar-H),7.54(d,1H,J=3.2Hz,Ar-H),7.29(d,1H,J=7.5Hz,Ar-H),7.26(t,2H,J=7.5Hz,Ar-H),7.21(d,1H,J=7.1Hz,Ar-H),6.95(d,1H,J=7.7Hz,Ar-H),6.93(dd,2H,J=7.6Hz,2.7Hz,Ar-H),6.61(d,1H,J=3.2Hz,Ar-H),5.81(s,2H,-CH2-).13C NMR(150MHz,DMSO-d6)δ140.2×2,133.3,132.4,129.1×2,127.6,127.0,126.3,121.4×2,121.1,103.6,102.6,51.0.ESI-MS m/z 286.0/288.0[M+H]+.
iii) preparation of 2- (1-ethyl-3-indole) -3- (1-benzyl-7-bromo-3-indole) maleic anhydride (58b)
According to the preparation of compound 24b, the compound 58a (700mg,2.5mmol), (COCl)2(714. mu.L, 7.5mmol), Compound 1a (686mg,3.3mmol) and Et3N (0.723mL,5.2mmol) was used as a starting material, and pure methanol was recrystallized to give 380mg of red powder (58b), with a yield of 30%.1H NMR(600MHz,DMSO-d6)δ8.04(s,1H,Ar-H),8.01(s,1H,Ar-H),7.50(d,1H,J=8.0Hz,Ar-H),7.31(t,2H,J=7.0Hz,Ar-H),7.25(t,1H,J=7.4Hz,Ar-H),7.21(d,1H,J=7.6Hz,Ar-H),7.09(t,1H,J=7.6Hz,Ar-H),6.99(d,2H,J=7.4Hz,Ar-H),6.94(d,1H,J=8.0Hz,Ar-H),6.77(d,1H,J=8.0Hz,Ar-H),6.71(t,1H,J=7.5Hz,Ar-H),6.63(t,1H,J=7.8Hz,Ar-H),5.90(s,2H,-CH2-Ph),4.31(q,2H,J=5.8Hz,-C 2H-CH3),1.34(t,3H,J=5.8Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ166.8,166.7,139.4,136.4,136.3,133.8,132.6,131.1,129.8,129.2,128.2,127.8,127.3,126.2,125.9,125.8,123.0,121.8,121.4,120.9,120.8,119.4,111.2,105.8,104.6,103.9,51.7,41.6,15.8.ESI-MS m/z 525.1/527.0[M+H]+.
iii) preparation of 2- (1-ethyl-3-indole) -3- (1-benzyl-7-bromo-3-indole) maleimide (58c)
According to the preparation of compound 24c, starting from compound 58b (110mg,0.45mmol), HMDS (4.5mL,21mmol) and MeOH (0.4mL,11mmol), separation by silica gel column chromatography and elution with dichloromethane afforded 100mg of a red powdered solid (58c) in 91% yield.1H NMR(600MHz,DMSO-d6)11.04(s,1H,imide-NH),7.93(s,1H,Ar-H),7.92(s,1H,Ar-H),7.45(d,1H,J=8.3Hz,Ar-H),7.31(t,2H,J=7.5Hz,Ar-H),7.25(s,1H,J=7.4Hz,Ar-H),7.15(dd,1H,J=7.6Hz,1.0Hz,Ar-H),7.04(d,1H,J=1.1Hz,Ar-H),6.97(d,2H,J=7.2Hz,Ar-H),6.88(dd,1H,J=8.0Hz,1.0Hz,Ar-H),6.76(d,1H,J=8.0Hz,Ar-H),6.67(d,1H,J=7.9Hz,Ar-H),6.56(t,1H,J=7.8Hz,Ar-H),5.88(s,2H,-CH2-Ph),4.27(q,2H,J=7.2Hz,-C 2H-CH3),1.35(t,3H,J=7.2Hz,-CH2-C 3H_).13C NMR(150MHz,DMSO-d6)δ173.2×2,139.7,136.0,135.6,135.5,132.5,132.4,130.3,130.2,129.1,127.7×2,126.3,126.2,125.7,122.4,121.7,121.6,121.1×2,120.2,110.8,106.5,105.1,103.7,51.5,41.4,15.8.ESI-MS m/z 523.8/525.8[M+H]+.
iv) preparation of 2- (1-ethyl-3-indole) -3- (7-bromo-3-indole) maleimide (58)
According to the preparation of compound 24d, compound 58c (292mg,0.558mmol), DMSO (0.85mL) and a 1M solution of t-BuOK/THF (8.4mL,8.4mmol) and O2Is prepared by taking the raw materials as raw materials. Silica gel column chromatography, dichloromethane and ethyl acetate 4:1(v/v) to give 150mg of red powder (58) in 64% yield.1H NMR(500MHz,DMSO-d6)δ11.86(s,1H,indole-NH),10.96(s,1H,imide-NH),7.78(s,1H,Ar-H),7.72(s,1H,Ar-H),7.46(d,1H,J=8.2Hz,Ar-H),7.19(d,1H,J=7.5Hz,Ar-H),7.03(t,1H,J=7.6Hz,Ar-H),6.82(d,1H,J=8.0Hz,Ar-H),6.76(d,1H,J=8.0Hz,Ar-H),6.69(t,1H,J=7.5Hz,Ar-H),6.57(t,1H,J=7.7Hz,Ar-H),4.24(q,2H,J=7.1Hz,-C 2H-CH3),1.31(t,3H,J=7.1Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ173.1×2,135.9,134.7,132.1,130.3,128.9,127.4,127.1,126.2,124.6,122.2,121.5,121.1,120.8,120.1,110.6,107.2,105.1,104.6,41.1,15.7.HR-ESIMS m/z 434.0509[M+H]+(calcd.for C22H17N3O2Br,434.0504).
Preparation of Compound 59
According to the method for synthesizing compound 42, compound 58(21mg,0.05mmol) and HCHO (5mL, mass fraction 37%) were synthesized, and subjected to silica gel column chromatography and eluted with dichloromethane methanol 70:1(v/v) to give N-hydroxymethyl-2- (1-ethyl-3-indole) -3- (7-bromo-3-indole) maleimide (59) as a red solid in a yield of 40 mg.1H NMR(500MHz,DMSO-d6)δ11.94(s,1H,indole-NH),7.84(s,1H,Ar-H),7.79(s,1H,Ar-H),7.49(d,1H,J=8.3Hz,Ar-H),7.22(d,1H,J=7.5Hz,Ar-H),7.06(t,1H,J=7.6Hz,Ar-H),6.86(d,1H,J=8.1Hz,Ar-H),6.77(d,1H,J=8.0Hz,Ar-H),6.73(d,1H,J=7.6Hz,Ar-H),6.59(t,1H,J=7.8Hz,Ar-H),6.34(t,1H,J=7.0Hz,N-CH2-OH),4.97(d,2H,J=7.0Hz,N-C 2H-OH),4.27(q,2H,J=7.2Hz,-C 2H-CH3),1.33(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ171.5×2,136.1,134.9,132.4,130.6,128.7,127.4,126.8,126.3,124.9,122.5,121.7,121.4,120.9,120.4,110.9,107.2,105.1,104.9,60.8,41.3,15.8.HR-ESIMS m/z 464.0592[M+H]+(calcd.for C23H19N3O3Br,464.0604).
Preparation of Compound 60
According to the preparation method of compound 2, the compound 59(75mg,0.173mmol) and NaHCO are used3(73mg,0.866mmol) and formaldehyde solution (3mL, mass fraction 37%) as raw materials, separating by silica gel column chromatography, eluting with petroleum ether and ethyl acetate (4: 1) (v/v) to obtain red solid N-hydroxymethyl-2- (1-ethyl-3-indole) -3- (1-hydroxymethyl-7-bromo-3-indole) maleimide (60) in 25mg with yield.1H NMR(600MHz,CDCl3)δ7.64(s,1H,Ar-H),7.61(s,1H,Ar-H),7.25(d,1H,J=6.6Hz,Ar-H),7.21(d,1H,J=7.6Hz,Ar-H),7.07(t,1H,J=7.6Hz,Ar-H),6.90(d,1H,J=8.2Hz,Ar-H),6.77(d,1H,J=8.0Hz,Ar-H),6.74(t,1H,J=7.9Hz,Ar-H),6.50(t,1H,J=7.9Hz,Ar-H),5.86(d,2H,J=7.2Hz,-C 2HOH),5.14(d,2H,J=6.1Hz,-C 2HOH),4.26(t,1H,J=7.2Hz,-CH2OH),4.17(t,1H,J=6.1Hz,-CH2OH),4.09(q,2H,J=7.3Hz,-C 2H-CH3),1.38(t,3H,J=7.3Hz,-CH2-C 3H).13C NMR(150MHz,CDCl3)δ172.0,171.7,136.0,134.1,132.3,132.0,129.9,129.7,127.7,126.3,124.6,122.5,122.2,121.7,121.6,120.6,109.7,106.7,105.5,103.5,71.1,61.5,41.6,15.2.HR-ESIMS m/z 516.0540[M+Na]+(calcd.for C24H20N3O4BrNa,516.0535) preparation of compound 61
Dissolve Compound 55(300mg,0.693mmol) in 6mL DMF in a 50mL single neck flask and add PPh3(36.3mg,0.139mmol)、PdCl2(6.1mg,0.0346mmol) and propenyl tributyltin (258. mu.L, 0.83mmol) in an oil bath at 110 ℃ with stirring under the protection of argonThe reaction was carried out for 23 h. Cooling to room temperature, extracting with diethyl ether, washing with saturated NaCl water solution for 3-4 times, drying the organic phase with anhydrous sodium sulfate, and vacuum rotary evaporating to dryness. The PdCl is removed by suction filtration2Silica gel column chromatography and elution with petroleum ether and ethyl acetate 4:1(v/v) gave 171mg of 2- (1-ethyl-3-indole) -3- (6-allyl-3-indole) maleimide (61) as a red solid in 62% yield.1H NMR(600MHz,DMSO-d6)δ11.60(s,1H,indole-NH),10.90(s,1H,imide-NH),7.70(d,1H,J=2.9Hz,Ar-H),7.70(s,1H,Ar-H),7.46(d,1H,J=8.3Hz,Ar-H),7.17(s,1H,Ar-H),7.05(t,1H,J=7.1Hz,Ar-H),6.92(d,1H,J=8.1Hz,Ar-H),6.71(t,1H,J=7.5Hz,Ar-H),6.64(d,1H,J=8.1Hz,Ar-H),6.47(d,1H,J=8.3Hz,Ar-H),5.94-5.86(m,1H,ArCH2CH=CH2),5.00-4.97(m,1H,ArCH2CH=CH 2),4.96-4.94(m,1H,ArCH2CH=C 2H),4.23(q,2H,J=7.3Hz,-C 2H-CH3),3.32(d,2H,J=6.7Hz,Ar-C 2HCH=CH2),1.30(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ173.6,173.5,138.8,137.0,136.0,133.7,131.9,129.6,128.6,127.4,126.6,124.1,122.2,121.9,121.5,121.1,120.1,115.9,111.8,110.6,106.0,105.5,41.2,39.0,15.8.HR-ESIMS m/z 396.1718[M+H]+(calcd.for C25H22N3O2,396.1712).
Preparation of Compound 62
In 20mL CH2Cl2Dissolve compound 61(128mg,0.324mmol) in a 50mL single neck flask, reflux with condensed water at 40 ℃ for 0.5h to dissolve all the compound, cool to room temperature, add 2-methyl-2-butene (1.2mL,11.34mmol) and Grubbs' 2 generation catalyst (27.5mg,0.0324mmol), reflux with condensed water at 40 ℃ under argon for 2h, cool to room temperature, and vacuum rotary evaporate to dryness. Silica gel column chromatography, petroleum ether and ethyl acetate 6:1(v/v) to give 91mg of 2- (1-ethyl-3-indole) -3- (6-isopentenyl-3-indole) maleimide (62) as a red solid in 66% yield.1H NMR(600MHz,DMSO-d6)δ11.50(s,1H,indole-NH),10.87(s,1H,imide-NH),7.67(d,1H,J=1.7Hz,Ar-H),7.66(s,1H,Ar-H),7.47(d,1H,J=8.3Hz,Ar-H),7.14(s,1H,Ar-H),7.06(t,1H,J=7.1Hz,Ar-H),6.96(d,1H,J=8.0Hz,Ar-H),6.74(t,1H,J=7.2Hz,Ar-H),6.64(d,1H,J=8.2Hz,Ar-H),6.47(dd,1H,J=8.3Hz,1.4Hz,Ar-H),5.27-5.22(m,1H,ArCH2CH=C(CH3)2),4.22(q,2H,J=7.2Hz,-C 2H-CH3),3.27(d,2H,J=7.4Hz,ArC 2HCH=C(CH3)2),1.67(s,3H,ArCH2CH=C(C 3H)2),1.64(s,3H,ArCH2CH=C(C 3H)2),1.29(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ172.9,172.8,136.4,135.4,134.8,131.2,131.1,128.9,128.0,126.7,125.9,123.8,123.1,121.6,121.3,120.8,120.3,119.4,101.0,105.3,104.8,100.0,40.5,33.6,25.4,17.5,15.0.HR-ESIMS m/z 424.2029[M+H]+(calcd.forC27H26N3O2,424.2025).
Preparation of Compound 63
According to the preparation method of the compound 2, the compound 62(43mg,0.1088mmol), formaldehyde solution (3mL, mass fraction of 37%) and NaHCO are used3(46mg,0.544mmol) as a starting material to give 17mg of N-hydroxymethyl-2- (1-ethyl-3-indole) -3- (1-hydroxymethyl-6-isopentenyl-3-indole) maleimide as a deep red solid in 34% yield.1H NMR(600MHz,DMSO-d6)δ7.90(s,1H,Ar-H),7.63(s,1H,Ar-H),7.48(d,1H,J=8.3Hz,Ar-H),7.34(s,1H,Ar-H),7.10(d,1H,J=7.9Hz,Ar-H),7.08(d,1H,J=8.3Hz,Ar-H),6.79(t,1H,J=7.0Hz,-CH2OH),6.73(t,1H,J=7.2Hz,Ar-H),6.48(q,2H,J=8.2Hz,Ar-H),6.38(t,1H,J=6.9Hz,imide-CH2OH),5.55(d,2H,J=7.0Hz,indole-C 2HOH),5.23(t,1H,J=7.2Hz,ArCH2CH=C(CH3)2),4.96(d,2H,J=6.9Hz,-C 2HOH),4.22(q,2H,J=7.2Hz,-C 2H-CH3),3.28(d,2H,J=7.4Hz,ArC 2HCH=C(CH3)2),1.65(s,3H,ArCH2CH=C(C 3H)2),1.63(s,3H,ArCH2CH=C(C 3H)2),1.26(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ171.6×2,136.6,136.0,135.9,132.4,132.0,131.8,127.7,127.5,126.8,124.4,122.4,121.9,121.7,121.5,120.4,110.8,110.6,105.6,105.4,100.0,69.5,60.8,41.2,34.5,26.1,18.2,15.6.ESI-MS m/z 484.2[M+H]+.
Preparation of Compound 64
Dissolve Compound 1(40mg,0.1mmol) in 1.0L acetone in an open quartz flask, adding catalytic amounts of I2Stirring under 250W mercury lamp for 24 hr, vacuum evaporating most of solvent, and pouring 100mL Na2S2O3To the saturated aqueous solution, stirring for 10min, extracting with ethyl acetate (50 mL. times.3 times), combining the organic layers, and adding anhydrous Na2SO4Drying, vacuum evaporating, separating with silica gel column chromatography, eluting with petroleum ether and ethyl acetate 3:1(v/v) to obtain yellow fluorescent powder 12-ethyl-13-cyanomethyl-12, 13-dihydro-5H-indole [2,3-a ]]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (64)28mg, yield 71%.1H NMR(600MHz,DMSO-d6)δ11.27(s,1H,indole-NH),9.12(d,1H,J=8.3Hz,Ar-H),9.11(d,1H,J=8.3Hz,Ar-H),7.96(d,1H,J=8.2Hz,Ar-H),7.91(d,1H,J=8.2Hz,Ar-H),7.73(t,1H,J=7.7Hz,Ar-H),7.67(t,1H,J=7.9Hz,Ar-H),7.53(t,1H,J=7.3Hz,Ar-H),7.43(t,1H,J=7.3Hz,Ar-H),5.79(s,2H,-N-CH 2-CN),4.75(q,2H,J=6.8Hz,-CH 2-CH3),1.10(t,3H,J=6.8Hz,-CH2-CH 3).13C NMR(150MHz,DMSO-d6)δ171.0,170.9,152.0,145.5,144.4,133.1,132.9,128.8,128.5,125.5,125.4,124.5,123.6,123.5,123.0,122.1,121.5,121.0,116.4,113.3,113.0,43.3,31.0,14.0.HR-ESIMS m/z 391.1206[M–H]–(calcd.for C24H15N4O2,391.1195).
Preparation of Compound 65
According to the preparation method of compound 2, compound 2(10mg, 24.6. mu. mol) and NaHCO are used3(4.1mg, 49.2. mu. mol) as raw material, separating with silica gel column chromatography, eluting with petroleum ether and ethyl acetate (3: 1 (v/v)) to obtain yellow fluorescent powder 6-hydroxymethyl-12-ethyl-13-cyanoethyl-12, 13-bisHydrogen-5H-indole [2,3-a ]]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (65)10.1mg, yield 94%.1H NMR(600MHz,CDCl3)δ9.24(d,1H,J=7.8Hz,Ar-H),9.22(d,1H,J=7.8Hz,Ar-H),7.66(dt,1H,J=7.5Hz,1.4Hz,Ar-H),7.65(d,1H,J=6.9Hz,Ar-H),7.64(dt,1H,J=7.8Hz,0.9Hz,Ar-H),7.59(d,1H,J=7.8Hz,Ar-H),7.49(dt,1H,J=7.8Hz,0.9Hz,Ar-H),7.46(dt,1H,J=7.5Hz,1.4Hz,Ar-H),5.40(d,2H,J=7.8Hz,-N-CH 2-OH),4.96(t,2H,J=7.8Hz,N-CH 2-CH2CN),4.66(q,2H,J=7.3Hz,-CH 2-CH3),3.18(t,1H,J=7.8Hz,NCH2-OH),2.21(t,2H,J=7.8Hz,NCH2-CH 2-CN),1.12(t,3H,J=7.3Hz,-CH3).13C NMR(150MHz,CDCl3)δ169.0,168.9,145.0,143.8,133.9,132.7,128.9,128.4,128.3,126.5,126.1,125.4,124.5,123.3,122.5,122.4,121.5,120.2,116.4,112.2,111.7,61.8,44.4,43.9,15.7,13.6.ESI-MS m/z 437.2[M+H]+.
Preparation of Compound 66
According to the preparation method of the compound 64, the compound 3(30mg,0.072mmol) is used as a raw material, and the yellow fluorescent powder 12-ethyl-13-cyanopropyl-12, 13-dihydro-5H-indole [2,3-a ] is obtained by silica gel column chromatography separation and elution of petroleum ether and ethyl acetate which are 3:1(v/v)]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (66)20.6mg, yield 68%.1H NMR(600MHz,CDCl3)δ9.25(d,1H,J=8.2Hz,Ar-H),9.24(d,1H,J=8.3Hz,Ar-H),7.77(s,1H,imide-NH),7.64(t,1H,J=7.4Hz,Ar-H),7.63(d,1H,J=7.4Hz,Ar-H),7.62(t,1H,J=7.7Hz,Ar-H),7.60(d,1H,J=7.8Hz,Ar-H),7.48(dt,1H,J=6.8Hz,1.7Hz,Ar-H),7.46(dt,1H,J=7.4Hz,1.7Hz,Ar-H),4.84(t,2H,J=7.1Hz,N-CH 2-(CH2)2CN),4.68(q,2H,J=7.1Hz,N-CH 2-CH3),1.77(t,2H,J=6.9Hz,N(CH2)2-CH 2-CN),1.26-1.24(m,2H,NCH2-CH 2-CH2CN),1.10(t,3H,J=7.1Hz,-CH2-CH 3).13C NMR(150MHz,CDCl3)δ169.5×2,145.0,144.1,133.7,133.4,128.1,128.0,126.4,126.1,124.6,124.5,122.6,122.3,122.1,121.6,121.5,121.2,118.2,112.2,111.8,46.9,44.1,29.8,24.0,14.7.HR-ESIMS m/z 419.1498[M–H]–(calcd.for C26H19N4O2,419.1508).
Preparation of Compound 67
According to the preparation method of compound 2, compound 66(10.2mg, 23.8. mu. mol) and NaHCO are used3(4mg, 47.6. mu. mol) as raw material, separating with silica gel column chromatography, eluting with petroleum ether and ethyl acetate 5:1(v/v) to obtain yellow fluorescent powder 6-hydroxymethyl-12-ethyl-13-cyanopropyl-12, 13-dihydro-5H-indole [2,3-a ] as fluorescent powder]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (67)10.5mg, yield 96%.1H NMR(600MHz,CDCl3)δ9.25(d,1H,J=7.7Hz,Ar-H),9.23(d,1H,J=7.7Hz,Ar-H),7.65-7.61(m,4H,Ar-H),7.47(t,1H,J=7.7Hz,Ar-H),7.44(t,1H,J=6.6Hz,Ar-H),5.41(d,2H,J=7.7Hz,N-CH 2-OH),4.84(t,2H,J=7.7Hz,N-CH 2-(CH2)2CN),4.68(q,2H,J=7.7Hz,N-CH 2-CH3),3.17(t,1H,J=7.7Hz,-OH),1.74-1.78(m,4H,NCH2-CH 2-CH 2-CN),1.11(t,3H,J=7.7Hz,CH3).13C NMR(150MHz,CDCl3)δ169.1×2,144.9,144.1,133.7,133.4,132.7,128.1,128.0,126.3,126.0,124.6,124.5,122.6,122.3,122.2,121.6,120.3,118.2,112.2,111.8,61.8,46.9,44.1,24.0,14.7,13.6.HR-ESIMS m/z 473.1575[M+H]+(calcd.forC27H22N4O3Na,473.1590).
Preparation of Compound 68
According to the preparation method of the compound 64, the compound 5(40mg,0.092mmol) is used as a raw material, and the yellow fluorescent powder 12-ethyl-13-cyanobutyl-12, 13-dihydro-5H-indole [2,3-a ] is obtained by silica gel column chromatography separation and elution with petroleum ether and ethyl acetate which are 3:1(v/v)]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (68)28.7mg, yield 72%.1H NMR(600MHz,CDCl3)δ9.26(d,1H,J=7.7Hz,Ar-H),9.24(d,1H,J=7.7Hz,Ar-H),7.72(s,1H,imide-NH),7.64(t,1H,J=7.3Hz,Ar-H),7.63(d,1H,J=7.4Hz,Ar-H),7.62(t,1H,J=7.7Hz,Ar-H),7.60(d,1H,J=7.8Hz,Ar-H),7.463(dt,1H,J=7.6Hz,1.1Hz,Ar-H),7.462(dt,1H,J=7.4Hz,0.9Hz,Ar-H),4.75(t,2H,J=6.9Hz,N-CH 2-(CH2)3CN),4.65(q,2H,J=7.4Hz,N-CH 2-CH3),1.99(t,2H,J=6.8Hz,N(CH2)3-CH 2-CN),1.67(m,2H,NCH2-CH 2-(CH2)2CN),1.10(t,3H,J=7.4Hz,-CH2-CH 3),1.00-0.98(m,2H,N(CH2)2-CH 2-CH2CN).13C NMR(150MHz,CDCl3)δ169.5×2,145.0,144.1,133.8,133.6,127.9,127.8,126.3,126.1,124.7,124.4,122.3,122.2,122.0,121.7,121.3,121.2,118.9,112.1,111.9,47.6,44.1,29.8,27.3,22.3,16.7.HR-ESIMS m/z 433.1663[M–H]–(calcd.for C27H21N4O2,433.1665).
Preparation of Compound 69
According to the preparation method of compound 2, compound 68(9.8mg, 22.6. mu. mol) and NaHCO are used3(4mg, 45.2. mu. mol) as raw material, separating with silica gel column chromatography, eluting with petroleum ether and ethyl acetate 4:1(v/v) to obtain yellow fluorescent powder 6-hydroxymethyl-12-ethyl-13-cyanobutyl-12, 13-dihydro-5H-indole [2,3-a ] as fluorescent powder]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (70)10mg, yield 95%.1H NMR(600MHz,CDCl3)δ9.26(d,1H,J=7.7Hz,Ar-H),9.24(d,1H,J=8.8Hz,Ar-H),7.64-7.60(m,4H,Ar-H),7.45(t,2H,J=7.7Hz,Ar-H),5.41(d,2H,J=7.2Hz,N-CH 2-OH),4.75(t,2H,J=6.6Hz,N-CH 2-(CH2)3CN),4.66(q,2H,J=6.6Hz,N-CH 2-CH3),3.15(t,1H,J=7.2Hz,-OH),1.97(t,2H,J=7.8Hz,N(CH2)3-CH 2-CN),1.68-1.64(m,2H,NCH2-CH 2-(CH2)2CN),1.10(t,3H,J=6.6Hz,-CH2-CH 3),0.98(m,2H,N(CH2)2-CH 2-CH2CN).13C NMR(150MHz,CDCl3)δ169.2×2,144.9,144.1,133.8,133.6,128.9,127.9,127.8,126.2,126.0,124.7,122.6,122.3×2,122.1,120.5,119.3,118.9,112.2,111.9,61.8,47.5,44.1,27.3,22.3,16.7,13.6.ESI-MS m/z 465.3[M+H]+.
Preparation of Compound 70
According to the preparation method of the compound 64, the compound 7(60mg,0.15mmol) is used as a raw material, and the yellow fluorescent powder 12, 13-dicyanomethyl-12, 13-dihydro-5H-indole [2,3-a ] is obtained by silica gel column chromatography separation and elution of petroleum ether and ethyl acetate which are 2:1(v/v)]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (70)25mg, yield 42%.1H NMR(600MHz,DMSO-d6)δ11.40(s,1H,imide-NH),9.12(d,2H,J=7.8Hz,Ar-H),8.02(d,2H,J=8.3Hz,Ar-H),7.77(dt,2H,J=7.3Hz,1.1Hz,Ar-H),7.56(t,2H,J=7.3Hz,Ar-H),5.75(s,4H,-C 2H-CN).13C NMR(150MHz,DMSO-d6)δ170.0×2,144.5×2,132.3×2,128.6×2,125.1×2,123.6×2,123.2×2,122.2×2,121.5×2,115.3×2,112.8×2,37.4×2.ESI-MS m/z 404.1[M+H]+.
Preparation of Compound 71
According to the preparation method of the compound 64, the compound 2,3-di (1-cyanoethyl-1H-indol-3-yl) maleimide (30mg,0.07mmol) is used as a raw material for preparation, and the yellow fluorescent powder 12, 13-dicyanoethyl-12, 13-dihydro-5H-indole [2,3-a ] is obtained by silica gel column chromatographic separation and elution of petroleum ether and ethyl acetate 2:1(v/v)]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (71)12mg, yield 40%.1H NMR(600MHz,DMSO-d6)δ11.27(s,1H,imide-NH),9.14(d,2H,J=8.3Hz,Ar-H),8.00(d,2H,J=8.2Hz,Ar-H),7.69(t,2H,J=7.7Hz,Ar-H),7.49(d,2H,J=7.7Hz,Ar-H),5.07(t,4H,J=6.6Hz,N-C 2H-CH2CN),2.64(4H,t,J=6.6Hz,NCH2-C 2H-CN).13C NMR(150MHz,DMSO-d6)δ171.2×2,143.8×2,133.6×2,128.3×2,125.6×2,124.5×2,122.7×2,121.8×2,121.2×2,118.2×2,113.6×2,44.3×2,21.5×2.ESI-MS m/z 430.0[M–H]–.
Preparation of Compound 72
The preparation method of the compound 65 comprises the steps of preparing a compound 9(45mg,0.09mmol) serving as a raw material, separating the compound by silica gel column chromatography, and eluting the compound by petroleum ether and ethyl acetate (2: 1 (v/v)) to obtain yellow fluorescent powder 12, 13-dicyanobutyl-12, 13-dihydro-5H-indole [2,3-a ] powder]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (74)17mg, yield43%。1H NMR(600MHz,DMSO-d6)δ11.18(s,1H,imide-NH),9.15(d,2H,J=7.8Hz,Ar-H),7.93(d,2H,J=8.2Hz,Ar-H),7.66(dt,2H,J=7.8Hz,1.0Hz,Ar-H),7.44(t,2H,J=7.8Hz,Ar-H),4.78(t,4H,J=7.4Hz,N-CH 2-(CH2)3CN),2.26(t,4H,J=7.3Hz,N(CH2)3-C 2H-CN),1.53-1.50(m,4H,NCH2-C 2H-(CH2)2CN),1.11-1.09(4H,m,N(CH2)2-C 2H-CH2CN).13C NMR(150MHz,DMSO-d6)δ171.2×2,144.6×2,133.4×2,128.0×2,125.4×2,123.7×2,122.0×2,121.4×2,120.7×2,120.3×2,113.4×2,48.1×2,27.6×2,22.5×2,16.1×2.ESI-MS m/z 486.1[M–H]–.
Preparation of Compound 73
i) Preparation of 12-ethyl-12, 13-dihydro-5H-indole [2,3-a ] pyrrolo [3,4-c ] carbazole-5, 7(6H) -dione (73a)
Compound 24d (400mg,1.13mmol), DDQ (282mg,1.24mmol) and p-TsOH (214mg,1.13mmol) were dissolved in 100mL of benzene, N2Refluxing for 30min under protection, evaporating to remove solvent, dissolving with 100mL ethyl acetate, and respectively dissolving with saturated NaHSO3Washing with water and salt, and washing organic layer with anhydrous Na2SO4Drying, evaporating to dryness, separating with silica gel column chromatography, eluting with petroleum ether and ethyl acetate 2:1(v/v) to obtain yellow powder (73a)280mg with yield of 70%.1H NMR(500MHz,DMSO-d6)δ11.96(s,1H,indole-NH),10.99(s,1H,imido-NH),9.12(d,1H,J=8.1Hz,Ar-H),9.07(d,1H,J=8.1Hz,Ar-H),7.79(d,2H,J=8.0Hz,Ar-H),7.59(t,1H,J=7.9Hz,Ar-H),7.56(t,1H,J=9.0Hz,Ar-H),7.36(d,1H,J=8.2Hz,Ar-H),7.34(d,1H,J=8.1Hz,Ar-H),4.94(q,2H,J=7.1Hz,-C 2H-CH3),1.42(t,3H,J=7.1Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ171.6×2,141.5,141.0,129.6,128.6,127.3,125.1,124.7,121.7,121.4,120.7×2,120.4,120.2,117.2,116.3,112.5,110.2,110.1,39.8,16.1.HR-ESIMS m/z 354.1249[M+H]+(calcd.forC22H16N3O2,354.1243).
ii) preparation of 6- (2-aminoethyl) -12-ethyl-12, 13-dihydro-5H-indole [2,3-a ] pyrrolo [3,4-c ] carbazole-5, 7(6H) -dione (73)
Suspending compound 73a (470mg,1.33mmol) with 100mL 10% KOH aqueous solution, refluxing at 110 deg.C for 1.5h to dissolve it as a pale yellow clear solution, cooling to room temperature, acidifying with 2N hydrochloric acid, extracting with ethyl acetate (100mL × 3 times), evaporating the organic layer to dryness to obtain 465mg crude 12-ethyl-12, 13-dihydrofuran [3,4-c ] as a crude product]Indole [2,3-a ]]Carbazole-5, 7-dione (73b), which has very poor solubility, but complete reaction and single product, was directly used in the next reaction without isolation. According to the preparation method of compound 14, using the crude product 73b thus obtained and 2mL of ethylenediamine as starting materials, 510mg of yellow powder (73) was obtained in a yield of 97%.1H NMR(500MHz,DMSO-d6)δ9.03(t,2H,J=8.5Hz,Ar-H),7.80(d,1H,J=8.1Hz,Ar-H),7.74(d,1H,J=8.1Hz,Ar-H),7.57(t,1H,J=7.8Hz,Ar-H),7.53(t,1H,J=7.6Hz,Ar-H),7.33(d,1H,J=8.1Hz,Ar-H),7.31(d,1H,J=8.0Hz,Ar-H),4.86(q,2H,J=6.9Hz,-C 2H-CH3),3.75(t,2H,J=6.1Hz,-NC 2HCH2NH2),2.97(t,2H,J=6.1Hz,-NCH2C 2H-NH2),1.36(t,3H,J=6.9Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ170.1×2,141.5,140.9,129.4,128.3,127.3,127.2,124.9,124.5,121.5,121.2,120.6×2,119.2,119.0,117.2,116.3,112.6,110.1,39.9,39.6,38.7,16.1.HR-ESIMS m/z 397.1671[M+H]+(calcd.for C24H21N4O2,397.1665).
Preparation of Compound 74
According to the preparation method of compound 16, 6- (2-aminoethyl) -12-ethyl-12, 13-dihydro-5H-indole [2,3-a ] was obtained as a yellow powder from compound 73(510mg,1.26mmol)]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione hydrochloride (74)540mg, yield 99%.1HNMR(600MHz,DMSO-d6)δ12.07(s,1H,indole-NH),9.11(d,1H,J=8.2Hz,Ar-H),9.08(d,1H,J=8.2Hz,Ar-H),7.90(brs,3H,-NH3 +),7.84(d,2H,J=8.1Hz,Ar-H),7.63(t,1H,J=7.1Hz,Ar-H),7.58(t,1H,J=7.7Hz,Ar-H),7.38(t,1H,J=7.8Hz,Ar-H),7.35(t,1H,J=7.7Hz,Ar-H),4.98(q,2H,J=6.9Hz,-C 2H-CH3),3.98(t,2H,J=5.9Hz,N-C 2H-CH2NH3 +),3.19(t,2H,J=6.0Hz,NCH2-C 2H-NH3 +),1.41(t,3H,J=6.9Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ170.1×2,141.6,141.1,129.6,128.5,127.5×2,124.9,124.5,121.6,121.2,120.8,120.8,119.5,119.3,117.3,116.5,112.7,110.4,39.6,38.5,35.8,16.1.HR-ESIMS m/z 397.1670[M-Cl]+(calcd.for C24H21N4O2,397.1665).
Preparation of Compound 75
After suspending NaH in 15mL of DMF at 0 ℃ in a 250mL two-necked flask, 1mL of dissolved compound 73a (40mg,0.113mmol) was added dropwise, the reaction was carried out at low temperature for 10min, and the reaction was carried out at room temperature for 30 min. Cooling to 0 ℃, and dripping ClCH2CH2OH (0.092mL,1.36 mol). And (3) under an oil bath at 55 ℃, under the protection of Ar gas, refluxing condensed water for 5 hours, detecting incomplete reaction by TLC, heating to 85 ℃, and reacting for 6 hours. The temperature was reduced to room temperature, and 10mL of methanol and 20mL of saturated aqueous ammonium chloride were added at low temperature. Extracting with ethyl acetate, and extracting the organic layer with anhydrous Na2SO4Drying and vacuum evaporating. Dissolving in THF, separating with silica gel column chromatography, eluting with petroleum ether and ethyl acetate 4:1(v/v) to obtain yellow solid 6- (2-hydroxyethyl) -12-ethyl-12, 13-dihydro-5H-indole [2,3-a ]]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (75)11mg, yield 25%.1H NMR(500MHz,DMSO-d6)δ11.95(s,1H,indole-NH),9.09(d,1H,J=8.1Hz,Ar-H),9.08(d,1H,J=8.1Hz,Ar-H),7.79(d,1H,J=7.8Hz,Ar-H),7.77(d,1H,J=7.6Hz,Ar-H),7.59(t,1H,J=7.4Hz,Ar-H),7.56(t,1H,J=7.4Hz,Ar-H),7.35(t,1H,J=8.1Hz,Ar-H),7.33(t,1H,J=7.4Hz,Ar-H),4.90(q,2H,J=6.9Hz,-C 2H-CH3),3.73-3.71(m,2H,-NCH2C 2H-OH),3.69(t,2H,J=5.4Hz,-NC 2HCH2OH),1.41(t,3H,J=6.9Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ170.1×2,141.8,141.0,129.5,128.4,127.3,125.0,124.6,121.6,121.3,120.7×2,119.3,119.1,117.2,116.4,112.5,110.1×2,58.8,40.5,39.5,16.1.HR-ESIMS m/z398.1508[M+H]+(calcd.for C24H20N3O3,398.1505).
Preparation of Compound 76
According to the preparation method of compound 24, compound 73b (49mg, 0.14mmol), 4-hydroxybenzylamine (51mg, 0.42mmol) and a catalytic amount of Et3N is used as raw material to prepare yellow solid 6- (4-hydroxybenzyl) -12-ethyl-12, 13-dihydro-5H-indole [2,3-a ]]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (76)15mg, yield 23%.1H NMR(600MHz,DMSO-d6)δ9.03(d,1H,J=7.0Hz,Ar-H),9.03(d,1H,J=6.8Hz,Ar-H),7.77(d,1H,J=8.2Hz,Ar-H),7.70(d,1H,J=8.4Hz,Ar-H),7.56(d,1H,J=7.0Hz,Ar-H),7.55(d,1H,J=6.9Hz,Ar-H),7.34(dd,1H,J=7.0Hz,0.9Hz,Ar-H),7.32(dd,1H,J=7.0Hz,0.9Hz,Ar-H),7.20(d,2H,J=8.2Hz,Ar-H),6.71(d,2H,J=8.2Hz,Ar-H),4.81(q,2H,J=7.2Hz,-C 2H-CH3),4.63(s,2H,-NCH2-Ar),1.38(t,3H,J=7.2Hz,-CH2-C 3H).13CNMR(150MHz,DMSO-d6)δ169.8,169.7,157.2,141.7,141.0,129.6×2,128.5,128.4,127.4,125.0,124.9,124.7,121.5,121.3,120.9,120.8,119.0,118.8,117.4,116.4,115.8×2,112.6,110.1,100.0,40.7,39.6,16.3.ESI-MS m/z 460.1[M+H]+.
Preparation of Compound 77
According to the preparation method of compound 24, using 73b (35mg, 0.098mmol), 4- (2-aminoethyl) morpholine (104. mu.L, 0.79mmol) and a catalytic amount of Et3N is used as raw material to prepare yellow solid 6- (2- (4-morpholine) ethyl) -12-ethyl-12, 13-dihydro-5H-indole [2,3-a ]]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (77)33mg, yield 72%.1H NMR(500MHz,DMSO-d6)δ12.01(s,1H,indole-NH),9.09(t,1H,J=8.1Hz,Ar-H),9.07(t,1H,J=7.9Hz,Ar-H),7.81(d,2H,J=8.0Hz,Ar-H),7.59(t,1H,J=8.0Hz,Ar-H),7.56(t,1H,J=7.8Hz,Ar-H),7.38(d,1H,J=8.0Hz,Ar-H),7.35(t,1H,J=8.0Hz,Ar-H),4.94(q,2H,J=7.1Hz,-C 2H-CH3),3.79(t,2H,J=6.2Hz,imide-NC 2HCH2-),3.50(t,4H,J=4.5Hz,morpholine-N(CH2-C 2H)2O),2.62(t,2H,J=6.2Hz,imide-NCH2C 2H-),2.46(t,4H,J=4.5Hz,morpholine-N(CH 2-CH2)2O),1.37(t,3H,J=7.1Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ170.0×2,141.7,140.9,129.4,128.5,127.5,127.3,125.0,124.7,121.6,121.5,121.4,121.2,120.9,119.0,117.4,116.5,112.7,110.2,66.8×2,56.6,53.7×2,39.6,34.9,16.2.HR-ESIMS m/z 467.2088[M+H]+(calcd.for C28H27N4O3,467.2083).
Preparation of Compound 78
According to the preparation method of compound 24, compound 73b (100mg, 0.282mmol), N-dimethylethylenediamine (247.7. mu.L, 2.256mmol) and a catalytic amount of Et3N is used as a raw material to prepare yellow solid 6- (2- (N, N-dimethylaminoethyl)) -12-ethyl-12, 13-dihydro-5H-indole [2,3-a ]]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (78)95.7mg, yield 80%.1H NMR(600MHz,DMSO-d6)δ11.88(s,1H,indole-NH),9.01(d,2H,J=7.4Hz,Ar-H),7.76(d,1H,J=8.1Hz,Ar-H),7.69(d,1H,J=8.3Hz,Ar-H),7.56(d,1H,J=8.1Hz,Ar-H),7.53(d,1H,J=7.9Hz,Ar-H),7.33(td,2H,J=7.8Hz,2.3Hz,Ar-H),4.80(q,2H,J=7.1Hz,-C 2H-CH3),3.63(t,2H,J=6.4Hz,imide-NC 2HCH2N(CH3)2),2.49(t,2H,J=6.4Hz,imide-NCH2C 2H-N(CH3)2),2.18(s,6H,-N(CH3)2),1.38(t,3H,J=7.1Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ169.9×2,141.6,141.0,129.5,128.4,127.4×2,125.0,124.8×2,121.6,121.3,120.7,119.1,118.9,117.3,116.4,112.6,110.1,57.5,45.7×2,39.7,35.7,16.2.HR-ESIMS m/z 425.1988[M+H]+(calcd.for C26H25N4O2,425.1978).
Preparation of Compound 79
According to the preparation method of compound 24, using 73b (80mg, 0.226mmol), 2- (2-aminoethyl) pyridine (135.3. mu.L, 1.13mmol) and a catalytic amount of Et3N is used as a raw material to prepare yellow solid 6- (2- (2-pyridine) ethyl) -12-ethyl-12, 13-dihydro-5H-indole [2,3-a ]]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (79)25mg, yield 64%. 72.5mg, yield 70%.1H NMR(500MHz,DMSO-d6)δ11.92(s,1H,indole-NH),9.02(d,1H,J=6.5Hz,Ar-H),9.01(t,1H,J=6.5Hz,Ar-H),8.43(d,1H,J=3.2Hz,Ar-H),7.77(t,2H,J=7.4Hz),7.66(t,1H,J=8.0Hz,Ar-H),7.58(t,1H,J=8.0Hz,Ar-H),7.55(t,1H,J=7.8Hz,Ar-H),7.33-7.28(m,3H,Ar-H),7.18(t,1H,J=6.3Hz,Ar-H),4.88(q,2H,J=7.0Hz,-C 2H-CH3),4.00(t,2H,J=6.5Hz,imide-NC 2HCH2-),3.13(t,2H,J=6.5Hz,imide-NCH2C 2H-),1.39(t,3H,J=7.0Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ169.8×2,159.0,149.7,141.6,141.0,137.1,129.5,128.4,127.3,125.0,124.7,123.8,123.7,122.9,122.2,121.6,121.3,120.7,119.1,118.9,117.3,116.4,112.5,110.1,39.6,37.7,36.9,16.2.HR-ESIMS m/z 459.1831[M+H]+(calcd.for C29H23N4O2,459.1821).
Preparation of Compound 80
According to the preparation method of the compound 64, the compound 62(41mg, 0.09mmol) is used as a raw material to prepare the yellow solid 2-isopentenyl-12-ethyl-12, 13-dihydro-5H-indole [2,3-a ]]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (80)38mg, yield 90%.1H NMR(600MHz,DMSO-d6)δ11.80(s,1H,indole-NH),10.95(s,1H,imide-NH),9.06(d,1H,J=7.6Hz,Ar-H),8.88(d,1H,J=8.1Hz,Ar-H),7.75(d,1H,J=8.3Hz,Ar-H),7.58(td,1H,J=7.1Hz,1.1Hz,Ar-H),7.50(s,1H,Ar-H),7.33(t,1H,J=7.5Hz,Ar-H),7.13(dd,1H,J=8.1Hz,1.3Hz,Ar-H),5.40(t,1H,J=7.5Hz,ArCH2CH=C(CH3)2),4.87(q,2H,J=7.1Hz,-C 2H-CH3),3.48(d,2H,J=7.5Hz,ArC 2HCH=C(CH3)2),1.75(s,6H,ArCH2CH=C(C 3H)2),1.39(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ170.7,170.6,141.0,140.0,139.9,131.5,128.6,127.5,126.2,124.0,123.5,122.8,120.7,119.6,119.1,118.8,118.4,116.3,115.1,110.3,109.0,106.5,33.6,28.3,25.1,17.2,15.2.HR-ESIMS m/z 422.1879[M+H]+(calcd.for C27H24N3O2,422.1869).
Preparation of Compound 81
According to the preparation method of the compound 2, the compound 80(30mg,0.071mmol) and formaldehyde solution (3mL, mass fraction 37%) are taken as raw materials to prepare yellow solid 2-isopentenyl-6-hydroxymethyl-12-ethyl-12, 13-dihydro-5H-indole [2,3-a ]]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (81)13mg, yield 25%.1H NMR(600MHz,DMSO-d6)δ11.78(s,1H,indole-NH),9.03(d,1H,J=7.8Hz,Ar-H),8.86(d,1H,J=8.1Hz,Ar-H),7.72(d,1H,J=8.3Hz,Ar-H),7.57(t,1H,J=7.0Hz,Ar-H),7.51(s,1H,Ar-H),7.34(t,1H,J=7.4Hz,Ar-H),7.14(d,1H,J=8.2Hz,Ar-H),6.28(t,1H,J=7.0Hz,-CH2OH),5.44(t,1H,J=7.6Hz,ArCH2CH=C(CH3)2),4.92(d,2H,J=6.1Hz,-C 2HOH),4.80(q,2H,J=7.2Hz,-C 2H-CH3),3.53(d,2H,J=7.5Hz,ArC 2HCH=C(CH3)2),1.78(s,6H,ArCH2CH=C(C 3H)2),1.39(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ168.6×2,141.3,140.3,140.2,131.8,128.8,127.7,126.6,124.1,123.6,123.0×2,120.8,112.0,118.6,118.1,117.7,116.5,115.4,110.6,109.3,59.4,38.8,33.9,25.4,17.5,15.4.HR-ESIMS m/z 450.1821[M-H]-(calcd.for C28H24N3O3,450.1812).
Preparation of Compound 82
i) Preparation of N-methyl-2, 3-dibromomaleimide (82a)
Suspending NaH (30mg,0.75mmol, 60% by mass in paraffin) in a 50mL two-necked flask with 5mL of DMF under stirring, adding 5mL of DMF-dissolved 2, 3-dibromomaleimide (127.5mg,0.5mmol) dropwise at-5 deg.C, reacting at low temperature for 30min, adding iodomethane (47. mu.L, 0.75mmol) dropwise, reacting at low temperature for 30min, adding saturated NH dropwise4Cl solutionLiquid termination reaction, CH2Cl2Extraction, evaporation of the organic layer to dryness, silica gel column chromatography and elution with petroleum ether and ethyl acetate (30: 1) (v/v) gave 92mg of white crystals (82a) with a yield of 69%.1HNMR(600MHz,CDCl3)δ3.12(s,3H,-CH3).13C NMR(150MHz,CDCl3)δ164.1×2,129.5×2,25.6.ESI-MS m/z 267.9[M+H]+.
ii) preparation of N-methyl-2, 3-bis (6-chloro-3-indolyl) maleimide (82)
Placing magnesium wire (200mg,8.35mmol) in a 50mL two-mouth bottle, suspending and stirring with 5mL of THF at room temperature, dropwise adding bromoethane (620 mu L,8.35mmol), reacting at room temperature for 20min, raising the temperature to 45 ℃, continuing to react for 30min, dropwise adding 6-chloroindole (1.27g,8.35mmol) dissolved in 8mL of toluene, reacting for 1h, slowly dropwise adding 82a (448mg,1.67mmol) dissolved in 8mL of toluene, raising the temperature to 110 ℃, refluxing for 2h after the dropwise adding is finished, reducing the temperature to-5 ℃, dropwise adding saturated NH4The reaction was terminated with Cl solution, extracted with ethyl acetate, the organic layer was concentrated, and separated by silica gel column chromatography and eluted with petroleum ether (ethyl acetate: 3:1 (v/v)) to give 300mg of red solid powder (82), yield 44%.1H NMR(500MHz,DMSO-d6)δ11.80(s,2H,indole-NH),7.80(s,2H,Ar-H),7.43(s,2H,Ar-H),6.71(d,2H,J=8.6Hz,Ar-H),6.65(d,2H,J=8.6Hz,Ar-H),3.02(s,3H,-CH3).13C NMR(125MHz,DMSO-d6)δ171.9×2,136.8×2,130.7×2,127.4×2,126.8×2,124.4×2,122.3×2,120.1×2,112.0×2,106.0×2,24.4.HR-ESIMS m/z 410.0467[M+H]+(calcd.for C21H14N3O2Cl2,410.0463).
Preparation of Compound 83
Dissolving compound 82(257mg,0.63mmol) in 10mL of DMF in a 25mL two-necked flask, adding NaH (28mg,0.69mmol, 60% by mass in paraffin) under stirring at 5 ℃, reacting at low temperature for 30min, slowly adding EtI (108mg,0.69mmol) dropwise, and reacting at low temperature for 30 min. Saturated NH is added dropwise4Stopping reaction with Cl solution, extracting with ethyl acetate, concentrating the organic layer, separating with silica gel column chromatography, eluting with petroleum ether and ethyl acetate 4:1(v/v) to obtain orange red powder N-methyl-2- (1-ethyl-6-chloro-3-indole) -3- (6-chloro-3-indole) maleimide (83)100mg, and obtaining the yield38%。1H NMR(500MHz,DMSO-d6)δ11.84(d,1H,J=2.2Hz,indole-NH),7.83(d,1H,J=2.2Hz,Ar-H),7.79(s,1H,Ar-H),7.64(d,1H,J=1.6Hz,Ar-H),7.45(d,1H,J=1.7Hz,Ar-H),6.81(d,1H,J=8.8Hz,Ar-H),6.72(dd,1H,J=8.3Hz,1.7Hz,Ar-H),6.66-6.64(m,2H,Ar-H),4.25(q,2H,J=7.1Hz,-CH 2-CH3),3.03(s,3H,N-CH3),1.31(t,3H,J=7.1Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ172.0,171.9,137.1,136.5,132.9,131.0,127.7,127.3,127.0,126.9,125.1,124.3,122.9,122.6,120.5,120.3,112.2,110.8,106.0,105.6,41.4,24.6,15.8.HR-ESIMS m/z 438.0780[M+H]+(calcd.for C23H18N3O2Cl2,438.0776).
Preparation of Compound 84
i) Preparation of 2- (1-ethyl-6-chloro-3-indole) -3- (6-chloro-3-indole) maleic anhydride (84a)
Suspending compound 83(100mg,0.23mmol) in 10mL ethanol in a 50mL single-neck flask, adding 10mL 5M KOH solution, refluxing at 78 deg.C for 8h, cooling to room temperature, adding 6N hydrochloric acid dropwise for acidification, extracting with ethyl acetate, drying the organic layer with anhydrous sodium sulfate, vacuum concentrating, separating with silica gel column chromatography, and eluting with dichloromethane to obtain 58mg of orange-red solid (84a) with yield of 60%.1H NMR(600MHz,DMSO-d6)δ12.06(d,1H,J=2.8Hz,indole-NH),7.92(d,1H,J=3.3Hz,Ar-H),7.88(s,1H,Ar-H),7.69(d,1H,J=1.6Hz,Ar-H),7.49(d,1H,J=1.6Hz,Ar-H),6.85(d,1H,J=8.8Hz,Ar-H),6.79(dd,1H,J=8.2Hz,1.6Hz,Ar-H),6.73(dd,1H,J=8.2Hz,1.6Hz,Ar-H),6.70(d,1H,J=8.8Hz,Ar-H),4.26(q,2H,J=7.1Hz,-C 2H-CH3),1.31(t,3H,J=7.1Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ166.8,166.7,137.2,136.7,134.0,132.3,128.8,128.1,127.7,127.4,124.7,124.0,123.2,122.9,121.0,120.7,112.5,111.1,105.4,104.8,41.6,15.7.ESI-MS m/z 425.0/427.0[M+H]+.
ii) preparation of 2- (1-ethyl-6-chloro-3-indole) -3- (6-chloro-3-indole) maleimide (84)
According to the preparation of compound 24c, toCompound 84a (53mg,0.125mmol), HMDS (2.6mL,12.5mmol) and MeOH (0.25mL,6.25mmol) were used as starting materials to afford 52mg of an orange-red powder (84) in 98% yield.1H NMR(500MHz,DMSO-d6)δ11.80(s,1H,indole-NH),10.97(s,1H,imide-NH),7.81(d,1H,J=2.8Hz,Ar-H),7.79(s,1H,Ar-H),7.62(s,1H,Ar-H),7.44(s,1H,Ar-H),6.80(d,1H,J=8.8Hz,Ar-H),6.71(dd,1H,J=8.8Hz,1.1Hz,Ar-H),6.69(d,1H,J=8.8Hz,Ar-H),6.65(dd,1H,J=8.8Hz,1.7Hz,Ar-H),4.25(q,2H,J=7.1Hz,-C 2H-CH3),1.31(t,3H,J=7.1Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ173.2×2,137.0,136.5,132.9,130.9,128.3,127.7,127.2,126.9,125.2,124.5,122.9,122.6,120.4,120.2,112.1,110.0,106.0,105.6,41.4,15.8.HR-ESIMS m/z 424.0629[M+H]+(calcd.for C22H16N3O2Cl2,424.0620).
Preparation of Compound 85
According to the preparation method of the compound 2, the compound 84(20mg,47 mu mol), formaldehyde solution (3mL, 37 percent by mass) and NaHCO are adopted3(11.9mg, 140. mu. mol) was prepared as a raw material, which was subjected to silica gel column chromatography and eluted with petroleum ether: ethyl acetate 2:1(v/v) to give 22mg of N-hydroxymethyl-2- (1-ethyl-6-chloro-3-indole) -3- (1-hydroxymethyl-6-chloro-3-indole) maleimide (85) as a red solid in a yield of 97%.1H NMR(500MHz,DMSO-d6)δ8.00(s,1H,Ar-H),7.80(s,1H,Ar-H),7.68(s,1H,Ar-H),7.64(s,1H,Ar-H),6.86(d,1H,J=8.6Hz,Ar-H),6.74(t,1H,J=7.2Hz,indole-CH2-OH),6.70(d,1H,J=8.7Hz,Ar-H),6.67(d,1H,J=8.6Hz,Ar-H),6.55(d,1H,J=8.6Hz,Ar-H),6.33(t,1H,J=7.0Hz,imide-CH2-OH),5.60(d,2H,J=7.2Hz,indole-C 2H-OH),4.95(d,2H,J=7.0Hz,imide-C 2H-OH),4.25(q,2H,J=7.2Hz,-C 2H-CH3),1.29(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ171.3×2,136.6×2,133.5,133.1,127.8,127.4×2,127.3,125.3,125.2,122.9,122.7,120.8,120.6,111.6,110.9,105.7,105.4,69.9,60.9,41.5,15.8.HR-ESIMS m/z 506.0656[M+Na]+(calcd.for C24H19N3O4Cl2Na,506.0650).
Preparation of Compound 86
According to the preparation method of compound 82, using compound 82a (710Mg,2.64mmol), Mg (317Mg,13.2mmol), bromoethane (982 μ L,13.2mmol) and 4-bromoindole (2g,132mmol) as raw materials, silica gel column chromatography separation and dichloromethane/ethyl acetate 9:1(v/v) elution were performed to obtain 500Mg of solid N-methyl-2, 3-bis (4-bromo-3-indole) maleimide (86) in 30% yield.1H NMR(500MHz,DMSO-d6)δ11.84(s,2H,indole-NH),7.84(d,2H,J=7.4Hz,Ar-H),7.42(d,2H,J=8.1Hz,Ar-H),7.18(d,2H,J=7.5Hz,Ar-H),7.02(t,2H,J=7.8Hz,Ar-H),3.07(s,3H,-CH3).13C NMR(125MHz,DMSO-d6)δ172.3×2,137.8×2,137.3×2,130.4×2,127.1×2,126.1×2,123.6×2,113.9×2,112.4×2,104.8×2,24.8.ESI-MS m/z 519.9/521.9/523.9[M+Na]+.
Preparation of Compound 87
According to the preparation method of the compound 83, using the compound 86(506mg,1.02mmol), NaH (81mg,2.04mmol, 60% by mass in paraffin) and iodoethane (90 μ L,1.2mmol) as raw materials, separation by silica gel column chromatography and elution with petroleum ether, ethyl acetate ═ 2:1(v/v) gave 182mg of N-methyl-2- (1-ethyl-4-bromo-3-indole) -3- (4-bromo-3-indole) maleimide (87) as an orange-red solid in 34% yield.1H NMR(500MHz,DMSO-d6)δ11.85(s,1H,indole-NH),7.92(s,1H,Ar-H),7.85(d,1H,J=2.7Hz,Ar-H),7.52(d,1H,J=8.3Hz,Ar-H),7.41(d,1H,J=8.1Hz,Ar-H),7.19(dd,2H,J=7.2Hz,,1.6Hz,Ar-H),7.06(t,1H,J=7.9Hz,Ar-H),7.02(t,1H,J=7.8Hz,Ar-H),4.22(q,2H,J=7.2Hz,-C 2H-CH3),3.06(s,3H,-NCH3),1.34(t,J=7.2Hz,3H,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ172.3×2,137.7×2,135.3,134.7,132.7,130.4,126.3,126.1,124.2,124.1,123.6,123.5,114.1,113.9,111.9,110.4,104.2,103.5,41.4,24.8,15.8.ESI-MS m/z 525.9/527.9/529.9[M+H]+.
Preparation of Compound 88
i) Preparation of 2- (1-ethyl-4-bromo-3-indole) -3- (4-bromo-3-indole) maleic anhydride (88a)
According to the preparation method of the compound 84a, the compound 87(100mg,0.23mmol) is used as a raw material, and the orange-red solid (88a) is obtained by silica gel column chromatography (eluting with dichloromethane) with the yield of 60%.1H NMR(600MHz,DMSO-d6)δ12.06(s,1H,indole-NH),8.00(s,1H,Ar-H),7.95(d,1H,J=2.7Hz,Ar-H),7.57(d,1H,J=8.2Hz,Ar-H),7.46(d,1H,J=8.1Hz,Ar-H),7.25(dd,2H,J=7.2Hz,7.1Hz,Ar-H),7.10(t,1H,J=7.9Hz,Ar-H),7.06(t,1H,J=7.9Hz,Ar-H),4.25(q,2H,J=7.2Hz,-C 2H-CH3),1.35(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ166.7×2,137.8,137.3,136.9,136.3,133.6,131.4,125.8,125.6,124.7,124.6,124.0×2,113.9,113.7,112.3,110.7,102.9,102.2,41.6,15.8.ESI-MS m/z 513.1/515.0/517.1[M+H]+.
ii) preparation of 2- (1-ethyl-4-bromo-3-indole) -3- (4-bromo-3-indole) maleimide (88)
According to the preparation of compound 24c, starting from compound 88a (126mg,0.32mmol), HMDS (6.7mL,32mmol) and MeOH (0.64mL,16mmol), silica gel column chromatography and dichloromethane elution gave 88 as an orange-red powder (118mg, 94% yield).1H NMR(500MHz,DMSO-d6)δ11.83(s,1H,indole-NH),10.98(s,1H,imide-NH),7.92(s,1H,Ar-H),7.85(d,1H,J=2.7Hz,Ar-H),7.52(t,1H,J=8.0Hz,Ar-H),7.41(d,1H,J=8.0Hz,Ar-H),7.20(t,1H,J=7.5Hz,Ar-H),7.18(d,1H,J=7.5Hz,Ar-H),7.06(d,1H,J=7.9Hz,Ar-H),7.01(t,1H,J=7.8Hz,Ar-H),4.21(q,2H,J=7.2Hz,-C 2H-CH3),1.35(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ173.5×2,137.7,137.2,135.8,135.3,132.6,130.3,126.4,124.1,124.0,123.5,114.2,113.9,113.7,111.9,110.3,104.4,103.7,100.0,41.4,15.8.ESI-MS m/z 512.1/514.0/516.1[M+H]+.
Preparation of Compound 89
According to the preparation method of the compound 1, the compound 88(36mg,70.5 mu mol), formaldehyde solution (3mL, 37 percent by mass) and NaHCO are adopted3(30mg, 352. mu. mol) as a raw materialThe preparation method comprises the steps of silica gel column chromatography separation and petroleum ether and ethyl acetate which are 1:2(v/v) elution to obtain orange solid N-hydroxymethyl-2- (1-ethyl-4-bromo-3-indole) -3- (1-hydroxymethyl-4-bromo-3-indole) maleimide (89)39mg with the yield of 97%.1H NMR(500MHz,DMSO-d6)δ7.99(s,1H,Ar-H),7.92(s,1H,Ar-H),7.61(d,1H,J=8.2Hz,Ar-H),7.53(d,1H,J=8.2Hz,Ar-H),7.24(d,1H,J=7.8Hz,Ar-H),7.21(d,1H,J=7.6Hz,Ar-H),7.09(t,1H,J=8.0Hz,Ar-H),7.06(t,1H,J=7.6Hz,Ar-H),6.69(t,1H,J=7.3Hz,-CH2OH),6.40(t,1H,J=7.0Hz,-CH2OH),5.56(d,2H,J=7.3Hz,-C 2HOH),4.97(d,2H,J=7.0Hz,-C 2HOH),4.02(q,2H,J=7.1Hz,-C 2H-CH3),1.17(t,3H,J=7.1Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ171.6×2,137.2,137.1,135.5,135.0,133.2,132.9,126.8,126.3,124.7,124.2,123.8,123.6,114.0,113.9,111.0,110.4,103.9,103.3,69.7,60.3,41.5,15.8.ESI-MS m/z 554.1/556/1/558.1[M–H2O+H]+.
Preparation of Compound 90
According to the preparation method of the compound 82, the compound 5-bromoindole (2g,13.2mmol), Mg (317Mg,13.2mmol) and the compound 82a (710Mg,2.64mmol) are used as raw materials, silica gel column chromatography separation and petroleum ether and ethyl acetate are carried out at a ratio of 3:1(v/v) to obtain orange-red solid N-methyl-2, 3-bis (5-bromo-3-indole) maleimide (90) of 500Mg with the yield of 30%.1H NMR(500MHz,DMSO-d6)δ11.91(s,2H,indole-NH),7.80(s,2H,Ar-H),7.36(d,2H,J=8.6Hz,Ar-H),7.10(d,2H,J=8.6Hz,Ar-H),6.84(s,2H,Ar-H),3.04(s,3H,-CH3).13C NMR(125MHz,DMSO-d6)δ171.9×2,135.2×2,130.9×2,127.5×2,127.3×2,124.7×2,123.6×2,114.2×2,112.4×2,105.5×2,24.5.HR-ESIMS m/z 497.9458[M+H]+(calcd.for C21H14N3O2Br2,497.9453).
Preparation of Compound 91
According to the preparation method of compound 84, compound 90(506mg,1.2mmol), NaH (81mg,2.04mmol, 60% by mass in paraffin) and EtI (90. mu.L, 1.2mmol) are usedmmol) as raw material, silica gel column chromatography separation, petroleum ether and ethyl acetate 3:1(v/v) elution to obtain orange red solid N-methyl-2- (1-ethyl-5-bromo-3-indole) -3- (5-bromo-3-indole) maleimide (91)200mg, yield 36%.1H NMR(500MHz,DMSO-d6)δ11.95(s,1H,indole-NH),7.88(s,1H,Ar-H),7.75(d,1H,J=1.4Hz,Ar-H),7.48(d,1H,J=8.1Hz,Ar-H),7.37(d,1H,J=8.5Hz,Ar-H),7.18(d,1H,J=8.5Hz,Ar-H),7.09(d,1H,J=7.9Hz,Ar-H),6.99(s,1H,Ar-H),6.68(s,1H,Ar-H),4.24(q,2H,J=7.1Hz,-C 2H-CH3),3.03(s,3H,-CH3),1.31(t,3H,J=7.1Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ172.0,171.9,135.4,134.8,133.0,131.3,128.1,127.9,127.1,126.8,124.8×2,124.0,123.7,114.3,112.8×2,112.6,105.6,105.0,41.5,24.6,16.0.HR-ESIMS m/z 525.9776[M+H]+(calcd.for C23H18N3O2Br2,525.9766).
Preparation of Compound 92
i) Preparation of 2- (1-ethyl-5-bromo-3-indole) -3- (5-bromo-3-indole) maleic anhydride (92a)
According to the preparation method of the compound 84a, starting from the compound 91(120mg, 0.229mmol), 88mg of a red solid (92a) was obtained by silica gel column chromatography and elution with dichloromethane, with a yield of 75%.1H NMR(600MHz,DMSO-d6)δ12.16(s,1H,indole-NH),7.97(d,1H,J=1.4Hz,Ar-H),7.87(s,1H,Ar-H),7.53(d,1H,J=8.7Hz,Ar-H),7.40(d,1H,J=8.5Hz,Ar-H),7.23(d,1H,J=8.8Hz,Ar-H),7.16(d,1H,J=8.4Hz,Ar-H),7.01(s,1H,Ar-H),6.72(s,1H,Ar-H),4.28(q,2H,J=7.2Hz,-C 2H-CH3),1.33(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ166.8,166.7,135.5,134.9,134.0,132.4,129.1,128.0,127.7,126.8,125.2×2,124.2,124.0,114.6,113.3,113.0×2,104.8,104.2,41.7,16.0.ESI-MS m/z ESI-MS m/z 512.9/514.9/516.9[M+H]+.
ii) preparation of 2- (1-ethyl-5-bromo-3-indole) -3- (5-bromo-3-indole) maleimide (92)
According to the preparation of compound 23c, toCompound 92a (88mg, 0.172mmol), HMDS (4mL,17.2mmol) and MeOH (0.5mL,8.6mmol) were prepared as starting materials and chromatographed on silica gel using dichloromethane to give 92 as a red solid (85mg, 97% yield).1H NMR(500MHz,DMSO-d6)δ11.93(s,1H,indole-NH),10.98(s,1H,imide-NH),7.86(d,1H,J=2.8Hz,Ar-H),7.77(s,1H),7.48(d,1H,J=8.7Hz,Ar-H),7.35(d,1H,J=8.5Hz,Ar-H),7.15(dd,1H,J=8.7Hz,1.8Hz,Ar-H),7.08(dd,1H,J=8.6Hz,1.9Hz,Ar-H),6.94(d,1H,J=7.8Hz,Ar-H),6.68(d,1H,J=1.7Hz,Ar-H),4.25(q,2H,J=7.2Hz,-C 2H-CH3),1.32(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ173.2,173.1,135.3,134.7,133.0,131.2,128.5,128.1,127.4,127.2,124.8,124.7,123.9,123.8,114.3,112.8,112.7,112.5,105.4,105.0,41.5,16.0.HR-ESIMS m/z 511.9617[M+H]+(calcd.forC22H16N3O2Br2,511.9609).
Preparation of Compound 93
According to the preparation method of the compound 2, 92(55mg,107.6 mu mol), formaldehyde solution (3mL, 37 percent by mass) and NaHCO are adopted3(45mg, 538. mu. mol) as a starting material, separating by silica gel column chromatography, eluting with petroleum ether and ethyl acetate (1: 2 (v/v)) to give an orange-yellow solid, N-hydroxymethyl-2- (1-ethyl-5-bromo-3-indole) -3- (1-hydroxymethyl-5-bromo-3-indole) maleimide (93)58mg, yield 95%.1HNMR(500MHz,DMSO-d6)δ8.04(s,1H,Ar-H),7.71(s,1H,Ar-H),7.55(d,1H,J=8.7Hz,Ar-H),7.50(d,1H,J=8.7Hz,Ar-H),7.18(dt,2H,J=8.9Hz,1.5Hz,Ar-H),7.12(d,1H,Ar-H,J=1.5Hz),6.58(d,1H,Ar-H J=1.5Hz),5.60(s,2H,indole-C 2H-OH),4.97(s,2H,imide-C 2H-OH),4.23(q,2H,J=7.1Hz,-C 2H-CH3),3.78(s,1H,N-CH2-OH),3.15(s,1H,N-CH2-OH),1.29(t,3H,J=7.1Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ171.2×2,134.9,134.8,133.9,133.2,128.2,128.1,127.6,127.5,127.0,125.0,124.1,124.0,113.5,113.2,113.1,112.8,104.9,104.8,69.9,60.9,41.5,16.0.HR-ESIMS m/z 593.9647[M+Na]+(calcd.for C24H19N3O4Br2Na,593.9640).
Preparation of Compound 94
According to the preparation method of the compound 82, using 6-bromoindole (850Mg,5.58mmol), Mg (134Mg,5,58mmol) and the compound 82(300Mg,1.12mmol) as raw materials, 180Mg of orange-red solid N-methyl-2, 3-bis (6-bromo-3-indole) maleimide (94) is prepared, with a yield of 30%.1H NMR(600MHz,DMSO-d6)δ11.83(s,2H,indole-NH),7.78(d,2H,J=7.7Hz,Ar-H),7.58(d,2H,J=7.7Hz,Ar-H),6.78(d,1H,J=7.8Hz,Ar-H),6.77(d,1H,J=7.8Hz,Ar-H),6.68(s,1H,Ar-H),6.67(s,1H,Ar-H),3.02(s,3H,-CH3).13C NMR(150MHz,DMSO-d6)δ172.0×2,137.4×2,130.8×2,127.5×2,124.8×2,122.9×2,122.8×2,115.1×2,115.0×2,106.1×2,24.6.HR-ESIMS m/z 497.9458[M+H]+(calcd.for C21H14N3O2Br2,497.9453).
Preparation of Compound 95
According to the preparation method of the compound 83, the compound 94(155mg,0.312mmol), NaH (14mg,0.343mmol, 60% by mass in paraffin) and EtI (28 μ L,0.343mmol) were used as raw materials, and subjected to silica gel column chromatography and eluted with ethyl acetate ═ 4:1(v/v) to obtain orange-red solid N-methyl-2- (1-ethyl-6-bromo-3-indole) -3- (6-bromo-3-indole) maleimide (95) in 56mg with a yield of 34%.1H NMR(500MHz,DMSO-d6)δ11.81(s,1H,indole-NH),7.79(s,1H,Ar-H),7.76(s,1H,Ar-H),7.57(s,1H,Ar-H),6.82(d,1H,J=8.6Hz,Ar-H),6.75(t,2H,J=7.7Hz,Ar-H),6.61(d,1H,J=8.6Hz,Ar-H),4.24(q,2H,J=7.2Hz,-C 2H-CH3),3.02(s,3H,-NCH3),1.29(t,3H,J=7.2Hz,-CH2-C 3H).13CNMR(125MHz,DMSO-d6)δ171.9,171.8,137.4,136.8,132.6,130.8,127.6,126.9,125.2,124.4,123.1,122.9,122.8,122.7,115.2,115.0,114.9,113.5,105.9,105.4,41.3,24.4,15.7.HR-ESIMS m/z 525.9771[M+H]+(calcd.for C23H18N3O2Br2,525.9766).
Preparation of Compound 96
i) Preparation of 2- (1-ethyl-6-bromo-3-indole) -3- (6-bromo-3-indole) maleic anhydride (96a)
According to the preparation of compound 84a, starting from compound 95(240mg,0.46mmol), silica gel column chromatography and dichloromethane elution gave 96a as an orange-red solid (144mg, 61% yield).1H NMR(600MHz,DMSO-d6)δ12.04(s,1H,indole-NH),7.89(d,1H,J=1.5Hz,Ar-H),7.87(s,1H,Ar-H),7.82(s,1H,Ar-H),7.63(s,1H,Ar-H),6.91(d,1H,J=8.6Hz,Ar-H),6.85(d,1H,J=8.6Hz,Ar-H),6.80(d,1H,J=8.6Hz,Ar-H),6.67(d,1H,J=8.6Hz,Ar-H),4.27(q,2H,J=7.1Hz,-C 2H-CH3),1.30(t,3H,J=7.1Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ166.8,166.7,137.7,137.1,133.9,132.2,128.8,128.1,124.9,124.2,123.6,123.5,123.3,123.2,115.8,115.5×2,114.0,105.4,104.8,41.6,15.7.ESI-MS m/z 535.1/537.0/539.1[M+Na]+.
ii) preparation of 2- (1-ethyl-6-bromo-3-indole) -3- (6-bromo-3-indole) maleimide (96)
Prepared according to the procedure for the preparation of compound 24c starting from compound 96a (100mg,0.195mmol), HMDS (4ml,17.2mmol) and MeOH (0.5ml,8.6mmol), and chromatographed on silica gel using dichloromethane to give 96 as a red solid (97mg, 97% yield).1HNMR(500MHz,DMSO-d6)δ11.82(s,1H,indole-NH),11.00(s,1H,imide-NH),7.79(d,1H,J=0.9Hz,Ar-H),7.78(s,1H,Ar-H),7.76(d,1H,J=7.5Hz,Ar-H),7.57(d,1H,J=7.6Hz,Ar-H),6.82(dd,1H,J=8.6Hz,1.6Hz,Ar-H),6.76(dd,1H,J=8.6Hz,1.7Hz,Ar-H),6.73(d,1H,J=8.5Hz,Ar-H),6.63(d,1H,J=8.6Hz,Ar-H),4.25(q,2H,J=7.2Hz,-C 2H-CH3),1.30(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ173.2×2,137.5,136.9,132.8,130.9,128.3,127.6,125.4,124.7,123.2,123.0,122.9,122.8,115.3,115.1,114.9,113.6,106.0,105.5,41.4,15.8.HR-ESIMS m/z 511.9617[M+H]+(calcd.forC22H16N3O2Br2,511.9609).
Preparation of Compound 97
According to the preparation method of the compound 2, the compound 96(14mg,27.4 mu mol), formaldehyde solution (3mL, 37 percent by mass) and NaHCO are adopted3(12mg, 137. mu. mol) as a starting material, and the red solid, N-hydroxymethyl-2- (1-ethyl-6-bromo-3-indole) -3- (1-hydroxymethyl-6-bromo-3-indole) maleimide (97), was obtained by silica gel column chromatography and eluting with petroleum ether and ethyl acetate: 3:1(v/v), 14.1mg, yield 90%.1HNMR(500MHz,DMSO-d6)δ7.98(s,1H,Ar-H),7.82(s,1H,Ar-H),7.78(s,2H,Ar-H),6.85–6.82(m,2H,Ar-H),6.79(d,1H,J=8.8Hz,Ar-H),6.74(t,1H,J=7.5Hz,indole-CH2-OH),6.51(d,1H,J=8.5Hz,Ar-H),6.32(t,1H,J=6.0Hz,imide-CH2-OH),5.59(d,2H,J=7.5Hz,indole-C 2H-OH),4.95(d,2H,J=6.0Hz,imide-C 2H-OH),4.25(q,2H,J=6.8Hz,-C 2H-CH3),1.29(d,3H,J=6.8Hz,-CH2-C 3H).13CNMR(125MHz,DMSO-d6)δ171.3,171.2,137.0,136.9,133.4,133.0,127.8,127.2,125.5,125.4,123.4,123.3,123.2,123.0×2,115.4,114.5,113.8,105.6,105.4,69.8,60.9,41.4,15.8.HR-ESIMS m/z 593.9650[M+Na]+(calcd.for C24H19N3O4Br2Na,593.9640).
Preparation of Compound 98
According to the preparation method of the compound 82, 180Mg of orange-red solid N-methyl-2, 3-bis (7-bromo-3-indole) maleimide (98) is prepared from 7-bromoindole (850Mg,5.6mmol), Mg (134Mg,5.6mmol) and the compound 82a (286Mg,1.1mmol) as raw materials, with a yield of 32%.1H NMR(500MHz,DMSO-d6)δ11.94(s,2H,indole-NH),7.77(d,2H,J=2.7Hz,Ar-H),7.20(d,2H,J=7.5Hz,Ar-H),6.77(d,2H,J=8.0Hz,Ar-H),6.60(t,2H,J=7.8Hz,Ar-H),3.04(s,3H,-CH3).13CNMR(125MHz,DMSO-d6)δ171.8×2,134.7×2,130.5×2,127.7×2,127.4×2,124.9×2,121.3×2,120.6×2,107.0×2,104.8×2,24.5.HR-ESIMS m/z 497.9464[M+H]+(calcd.for C21H14N3O2Br2,497.9453).
Preparation of Compound 99
According to the preparation method of the compound 83, the compound 98(317mg,0.638mmol), NaH (28.1mg,0.702mmol, 60% by mass in paraffin) and EtI (57 μ L,0.702mmol) are used as raw materials, and the raw materials are separated by silica gel column chromatography and eluted with ethyl acetate (5: 1 (v/v)) to obtain orange-red solid N-methyl-2- (1-ethyl-7-bromo-3-indole) -3- (7-bromo-3-indole) maleimide (99)110mg, with the yield of 33%.1H NMR(500MHz,DMSO-d6)δ11.96(s,1H,indole-NH),7.83(s,1H,Ar-H),7.77(s,1H,Ar-H),7.24(d,1H,J=7.5Hz,Ar-H),7.20(d,1H,J=7.5Hz,Ar-H),6.95(d,1H,J=7.9Hz,Ar-H),6.64(t,1H,J=6.7Hz,Ar-H),6.62(d,1H,J=6.6Hz,Ar-H),6.57(t,1H,J=7.8Hz,Ar-H),4.59(q,2H,J=7.2Hz,-C 2H-CH3),3.04(s,3H,-NCH3),1.31(d,3H,J=7.2Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ171.7×2,134.8×2,131.9,130.8,129.8,128.7,127.5,127.0,126.6,124.9,121.5,121.3,121.1,120.6,106.9,105.6,104.8,103.4,43.5,24.5,17.9.HR-ESIMS m/z 525.9772[M+H]+(calcd.for C23H18N3O2Br2,525.9766).
Preparation of Compound 100
i) Preparation of 2- (1-ethyl-7-bromo-3-indole) -3- (7-bromo-3-indole) maleic anhydride (100a)
According to the preparation method of compound 84a, compound 99(200mg,0.38mmol) was used as a starting material, and separation by silica gel column chromatography and elution with dichloromethane gave orange-red solid 100a (84mg, yield 43%).1H NMR(600MHz,DMSO-d6)δ12.23(s,1H,indole-NH),7.90(d,1H,J=2.5Hz,Ar-H),7.87(s,1H,Ar-H),7.29(d,1H,J=7.5Hz,Ar-H),7.26(d,1H,J=7.3Hz,Ar-H),7.00(d,1H,J=8.0Hz,Ar-H),6.71–6.68(m,1H,Ar-H),6.68–6.62(m,2H,Ar-H),4.60(q,2H,J=7.1Hz,-C 2H-CH3),1.32(t,3H,J=7.1Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ166.6,166.5,135.9,135.1,132.2,130.0,129.5,128.1,127.8,126.7,125.5,122.1,122.0,121.4,121.0,106.4,105.2,104.9,103.7,43.8,17.9.ESI-MS m/z 512.9/514.9/516.9[M+H]+.
ii) preparation of 2- (1-ethyl-7-bromo-3-indole) -3- (7-bromo-3-indole) maleimide (100)
According to the preparation of compound 24c, starting from compound 100a (150mg, 0.293 mmol), HMDS (4mL,17.2mmol) and MeOH (0.5mL,8.6mmol), column chromatography on silica gel eluting with dichloromethane afforded 100 as a red solid (123mg, 82% yield).1H NMR(500MHz,DMSO-d6)δ11.94(s,1H,indole-NH),11.03(s,1H,imide-NH),7.80(s,1H,Ar-H),7.76(s,1H,Ar-H),7.23(d,1H,J=7.6Hz,Ar-H),7.19(d,1H,J=7.4Hz,Ar-H),6.92(d,1H,J=8.0Hz,Ar-H),6.64(d,1H,J=7.9Hz,Ar-H),6.62(t,1H,J=7.9Hz,Ar-H),6.56(t,1H,J=7.7Hz,Ar-H),4.58(d,2H,J=7.1Hz,-C 2H-CH3),1.32(t,3H,J=7.1Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ172.9,172.8,134.8×2,131.9,130.8,129.9,129.2,127.5,127.2,127.1,124.8,121.4,121.3,121.1,120.6,106.9,105.6,104.8,103.3,43.5,17.9.HR-ESIMS m/z 511.9613[M+H]+(calcd.for C22H16N3O2Br2,511.9609).
Preparation of Compound 101
According to the preparation method of compound 2, compound 100(55mg, 107. mu. mol), formaldehyde solution (3mL, mass fraction 37%) and NaHCO are used3(45mg,537 μmol) as a raw material, and the red solid, N-hydroxymethyl-2- (1-ethyl-7-bromo-3-indole) -3- (1-hydroxymethyl-7-bromo-3-indole) maleimide (101), was obtained by silica gel column chromatography separation and elution with petroleum ether and ethyl acetate: 3:1(v/v), 20.2mg, yield 33%.1HNMR(500MHz,DMSO-d6)δ12.06(s,1H,indole-NH),7.87(s,1H,),7.82(s,1H,Ar-H),7.26(d,2H,J=7.6Hz,Ar-H),7.22(d,1H,J=7.4Hz,Ar-H),6.95(d,1H,J=8.0Hz,Ar-H),6.65(d,1H,J=7.8Hz,Ar-H),6.63(d,1H,J=6.0Hz,Ar-H),5.82(t,1H,J=7.0Hz,-CH2OH),4.97(d,2H,J=7.0Hz,-C 2HOH),4.62(q,2H,J=7.0Hz,-C 2H-CH3),1.33(t,3H,J=7.0Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ170.5,170.4,134.3×2,134.2,131.3,130.4,129.2,128.2,126.9,126.9,126.4×2,126.1×2,120.9,120.8,119.9,104.8,104.2,60.1,42.9,17.2.HR-ESIMS m/z 541.9725[M+H]+(calcd.for C23H18N3O3Br2,541.9715).
Preparation of Compound 102
i) Preparation of N-methyl-2- (3-indole) -3-bromomaleimide (102a)
Magnesium turnings (360mg,15mmol) were suspended in THF (5mL) in a 50mL two-necked flask, ethyl bromide (1.12mL,15mmol) was slowly added dropwise, the mixture was stirred at room temperature for 20min, then the temperature was raised to 45 ℃ and the mixture was stirred for 20min, indole (1.75g,15mmol) dissolved in THF (5mL) was added dropwise, and the stirring was continued for 30 min. After cooling to room temperature, THF (10mL) dissolved Compound 82a (2g,7.5mmol) was added dropwise and stirred at room temperature overnight. TLC detection till the reaction is finished, saturated ammonium chloride aqueous solution (50mL) is slowly dropped to quench the reaction, ethyl acetate is extracted (2 times × 100mL), saturated common salt solution is washed (2 times × 100mL), organic phases are combined and dried by anhydrous sodium sulfate, the solvent is removed by rotary evaporation in vacuum, silica gel column chromatography is carried out, and petroleum ether and ethyl acetate are 4:1(v/v) to obtain 2.2g of orange solid (102a) and the yield is 96%.1H NMR(500MHz,DMSO-d6)δ12.12(s,1H,indole-NH),8.06(d,1H,J=8.0Hz,Ar-H),7.91(d,1H,J=8.0Hz,Ar-H),7.55(dt,1H,J=8.0Hz,0.6Hz,Ar-H),7.23(dt,1H,J=7.9Hz,0.9Hz,Ar-H),7.15(dt,1H,J=7.7Hz,1.0Hz,Ar-H),3.01(s,3H,-NCH3).13C NMR(125MHz,DMSO-d6)δ169.7,167.1,138.2,137.1,131.6,125.1,123.1,122.8,121.0,114.1,112.9,104.4,25.1.ESI-MS m/z 304.9[M+H]+.
ii) preparation of N-methyl-2- (1-tert-butyloxycarbonyl-3-indole) -3-bromomaleimide (102b)
Compound 102a (2g,6.58mmol) was dissolved in THF (80mL) at 0 deg.C in a 250mL single-neck flask, a catalytic amount of DMAP was added, and THF (20mL) dissolved (Boc) was slowly added dropwise2O (2.9g,13.16mmol), warmed to room temperature and stirred for 2 h. TLC detection was performed until the reaction was complete, the solvent was removed by rotary evaporation in vacuo and the residue was chromatographed on silica gel with petroleum ether and ethyl acetate 10:1(v/v) to give 2.5g of a yellow solid (102b) in 94% yield.1H NMR(500MHz,DMSO-d6)δ8.13(d,1H,J=8.4Hz,Ar-H),8.08(s,1H,Ar-H),7.77(d,1H,J=7.9Hz,Ar-H),7.43(dt,1H,J=7.9Hz,0.9Hz,Ar-H),7.36(dt,1H,J=7.7Hz,1.0Hz,Ar-H),3.02(s,3H,-NCH3),1.65(s,9H,-C(CH3)3).13C NMR(125MHz,DMSO-d6)δ168.9,166.4,149.0,136.3,135.1,129.4,127.2,125.8,123.7,123.0,122.1,115.5,109.0,85.7,28.1,25.3.ESI-MS m/z 405.0[M+H]+Iii) preparation of N-methyl-2- (1-tert-butyloxycarbonyl-3-indole) -3- (3-indole) maleimide (102c)
According to the method for synthesizing compound 102a, the compound was synthesized from compound 102b (1.8g,4.46mmol), magnesium turnings (321mg, 13.37mmol), bromoethane (1mL,13.37mmol) and indole (1.57g,13.37mmol), and the product was separated by silica gel column chromatography and eluted with petroleum ether and ethyl acetate at a ratio of 4:1(v/v) to give 1.6g of yellow solid (102c) with a yield of 81%.1H NMR(500MHz,DMSO-d6)δ11.83(s,1H,indole-NH),8.03(d,1H,J=8.3Hz,Ar-H),7.91(s,1H,Ar-H),7.85(d,1H,J=2.8Hz,Ar-H),7.37(d,1H,J=8.1Hz,Ar-H),7.18(t,1H,J=7.7Hz),6.98(t,1H,J=7.6Hz,Ar-H),6.87(d,1H,J=8.2Hz,Ar-H),6.86(d,1H,J=8.3Hz,Ar-H),6.82(t,1H,J=7.5Hz,1H,Ar-H),6.67(t,1H,J=7.6Hz,Ar-H),3.04(s,3H,-NCH3),1.60(s,9H,-C(CH3)3).13C NMR(125MHz,DMSO-d6)δ171.6,171.5,149.1,136.6,134.7,132.5,131.0,128.4,128.1,125.5,125.0,123.4,122.9,122.4,121.7,121.2,120.3,115.1,112.4,111.2,105.7,85.0,28.0,24.5.ESI-MS m/z 442.2[M+H]+.
iv) preparation of phenethyl p-toluenesulfonate (102d)
Phenethyl alcohol (2g,16.3mmol) was dissolved in dichloromethane (50mL) in a 250mL two-necked flask at 0 deg.C, triethylamine (3.38mL,24.5mmol) was added, p-toluenesulfonyl chloride (4.67g,24.5mmol) dissolved in dichloromethane (20mL) was added dropwise, and the mixture was allowed to warm to room temperature overnight. TLC detection till the reaction is finished, the solvent is removed by rotary evaporation in vacuum, and the mixture is separated by silica gel column chromatography and eluted by petroleum ether and ethyl acetate of 25:1(v/v) to obtain 3.6g of yellow solid (102d) with the yield of 80%. ESI-MS M/z 277.1[ M + H ]]+.
v) preparation of N-methyl-2- (1-tert-butyloxycarbonyl-3-indole) -3- (1-phenethyl-3-indole) maleimide (102e)
Sodium hydride (11mg,0.272mmol, content 60%; was suspended in DMF (5mL) in a 25mL three-necked flaskDispersed in paraffin oil), -after stirring for 30min at 5 ℃, compound 102c (60mg,0.136mmol) dissolved in DMF (5mL) was slowly added dropwise, stirring was continued for 45min at low temperature, compound 102d (100 μ L,0.272mmol) dissolved in DMF (2mL) was slowly added dropwise, warmed to room temperature, and reacted overnight. TLC detection till the reaction is finished, cooling to 0 ℃, slowly dropwise adding saturated ammonium chloride aqueous solution (50mL) to quench the reaction, extracting with ethyl acetate (3 times × 100mL), washing with brine (2 times × 100mL), combining organic phases, drying with anhydrous sodium sulfate, removing the solvent by vacuum rotary evaporation, separating by silica gel column chromatography, eluting with petroleum ether and ethyl acetate (7: 1 (v/v)) to obtain 47mg of red solid, wherein the yield is 63%.1H NMR(500MHz,DMSO-d6)δ8.03(d,1H,J=8.4Hz,Ar-H),7.93(s,1H,Ar-H),7.72(s,1H,Ar-H),7.47(d,1H,J=8.3Hz,Ar-H),7.22(t,1H,J=6.6Hz,Ar-H),7.18(m,2H,Ar-H),7.14(m,2H,Ar-H),7.03–6.98(dt,1H,J=7.8Hz,0.9Hz,Ar-H),6.81(m,3H,Ar-H),6.66(dd,1H,J=7.0Hz,7.1Hz,Ar-H),4.47(t,2H,J=7.1Hz,N-C 2H-CH2Ph),3.01(s,3H,-NCH3),2.99(t,2H,J=7.1Hz,NCH2-C 2H-Ph),1.61(s,9H,-C(CH3)3).13C NMR(125MHz,DMSO-d6)δ171.5,171.4,149.2,138.7,136.2,134.7,133.7,131.7,129.2×2,128.7×2,128.6,128.2,126.9,126.1,125.1,123.3,122.8,122.6,121.7,121.4,120.5,115.1,111.2,110.9,104.9,85.1,47.8,36.1,28.1×3,24.5.ESI-MS m/z 546.3[M+H]+.
vi) preparation of N-methyl-2- (3-indole) -3- (1-phenethyl-3-indole) maleimide (102f)
Compound 102e (34mg,0.062mmol) was dissolved in toluene (10mL) in a 100mL single-neck flask, silica gel (200mg) was added, and the mixture was heated at reflux for 2 h. Cooling to room temperature, detecting by TLC until the reaction is finished, removing the solvent by vacuum rotary evaporation, separating by silica gel column chromatography, and eluting with petroleum ether and ethyl acetate (3: 1 (v/v)) to obtain red solid (102f)26mg with a yield of 94%.1H NMR(500MHz,DMSO-d6)δ11.68(s,1H,indole-NH),7.76(s,1H,Ar-H),7.63(s,1H,Ar-H),7.45(d,1H,J=8.3Hz,Ar-H),7.36(d,1H,J=8.1Hz,Ar-H),7.25(d,1H,J=7.8Hz,Ar-H),7.24(d,2H,J=7.2Hz,Ar-H),7.18–7.16(m,3H,Ar-H),6.99(d,1H,J=7.9Hz,Ar-H),6.95(d,1H,J=7.8Hz,Ar-H),6.75(d,1H,J=8.3Hz,Ar-H),6.73(d,1H,J=8.0Hz,Ar-H),6.64(d,1H,J=8.1Hz,Ar-H),6.60(d,1H,J=8.1Hz,Ar-H),4.46(t,2H,J=7.3Hz,N-C 2H-CH2Ph),3.03(t,2H,J=7.3Hz,NCH2-C 2H-Ph),3.01(s,3H,-NCH3).13C NMR(125MHz,DMSO-d6)δ172.2,172.1,138.8,136.4,136.0,134.7,132.3,129.6,129.2×2,128.7×2,127.4,126.9,126.7,126.4,125.8,122.1,121.6,121.4,119.9,119.7,112.2,110.6,106.1,105.3,47.7,36.2,24.4.ESI-MS m/z446.3[M+H]+.
vii) preparation of 6-methyl-12-phenethyl-12, 13-dihydro-5H-indole [2,3-a ] pyrrolo [3,4-c ] carbazole-5, 7(6H) -dione (102)
According to the preparation method of compound 73a, compound 102f (406mg,0.912mmol), DDQ (269mg,1.19mmol) and p-TsOH (154mg,0.81mmol) were synthesized, and subjected to silica gel column chromatography and eluted with ethyl acetate: 3:1(v/v) to give 340mg of (102) as a yellow solid in 84% yield.1H NMR(500MHz,DMSO-d6)δ11.83(s,1H,indole-NH),9.03(d,1H,J=8.0Hz,Ar-H),9.00(d,1H,J=7.8Hz,Ar-H),7.77(d,1H,J=8.1Hz,Ar-H),7.55(t,1H,J=7.5Hz,Ar-H),7.50(d,1H,J=8.1Hz,Ar-H),7.44(t,1H,J=7.0Hz,Ar-H),7.33(t,1H,J=6.9Hz,Ar-H),7.27(t,1H,J=6.9Hz,Ar-H),7.03–7.00(m,5H,Ar-H),5.07(t,2H,J=7.4Hz,N-C 2H-CH2Ph),3.05(s,3H,NCH3),3.03(t,2H,J=7.4Hz,NCH2-C 2H-Ph).13C NMR(125MHz,DMSO-d6)δ170.1×2,141.7,141.6,138.4,129.8,129.6,129.5,128.7×2,128.6,128.5,127.4,127.2,126.8,124.8,124.7,121.5,120.8,120.7×2,119.7,117.5,116.6,112.6,110.6,45.8,36.9,24.1.ESI-MS m/z 444.2[M+H]+.
Preparation of Compound 103
i) Preparation of 12-phenethyl-12, 13-dihydrofuran [3,4-c ] indole [2,3-a ] carbazole-5, 7-dione (103a)
Synthesized from compound 102(200mg,0.45mmol) and KOH (5M,30mL) according to the method for the synthesis of compound 73b, 164mg of a yellow solid (103a) was obtained in 84% yield. Because the solubility of the product is very poor and the reaction is complete, the product is directly put into the next reaction without separation and purification.
ii) preparation of 12-phenethyl-12, 13-dihydro-5H-indole [2,3-a ] pyrrolo [3,4-c ] carbazole-5, 7(6H) -dione (103)
According to the method for synthesizing compound 23c, compound 103a (20mg,0.047mmol), HMDS (500 μ L,2.35mmol) and methanol (50 μ L,1.18mmol) were synthesized, and subjected to silica gel column chromatography and eluted with ethyl acetate (3: 1 (v/v)) as a yellow solid (103) at 16mg in 90% yield.1H NMR(500MHz,DMSO-d6)δ11.83(s,1H,indole-NH),11.02(s,1H,imide-NH),9.08(d,1H,J=7.8Hz,Ar-H),9.06(d,1H,J=7.8Hz,Ar-H),7.79(d,1H,J=8.1Hz,Ar-H),7.62(d,1H,J=8.3Hz,Ar-H),7.56(t,1H,J=7.6Hz,Ar-H),7.47(t,1H,J=7.7Hz,Ar-H),7.35(t,1H,J=7.5Hz,Ar-H),7.30(t,1H,J=7.5Hz,Ar-H),7.10–6.98(m,5H,Ar-H),5.20(t,2H,J=7.1Hz,N-C 2H-CH2-Ph),3.07(t,2H,J=7.1Hz,N-CH2-C 2H-Ph).13C NMR(125MHz,DMSO-d6)δ171.6,171.5,141.6,141.5,138.2,133.0,129.5×2,128.9,128.4×2,127.3,127.1,126.7,124.9,124.7,123.5,121.6,121.4,120.7×2,120.3,117.4,116.6,112.5,110.6,45.8,36.5.ESI-MS m/z 430.2[M+H]+.
Preparation of Compound 104
According to the preparation method of the compound 2, the compound 103(18mg,0.06mmol) is used as a raw material, silica gel column chromatography separation is carried out, and petroleum ether and ethyl acetate are respectively 3:1(v/v) and eluted to obtain yellow fluorescent powder 6-hydroxymethyl-12-phenethyl-12, 13-dihydro-5H-indole [2,3-a ] powder]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (104)21mg, yield 80%.1H NMR(500MHz,DMSO-d6)δ11.92(s,1H,indole-NH),9.07(d,1H,J=7.9Hz,Ar-H),9.06(d,1H,J=7.8Hz,Ar-H),7.79(d,1H,J=8.1Hz,Ar-H),7.58(d,1H,J=8.2Hz,Ar-H),7.56(d,1H,J=8.1Hz,Ar-H),7.47(t,1H,J=7.6Hz,Ar-H),7.35(t,1H,J=7.4Hz,Ar-H),7.30(t,1H,J=7.4Hz,Ar-H),7.00–6.97(m,5H),6.29(t,1H,J=7.0Hz,-CH2OH),5.16(t,2H,J=6.8Hz,N-C 2H-CH2Ph),5.04(d,2H,J=7.0Hz,-C 2HOH),3.08(t,2H,J=6.8Hz,NCH2-C 2H-Ph).13C NMR(125MHz,DMSO-d6)δ169.5,169.4,141.6,141.5,138.2,130.0,129.4×2,128.9,128.4,127.4,127.2,126.7,124.9,124.7,124.5,123.5,121.4,121.3,120.8,120.7,119.1,117.4,116.6,112.6,110.6,60.2,45.8,36.4.ESI-MS m/z 460.2[M+H]+.
Preparation of Compound 105
According to the method for synthesizing compound 14, compound 103a (40mg,0.09mmol) and ethylenediamine (75 μ L,0.9mmol) were synthesized and subjected to silica gel column chromatography and eluted with dichloromethane methanol 50:1(v/v) to give 6- (2-aminoethyl) -12-phenethyl-12, 13-dihydro-5H-indole [2,3-a ] as a yellow solid]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (105)34mg, yield 80%.1H NMR(500MHz,DMSO-d6)δ12.07(s,1H,indole-NH),9.08(d,1H,J=7.2Hz,Ar-H),9.07(d,1H,J=7.9Hz,Ar-H),7.83(d,1H,J=8.0Hz,Ar-H),7.62(d,1H,J=8.1Hz,Ar-H),7.58(t,1H,J=7.8Hz,Ar-H),7.47(t,1H,J=7.3Hz,Ar-H),7.35(t,1H,J=7.3Hz,Ar-H),7.30(t,1H,J=7.2Hz,Ar-H),7.01(m,5H,Ar-H),5.23(t,2H,J=6.6Hz,N-C 2H-CH2-Ph),3.90(t,2H,J=5.7Hz,N-C 2H-CH2NH2),3.10(t,2H,J=5.7Hz,NCH2-C 2H-NH2),3.09(t,2H,J=6.6Hz,N-CH2-C 2H-Ph).13C NMR(125MHz,DMSO-d6)δ170.2×2,141.7,141.6,138.2,129.5×2,128.8,128.4×2,127.4,127.2,126.7,124.7,124.6,121.9,121.4,120.9,120.7,119.4,119.3,117.5,116.7,112.7,111.6,110.7,45.9,40.9,40.9,36.5.ESI-MS m/z 473.3[M+H]+.
Preparation of Compound 106
According to the synthesis method of compound 16, from compound 105(25mg,0.05mmol) was obtained 6- (2-aminoethyl) -12-phenethyl-12, 13-dihydro-5H-indole [2,3-a ] as a yellow solid]Pyrrole [3,4-c ]]173mg of carbazole-5, 7(6H) -dione hydrochloride (106) was obtained in a yield of 90%.1H NMR(500MHz,DMSO-d6)δ12.24(s,1H,indole-NH),9.05(d,1H,J=7.5Hz,Ar-H),9.04(d,1H,J=7.0Hz,Ar-H),8.21(brs,3H,-NH3 +),7.87(d,1H,J=8.1Hz,Ar-H),7.56(d,1H,J=7.7Hz,Ar-H),7.55(d,1H,J=8.1Hz,Ar-H),7.45(d,1H,J=7.3Hz,Ar-H),7.34(t,1H,J=7.5Hz,Ar-H),7.28(t,1H,J=7.4Hz,Ar-H),7.03–6.93(m,5H),5.23(t,2H,J=6.4Hz,N-C 2H-CH2Ph),3.97(t,2H,J=6.4Hz,N-C 2H-CH2NH3 +),3.18(t,2H,J=6.4Hz,NCH2-C 2H-NH3 +),3.07(t,2H,J=6.4Hz,NCH2-C 2H-Ph).13C NMR(125MHz,DMSO-d6)δ170.1×2,141.8,141.6,138.2,129.8,129.4,128.7,128.3,127.4,127.1,126.6,124.6,124.5,121.4,120.9,121.2,120.7,120.6,119.3×2,117.4,116.7,112.8,110.7,110.6.45.8,38.2,36.6,35.7.ESI-MSm/z 473.2[M–Cl]+.
Preparation of Compound 107
According to the method for synthesizing compound 14, compound 103a (25mg,0.06mmol) and 1, 3-propanediamine (99 μ L,1.2mmol) were synthesized, and subjected to silica gel column chromatography and eluted with dichloromethane methanol 50:1(v/v) to give 6- (3-aminopropyl) -12-phenethyl-12, 13-dihydro-5H-indole [2,3-a ] as a yellow solid]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (107)22mg, yield 75%.1H NMR(500MHz,DMSO-d6)δ12.19(s,1H,indole-NH),9.05(d,1H,J=7.8Hz,Ar-H),9.03(d,1H,J=7.8Hz,Ar-H),7.87(d,1H,J=8.1Hz,Ar-H),7.57(dt,1H,J=8.1Hz,1.1Hz,Ar-H),7.54(d,1H,J=8.1Hz,Ar-H),7.45(dt,1H,J=8.1Hz,1.1Hz,Ar-H),7.35(dt,1H,J=8.1Hz,1.1Hz,Ar-H),7.28(t,1H,J=7.9Hz,Ar-H),7.05–7.03(m,5H,Ar-H),5.20(t,2H,J=7.0Hz,N-C 2H-CH2Ph),3.76(t,2H,J=6.6Hz,N-C 2H-(CH2)2NH2),3.07(t,2H,J=7.0Hz,NCH2-C 2H-Ph),2.90(t,2H,J=6.6Hz,N(CH2)2-C 2H-NH2),2.04–2.00(m,2H,NCH2-C 2H-CH2NH2).13C NMR(125MHz,DMSO-d6)δ170.2×2,141.9,141.7,138.4,130.0,129.6×2,128.9,128.5×2,127.5,127.3,126.8,124.8,124.6,121.5,121.4,120.8×2,119.1×2,117.6,116.8,112.9,110.7,45.9,37.5,36.7,35.2,27.4.ESI-MS m/z 487.1[M+H]+.
Preparation of Compound 108
According to the synthesis method of compound 16, yellow solid 6- (3-aminopropyl) -12-phenethyl-12, 13-dihydro-5H-Indole [2,3-a ]]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione hydrochloride (108)20mg, yield 90%.1H NMR(500MHz,DMSO-d6)δ12.18(s,1H,indole-NH),9.06(d,2H,J=7.9Hz,Ar-H),8.01(brs,3H,-NH3 +),7.85(d,1H,J=8.1Hz,Ar-H),7.59(d,1H,J=8.1Hz,Ar-H),7.56(d,1H,J=8.1Hz,Ar-H),7.45(t,1H,J=7.6Hz,Ar-H),7.34(t,1H,J=7.5Hz,Ar-H),7.29(t,1H,J=7.5Hz,Ar-H),7.04–6.97(m,5H),5.22(t,2H,J=6.8Hz,N-C 2H-CH2Ph),3.77(d,2H,J=6.8Hz,N-C 2H-(CH2)2N 3H +),3.07(t,2H,J=6.7Hz,NCH2-C 2H-Ph),2.93(t,2H,J=6.7Hz,N(CH2)2-C 2H-NH3 +),2.05–1.97(m,2H,NCH2-C 2H-CH2NH3 +).13C NMR(125MHz,DMSO-d6)δ170.2,170.1,141.8,141.6,138.3,130.0,129.8,129.5,128.8,128.4,127.4,127.3,127.2,126.7,124.7,124.5,121.4,121.2,120.7×2,119.0×2,117.5,116.7,112.8,110.7,45.8,37.4,36.5,35.1,27.3.ESI-MS m/z 487.1[M–Cl]+.
Preparation of Compound 109
According to the synthesis method of compound 24, compound 103a (21mg,0.049mmol), 4- (2-aminoethyl) -morpholine (50 μ L,0.49mmol) and a catalytic amount of triethylamine are synthesized, and the obtained product is subjected to silica gel column chromatography and eluted with dichloromethane and methanol at a ratio of 50:1(v/v) to obtain 6- (2- (4-morpholine) ethyl) -12-phenethyl-12, 13-dihydro-5H-indole [2,3-a ] as a yellow solid]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (109)19mg, yield 80%.1H NMR(500MHz,DMSO-d6)δ11.91(s,1H,indole-NH),9.05(d,1H,J=7.9Hz,Ar-H),9.04(d,1H,J=7.8Hz,Ar-H),7.78(d,1H,J=8.1Hz),7.57(d,1H,J=7.8Hz,Ar-H),7.57(t,1H,J=7.3Hz,Ar-H),7.46(d,1H,J=7.2Hz,Ar-H),7.34(t,1H,J=7.2Hz,Ar-H),7.29(t,1H,J=7.4Hz,Ar-H),7.03–7.01(m,5H,Ar-H),5.16(t,2H,J=7.0Hz,N-C 2H-CH2Ph),3.78(t,2H,J=6.5Hz,imide-N-C 2H-CH2-morpholine),3.50(t,4H,J=3.9Hz,morpholine-N(CH2-CH 2)2O),3.07(t,2H,J=7.0Hz,NCH2-C 2H-Ph),2.61(t,2H,J=6.5Hz,imide-NCH2-C 2H-morpholine),2.47(t,4H,J=3.9Hz,morpholine-N(CH 2-CH2)2O).13C NMR(125MHz,DMSO-d6)δ170.0,169.9,141.6,141.5,138.2,130.0,129.8,129.5×2,128.8,128.7,128.4×2,127.4,127.2,126.7,124.6,121.4,121.3,120.8,120.1,119.0,117.4,116.7,112.6,110.6,66.6×2,56.5×2,53.6,45.8,36.5,34.9.ESI-MS m/z 543.2[M+H]+.
Preparation of Compound 110
According to the synthesis method of compound 24, compound 103a (23mg,0.054mmol), 4- (2-aminoethyl) -piperazine (60 μ L,0.54mmol) and a catalytic amount of triethylamine are synthesized, and the obtained product is subjected to silica gel column chromatography and eluted with dichloromethane and methanol at a ratio of 50:1(v/v) to obtain 6- (2-piperazineethyl) -12-phenethyl-12, 13-dihydro-5H-indole [2,3-a ] as a yellow solid]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (110)16mg, yield 80%.1HNMR(500MHz,DMSO-d6)δ12.12(s,1H,indole-NH),10.24(s,1H,piperazin-NH),9.04(d,1H,J=7.1Hz,Ar-H),9.03(d,1H,J=6.9Hz,Ar-H),7.83(d,1H,J=8.1Hz,Ar-H),7.58–7.52(m,2H,Ar-H),7.44(t,1H,J=7.5Hz,Ar-H),7.33(t,1H,J=7.4Hz,Ar-H),7.28(t,1H,J=7.4Hz,Ar-H),7.05–6.94(m,5H,Ar-H),5.19(t,2H,J=7.0Hz,N-C 2H-CH2Ph),3.80(t,2H,J=6.5Hz,imide-N-C 2H-CH2-piperazine),3.07(t,2H,J=7.0Hz,NCH2-C 2H-Ph),3.01(t,4H,J=4.4Hz,piperazine-N(CH 2-CH2)2NH),2.75(t,4H,J=4.4Hz,piperazine-N(CH2-CH 2)2NH),2.48(t,2H,J=6.5Hz,imide-NCH2-C 2H-piperazine).13C NMR(125MHz,DMSO-d6)δ170.0,169.9,141.7,141.6,138.2,129.9,129.5×2,128.7,128.4×2,127.4,127.1,126.7,124.7,124.5,121.4,121.2,120.7,120.6,119.0,118.9,117.4,116.6,112.7,110.6,55.6×2,53.6,49.5×2,43.1,36.5,34.8.ESI-MS m/z 542.3[M+H]+.
Preparation of Compound 111
According to the synthesis of compound 24, the compoundCompound 103a (15mg,0.035mmol), 2-chloro-6-fluorophenethylamine (20 μ L,0.35mmol) and a catalytic amount of triethylamine were synthesized and chromatographed on silica gel with dichloromethane and methanol at 50:1(v/v) to give 6- (2-chloro-6-fluorophenethyl) -12-phenethyl-12, 13-dihydro-5H-indole [2,3-a ] as a yellow solid]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (111)13mg, yield 68%.1H NMR(500MHz,DMSO-d6)δ11.93(s,1H,indole-NH),9.00(d,1H,J=7.8Hz,Ar-H),8.98(d,1H,J=7.9Hz,Ar-H),7.78(d,1H,J=8.1Hz,Ar-H),7.60(d,1H,J=8.4Hz,Ar-H),7.55(t,1H,J=7.6Hz,Ar-H),7.46(t,1H,J=7.4Hz,Ar-H),7.35(t,1H,J=7.7Hz,Ar-H),7.29(d,1H,J=7.6Hz,Ar-H),7.25(m,2H,Ar-H),7.11(dd,J=7.1Hz,5.9Hz,1H),7.08–6.95(m,5H,Ar-H),5.17(t,2H,J=7.0Hz,N-C 2H-CH2Ph),3.94(t,2H,J=6.5Hz,imide-N-C 2H-CH2-C6H3FCl),3.19(t,2H,J=6.5Hz,imide-NCH2-C 2H-C6H3FCl),3.07(t,2H,J=7.0Hz,NCH2-C 2H-Ph).13C NMR(125MHz,DMSO-d6)δ169.8,169.7,161.8(d,1JCF=244Hz),141.6(d,3JCF=11Hz),138.2,135.0,129.8(d,2JCF=11Hz),129.4×2,128.7,128.4×2,127.4,127.2,126.7,125.8×2,124.8,124.7,124.6,124.5×2,121.4(d,2JCF=22Hz),120.8,120.7,119.0,118.9,117.4,116.6,114.7(d,2JCF=23Hz),112.6,110.6,45.8,36.9,36.5,25.9.ESI-MS m/z 586.2[M+H]+.
Preparation of Compound 112
According to the method for synthesizing the compound 24, the compound 103a (15mg,0.035mmol), 1- (2-aminoethyl) piperidine (50 μ L,0.47mmol) and a catalytic amount of triethylamine are synthesized, and the obtained product is subjected to silica gel column chromatography and eluted with dichloromethane and methanol at a ratio of 50:1(v/v) to obtain 6- (2-piperidineethyl) -12-phenethyl-12, 13-dihydro-5H-indole [2,3-a ] as a yellow solid]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (112)17mg, yield 67%.1HNMR(500MHz,DMSO-d6)δ11.92(s,1H,indole-NH),9.04(d,1H,J=8.2Hz,Ar-H),9.02(d,1H,J=8.5Hz,Ar-H),7.78(d,1H,J=8.1Hz,Ar-H),7.56(d,1H,J=7.3Hz,Ar-H),7.54(d,1H,J=8.0Hz,Ar-H),7.45(d,1H,J=7.2Hz,Ar-H),7.34(d,1H,J=7.3Hz,Ar-H),7.28(d,1H,J=7.3Hz,Ar-H),7.08–6.96(m,5H,Ar-H),5.14(t,2H,J=6.6Hz,N-C 2H-CH2Ph),3.77(t,2H,J=5.4Hz,imide-N-C 2H-CH2-piperidine),3.06(t,2H,J=6.6Hz,NCH2-C 2H-Ph),2.65(t,2H,J=6.5Hz,imide-NCH2-C 2H-piperidine),2.49(t,4H,J=3.1Hz,piperidine-N(CH 2-CH2)2CH2),1.45(m,4H,piperidine-N(CH2-CH 2)2CH2),1.34(t,2H,J=3.4Hz,piperidine-N(CH2-CH2)2CH 2).13C NMR(125MHz,DMSO-d6)δ169.9×2,141.6,141.5,138.2,129.8,129.4×2,128.7,128.4×2,127.4,127.1,126.7,124.7,124.6,121.4,121.3,120.7,120.6,119.1,119.0,117.4,116.5,112.6,110.6,56.5×2,54.2,45.8,36.5,25.9,25.6×2,24.1.ESI-MS m/z 541.2[M+H]+.
Preparation of Compound 113
According to the synthesis method of compound 24, compound 103a (23mg,0.054mmol), 4-methyl-1-piperazineethylamine (50 μ L,0.55mmol) and a catalytic amount of triethylamine are synthesized, and the obtained product is subjected to silica gel column chromatography and eluted with dichloromethane and methanol at a ratio of 50:1(v/v) to obtain 6- (2- (4-methylpiperazine) ethyl) -12-phenethyl-12, 13-dihydro-5H-indole [2,3-a ] as a yellow solid]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (113)19mg, yield 65%.1H NMR(500MHz,DMSO-d6)δ11.94(s,1H,indole-NH),9.06(d,1H,J=7.3Hz,Ar-H),9.05(d,1H,J=7.0Hz,Ar-H),7.79(d,1H,J=8.2Hz,Ar-H),7.59(d,1H,J=7.7Hz,Ar-H),7.56(d,1H,J=7.7Hz,Ar-H),7.46(t,1H,J=7.6Hz,Ar-H),7.35(t,1H,J=7.5Hz,Ar-H),7.07–6.97(m,5H,Ar-H),5.17(t,2H,J=6.8Hz,N-C 2H-CH2Ph),3.79(t,2H,J=6.3Hz,N-C 2H-CH2-piperazine),3.07(t,2H,J=6.9Hz,NCH2-C 2H-Ph),2.62(t,2H,J=6.5Hz,NCH2-C 2H-piperazine),2.48(t,4H,J=4.5Hz,piperazine-N(CH 2-CH2)2NCH3),2.35(t,4H,J=4.5Hz,piperazine-N(CH2-CH 2)2NCH3),2.15(s,3H,piperazine-N(CH2-CH2)2NCH 3).13C NMR(125MHz,DMSO-d6)δ169.9×2,141.6×2,138.2,129.9,129.5×2,128.7,128.4×2,127.5,127.2,126.7,124.7,124.6,121.4,121.3,120.8,120.7,119.1,119.0,117.4,116.7,112.6,110.6,55.9×2,54.8×2,52.6,45.8,45.6,36.5,35.2.ESI-MS m/z 556.3[M+H]+.
Preparation of Compound 114
According to the synthesis method of compound 24, compound 103a (40mg,0.093mmol), ethanolamine (102 μ L,1.86mmol) and a catalytic amount of triethylamine are synthesized, and the obtained product is subjected to silica gel column chromatography and eluted with dichloromethane and methanol at a ratio of 50:1(v/v) to obtain 6- (2-hydroxyethyl) -12-phenethyl-12, 13-dihydro-5H-indole [2,3-a ] as a yellow solid]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (114)28mg, yield 67%.1H NMR(500MHz,DMSO-d6)δ11.86(s,1H,indole-NH),9.06(d,1H,J=8.0Hz,Ar-H),9.04(d,1H,J=7.9Hz,Ar-H),7.78(d,1H,J=8.1Hz,Ar-H),7.57(t,1H,J=7.3Hz,Ar-H),7.53(d,1H,J=8.1Hz,Ar-H),7.45(t,1H,J=7.3Hz,Ar-H),7.35(d,1H,J=7.0Hz,Ar-H),7.28(t,1H,J=7.5Hz,Ar-H),7.07–7.00(m,5H,Ar-H),5.12(t,2H,J=6.6Hz,N-C 2H-CH2Ph),4.93(t,1H,J=5.7Hz,-OH),3.72(t,2H,J=5.7Hz,N-C 2H-CH2OH),3.69(t,2H,J=5.7Hz,-C 2HOH),3.07(t,2H,J=6.6Hz,NCH2-C 2H-Ph).13C NMR(125MHz,DMSO-d6)δ170.2×2,141.7,141.6,138.4,129.8,129.5×2,128.8,128.5×2,127.5,127.2,126.8,124.9,124.8,121.5,121.4,120.8,120.7,119.3×2,117.5,116.7,112.6,110.6,58.9,45.9,45.8,36.6.ESI-MS m/z 474.3[M+H]+.
Preparation of Compound 115
According to the synthesis method of compound 24, compound 103a (30mg,0.07mmol), 3-hydroxypropylamine (100 μ L,1.4mmol) and a catalytic amount of triethylamine are synthesized, and subjected to silica gel column chromatography and elution with dichloromethane and methanol at 50:1(v/v) to obtain 6- (3-hydroxypropyl) -12-phenylethyl-12, 13-dihydro-5H-indole [2,3-a ] as a yellow solid]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (115)24mg, yield 70%.1H NMR(500MHz,DMSO-d6)δ11.93(s,1H,indole-NH),9.07(d,1H,J=7.9Hz,Ar-H),9.05(d,1H,J=7.9Hz,Ar-H),7.80(d,1H,J=8.1Hz,Ar-H),7.58(dd,1H,J=8.3Hz,1.1Hz,Ar-H),7.57(t,1H,J=7.7Hz,Ar-H),7.48(dt,1H,J=8.1Hz,1.1Hz,Ar-H),7.35(d,J=8.3Hz,1H,Ar-H),7.29(t,1H,J=7.5Hz,Ar-H),7.08–7.01(m,5H,Ar-H),5.15(t,2H,J=7.1Hz,N-C 2H-CH2Ph),4.59(t,1H,J=5.1Hz,N(CH2)2CH2-OH),3.73(t,2H,J=7.2Hz,N-C 2H-CH2CH2OH),3.53–3.51(m,2H,N(CH2)2-C 2H-OH),3.07(t,2H,J=7.1Hz,NCH2-C 2H-Ph),1.88–1.83(m,2H,NCH2-C 2H-CH2OH).13C NMR(125MHz,DMSO-d6)δ170.2×2,141.8,141.7,138.4,129.9,129.6×2,128.8,128.5×2,127.5,127.3,126.9,124.9,124.8,121.6,121.4,120.8,120.7,119.2×2,117.5,116.8,112.9,110.7,59.3×2,45.9,36.6,32.3.ESI-MS m/z 488.1[M+H]+.
Preparation of Compound 116
i) Preparation of p-toluenesulfonic acid (1-naphthylethyl) ester (116a)
According to the method for synthesizing compound 102d, the compound was synthesized from naphthaleneethanol (5g,0.029mmol), p-toluenesulfonyl chloride (11.65g,0.061mmol) and triethylamine (8.46mL,0.061mmol), and the product was separated by silica gel column chromatography and eluted with petroleum ether and ethyl acetate of 3:1(v/v) to obtain 9.6g of a white solid with a yield of 85%. ESI-MS M/z 278.1[ M + H ]]+.
ii) preparation of N-methyl-2- (1-tert-butyloxycarbonyl-3-indole) -3- (1- (1-naphthylethyl) -3-indole) maleimide (116b)
According to the method for synthesizing compound 102e, the compound was synthesized from compound 102c (1g,2.27mmol), sodium hydride (200mg,4.54mmol) and compound 116a (1.13g,3.41 mmol). Silica gel column chromatography, petroleum ether and ethyl acetate 4:1(v/v) to give red solid (116b)563mg, 41% yield.1H NMR(500MHz,DMSO-d6)δ8.08(d,1H,J=8.0Hz,Ar-H),8.07(d,1H,J=8.0Hz,Ar-H),7.97(s,1H,Ar-H),7.94(d,1H,J=7.8Hz,Ar-H),7.80(d,1H,J=8.2Hz,Ar-H),7.74(s,1H,Ar-H),7.59(dd,1H,J=8.3Hz,1.4Hz,Ar-H),7.56(d,1H,J=6.9Hz,Ar-H),7.44(d,1H,J=8.3H,Ar-H),7.38(t,1H,J=7.2Hz,Ar-H),7.24(d,1H,J=7.2Hz,Ar-H),7.19(d,1H,J=7.1Hz,Ar-H),7.04(t,1H,J=7.6Hz,Ar-H),6.95(d,1H,J=8.0Hz,Ar-H),6.89(d,1H,J=7.9Hz,Ar-H),6.85(d,1H,J=7.9Hz,Ar-H),6.74(t,1H,J=7.6Hz,Ar-H),4.58(t,2H,J=7.3Hz,N-C 2H-CH2-Nap),3.46(t,2H,J=7.3Hz,NCH2-C 2H-Nap),3.04(s,3H,NCH3),1.64(s,9H,-C(CH3)3).13C NMR(125MHz,DMSO-d6)δ171.5×2,149.3,136.4,134.9,134.8,134.0,133.9,131.9,131.8,129.3,128.4,128.3,127.8,127.4,126.9,126.3,125.9,125.2,124.0,123.6,123.0,122.8,122.0,121.7,120.7,115.3,111.3,110.9,105.1,85.2,47.2,33.3,28.2×3,24.9.ESI-MS m/z596.2[M+H]+.
iii) preparation of N-methyl-2- (3-indole) -3- (1- (1-naphthylethyl) -3-indole) maleimide (116c)
According to the method for synthesizing the compound 102f, the compound 116b (100mg,0.168mmol) and silica gel (400mg) were synthesized, and the product was separated by silica gel column chromatography and eluted with ethyl acetate (4: 1) (v/v) as a petroleum ether to give 79mg of a yellow solid (116c) with a yield of 95%.1H NMR(500MHz,DMSO-d6)δ11.72(d,1H,J=2.5Hz,indole-NH),8.09(d,1H,J=8.2Hz,Ar-H),7.94(s,1H,Ar-H),7.80(d,1H,J=8.2Hz,Ar-H),7.75(d,1H,J=2.8Hz,Ar-H),7.62(s,1H,Ar-H),7.58(t,1H,J=7.7Hz,Ar-H),7.54(t,1H,J=7.7Hz,Ar-H),7.43–7.40(m,2H,Ar-H),7.36(dd,1H,J=8.2Hz,7.0Hz,Ar-H),7.25(d,1H,J=7.0Hz,Ar-H),7.01(dt,2H,J=7.5Hz,1.1Hz,Ar-H),6.84(d,1H,J=8.0Hz,Ar-H),6.80(d,1H,J=8.1Hz,Ar-H),6.69(dt,1H,J=7.5Hz,1.1Hz,Ar-H),6.66(dt,1H,J=7.5Hz,1.1Hz,Ar-H),4.57(t,2H,J=7.3Hz,N-C 2H-CH2-Nap),3.51(t,2H,J=7.3Hz,NCH2-C 2H-Nap),3.02(s,3H,NCH3).13C NMR(125MHz,DMSO-d6)δ172.3,172.2,136.6,136.2,134.9,134.0,132.5,131.9,129.9,129.3,127.7,127.5,126.9,126.4,126.3,126.0,125.7,124.1,122.3×2,121.9,121.6,120.1,119.9,112.4,110.6,106.2,105.6,47.2,33.3,24.5.ESI-MS m/z 496.2[M+H]+.
iv) preparation of 6-methyl-12- (1-naphthylethyl) -12, 13-dihydro-5H-indole [2,3-a ] pyrrolo [3,4-c ] carbazole-5, 7(6H) -dione (116)
According to the method for synthesizing compound 102, from compound 116c (400mg,0.808mmol), DDQ (238mg,1.05mmol) and p-TsOH (154mg,0.81mmol), silica gel column chromatography was performed, and petroleum ether and ethyl acetate: 4:1(v/v) were eluted, whereby 270mg of yellow solid (116) was obtained in 65% yield.1H NMR(600MHz,DMSO-d6)δ11.85(s,1H,indole-NH),9.07(d,1H,J=7.9Hz,Ar-H),9.00(d,1H,J=7.8Hz,Ar-H),8.00(d,1H,J=7.9Hz,Ar-H),7.83(d,1H,J=7.3Hz,Ar-H),7.73(d,1H,J=8.1Hz,Ar-H),7.62(d,1H,J=8.1Hz,Ar-H),7.60(dt,1H,J=7.7Hz,1.1Hz,Ar-H),7.48–7.40(m,2H,Ar-H),7.39(t,1H,J=7.7Hz,Ar-H),7.33(t,1H,J=7.7Hz,Ar-H),7.23(d,1H,J=7.7Hz,Ar-H),7.22(d,1H,J=8.1Hz,Ar-H),7.16(t,1H,J=7.4Hz,Ar-H),7.02(d,1H,J=6.6Hz,Ar-H),5.24(t,2H,J=7.0Hz,N-C 2H-CH2-Nap),3.53(t,2H,J=7.0Hz,NCH2-C 2H-Nap),3.12(s,3H,NCH3).13C NMR(150MHz,DMSO-d6)δ170.2,170.1,141.8,141.7,134.5,133.8,132.0,129.9,129.0,128.8,127.6,127.5×2,127.0,126.6,126.1,125.7,124.8,124.7,123.8,121.6×2,120.9,120.7,119.4,119.3,117.7,117.0,112.6,110.2,45.3,33.4,24.1.ESI-MS m/z 494.2[M+H]+.
Preparation of Compound 117
i) Preparation of 12- (1-naphthylethyl) -12, 13-dihydrofuran [3,4-c ] indole [2,3-a ] carbazole-5, 7-dione (117a)
Synthesized according to the method for the synthesis of compound 73b, from compound 116(200mg,0.45mmol) and KOH (5M,30mL), 164mg of a yellow solid (117a) was obtained in 84% yield. Because the solubility of the product is very poor and the reaction is complete, the product is directly put into the next reaction without separation and purification.
ii) preparation of 12- (1-naphthylethyl) -12, 13-dihydro-5H-indole [2,3-a ] pyrrolo [3,4-c ] carbazole-5, 7(6H) -dione (117)
According to the method for synthesizing compound 23c, the compound was synthesized from compound 117a (26mg,0.054mmol), HMDS (500 μ L,2.35mmol) and methanol (50 μ L,1.18mmol), separated by silica gel column chromatography, and petroleum ether/ethyl acetate ═ 4:1 (v/ion-v) elution gave 22mg of a yellow solid (117) in 87% yield.1H NMR(500MHz,DMSO-d6)δ11.91(s,1H,indole-NH),11.03(s,1H,imide-NH),9.10(d,1H,J=7.9Hz,Ar-H),9.04(d,1H,J=7.8Hz,Ar-H),8.00(d,1H,J=8.0Hz,Ar-H),7.80(d,1H,J=7.3Hz,Ar-H),7.75(d,1H,J=7.5Hz,Ar-H),7.62(d,1H,J=8.1Hz,Ar-H),7.60(t,1H,J=7.8Hz,Ar-H),7.47–7.42(m,2H,Ar-H),7.37(t,1H,J=7.7Hz,Ar-H),7.33–7.30(m,2H,Ar-H),7.25(d,1H,J=7.6Hz,Ar-H),7.15(t,1H,J=7.8Hz,Ar-H),7.05(d,1H,J=7.0Hz,Ar-H),5.32(t,2H,J=7.0Hz,N-C 2H-CH2-Nap),3.54(t,2H,J=7.0Hz,NCH2-C 2H-Nap).13C NMR(125MHz,DMSO-d6)δ171.7,171.6,141.8,134.5,133.8,132.0,130.2,129.1,129.0,127.7,127.6,127.5,127.1,126.6,126.4,126.1,125.7,125.0,124.9,123.8,121.8,121.7,120.9,120.8,120.5,120.4,117.6,117.0,112.6,110.3,45.4,33.3.ESI-MS m/z 480.3[M+H]+.
Preparation of Compound 118
According to the synthesis method of the compound 2, the compound 117(20mg,0.04mmol) and formaldehyde (3mL, mass fraction 37%) are synthesized, separated by silica gel column chromatography, and eluted by petroleum ether and ethyl acetate (4: 1 (v/v)) to obtain yellow solid 6-hydroxymethyl-12- (1-naphthylethyl) -12, 13-dihydro-5H-indole [2,3-a ] -indole [2]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (118)16mg, yield 80%.1H NMR(600MHz,DMSO-d6)δ11.90(s,1H,imide-NH),9.08(d,1H,J=7.9Hz,Ar-H),9.00(d,1H,J=7.4Hz,Ar-H),7.96(d,1H,J=7.6Hz,Ar-H),7.77(d,1H,J=8.4Hz,Ar-H),7.72(d,1H,J=8.2Hz,Ar-H),7.59(d,1H,J=8.1Hz,Ar-H),7.56(d,J=7.4Hz,1H),7.45–7.39(m,2H),7.36(t,1H,J=7.5Hz,Ar-H),7.29(t,1H,J=7.8Hz,Ar-H),7.22(t,2H,J=7.0Hz,Ar-H),7.10(t,1H,J=7.6Hz,Ar-H),6.98(d,1H,J=6.9Hz,Ar-H),6.30(t,1H,J=6.6Hz,-CH2OH),5.26(t,2H,J=6.9Hz,N-C 2H-CH2-Nap),5.03(d,2H,J=6.6Hz,-C 2HOH),3.53(t,2H,J=6.9Hz,NCH2-C 2H-Nap).13C NMR(150MHz,DMSO-d6)δ169.4,169.3,141.7,141.6,134.3,133.6,131.9,130.1,128.9×2,127.5,127.4,127.0,126.4,126.3,126.0,125.5,124.6,124.5,123.7,122.3,121.5,121.4,120.8,120.6,119.1,119.0,117.5,116.8,112.6,110.2,60.3,45.3,33.2.ESI-MS m/z 510.2[M+H]+.
Preparation of Compound 119
According to the method for synthesizing compound 14, compound 117a (36mg,0.074mmol) and ethylenediamine (500 μ L,7.5mmol) were synthesized and subjected to silica gel column chromatography and eluted with dichloromethane methanol 3:1(v/v) to give 6- (2-aminoethyl) -12- (1-naphthylethyl) -12, 13-dihydro-5H-indole [2,3-a ] as a yellow solid]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (119)35mg, yield 90%.1H NMR(500MHz,DMSO-d6)δ9.10(d,1H,J=7.9Hz,Ar-H),9.02(d,1H,J=7.7Hz,Ar-H),8.02(dd,1H,J=6.7Hz,2.2Hz,Ar-H),7.82(dd,1H,J=6.4Hz,2.5Hz,Ar-H),7.81(d,1H,J=8.3Hz,Ar-H),7.62(d,1H,J=8.2Hz,Ar-H),7.61(t,1H,J=7.6Hz,Ar-H),7.48(dd,2H,J=6.6Hz,3.2Hz,Ar-H),7.40(t,1H,J=7.7Hz,Ar-H),7.31(t,1H,J=8.1Hz,Ar-H),7.23(t,1H,J=8.2Hz,Ar-H),7.20(d,1H,J=7.8Hz,Ar-H),7.11(t,1H,J=8.1Hz,Ar-H),6.96(d,1H,J=6.9Hz,Ar-H),5.33(t,2H,J=6.1Hz,N-C 2H-CH2-Nap),3.93(t,2H,J=6.7Hz,N-C 2H-CH2NH2),3.54(t,2H,J=6.1Hz,NCH2-C 2H-Nap),3.14(t,2H,J=6.7Hz,NCH2-C 2H-NH2).13C NMR(125MHz,DMSO-d6)δ170.3,170.2,142.0,141.9,134.5,133.8,132.0,130.0,129.1,129.0,127.7,127.6,127.1,126.6,126.4,126.1,125.7,124.8,124.7,123.8,121.6,121.5,121.0,120.7,119.6,119.5,117.7,117.1,112.9,110.3,45.4,39.1,37.1,33.5.ESI-MS m/z 523.4[M+H]+.
Preparation of Compound 120
According to the method for synthesizing compound 16, from compound 119(23mg,0.04mmol) and a solution of hydrochloric acid in ethyl acetate (3N,3mL), 20mg of 6- (2-aminoethyl) -12- (1-naphthylethyl) -12, 13-dihydro-5H-indole [2,3-a ] as a yellow solid was synthesized]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione hydrochloride (120) in 90% yield.1H NMR(500MHz,DMSO-d6)δ12.16(s,1H,indole-NH),9.07(d,1H,J=7.9Hz,Ar-H),9.00(d,1H,J=7.6Hz,Ar-H),8.13(s,3H,-NH3 +),8.00(d,1H,J=5.6Hz,Ar-H),7.79(d,2H,J=7.7Hz,Ar-H),7.59(d,1H,J=8.0Hz,Ar-H),7.56(d,1H,J=7.5Hz,Ar-H),7.45(d,1H,J=7.5Hz,Ar-H),7.43(d,1H,J=7.5Hz,Ar-H),7.36(t,1H,J=7.4Hz,Ar-H),7.28(t,1H,J=7.6Hz,Ar-H),7.22(d,1H,J=7.4Hz,Ar-H),7.18(t,1H,J=6.8Hz,Ar-H),7.07(t,1H,J=7.5Hz,Ar-H),6.92(d,1H,J=6.9Hz,Ar-H),5.33(t,2H,J=6.9Hz,N-C 2H-CH2-Nap),3.97(t,2H,J=6.7Hz,N-C 2H-CH2NH3 +),3.52(t,2H,J=6.9Hz,NCH2-C 2H-Nap),3.19(t,2H,J=6.7Hz,NCH2-C 2H-NH3 +).13C NMR(125MHz,DMSO-d6)δ170.1,170.0,141.8×2,134.3,133.6,131.8,129.8,129.0,128.8,127.5,127.4,127.0,126.5,126.0,125.5,124.6,124.5,123.7,121.4,121.3,120.8,120.6,119.4,119.3,117.6,116.9,112.8,110.2,45.3,38.3,35.7,33.4.ESI-MS m/z 523.3[M–Cl]+.
Preparation of Compound 121
According to the method for synthesizing compound 14, 25mg of yellow solid 6- (3-aminopropyl) -12- (1-naphthylethyl) -12, 13-dihydro-5H-indole [2, 3-a) was synthesized from compound 117a (25mg,0.05mmol) and 1, 3-propanediamine (60. mu.L, 0.78mmol)]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (121) in 90% yield.1H NMR(500MHz,DMSO-d6)δ12.16(s,1H,indole-NH),9.08(d,1H,J=8.0Hz,Ar-H),9.01(d,1H,J=7.7Hz,Ar-H),7.97(d,1H,J=7.4Hz,Ar-H),7.81–7.79(m,2H,Ar-H),7.62(t,1H,J=7.5Hz,Ar-H),7.61(d,1H,J=7.6Hz,Ar-H),7.59(t,1H,J=7.5Hz,Ar-H),7.48–7.42(m,2H,Ar-H),7.37(t,1H,J=7.4Hz,Ar-H),7.31(t,1H,J=7.6Hz,Ar-H),7.23(t,1H,J=7.7Hz,Ar-H),7.21(t,1H,J=7.4Hz,Ar-H),7.11(t,1H,J=7.8Hz,Ar-H),6.99(d,1H,J=7.0Hz,Ar-H),5.33(t,2H,J=6.8Hz,N-C 2H-CH2-Nap),3.79(t,2H,J=7.2Hz,N-C 2H-(CH2)2-NH2),3.54(t,2H,J=6.8Hz,NCH2-C 2H-Nap),2.91(t,2H,J=7.2Hz,N(CH2)2-C 2H-NH2),2.11–1.93(m,2H,NCH2-C 2H-CH2NH2).13C NMR(125MHz,DMSO-d6)δ170.3,170.2,142.0,141.9,134.5,133.8,132.0,130.1,129.0×2,127.7,127.6,127.5,127.1,126.6,126.1,125.7,124.8,124.7,123.8,121.6,121.5,120.9,120.7,119.2,119.1,117.7,117.1,112.9,110.4,45.9,45.4,37.6,35.2,27.4.ESI-MS m/z 537.4[M+H]+.
Preparation of Compound 122
According to the method for synthesizing the compound 16, 6- (3-aminopropyl) -12- (1-naphthylethyl) -12, 13-dihydro-5H-indole [2,3-a ] was synthesized from the compound 121(25mg,0.04mmol) and an ethyl acetate solution (3N,3mL) of hydrochloric acid as a yellow solid]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione hydrochloride (122)20mg, yield 90%.1H NMR(500MHz,DMSO-d6)δ12.14(s,1H,indole-NH),9.07(d,1H,J=7.8Hz,Ar-H),9.01(d,1H,J=7.8Hz,Ar-H),7.99(s,3H,-NH3 +),7.96(d,1H,J=9.0Hz,Ar-H),7.78(d,2H,J=7.9Hz,Ar-H),7.59(d,1H,J=8.0Hz,Ar-H),7.56(d,1H,J=7.9Hz,Ar-H),7.46–7.40(m,2H,Ar-H),7.35(t,1H,J=7.5Hz,Ar-H),7.28(d,1H,J=7.2Hz,Ar-H),7.24(d,1H,J=7.9Hz,Ar-H),7.22(d,1H,J=7.2Hz,Ar-H),7.11(t,1H,J=7.5Hz,Ar-H),6.98(d,1H,J=6.8Hz,Ar-H),5.34(t,2H,J=6.8Hz,N-C 2H-CH2-Nap),3.81(t,2H,J=7.2Hz,N-C 2H-(CH2)2-NH3 +),3.52(t,2H,J=6.8Hz,NCH2-C 2H-Nap),2.93(t,2H,J=7.2Hz,N(CH2)2-C 2H-NH3 +),2.05–1.99(m,2H,NCH2-C 2H-CH2NH2).13C NMR(125MHz,DMSO-d6)δ170.1,170.0,141.8,141.7,134.3,133.6,131.8,130.0,129.3,128.9×2,127.5,127.4,127.0,126.4,125.9,125.5,124.6,124.5,123.6,121.4,121.3,120.8,120.6,119.1,119.0,117.6,116.9,112.7,110.3,45.3,37.4,35.1,33.3,27.3.ESI-MS m/z 573.3[M–Cl]+.
Preparation of Compound 123
According to the synthesis method of compound 24, compound 117a (20mg,0.04mmol), 4- (2-aminoethyl) -morpholine (50 μ L,0.42mmol) and a catalytic amount of triethylamine were synthesized, and subjected to silica gel column chromatography and eluted with dichloromethane and methanol at a ratio of 3:1(v/v) to give 6- (2-morpholinoethyl) -12- (1-naphthylethyl) -1 as a yellow solid2, 13-dihydro-5H-indole [2,3-a ]]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (123)19mg, yield 76%.1HNMR(500MHz,DMSO-d6)δ11.90(s,1H,indole-NH),9.07(d,1H,J=8.0Hz,Ar-H),9.00(d,1H,J=7.8Hz,Ar-H),7.97(d,1H,J=7.7Hz,Ar-H),7.79(dd,1H,J=6.9Hz,2.4Hz,Ar-H),7.72(d,1H,J=8.1Hz,Ar-H),7.60(d,1H,J=8.2Hz,Ar-H),7.57(t,1H,J=7.7Hz,Ar-H),7.47–7.40(m,2H,Ar-H),7.36(t,1H,J=7.5Hz,Ar-H),7.29(d,1H,J=6.9Hz,Ar-H),7.25(d,1H,J=8.6Hz,Ar-H),7.23(t,1H,J=7.3Hz,Ar-H),7.14(t,1H,J=7.7Hz,Ar-H),7.02(d,1H,J=6.9Hz,Ar-H),5.28(t,2H,J=6.4Hz,N-C 2H-CH2-Nap),3.80(t,2H,J=5.8Hz,N-C 2H-CH2-morpholine),3.54(t,2H,J=6.4Hz,NCH2-C 2H-Nap),3.56(t,4H,J=3.9Hz,morpholine-N(CH2-CH 2)2O),2.63(t,2H,J=5.8Hz,imide-NCH2-C 2H-morpholine),2.49(t,4H,J=3.9Hz,morpholine-N(CH 2-CH2)2O).13C NMR(125MHz,DMSO-d6)δ169.9,169.8,141.7,134.4,133.6,131.9,129.9,128.9×2,127.5,127.4,127.0,126.4,126.0,125.6,124.7,124.6,123.7,121.5,121.4,120.8,120.6,119.1×2,117.6,116.9,112.5,110.2,66.6×2,56.5,53.6×2,45.3,34.9,33.2.ESI-MS m/z 593.3[M+H]+.
Preparation of Compound 124
According to the method for synthesizing the compound 24, the compound 117a (20mg,0.042mmol), 4- (2-aminoethyl) piperazine (45 μ L,0.42mmol) and a catalytic amount of triethylamine are synthesized, and the obtained product is separated by silica gel column chromatography and eluted by dichloromethane and methanol, namely 10:1(v/v), to obtain 6- (2-piperazineethyl) -12- (1-naphthylethyl) -12, 13-dihydro-5H-indole [2,3-a ] as a yellow solid]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (124)20mg, yield 80%.1H NMR(500MHz,DMSO-d6)δ9.05(d,1H,J=7.9Hz,Ar-H),8.97(d,1H,J=7.6Hz,Ar-H),7.94(d,1H,J=8.0Hz,Ar-H),7.84(d,1H,J=8.0Hz,Ar-H),7.80(d,1H,J=7.8Hz,Ar-H),7.59(d,1H,J=8.7Hz,Ar-H),7.57(d,1H,J=7.6Hz,Ar-H),7.46–7.39(m,2H,Ar-H),7.35(dd,1H,J=11.4Hz,4.3Hz,Ar-H),7.23(dd,1H,J=8.1Hz,1.2Hz,Ar-H),7.20(t,1H,J=7.6Hz,Ar-H),7.11(d,1H,J=8.2Hz,Ar-H),7.10(t,1H,J=8.2Hz,Ar-H),6.98(d,1H,J=6.9Hz,Ar-H),5.33(t,2H,J=6.6Hz,N-C 2H-CH2-Nap),3.78(t,2H,J=6.5Hz,N-C 2H-CH2-piperazine),3.56(t,2H,J=6.6Hz,NCH2-C 2H-Nap),2.97(t,4H,J=5.1Hz,piperazine-N(CH 2-CH2)2NH),2.70(t,4H,J=5.1Hz,piperazine-N(CH2-CH 2)2NH),2.68(t,2H,J=6.5Hz,NCH2-C 2H-piperazine).13C NMR(125MHz,DMSO-d6)δ170.1,170.0,142.0,141.8,134.6,134.3,133.7,133.3,131.9,131.5,130.0,129.0×2,128.1,127.6,127.0,126.5,126.0,125.6,124.7,123.8,121.5,120.8,120.6,119.2,119.0,117.6,116.9,112.9,110.2,55.9×2,50.0,45.4×2,43.5,35.0,33.5.ESI-MS m/z 592.3[M+H]+.
Preparation of Compound 125
According to the synthesis method of compound 24, compound 117a (20mg,0.042mmol), 2-chloro-6-fluorophenethylamine (30 μ L,0.42mmol) and a catalytic amount of triethylamine are synthesized, and the obtained product is subjected to silica gel column chromatography and eluted with dichloromethane and methanol at a ratio of 25:1(v/v) to obtain 6- (2-chloro-6-fluorophenethyl) -12- (1-naphthylethyl) -12, 13-dihydro-5H-indole [2,3-a ] as a yellow solid]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (125)12mg, yield 60%.1HNMR(500MHz,DMSO-d6)δ11.90(s,1H,indole-NH),9.02(d,1H,J=7.8Hz,Ar-H),8.95(d,2H,J=7.8Hz,Ar-H),7.95(d,1H,J=8.2Hz,Ar-H),7.80(d,1H,J=7.9Hz,Ar-H),7.73(d,1H,J=8.1Hz,Ar-H),7.62(d,1H,J=8.1Hz,Ar-H),7.58(t,1H,J=7.5Hz,Ar-H),7.47(t,1H,J=7.2Hz,Ar-H),7.42(dd,1H,J=8.2Hz,1.8Hz,Ar-H),7.36(t,1H,J=7.5Hz,Ar-H),7.31(d,1H,J=7.3Hz,Ar-H),7.29–7.27(m,2H,Ar-H),7.23(t,1H,J=7.0Hz,Ar-H),7.17(d,1H,J=7.1Hz,Ar-H),7.15(t,1H,J=7.0Hz,Ar-H),7.14(dd,1H,J=7.4Hz,1.2Hz,Ar-H),7.07(d,1H,J=6.9Hz,Ar-H),5.29(t,2H,J=6.8Hz,N-C 2H-CH2-Nap),3.95(t,2H,J=6.7Hz,N-C 2H-CH2-C6H3FCl),3.54(t,2H,J=6.8Hz,NCH2-C 2H-Nap),3.21(t,2H,J=6.7Hz,NCH2-C 2H-C6H3FCl).13C NMR(125MHz,DMSO-d6)δ169.9,169.8,162.7(d,1JCF=244Hz),141.8(d,3JCF=11Hz),135.1,134.8,134.5,133.7,133.4,132.0,130.1,129.9(d,3JCF=11Hz),128.9,128.8,127.6,127.5,127.1,126.5,126.1,125.9,125.7,124.9,124.8,123.8,122.8,121.6(d,2JCF=22Hz),120.9,120.8,119.1,119.0,117.7,117.0,114.9(d,2JCF=23Hz),112.6,110.3,90.3,45.4,36.5,33.3,29.4.ESI-MS m/z636.2[M+H]+.
Preparation of Compound 126
According to the method for synthesizing the compound 24, the compound 117a (20mg,0.042mmol), 1- (2-aminoethyl) piperidine (50 μ L,0.42mmol) and a catalytic amount of triethylamine are synthesized, and the obtained product is separated by silica gel column chromatography and eluted with dichloromethane and methanol at a ratio of 10:1(v/v) to obtain 6- (2-piperidineethyl) -12- (1-naphthylethyl) -12, 13-dihydro-5H-indole [2,3-a ] as a yellow solid]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (126)19mg, yield 67%.1H NMR(500MHz,DMSO-d6)δ11.89(s,1H,indole-NH),9.05(d,1H,J=7.9Hz,Ar-H),8.97(d,1H,J=7.6Hz,Ar-H),7.95(d,1H,J=8.9Hz,Ar-H),7.78(d,1H,J=7.4Hz,Ar-H),7.71(d,1H,J=8.1Hz,Ar-H),7.59(d,1H,J=8.2Hz,Ar-H),7.56(t,1H,J=7.6Hz,Ar-H),7.44–7.40(m,2H,Ar-H),7.34(t,1H,J=7.5Hz,Ar-H),7.26(d,1H,J=7.0Hz,Ar-H),7.20(d,1H,J=8.0Hz,Ar-H),7.18(d,1H,J=7.5Hz,Ar-H),7.13(t,1H,J=7.5Hz,Ar-H),7.00(d,1H,J=6.8Hz,Ar-H),5.29(t,2H,J=6.8Hz,N-C 2H-CH2-Nap),3.73(t,2H,J=6.6Hz,N-C 2H-CH2-piperidine),3.51(t,2H,J=6.8Hz,NCH2-C 2H-Nap),2.58(t,2H,J=6.2Hz,NCH2-C 2H-piperidine),2.44(t,4H,J=3.3Hz,piperidine-N(CH 2-CH2)2CH2),1.45–1.41(m,4H,piperidine-N(CH2-CH 2)2CH2),1.33(t,2H,J=4.4Hz,piperidine-N(CH2-CH2)2CH 2).13C NMR(125MHz,DMSO-d6)δ169.9,169.8,141.7,141.6,135.1,134.4,133.6,131.9,129.9,128.9,128.8,127.5,127.4,127.4,126.9,126.4,126.0,125.6,125.1,124.7,124.6,123.7,121.4,121.4,120.7,120.6,119.1,119.0,117.5,116.9,112.5,110.1,56.6×2,54.3,45.2,35.2,33.3,25.9×2,24.3.ESI-MS m/z 591.3[M+H]+.
Preparation of Compound 127
According to the synthesis method of compound 24, compound 117a (22mg,0.046mmol), 4-methyl-1-piperazineethylamine (50 μ L,0.55mmol) and a catalytic amount of triethylamine are synthesized, silica gel column chromatography is performed, and dichloromethane and methanol are eluted at a ratio of 10:1(v/v) to obtain 6- (2- (4-methylpiperazine) ethyl) -12- (1-naphthylethyl) -12, 13-dihydro-5H-indole [2,3-a ] as a yellow solid]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (127)22mg, yield 80%.1H NMR(500MHz,DMSO-d6)δ11.95(s,1H,indole-NH),9.06(d,1H,J=7.0Hz,Ar-H),8.98(d,1H,J=7.2Hz,Ar-H),7.95(d,1H,J=6.7Hz,Ar-H),7.78(d,1H,J=6.8Hz,Ar-H),7.73(d,1H,J=8.1Hz,Ar-H),7.62–7.54(m,2H,Ar-H),7.42(d,2H,J=7.8Hz,Ar-H),7.34(t,1H,J=7.8Hz,Ar-H),7.27(t,1H,J=7.3Hz,Ar-H),7.20(d,2H,J=6.9Hz,Ar-H),7.11(d,1H,J=7.6Hz,Ar-H),7.01(d,1H,J=7.6Hz,Ar-H),5.27(t,2H,J=6.3Hz,N-C 2H-CH2-Nap),3.75(t,2H,J=6.3Hz,N-C 2H-CH2-piperazine),3.51(t,2H,J=6.3Hz,NCH2-C 2H-Nap),2.60(d,2H,J=5.8Hz,NCH2-C 2H-piperazine),2.48(t,4H,J=4.6Hz,piperazine-N(CH 2-CH2)2NCH3),2.25(t,4H,J=4.6Hz,piperazine-N(CH2-CH 2)2NCH3),2.07(s,3H,piperazine-N(CH2-CH2)2NC 3H).13C NMR(125MHz,DMSO-d6)δ169.9,169.8,141.7,141.6,134.4,133.6,131.8,129.9,128.9,127.5,127.4,126.9,126.4,125.9,125.6,124.7,124.6,123.7,121.4,121.4,120.8,120.6,119.15,119.0,117.5,116.9,112.6,110.1,56.1,55.1×2,53.0×2,46.1,45.3,35.2,33.3.ESI-MS m/z 605.4[M+H]+.
Preparation of Compound 128
According to the synthesis of compound 24, starting from compound 117a (30mg,0.063mmol), ethanolamine (55. mu.L, 0.9)4mmol) and a catalytic amount of triethylamine, separating by silica gel column chromatography, eluting with dichloromethane and methanol (50: 1(v/v) to obtain 6- (2-hydroxyethyl) -12- (1-naphthylethyl) -12, 13-dihydro-5H-indole [2,3-a ] as a yellow solid]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (128)26mg, yield 89%.1H NMR(500MHz,DMSO-d6)δ11.95(s,1H,indole-NH),9.11(d,1H,J=7.8Hz,Ar-H),9.05(d,1H,J=7.9Hz,Ar-H),8.02(d,1H,J=7.7Hz,Ar-H),7.83(d,1H,J=8.1Hz,Ar-H),7.75(d,1H,J=8.1Hz,Ar-H),7.63(d,1H,J=8.0Hz,Ar-H),7.59(t,1H,J=7.8Hz,Ar-H),7.47(m,2H,Ar-H),7.38(t,1H,J=7.5Hz,Ar-H),7.34(t,1H,J=7.8Hz,Ar-H),7.26–7.24(m,2H,Ar-H),7.15(t,1H,J=7.8Hz,Ar-H),7.00(d,1H,J=7.2Hz,Ar-H),5.32(t,2H,J=7.0Hz,N-C 2H-CH2-Nap),4.94(t,1H,J=6.1Hz,N-C 2H-CH2-OH),4.2(brs,-OH),3.80(t,2H,J=6.1Hz,NCH2-C 2H-OH),3.56(t,2H,J=7.0Hz,NCH2-C 2H-Nap).13C NMR(125MHz,DMSO-d6)δ170.3,170.2,141.9,134.5,133.8,132.0,130.1,129.1,129.0,127.7,127.6,127.5,127.1,126.6,126.1,125.7,124.9,124.8,123.8,121.6,121.6,120.9,120.8,119.8,119.4,117.7,117.0,112.7,112.4,110.3,58.9,45.4,40.7,33.4.ESI-MS m/z 524.4[M+H]+.
Preparation of Compound 129
According to the method for synthesizing the compound 24, the compound 117a (25mg,0.052mmol), 3-hydroxypropylamine (50 μ L,0.52mmol) and a catalytic amount of triethylamine are synthesized, and the obtained product is separated by silica gel column chromatography and eluted with dichloromethane and methanol at a ratio of 50:1(v/v) to obtain 6- (3-hydroxypropyl) -12- (1-naphthylethyl) -12, 13-dihydro-5H-indole [2,3-a ] as a yellow solid]Pyrrole [3,4-c ]]Carbazole-5, 7(6H) -dione (129)24mg, yield 80%.1HNMR(500MHz,DMSO-d6)δ11.91(s,1H,indole-NH),9.10(d,1H,J=7.9Hz,Ar-H),9.04(d,1H,J=7.7Hz,Ar-H),8.01(d,1H,J=8.0Hz,Ar-H),7.82(dd,2H,J=7.6Hz,3.2Hz,Ar-H),7.74(d,1H,J=8.1Hz,Ar-H),7.62(d,1H,J=8.2Hz,Ar-H),7.59(dt,1H,J=8.2Hz,1.2Hz,Ar-H),7.48–7.43(m,2H,Ar-H),7.39(dt,1H,J=7.8Hz,1.1Hz,Ar-H),7.34(t,1H,J=7.8Hz,Ar-H),7.27(d,1H,J=8.1Hz,Ar-H),7.27(t,1H,J=7.6Hz,Ar-H),7.14(t,1H,J=7.7Hz,Ar-H),7.03(d,1H,J=6.6Hz,Ar-H),5.30(t,2H,J=6.9Hz,N-C 2H-CH2-Nap),4.57(brs,-OH),3.77(t,2H,J=7.2Hz,N-C 2H-CH2CH2OH),3.54(t,2H,J=6.9Hz,NCH2-C 2H-Nap),3.53(t,2H,J=6.2Hz,N(CH2)2-C 2H-OH),1.90–1.84(m,2H,NCH2-C 2H-CH2OH).13CNMR(125MHz,DMSO-d6)δ170.2,170.1,141.8,134.5,133.8,132.0,130.1,129.1,129.0,127.7,127.6,127.1,126.6,126.1,125.7,124.9,124.8,123.8,121.7,121.6,120.9,120.8,119.3,119.3,117.7,117.0,112.7,112.4,110.3,59.3,45.4,35.5,33.3,32.3.ESI-MS m/z 538.5[M+H]+.
Preparation of Compound 130
Adding staurosporine (46.6mg,0.1mmol) into a 25mL two-mouth reaction bottle under the protection of argon, dissolving with 3mL dichloromethane, dropwise adding excessive triethylamine, adding p-fluorobenzenesulfonyl chloride, stirring at room temperature for 4 hours, adding water to stop the reaction, extracting with dichloromethane, and extracting with anhydrous Na2SO4Drying, vacuum evaporating, separating by gel column chromatography, eluting with methanol to obtain 3' -N-p-fluorobenzenesulfonyl staurosporine (130)52.0mg with yield of 83.3%.1H NMR(600MHz,CDCl3)δ9.40(d,1H,J=7.4Hz,Ar-H),7.92(m,2H,Ar-H),7.85(d,1H,J=7.3Hz,Ar-H),7.72(d,1H,J=7.8Hz,Ar-H),7.47(t,1H,J=7.3Hz,Ar-H),7.46(t,1H,J=7.3Hz,Ar-H),7.43(d,2H,J=7.3Hz,Ar-H),7.32(m,2H,J=7.3Hz,Ar-H),7.06(d,1H,J=7.8Hz,Ar-H),6.84(brs,1H,-NH),6.56(m,1H,H-1'),4.95(d,1H,J=16.0Hz,H-7a),4.89(d,1H,J=16.0Hz,H-7b),4.53(dd,1H,J=12.4Hz,5.5Hz,H-3'),3.94(s,1H,H-4'),2.71(s,3H,4'-OCH3),2.47(s,3H,3'-NCH3),2.43(m,1H,H-1'a),2.37(s,3H,H-6'),2.27(m,1H,H-2'b);13C NMR(150MHz,CDCl3)δ173.5,164.6(d,1JC-F=247.2Hz),138.4,136.5,136.5,132.5,130.5,129.7×2(d,3JC-F=9.2Hz),126.9,126.3,125.5,125.3,124.8,123.6,121.7,120.8,120.2,119.2,116.8×2(d,2JC-F=13.7Hz),116.3,114.6,112.2,107.6,94.7,86.5,82.4,60.3,52.1,46.0,30.8,29.1,28.3.ESI-MS m/z 625.3[M+H]+。
Preparation of Compound 131
Synthesized according to the synthesis of compound 130 from staurosporine (46.6mg,0.1mmol), triethylamine and p-chlorobenzenesulfonyl chloride. Separating by gel column chromatography, eluting with methanol to obtain 51.3mg of 3' -N-p-chlorobenzenesulfonyl staurosporine (131), with yield of 80.1%.1H NMR(600MHz,CDCl3)δ9.41(d,1H,J=7.7Hz,Ar-H),7.86(d,1H,J=7.8Hz,Ar-H),7.84(d,2H,J=8.2Hz,Ar-H),7.72(d,1H,J=8.7Hz,Ar-H),7.61(d,2H,J=8.2Hz,Ar-H),7.48(t,1H,J=8.3Hz,Ar-H),7.44(t,1H,J=6.8Hz,Ar-H),7.36(t,1H,J=7.8Hz,Ar-H),7.34(t,1H,J=7.8Hz,Ar-H),7.09(d,1H,J=8.2,Ar-H),6.61(br s,1H,-NH),6.58(dd,1H,J=9.2Hz,4.1Hz,H-1'),4.93(m,2H,H-7),4.52(ddd,1H,J=12.8Hz,5.5Hz,1.9Hz,H-3'),3.96(s,1H,H-4'),2.72(s,3H,4'-OCH3),2.48(s,1H,3'-NCH3),2.44(m,1H,H-2'a),2.41(s,3H,H-6'),2.26(m,1H,H-2'a).13C NMR(150MHz,CDCl3)δ173.3,139.8,138.5,137.7,136.5,132.5,130.5,129.9×2,128.5×2,126.9,126.3,125.6,125.3,124.8,123.7,121.7,120.8,120.3,119.3,116.4,114.7,112.2,107.6,94.7,86.6,82.4,60.4,52.2,45.9,30.8,29.2,28.3.ESI-MS m/z 641.4/643.4[M+H]+。
Preparation of Compound 132
Synthesized according to the synthesis of compound 130 from staurosporine (46.6mg,0.1mmol), triethylamine and p-bromobenzenesulfonyl chloride. Separating by gel column chromatography, eluting with methanol to obtain 52.6mg of 3' -N-p-bromophenylsulfonyl staurosporine (132), with yield of 76.8%.1H NMR(600MHz,CDCl3)δ9.40(d,1H,J=7.1Hz,Ar-H),7.99(d,1H,J=6.9Hz,Ar-H),7.83(d,1H,J=7.7Hz,Ar-H),7.72(d,1H,J=8.3Hz,Ar-H),7.61(d,2H,J=6.9Hz,Ar-H),7.47(t,1H,J=7.7Hz,Ar-H),7.42(t,1H,J=7.2Hz,Ar-H),7.34(t,2H,J=7.1Hz,Ar-H),7.04(d,2H,J=7.7,Ar-H),6.51(br s,1H,-NH),4.99(d,1H,J=18.0Hz,H-7a),4.92(d,1H,J=16.4Hz,H-7b),4.50(dd,1H,J=5.5Hz,12.7Hz,H-3'),3.91(s,1H,H-4'),2.69(s,3H,4'-OCH3),2.47(s,1H,3'-NCH3),2.45(t,1H,J=12.6Hz,H-2'a),2.35(s,3H,H-6'),2.45(t,1H,J=12.4Hz,H-2'a);13C NMR(150MHz,CDCl3)δ173.4,138.4,132.9×2,138.3,136.4,132.5,130.5,128.6×2,128.2,126.8,126.3,125.5,125.3,124.7,123.6,121.7,120.7,120.3,119.0,116.2,114.6,112.2,107.7,94.6,86.6,82.4,60.3,52.2,46.1,30.8,29.1,28.3.ESI-MS m/z 685.3/687.3[M+H]+。
Preparation of Compound 133
Synthesized according to the synthesis of compound 130 from staurosporine (46.6mg,0.1mmol), triethylamine and benzenesulfonyl chloride. Separating by gel column chromatography, eluting with methanol to obtain 3' -N-benzenesulfonyl staurosporine (133)50.4mg with yield 83.2%.1H NMR(600MHz,CDCl3)δ9.40(d,1H,J=7.8Hz,Ar-H),7.91(d,2H,J=7.4Hz,Ar-H),7.87(d,1H,J=7.3Hz,Ar-H),7.70(d,1H,J=7.8Hz,Ar-H),7.64(t,2H,J=7.8Hz,Ar-H),7.46(t,1H,J=7.8Hz,Ar-H),7.42(t,1H,J=7.8Hz,Ar-H),7.34(t,1H,J=7.3Hz,Ar-H),7.32(t,1H,J=7.3Hz,Ar-H),7.07(d,1H,J=8.2Hz,Ar-H),6.71(brs,1H,-NH),6.69(dd,1H,J=9.2Hz,4.6Hz,H-1'),4.94(m,2H,H-7),4.54(dd,2H,J=12.8Hz,5.5Hz,H-3'),3.91(s,1H,H-4'),2.73(s,3H,4'-OCH3),2.45(s,3H,3'-NCH3),2.43(br m,1H,H-2'a),2.39(s,3H,H-6'),2.25(br m,1H,H-2'b).13C NMR(150MHz,CDCl3)δ173.3,139.1,138.4,136.4,133.3,132.4,130.4,129.5×2,127.0×2,126.8,126.2,125.4,125.1,124.7,123.6,121.5,120.6,120.2,119.1,116.2,114.5,112.1,107.5,94.6,86.2,82.4,60.3,51.9,45.9,30.7,29.1,28.1.ESI-MS m/z 607.3[M+H]+。
Preparation of Compound 134
Adding 3' -N-p-fluorobenzoyl staurosporine (15.0mg,0.025mmol) into a 25mL two-mouth reaction flask under the protection of argon, dissolving with 1mL of methanol, adding bromosuccinimide (5.0mg,0.027mmol), stirring at room temperature for reaction for 2h, adding water to terminate the reaction, extracting with dichloromethane, and extracting with anhydrous Na2SO4Drying, vacuum evaporating, separating by gel column chromatography, eluting with methanol to obtain 8.4mg of 3-bromo-3' -N-p-fluorobenzoyl staurosporine (134), with yield 49.0%.1H NMR(600MHz,CDCl3)δ9.51(s,1H,Ar-H),7.86(d,1H,J=7.8Hz,Ar-H),7.75(d,1H,J=7.3Hz,Ar-H),7.46(t,2H,J=7.8Hz,Ar-H),7.43(m,2H,J=7.3Hz,Ar-H),7.36(t,1H,J=7.8Hz,Ar-H),7.34(d,1H,J=7.8Hz,Ar-H),7.09(d,2H,J=7.3Hz,Ar-H),7.02(br s,1H,-NH),6.66(br s,1H,H-1'),5.18(d,1H,J=7.8Hz,H-3'),4.93(br s,2H,H-7),4.17(s,1H,H-4'),2.82(s,3H,4'-OCH3),2.71(dt,1H,J=12.5Hz,3.2Hz,H-2'a),2.56(s,3H,3'-NCH3),2.44(dt,1H,J=12.5Hz,3.2Hz,H-2'b),2.36(s,3H,H-6').13C NMR(150MHz,CDCl3)δ171.6,171.4,163.5(d,1JC-F=247.2Hz),138.5×2,132.9,132.1,131.5,130.4,129.4×2(d,3JC-F=6.9Hz),129.0,128.1,126.8,125.4,125.1,124.6,121.8,120.8,119.2,115.7×2(d,2JC-F=13.7Hz),115.5,115.0,112.3,109.1,94.7,84.7,82.6,60.5,49.8,46.2,34.6,29.2,28.1.ESI-MS m/z 667.3/669.3[M+H]+。
Preparation of Compound 135
i) Preparation of Compound 135a
Adding staurosporine (6.6mg,0.1mmol) into a 25mL two-mouth reaction bottle filled with oxygen, dissolving with 3mL DMSO, adding excessive potassium tert-butoxide, reacting at room temperature for 6h, adding water to stop the reaction, extracting with ethyl acetate for three times, evaporating to dryness in vacuum, separating by gel column chromatography, and eluting with methanol to obtain 42.5mg of 7-subunit staurosporine (135a) with a yield of 88.6%.1H NMR(600MHz,DMSO-d6)δ11.04(s,1H,-NH),9.21(d,1H,J=8.8Hz,Ar-H),9.08(d,1H,J=7.7Hz,Ar-H),8.03(d,1H,J=8.8Hz,Ar-H),7.71(t,1H,J=8.8Hz,Ar-H),7.60(t,1H,J=7.7Hz,Ar-H),7.51(t,1H,J=7.7Hz,Ar-H),7.41(t,1H,J=7.7Hz,Ar-H),7.33(d,1H,J=7.7Hz,Ar-H),6.77(br s,1H,H-1'),4.14(m,1H,H-3'),3.38(s,1H,H-4'),3.36(s,3H,4'-OCH3),2.55(m,2H,H-2'),2.34(s,1H,3'-NCH3),1.22(s,3H,H-6').13C NMR(150MHz,DMSO-d6)δ171.4,171.2,142.1,139.2,132.3,131.7,127.5,126.5,126.4,125.6,124.4,122.8,121.2,121.1,120.6,120.2,117.2,116.4,115.8,109.2,92.1,84.5,81.3,57.4,51.5,33.6,30.4,30.1.ESI-MS m/z481.1[M+H]+。
ii) preparation of Compound 135
Synthesized according to the method for the synthesis of compound 130 from 135a (10.0mg,0.021mmol), triethylamine and p-fluorobenzoyl chloride. Separating by gel column chromatography, eluting with methanol to obtain 7-oxyl subunit10.8mg of (135) 3' -N-p-fluorobenzoyl staurosporine, yield 86.1%.1H NMR(600MHz,CDCl3)δ9.33(d,1H,J=7.7Hz,Ar-H),9.17(d,1H,J=7.8Hz,Ar-H),7.73(d,1H,J=7.7Hz,Ar-H),7.68(t,1H,J=7.4Hz,Ar-H),7.56(t,1H,J=7.8Hz,Ar-H),7.51(t,1H,J=7.8Hz,Ar-H),7.42(t,1H,J=7.8Hz,Ar-H),7.41(d,2H,J=7.7Hz,Ar-H),7.41(t,1H,J=7.8Hz,Ar-H),7.11(d,2H,J=7.4Hz,Ar-H),6.72(br s,1H,H-1'),5.20(d,1H,J=5.8Hz,H-3'),4.16(s,1H,H-4'),2.86(s,3H,4'-OCH3),2.80(m,1H,H-2'a),2.53(s,3H,3'-NCH3),2.38(m,1H,H-2'b),2.35(s,3H,H-6').13C NMR(150MHz,CDCl3)δ169.8,169.6,163.8(d,1JC-F=270.0Hz),139.3,139.2,137.8,133.2×2,130.3,129.6×2(d,3JC-F=6.9Hz),127.0×2(d,2JC-F=13.7Hz),126.5,126.3,123.8,122.5,121.4,121.3,121.0,119.4,117.4,116.3,114.7,111.3,108.2,94.7,86.0,82.5,60.1,51.9,30.7,28.9,28.3.ESI-MS m/z 603.2[M+H]+。
Preparation of Compound 136
Synthesized according to the method for the synthesis of compound 130 from 135a (10.0mg,0.021mmol), triethylamine and p-chlorobenzoyl chloride. 10.6mg of 7-oxoidene-3' -N-p-chlorobenzoyl staurosporine (136) is obtained by gel column chromatographic separation and methanol elution, and the yield is 82.3 percent.1H NMR(600MHz,CDCl3)δ9.38(d,1H,J=7.7Hz,Ar-H),9.24(d,1H,J=7.8Hz,Ar-H),7.94(t,1H,J=7.4Hz,Ar-H),7.76(t,1H,J=7.8Hz,Ar-H),7.61(t,1H,J=7.8Hz,Ar-H),7.54(d,2H,J=7.7Hz,Ar-H),7.52(d,2H,J=7.7Hz,Ar-H),7.51(br s,1H,-NH),7.41(t,1H,J=7.8Hz,Ar-H),7.40(d,1H,J=7.8Hz,Ar-H),7.11(d,1H,J=7.4Hz,Ar-H),6.80(br s,1H,H-1'),5.26(dd,1H,J=5.4Hz,12.3Hz,H-3'),4.22(s,1H,H-4'),2.88(s,3H,4'-OCH3),2.83(dt,1H,J=3.2Hz,10.8Hz,H-2'a),2.74(dt,1H,J=3.2Hz,10.8Hz,H-2'b),2.58(s,3H,3'-NCH3),2.44(s,3H,H-6').13C NMR(150MHz,CDCl3)δ171.4,169.9,169.7,139.5,137.9,136.3,131.6,130.2,129.0,128.6,129.6×2,127.1×2,126.5,126.4,123.8,122.6,121.4,121.3,121.0,119.5,117.4,116.4,111.7,111.6,108.3,94.8,84.7,82.5,60.5,49.7,30.4,29.0,28.1.ESI-MS m/z619.5/621.5[M+H]+。
Preparation of Compound 137
Synthesized according to the method for the synthesis of compound 130 from 135a (10.0mg,0.021mmol), triethylamine and p-bromobenzoyl chloride. Separating by gel column chromatography, eluting with methanol to obtain 7-oxoidene-3' -N-p-bromobenzoyl staurosporine (137)11.1mg with yield of 80.3%.1H NMR(500MHz,CDCl3)δ9.34(d,1H,J=7.7Hz,Ar-H),9.19(d,1H,J=7.8Hz,Ar-H),7.74(t,1H,J=7.4Hz,Ar-H),7.71(t,1H,J=7.8Hz,Ar-H),7.56(t,1H,J=7.8Hz,Ar-H),7.54(d,2H,J=7.7Hz,Ar-H),7.52(d,2H,J=7.7Hz,Ar-H),7.51(br s,1H,-NH),7.41(t,1H,J=7.8Hz,Ar-H),7.40(d,1H,J=7.8Hz,Ar-H),7.29(d,1H,J=7.4Hz,Ar-H),6.71(br s,1H,H-1'),5.21(dd,1H,J=5.5Hz,12.4Hz,H-3'),4.15(s,1H,H-4'),2.84(s,3H,4'-OCH3),2.80(dt,1H,J=3.2Hz,10.8Hz,H-2'a),2.67(dt,1H,J=3.2Hz,10.8Hz,H-2'b),2.53(s,3H,3'-NCH3),2.35(s,3H,H-6').13C NMR(150MHz,CDCl3)δ171.4,170.0,169.7,139.4,137.8,134.8,131.5,130.1,129.0,128.6,128.7×2,127.1×2,126.5,126.3,126.2,123.8,122.5,121.4,121.3,121.1,119.5,117.4,116.3,111.6,108.3,94.7,84.7,82.5,60.4,49.7,34.4,28.9,28.1.ESI-MS m/z663.5/665.5[M+H]+。
Preparation of Compound 138
Synthesized according to the synthesis of compound 130 from 135a (10.0mg,0.021mmol), triethylamine and p-iodobenzoyl chloride. The 7-oxoidene-3' -N-iodobenzoyl staurosporine (138) is separated by gel column chromatography and eluted by methanol to obtain 11.6mg with the yield of 78.5 percent.1H NMR(600MHz,CDCl3)δ9.38(d,1H,J=7.7Hz,Ar-H),9.24(d,1H,J=7.8Hz,Ar-H),7.94(t,1H,J=7.4Hz,Ar-H),7.76(t,1H,J=7.8Hz,Ar-H),7.61(t,1H,J=7.8Hz,Ar-H),7.54(d,2H,J=7.7Hz,Ar-H),7.52(t,2H,J=7.7Hz,Ar-H),7.51(br s,1H,-NH),7.41(t,1H,J=7.8H,Ar-H),7.40(d,1H,J=7.8Hz,Ar-H),7.11(d,1H,J=7.4Hz,Ar-H),6.80(dd,1H,J=3.7Hz,9.2Hz,H-1'),5.26(dd,1H,J=5.5Hz,12.4Hz,H-3'),4.22(s,1H,H-4'),2.88(s,3H,4'-OCH3),2.83(dt,1H,J=3.2Hz,10.8Hz,H-2'a),2.74(dt,1H,J=3.2Hz,10.8Hz,H-2'b),2.58(s,3H,3'-NCH3),2.44(s,3H,H-6').13C NMR(150MHz,CDCl3)δ171.4,170.0,169.8,139.5,137.9,136.3,131.9,130.2,129.0,128.6,129.6×2,127.1×2,126.5,126.4,123.8,122.6,121.4,121.3,121.0,120.9,119.5,117.4,116.4,111.7,108.3,94.8,84.7,82.5,60.5,49.7,30.4,29.0,28.1.ESI-MS m/z 711.5[M+H]+.
Preparation of Compound 139
Adding 3' -N-p-fluorobenzoyl staurosporine (20.0mg,0.034mmol) into a 25mL two-mouth reaction flask under the protection of argon, dissolving with 1mL DMSO, adding 0.03mL 2N NaOH solution, stirring at room temperature for reaction for 4h, adding water to terminate the reaction, extracting with ethyl acetate, and adding anhydrous Na2SO4Drying, vacuum evaporating, separating by gel column chromatography, eluting with methanol to obtain 7.6mg of 7 α -hydroxy-3' -N-p-fluorobenzoyl staurosporine (139), with yield of 37.0%.1H NMR(600MHz,CDCl3)δ9.00(d,1H,J=7.7Hz,Ar-H),8.64(d,1H,J=7.7Hz,-NH),7.50(t,1H,J=8.2Hz,Ar-H),7.49(t,2H,J=8.2Hz,Ar-H),7.44(t,2H,J=7.3Hz,Ar-H),7.37(t,1H,J=7.7Hz,Ar-H),7.36(t,1H,J=7.7Hz,Ar-H),7.25(d,1H,J=7.7Hz,Ar-H),7.19(t,1H,J=7.7Hz,Ar-H),7.11(t,2H,J=7.7Hz,Ar-H),7.10(s,1H,H-7),6.71(br s,1H,-OH),6.47(br s,1H,H-1'),5.19(d,1H,J=8.2Hz,H-3'),3.84(s,1H,H-4'),2.70(s,3H,4'-OCH3),2.35(m,1H,H-2'a),2.24(m,1H,H-2'b),2.19(s,3H,3'-NCH3),2.04(s,3H,H-6').13C NMR(150MHz,CDCl3)δ173.3,171.5,163.6(d,1JC-F=247.2Hz),136.5×2,132.5,132.2,130.6,129.5×2(d,3JC-F=6.9Hz),126.7,126.4,125.5,125.2,124.9,123.8,121.6,120.6,120.3,119.2,116.3,115.8×2(d,2JC-F=13.7Hz),114.6,112.4,107.6,94.7,84.8,82.5,79.4,60.5,49.8,34.5,29.2,28.2.ESI-MS m/z 605.3[M+H]+.
Preparation of Compounds 140 and 141
Synthesized from 3' -N-p-chlorobenzoyl staurosporine (20.0mg,0.034mmol), DMSO, and NaOH solution according to the synthesis method of compound 139. Separating by gel column chromatography, eluting with methanol to obtain 7.2mg (yield: 35.1%) of 7 α -hydroxy-3 '-N-p-chlorobenzoyl staurosporine (140) and 5.4mg (yield: 26.3%) of 7 β -hydroxy-3' -N-p-chlorobenzoyl staurosporine (141).
Compound 140:1H NMR(600MHz,DMSO-d6)δ9.25(d,1H,J=7.8Hz,Ar-H),8.87(s,1H,-NH),8.46(d,1H,J=7.7Hz,Ar-H),7.99(d,1H,J=7.8Hz,Ar-H),7.68(d,2H,J=7.8Hz,Ar-H),7.52(d,2H,J=7.3Hz,Ar-H),7.50(t,1H,J=8.0Hz,Ar-H),7.49(t,2H,J=7.3Hz,Ar-H),7.34(t,1H,J=7.8Hz,Ar-H),7.31(t,1H,J=7.8Hz,Ar-H),7.19(s,1H,-OH),6.54(d,1H,J=10.0Hz,H-7),6.44(d,1H,J=8.0Hz,H-1'),5.19(d,1H,J=9.2Hz,H-3'),4.50(s,1H,H-4'),2.84(s,3H,4'-OCH3),2.73(m,1H,H-2'a),2.67(m,1H,H-2'b),2.54(s,3H,3'-NCH3),2.48(s,3H,H-6').13C NMR(150MHz,DMSO-d6)δ171.0,171.1,137.4,136.6,134.8,133.8,132.5,130.6,129.1×2,128.6×2,126.9,126.5,125.6,125.2,124.8,123.7,121.6,120.7,120.3,119.3,116.4,114.7,112.5,109.6,95.1,84.7,82.7,79.1,60.6,49.8,34.5,29.9,27.0.ESI-MS m/z605.3/607.3[M+H]+。
compound 141:1H NMR(600MHz,CDCl3)δ9.25(d,1H,J=7.8Hz,Ar-H),8.46(d,1H,J=7.7Hz,-NH),7.72(d,1H,J=7.8Hz,Ar-H),7.49(t,1H,J=7.8Hz,Ar-H),7.46(t,2H,J=7.8Hz,Ar-H),7.40(d,2H,J=7.3Hz,Ar-H),7.38(d,2H,J=7.3Hz,Ar-H),7.35(t,2H,J=7.8Hz,Ar-H),7.22(d,1H,J=7.8Hz,Ar-H),6.68(s,1H,H-7),6.66(s,1H,-OH),6.41(d,1H,J=8.0Hz,H-1'),5.19(d,1H,J=9.2Hz,H-3'),4.21(s,1H,H-4'),2.81(s,3H,4'-OCH3),2.71(m,1H,H-2'a),2.61(m,1H,H-2'b),2.51(s,3H,3'-NCH3),1.66(s,3H,H-6').13C NMR(150MHz,CDCl3)δ171.3,171.2,136.9,136.4,133.4,132.5,130.9,130.6,129.0×2,128.6×2,126.9,126.5,125.6,125.2,124.8,123.7,121.6,120.7,120.3,119.3,115.9,115.6,112.5,107.8,94.7,84.7,82.4,79.4,60.7,49.8,34.5,29.3,28.1.ESI-MS m/z 605.3/607.3[M+H]+。
preparation of Compounds 142 and 143
According to the method for synthesizing compound 139, it is synthesized from 3' -N-p-trifluoromethylbenzoyl staurosporine (20.0mg,0.031mmol), DMSO, and NaOH solution. Separating by gel column chromatography, eluting with methanol to obtain 7 α -hydroxy-3 '-N-p-trifluoromethyl benzoyl staurosporine (142)7.5mg (yield 36.6%) and 7 β -hydroxy-3' -N-p-trifluoromethyl benzoyl staurosporine (143)5.4mg (yield 26.3%).
Compound 142:1H NMR(600MHz,CDCl3)δ8.93(d,1H,J=7.4Hz,Ar-H),8.62(d,1H,J=7.4Hz,-NH),7.69(m,3H,Ar-H),7.60(d,1H,J=7.9Hz,Ar-H),7.51(m,2H,Ar-H),7.43(t,2H,J=7.8Hz,Ar-H),7.37(t,2H,J=7.8Hz,Ar-H),7.16(d,1H,J=7.8Hz,Ar-H),6.89(s,1H,H-7),6.87(m,1H,H-1'),6.49(br s,1H,-OH),5.19(m,1H,H-3'),3.90(s,1H,H-4'),2.70(s,3H,4'-OCH3),2.54(m,1H,H-2'a),2.35(m,1H,H-2'b),2.09(s,3H,3'-NCH3),2.06(s,3H,H-6').13C NMR(150MHz,CDCl3)δ170.2,170.1,141.1,139.7,138.3,134.8×2,132.8,130.1,128.8×2(q,2JC-F=27.0Hz),127.9,127.1,127.3,126.7,125.8,125.3(q,3JC-F=8.0Hz),125.1,124.6,122.7(q,1JC-F=270.0Hz),121.8,120.1(q,3JC-F=7.1Hz),119.6,115.0,114.7,113.2,109.0,94.5,83.0,82.0,78.2,60.3,48.8,33.7,29.3,28.2.ESI-MS m/z 655.2[M+H]+。
compound 143:1H NMR(600MHz,DMSO-d6)δ9.28(d,1H,J=7.4Hz,Ar-H),8.88(s,1H,-NH),8.51(d,1H,J=6.6Hz,Ar-H),7.99(d,1H,J=7.7Hz,Ar-H),7.83(d,1H,J=7.1Hz,Ar-H),7.70(d,1H,J=7.3Hz,Ar-H),7.66(d,1H,J=7.3Hz,Ar-H),7.49(m,3H,Ar-H),7.34(t,1H,J=8.3Hz,Ar-H),7.30(m,2H,Ar-H),7.09(d,1H,J=9.0Hz,H-7),6.46(br s,1H,-OH),6.45(m,1H,H-1'),5.09(d,1H,J=10.0Hz,H-3'),4.53(s,1H,H-4'),2.90(s,3H,4'-OCH3),2.78(m,1H,H-2'a),2.73(s,3H,3'-NCH3),2.57(m,1H,H-2'b),2.39(s,3H,H-6').13C NMR(150MHz,DMSO-d6)δ170.9,170.8,139.8,137.1,138.3,134.8×2,132.8,130.1,128.7×2(q,2JC-F=27.0Hz),127.9,127.1,127.3,126.7,125.8,125.0(q,3JC-F=8.0Hz),125.1,124.6,122.6(1JC-F=270.0Hz),121.8,120.1(q,3JC-F=7.1Hz),119.6,115.0,114.7,113.2,109.0,94.5,83.0,82.0,78.3,60.3,48.9,33.8,29.2,28.1.ESI-MS m/z 655.2[M+H]+。
preparation of Compounds 144 and 145
Synthesized according to the synthesis of compound 139 from 130(25.0mg,0.040mmol), DMSO, and NaOH solution. After separation by gel column chromatography and elution with methanol, 8.4mg (yield: 32.8%) of 7 α -hydroxy-3 '-N-p-fluorophenyl sulfonyl staurosporine (144) and 6.0mg (yield: 23.4%) of 7 β -hydroxy-3' -N-p-fluorophenyl sulfonyl staurosporine (145) were obtained.
Compound 144:1H NMR(600MHz,DMSO-d6)δ9.22(d,1H,J=7.9Hz,Ar-H),8.86(s,1H,-NH),8.45(d,1H,J=8.6Hz,Ar-H),9.07(m,2H,Ar-H),7.99(d,1H,J=8.4Hz,Ar-H),7.56(m,2H,Ar-H),7.50(m,3H,Ar-H),7.34(t,1H,J=7.3Hz,Ar-H),7.30(d,1H,J=7.7Hz,H-7),6.95(m,1H,H-1'),6.44(br s,1H,-OH),4.53(d,1H,J=13.4Hz,H-3'),4.18(s,1H,H-4'),2.63(s,3H,4'-OCH3),2.59(s,3H,3'-NCH3),2.57(m,1H,H-2'a),2.43(m,1H,H-2'b),2.40(s,3H,H-6').13C NMR(150MHz,DMSO-d6)δ170.3,163.5(d,1JC-F=85.7Hz),138.8,136.5,134.9,130.2×2(d,3JC-F=9.9Hz),129.6,126.0,125.6,125.6,125.4,123.5,123.4,123.4,122.6,120.3,119.7,118.8,117.0×2(d,2JC-F=19.1Hz),115.1,114.8,113.0,109.1,94.8,85.1,82.1,60.3,51.8,40.1,30.60,29.0,26.9.ESI-MS m/z 641.2[M+H]+。
compound 145:1H NMR(600MHz,CDCl3)δ9.19(d,1H,J=8.2Hz,Ar-H),8.37(d,1H,J=7.9Hz,-NH),7.87(m,2H,Ar-H),7.65(d,1H,J=8.3Hz,Ar-H),7.44(ddd,1H,J=1.3,7.3,8.0Hz,Ar-H),7.36(ddd,1H,J=1.5,6.9,8.1Hz,Ar-H),7.31(d,1H,J=7.3Hz,Ar-H),7.29(dt,2H,J=2.8,8.2Hz,Ar-H),7.26(m,1H,Ar-H),7.24(t,1H,J=7.4Hz,Ar-H),6.99(d,1H,J=8.1Hz,Ar-H),6.82(s,1H,H-7),6.48(dd,1H,J=4.5,8.9Hz,H-1'),6.27(s,1H,-OH),4.49(ddd,1H,J=2.1,5.5,13.0Hz,H-3'),3.87(s,1H,H-4),2.57(s,3H,4'-OCH3),2.44(s,3H,3'-NCH3),2.34(dt,1H,J=4.6,13.3Hz,H-2'a),2.27(s,3H,H-6'),2.22(m,1H,H-2'b).13C NMR(150MHz,CDCl3)δ171.3,165.4(d,1JC-F=254.9Hz),138.8,136.8,135.3,133.5,130.7,129.7×2(d,3JC-F=9.2Hz),127.2,126.6,125.8,125.7,124.1,123.9,123.2,120.9,120.4,118.1,115.9×2(d,2JC-F=22.8Hz),115.8,115.5,112.0,107.7,94.7,86.6,82.3,79.3,60.4,52.1,33.7,29.3,28.2.ESI-MS m/z641.2[M+H]+。
preparation of Compounds 146 and 147
Synthesized according to the synthesis of compound 139 from 131(25.0mg,0.039mmol), DMSO and NaOH solution. After separation by gel column chromatography and elution with methanol, 8.2mg (yield: 32.0%) of 7 α -hydroxy-3 '-N-p-chlorobenzenesulfonyl staurosporine (146) and 5.9mg (yield: 23.0%) of 7 β -hydroxy-3' -N-p-chlorobenzenesulfonyl staurosporine (147) were obtained.
Compound 146:1H NMR(600MHz,CDCl3)δ8.63(d,2H,J=7.7Hz,Ar-H),8.23(s,1H,-NH),7.84(m,2H,Ar-H),7.61(m,2H,Ar-H),7.49(d,1H,J=8.4Hz,Ar-H),7.43(t,1H,J=7.3,Ar-H),7.36(t,1H,J=7.7Hz,Ar-H),6.87(t,1H,J=7.7Hz,Ar-H),6.80(d,1H,J=7.7Hz,Ar-H),6.79(dd,1H,J=3.7,11.7Hz,Ar-H),6.54(d,1H,J=7.7Hz,H-7),6.53(m,1H,H-1'),5.43(br s,1H,-OH),4.53(dd,1H,J=6.3,12.4Hz,H-3'),3.60(s,1H,H-4'),2.58(s,3H,4'-OCH3),2.47(s,3H,3'-NCH3),2.34(m,1H,H-2'a),2.22(dt,1H,J=4.2,12.3Hz,H-2'b),1.92(s,3H,H-6').13C NMR(150MHz,CDCl3)δ173.3,139.7,138.3,138.0,135.8,133.7,130.4,129.9×2,128.5×2,126.7,125.9,125.5,124.6,124.4,124.3,122.5,120.7,119.6,117.9,116.3,114.9,111.0,107.1,94.3,86.2,82.2,80.3,59.7,52.2,30.6,29.2,28.7.ESI-MS m/z 657.6/659.6[M+H]+. Compound 147:1H NMR(600MHz,CDCl3)δ9.14(d,1H,J=7.9Hz,Ar-H),8.28(d,1H,J=7.8Hz,-NH),7.76(br d,2H,J=8.0Hz,Ar-H),7.62(d,1H,J=8.5Hz,Ar-H),7.54(br d,2H,J=8.7Hz,Ar-H),7.40(t,1H,J=7.3Hz,Ar-H),7.30(t,1H,J=7.8Hz,Ar-H),7.25(m,2H,Ar-H),7.19(t,1H,J=7.7Hz,Ar-H),7.06(s,1H,H-7),6.92(d,1H,J=8.0Hz,Ar-H),6.41(dd,1H,J=4.5,8.9Hz,H-1'),6.16(s,1H,-OH),4.44(dd,J=5.4,11.9Hz H-3'),3.79(s,1H,H-4'),2.51(s,3H,4'-OCH3),2.43(s,3H,3'-NCH3),2.28(m,1H,J=4.2,13.2Hz,H-2'a),2.19(m,1H,H-2'b),2.15(s,3H,H-6').13C NMR(150MHz,CDCl3)δ171.5,139.7,138.6,137.7,136.7,133.5,130.6,119.9×2,118.4×2,127.0,126.4,135.7,125.6,124.1,123.9,123.1,120.8,120.3,118.0,115.6,115.5,111.8,107.7,94.6,86.6,82.2,79.3,60.2,52.1,30.6,29.2,28.2.ESI-MSm/z 657.6/659.6[M+H]+.
preparation of Compounds 148 and 149
Synthesized according to the synthesis of compound 139 from 132(25.0mg,0.036mmol), DMSO and NaOH solution. The 7 alpha-hydroxy-3 '-N-p-bromobenzenesulfonyl staurosporine (148)7.8mg (yield 30.5%) and the 7 beta-hydroxy-3' -N-p-bromobenzenesulfonyl staurosporine (149)5.5mg (yield 21.5%) were obtained by gel column chromatography and methanol elution.
Compound 148:1H NMR(600MHz,CDCl3)δ8.90(s,1H,Ar-H),8.66(d,1H,J=7.4Hz,-NH),8.59(d,1H,J=7.8Hz,Ar-H),7.77(m,4H,Ar-H),7.46(d,1H,J=8.1Hz,Ar-H),7.42(d,1H,J=8.5Hz,Ar-H),7.36(t,1H,J=7.7Hz,Ar-H),6.82(dd,1H,J=3.5,9.8Hz,Ar-H),6.78(m,2H,Ar-H),6.56(d,1H,J=10.9Hz,H-7),6.46(t,1H,J=7.2Hz,H-1'),5.78(d,1H,J=11.1Hz,-OH),4.52(dd,1H,J=6.2,12.8Hz,H-3'),3.56(s,1H,H-4'),2.56(s,3H,4'-OCH3),2.48(s,3H,3'-NCH3),2.35(m,1H,H-2'a),2.19(dt,1H,J=2.5,13.5Hz,H-2'b),2.86(s,3H,H-6').13C NMR(150MHz,CDCl3)δ173.2,138.5,138.2,135.6,133.8,132.9×2,130.3,128.6×2,128.1,126.5,125.8,125.4,124.8,124.4,124.2,122.4,120.6,119.5,117.9,116.2,114.8,110.8,107.0,94.2,86.2,82.4,80.5,59.6,52.2,30.5,29.1,28.7.ESI-MS m/z 701.5/703.5[M+H]+. Compound 149:1H NMR(600MHz,CDCl3)δ9.07(d,1H,J=7.8Hz,Ar-H),8.36(d,1H,J=7.8Hz,-NH),7.77(m,4H,Ar-H),7.64(d,1H,J=8.2Hz,Ar-H),7.43(t,1H,J=6.8Hz,Ar-H),7.37(d,1H,J=3.9Hz,Ar-H),7.31(m,2H,Ar-H),7.13(t,1H,J=7.7Hz,Ar-H),7.08(s,1H,H-7),6.99(d,1H,J=8.1Hz,Ar-H),6.51(dd,1H,J=4.0,9.2Hz,H-1'),6.34(s,1H,-OH),4.49(ddd,1H,J=1.9,5.5,12.8Hz,H-3'),3.86(s,1H,H-4'),2.58(s,3H,4'-OCH3),2.48(s,3H,3'-NCH3),2.44(m,1H,H-2'a),2.25(s,3H,H-6'),2.22(m,1H,H-2'b).13C NMR(150MHz,CDCl3)δ171.6,138.7,138.3,136.7,134.4,132.9×2,130.6,128.5×2,128.2,127.1,126.1,126.5,125.7,125.7,124.2,123.1,120.9,120.3,118.0,115.7,115.6,111.8,107.6,94.6,86.6,82.3,79.4,60.3,52.1,33.7,29.3,28.2.ESI-MS m/z 701.5/703.5[M+H]+。
preparation of Compound 150
Synthesized from 3' -N-p-iodobenzenesulfonyl staurosporine (25.0mg,0.034mmol), DMSO, and NaOH solution according to the synthesis method for compound 139. Separating by gel column chromatography, eluting with methanol to obtain 7 α -hydroxy-3' -N-p-iodobenzenesulfonyl staurosporine (150)8.1mg (yield 31.7%).1H NMR(600MHz,CDCl3)δ8.65(d,1H,J=7.4Hz,Ar-H),8.60(d,1H,J=7.9Hz,Ar-H),8.57(s,1H,-NH),7.99(m,2H,Ar-H),7.60(m,2H,Ar-H),7.47(d,1H,J=8.0Hz,Ar-H),7.43(t,1H,J=7.3Hz,Ar-H),7.36(t,1H,J=7.3Hz,Ar-H),6.83(t,1H,J=7.8Hz,Ar-H),6.79(t,2H,J=8.0Hz,Ar-H),6.54(d,1H,J=11.8Hz,H-7),6.49(t,1H,J=7.8Hz,H-1'),5.62(d,1H,J=12.2Hz,-OH),4.50(dd,1H,J=5.8,12.8Hz,H-3'),3.57(s,1H,H-4'),2.57(s,3H,4'-OCH3),2.47(s,1H,3'-NCH3),2.34(m,1H,H-2'a),2.20(dt,1H,J=3.2,12.4Hz,H-2'b),1.90(s,3H,H-6').13C NMR(150MHz,CDCl3)δ173.5,139.3×2,138.8×2,138.3,135.7,133.8,130.4,128.5×2,126.6×2,125.8,125.4,124.4,122.4,120.6,119.6,117.9,116.3,114.9,110.9,109.4,100.5,94.3,86.2,82.2,80.4,59.6,52.3,30.6,29.1,28.7.ESI-MS m/z 749.6[M+H]+.
Preparation of Compounds 151 and 152
Synthesized according to the synthesis of compound 139 from 133(25.0mg,0.034mmol), DMSO, and NaOH solution. Separating by gel column chromatography, eluting with methanol to obtain 7 α -hydroxy-3 '-N-benzenesulfonyl staurosporine (151)7.9mg (yield 30.8%) and 7 β -hydroxy-3' -N-benzenesulfonyl staurosporine (152)5.4mg (yield 21.1%).
Compound 151:1H NMR(600MHz,CDCl3)δ8.66(s,1H,-NH),8.63(t,2H,J=7.4Hz,Ar-H),7.91(d,2H,J=7.4Hz,Ar-H),7.70(t,1H,J=7.8Hz,Ar-H),7.64(m,2H,Ar-H),7.40(m,2H,Ar-H),7.34(t,1H,J=7.4Hz,Ar-H),6.77(m,2H,Ar-H),6.73(d,1H,J=7.6Hz,Ar-H),6.54(d,1H,J=10.0Hz,H-7),6.48(d,1H,J=8.0Hz,H-1'),5.75(d,1H,J=10.0Hz,-OH),4.53(dd,1H,J=12.8,5.5Hz,H-3'),3.48(s,1H,H-4'),2.58(s,3H,4'-OCH3),2.42(s,3H,3'-NCH3),2.36(m,1H,H-2'a),2.18(m,1H,H-2'b),1.82(s,3H,H-6').13CNMR(150MHz,CDCl3)δ173.5,139.5,138.2,135.7,133.7,133.2,130.4,129.6×2,127.0×2,126.6,125.7,125.3,124.7,124.3,124.2,122.4,120.5,119.5,117.8,116.1,114.8,110.8,107.0,94.2,85.8,82.2,80.4,59.4,52.1,30.5,29.0,28.6.ESI-MS m/z 623.2[M+H]+.
compound 152:1H NMR(600MHz,CDCl3)δ9.19(d,1H,J=7.8Hz,Ar-H),8.38(d,1H,J=7.4Hz,-NH),7.88(d,2H,J=7.3Hz,Ar-H),7.70(d,1H,J=7.8Hz,Ar-H),7.62(m,3H,Ar-H),7.43(t,1H,J=7.8Hz,Ar-H),7.36(t,1H,J=7.8Hz,Ar-H),7.30(t,1H,J=7.3Hz,Ar-H),7.24(t,1H,J=7.3Hz,Ar-H),6.99(d,1H,J=7.9Hz,ArH),6.83(s,1H,H-7),6.47(dd,1H,J=9.2,4.6Hz,H-1'),6.31(br s,1H,-OH),4.50(ddd,1H,J=1.9,5.3,13.0Hz,H-3'),3.83(s,1H,H-4'),2.61(s,3H,4'-OCH3),2.42(s,3H,3'-NCH3),2.34(m,1H,H-2'a),2.29(s,3H,H-6'),2.22(m,1H,H-2'b).13C NMR(150MHz,CDCl3)δ171.3,139.2,138.8,136.8,133.4,133.2,130.7,129.5×2,127.2,127.1×2,126.6,125.6,125.8,125.7,124.1,124.0,123.3,120.9,120.4,118.1,115.6,112.0,107.7,94.7,86.3,82.4,79.4,60.3,52.1,20.7,29.3,28.1.ESI-MS m/z 623.2[M+H]+。
preparation of Compound 153
Synthesized from staurosporine (46.6mg,0.1mmol), triethylamine and p-fluorobenzoyl chloride according to the synthesis of compound 130. Separating by gel column chromatography, eluting with methanol to obtain 3' -N-p-fluorobenzoyl staurosporine (153)53.8mg, with yield 91.5%.1H NMR(600MHz,CDCl3)δ9.45(d,1H,J=8.2Hz,Ar-H),7.87(d,1H,J=7.8Hz,Ar-H),7.78(d,1H,J=7.8Hz,Ar-H),7.48(t,1H,J=7.8Hz,Ar-H),7.46(t,1H,J=7.3Hz,Ar-H),7.43(m,2H,J=7.3Hz,Ar-H),7.37(t,1H,J=7.3Hz,Ar-H),7.33(t,1H,J=7.3Hz,Ar-H),7.21(d,1H,J=7.3Hz,Ar-H),7.10(d,2H,J=7.3Hz,Ar-H),6.94(br s,1H,-NH),6.66(br s,1H,H-1'),5.17(d,1H,J=7.8Hz,H-3'),4.97(d,1H,J=16.0Hz,H-7a),4.93(d,1H,J=16.0Hz,H-7b),4.21(s,1H,H-4'),2.84(s,3H,4'-OCH3),2.72(m,1H,H-2'a),2.65(m,1H,H-2'b),2.53(s,3H,3'-NCH3),2.45(s,3H,H-6').13C NMR(150MHz,CDCl3)δ173.5,171.5,163.6(d,1JC-F=247.2Hz),136.6×2,132.5,132.2,130.6,129.4×2(d,3JC-F=6.9Hz),126.9,126.4,125.5,125.1,124.8,123.7,121.6,120.6,120.2,119.2,116.3,115.8×2(d,2JC-F=13.7Hz),114.6,112.4,107.8,94.7,84.8,82.4,60.5,49.8,46.1,34.6,29.2,28.2.ESI-MS m/z 589.2[M+H]+。
Preparation of Compound 154
According to the method for synthesizing compound 134, it is synthesized from compound 153(15.0mg,0.025mmol) and chlorosuccinimide (7.5mg,0.056 mmol). After the gel column chromatographic separation and methanol elution, 10.5mg of 3-chloro-3' -N-p-fluorobenzoyl staurosporine (154) is obtained, and the yield is 33.2 percent.1H NMR(600MHz,CDCl3)δ9.38(s,1H,Ar-H),7.89(d,1H,J=7.8Hz,Ar-H),7.77(d,1H,J=7.3Hz,Ar-H),7.48(d,2H,J=7.8Hz,Ar-H),7.43(d,2H,J=7.3,Ar-H),7.36(t,1H,J=7.8Hz,Ar-H),7.35(d,1H,J=7.8Hz,Ar-H),7.12(t,2H,J=7.3Hz,Ar-H),7.10(br s,1H,-NH),6.74(br s,1H,H-1'),5.20(d,1H,J=7.8Hz,H-4'),4.98(br s,2H,H-7),4.22(s,1H,H-3'),2.86(s,3H,4'-OCH3),2.75(m,1H,H-2'a),2.62(m,1H,H-2'b),2.57(s,3H,3'-NCH3),2.44(s,3H,H-6').13C NMR(150MHz,CDCl3)δ173.0,171.5,163.6(d,1JC-F=247.2Hz),134.8×2,132.8,132.2,130.4,129.3×2(d,3JC-F=6.9Hz),,127.1,126.1,125.7,125.4,124.7,124.6,121.7,120.8,119.2,115.9×2(d,2JC-F=13.7Hz),115.4,115.0,112.4,108.6×2,94.8,84.7,82.5,60.5,49.8,46.1,34.5,29.2,28.1.ESI-MS m/z 623.3/625.3[M+H]+。
Preparation of Compound 155
Synthesized according to the synthesis method of compound 139, from compound 153(20.0mg,0.034mmol), DMSO, and NaOH solution. 7 beta-hydroxy-3' -N-p-fluorobenzoyl staurosporine (155)7.6mg is obtained by gel column chromatographic separation and methanol elution, and the yield is 37.0%.1HNMR(600MHz,DMSO)δ9.28(d,1H,J=7.7Hz,Ar-H),8.52(d,1H,J=7.7Hz,-NH),7.77(d,1H,J=7.7Hz,Ar-H),7.50(t,1H,J=8.2Hz,Ar-H),7.49(t,1H,J=8.2Hz,Ar-H),7.44(d,2H,J=7.3Hz,Ar-H),7.39(t,1H,J=7.7Hz,Ar-H),7.37(t,1H,J=7.7Hz,Ar-H),7.35(t,1H,J=7.7Hz,Ar-H),7.11(d,2H,J=7.7Hz,Ar-H),7.06(s,1H,H-7),6.71(br s,1H,-OH),6.50(br s,1H,H-1'),5.20(d,1H,J=8.2Hz,H-3'),4.26(s,1H,H-4'),2.87(s,3H,4'-OCH3),2.74(m,1H,H-2'a),2.68(m,1H,H-2'b),2.54(s,3H,3'-NCH3),1.67(s,3H,H-6');13C NMR(150MHz,DMSO)δ171.0,170.9,163.9(d,1JC-F=247.2Hz),137.1×2,135.4,133.5,130.2,129.9×2(d,3JC-F=6.9Hz),126.1×2,125.8,124.0,123.9,123.1,120.7,120.2,119.3×2,116.1,115.7×2(d,2JC-F=13.7Hz),113.9,112.7,109.6,95.2,82.7,82.7,78.9,61.0,49.9,34.6,29.9,27.5;ESI-MSm/z 604.2[M+H]+。
Preparation of Compound 156
Synthesized according to the method for the synthesis of compound 130 from 135a (48.0mg,0.1mmol), triethylamine and p-trifluoromethylbenzoyl chloride. The 7-oxoidene-3' -N-p-trifluoromethyl benzoyl staurosporine (156) is separated by gel column chromatography and eluted by methanol with the yield of 91.3 mg.1H NMR(600MHz,CDCl3)δ9.34(d,1H,J=7.7Hz,Ar-H),9.17(d,1H,J=7.8Hz,Ar-H),7.91(d,2H,J=7.7Hz,Ar-H),7.71(t,1H,J=7.4Hz,Ar-H),7.66(t,1H,J=7.8Hz,Ar-H),7.63(t,1H,J=7.8Hz,Ar-H),7.53(t,2H,J=7.7Hz,Ar-H),7.52(br s,1H,-NH),7.41(t,1H,J=7.8Hz,Ar-H),7.40(d,1H,J=7.8Hz,Ar-H),7.12(d,1H,J=7.4Hz,Ar-H),6.60(dd,1H,J=3.7Hz,9.2Hz,H-1'),4.56(dd,1H,J=5.5Hz,12.4Hz,H-3'),3.83(s,1H,H-4'),2.74(s,3H,4'-OCH3),2.47(m,1H,H-2'a),2.42(s,3H,3'-NCH3),2.38(m,1H,H-2'b),2.26(s,3H,H-6').13C NMR(150MHz,CDCl3)δ169.8,169.6,167.8,139.3,139.2,137.8×2,133.2×2,131.4(q,2JC-F=27.3Hz),130.0,129.6×2,127.1×2,126.5(q,3JC-F=8.4Hz),126.3,123.8(q,1JC-F=270.0Hz),122.5,121.4,121.3,121.0(q,3JC-F=7.8Hz),119.4,117.4,116.4,114.7,111.3,108.2,94.7,86.0,82.5,60.1,51.9,30.7,28.9,28.3;ESI-MS m/z 653.2[M+H]+。
Preparation of Compound 157
According to the synthesis of compound 130 from staurosporine(46.6mg,0.1mmol), triethylamine and p-iodobenzenesulfonyl chloride. Separating by gel column chromatography, eluting with methanol to obtain 62.1mg of 3' -N-p-iodobenzenesulfonyl staurosporine (157), with yield of 84.8%.1H NMR(600MHz,CDCl3)δ9.42(d,1H,J=7.8Hz,Ar-H),7.99(d,2H,J=6.9Hz,Ar-H),7.89(d,1H,J=7.8Hz,Ar-H),7.72(d,1H,J=8.3Hz,Ar-H),7.61(d,2H,J=6.9Hz,Ar-H),7.48(t,1H,J=7.3Hz,Ar-H),7.45(t,1H,J=7.3Hz,Ar-H),7.37(t,1H,J=7.8Hz,Ar-H),7.35(t,1H,J=7.8Hz,Ar-H),7.10(d,1H,J=8.2Hz,Ar-H),6.61(br s,1H,-NH),6.57(dd,1H,J=4.6Hz,9.2Hz,H-1'),4.99(d,1H,J=16.5Hz,H-7a),4.92(d,1H,J=16.5Hz,H-7b),4.50(m,1H,H-4'),3.96(s,1H,H-3'),2.72(s,3H,4'-OCH3),2.47(s,1H,3'-NCH3),2.45(m,1H,H-2'a),2.43(s,3H,H-6'),2.45(m,1H,H-2'a);13C NMR(150MHz,CDCl3)δ173.3,138.9×2,138.5,136.6×2,132.5,130.5,128.4×2,127.0,126.4,125.6,125.3,124.8,123.7,121.7,120.8,120.3,119.3,116.4,114.7,112.3,107.7,100.6,94.7,86.6,82.5,60.5,52.2,46.0,30.9,29.2,28.2.ESI-MS m/z 733.3[M+H]+。
Preparation of Compound 158
i) Preparation of N-methyl-3, 4-bis (3-indole) maleimide (158a)
According to the method for synthesizing compound 82, the compound was synthesized from magnesium filament (128mg,5.3mmol), bromoethane (396 μ L,5.3mmol) and indole (622mg,5.3mmol), and the red solid (158a) was obtained by silica gel column chromatography and eluted with ethyl acetate (3: 1 (v/v)) as 263mg of red solid (158a) with a yield of 73%.1H NMR(600MHz,DMSO-d6)δ11.70(s,2H,indole-NH),7.77(d,2H,J=2.3Hz,Ar-H),7.38(d,2H,J=8.2Hz,Ar-H),6.98(t,2H,J=7.7Hz,Ar-H),6.82(d,2H,J=7.8Hz,Ar-H),6.64(t,2H,J=7.8Hz,Ar-H),3.04(s,3H,-CH3).13C NMR(150MHz,DMSO-d6)δ172.4×2,136.6×2,129.7×2,127.6×2,125.9×2,122.2×2,121.5×2,119.9×2,112.3×2,106.2×2,24.5.ESI-MS m/z 342.1[M+H]+。
ii) preparation of 3, 4-bis (3-indole) maleic anhydride (158b)
According to the method for synthesizing compound 84a, the compound 158a (120mg,0.35mmol) and 10% KOH solution are synthesized, and the product is subjected to silica gel column chromatography and purificationThe methyl chloride eluted 104mg of a red solid (158b) in 90% yield.1H NMR(600MHz,DMSO-d6)δ11.93(d,2H,J=2.8Hz,indole-NH),7.86(d,2H,J=2.8Hz,Ar-H),7.44(d,2H,J=8.2Hz,Ar-H),7.04(t,2H,J=8.2Hz,Ar-H),6.87(d,2H,J=7.7Hz,Ar-H),6.71(t,2H,J=7.7Hz,Ar-H).13C NMR(150MHz,DMSO-d6)δ167.1×2,136.7×2,131.1×2,125.8×2,125.5×2,122.6×2,121.7×2,120.4×2,112.7×2,105.5×2.ESI-MS m/z 329.1[M+H]+。
iii) preparation of 3, 4-bis (3-indole) maleimide (158c)
According to the preparation of compound 1, from compound 158b (100mg,0.3mmol), HMDS (6.4mL,30.5mmol), MeOH (0.61mL,15.2mmol), 70mg of orange-red powder (158c) was prepared in 71% yield.1H NMR(600MHz,DMSO-d6)δ11.65(brs,2H,indole-NH),10.89(brs,1H,imide-NH),7.72(d,2H,J=2.8Hz,Ar-H),7.36(d,2H,J=8.2Hz,Ar-H),6.96(dt,2H,J=8.2Hz,1.0Hz,Ar-H),6.79(d,2H,J=7.8Hz,Ar-H),6.61(dt,2H,J=8.2Hz,1.0Hz,Ar-H).13C NMR(150MHz,DMSO-d6)δ173.6×2,136.4×2,129.6×2,128.2×2,125.9×2,122.1×2,121.4×2,119.8×2,112.3×2,106.1×2.ESI-MS m/z 328.2[M+H]+。
Iv) preparation of N-hydroxymethyl-3, 4-bis (1-hydroxymethyl-3-indole) maleimide (158)
According to the preparation of compound 4, starting from 158c (76.5mg,0.23mmol), NaHCO3(98mg,1.17mmol) and formaldehyde solution (3mL, 37% by mass) gave 96mg of red powdery solid (158), 99% yield.1H NMR(600MHz,DMSO-d6)δ7.95(s,2H,Ar-H),7.55(d,2H,J=8.2Hz,Ar-H),7.03(t,2H,J=7.3Hz,Ar-H),6.76(d,2H,J=8.2Hz,Ar-H),6.64(t,2H,J=7.3Hz,Ar-H),5.60(s,4H,indole-C 2H-OH),4.98(s,2H,imide-C 2H-OH).13C NMR(150MHz,DMSO-d6)δ171.6×2,136.0×2,132.4×2,127.6×2,127.0×2,122.4×2,121.5×2,120.6×2,111.4×2,105.9×2,69.7,60.9×2.HR-ESIMS m/z 440.1236[M+H]+(calcd.for C23H19N3O5Na,440.1222).
Preparation of Compound 159
According to the preparation method of compound 14, compound 8b (30mg,0.055mmol) and ethylenediamine (0.5mL) were reacted, and the reaction mixture was separated by silica gel column chromatography and eluted with dichloromethane and methanol (8: 1 (v/v)) to give N- (2-aminoethyl) -2, 3-bis (1-cyanopropyl-3-indole) maleimide (159) as a deep red solid in a yield of 94 mg.1H NMR(600MHz,DMSO-d6)δ7.76(s,2H,Ar-H),7.50(d,2H,J=8.2Hz,Ar-H),7.07(t,2H,J=7.6Hz,Ar-H),6.89(d,2H,J=7.9Hz,Ar-H),6.72(s,2H,Ar-H),4.28(t,4H,J=5.5Hz,-N-C 2H-(CH2)2CN),3.63(t,2H,J=5.7Hz,-N-C 2H-CH2NH2),2.86(t,2H,J=5.7Hz,-NCH2-C 2H-NH2),2.37(t,J=6.8Hz,4H,N(CH2)2-C 2H-CN),2.03-1.98(m,4H,N-CH2-C 2H-CH2CN).13C NMR(150MHz,DMSO-d6)δ171.9×2,136.3×2,132.4×2,127.4×2,126.0×2,122.5×2,121.9×2,120.3×2,120.1×2,110.6×2,105.7×2,54.0,45.0×2,39.9,26.0×2,14.2×2.ESI-MS m/z 505.1[M+H]+.
Preparation of Compound 160
According to the preparation method of compound 24, from compound 8b (60mg,0.129mmol), 4- (2-aminoethyl) morpholine (120. mu.L, 0.909mmol) and a catalytic amount of Et3N synthesis, silica gel column chromatography, dichloromethane/methanol 30:1(v/v) elution gave 44mg of N- (2- (4-morpholine) ethyl) -2, 3-bis (1-cyanopropyl-3-indole) maleimide (160) as a red solid in 59% yield.1H NMR(500MHz,DMSO-d6)δ7.77(s,2H,Ar-H),7.51(d,2H,J=8.3Hz,Ar-H),7.07(t,2H,J=7.6Hz,Ar-H),6.87(d,2H,J=8.0Hz,Ar-H),6.73(t,2H,J=7.5Hz,Ar-H),4.27(t,4H,J=6.6Hz,-N-C 2H-(CH2)2CN),3.69(t,2H,J=6.0Hz,-N-C 2H-CH2-morpholine),3.52(t,4H,J=4.5Hz,morpholine-N(CH2CH 2)2O),2.53(t,2H,J=6.0Hz,-NCH2-C 2H-morpholine),2.42(t,4H,J=5.3Hz,N(CH2)2-C 2H-CN),2.37(t,4H,J=3.9Hz,morpholine-N(CH 2CH2)2O),2.03-1.98(m,4H,NCH2-C 2H-CH2CN).13C NMR(125MHz,DMSO-d6)δ171.8×2,136.3×2,132.5×2,127.2×2,126.0×2,122.5×2,121.8×2,120.4×2,120.2×2,110.6×2,105.6×2,66.7×2,56.4,53.6×2,45.0×2,35.3,26.0×2,14.2×2.ESI-MS m/z 575.2[M+H]+.
Preparation of Compound 161
According to the synthesis of compound 24, starting from compound 8b (60mg,0.129mmol), 4- (2-aminoethyl) piperazine (100. mu.L, 0.90mmol) and a catalytic amount of Et3N synthesis, silica gel column chromatography, dichloromethane/methanol 10:1(v/v) elution gave 44mg of N- (2-piperazineethyl) -2, 3-bis (1-cyanopropyl-3-indole) maleimide (161) as a red solid in 75% yield.1H NMR(600MHz,DMSO-d6)δ7.77(s,2H,Ar-H),7.51(d,2H,J=8.3Hz,Ar-H),7.07(t,2H,J=7.6Hz,Ar-H),6.87(d,2H,J=8.0Hz,Ar-H),6.73(t,2H,J=7.5Hz,Ar-H),4.27(t,4H,J=6.5Hz,-N-C 2H-(CH2)2CN),3.67(t,4H,J=6.1Hz,piperazine-N(CH2CH2)2NH),2.73(t,4H,J=4.9Hz,piperazine-N(CH2CH 2)2NH),2.52(t,2H,J=6.1Hz,imide-NCH 2-CH2-piperazine),2.43(t,2H,J=4.9Hz,imide-NCH2-CH 2-piperazine),2.37(t,4H,J=7.1Hz,N(CH2)2-C 2H-CN),1.99-2.02(m,4H,NCH2-C 2H-CH2CN).13C NMR(150MHz,DMSO-d6)δ171.8×2,136.3×2,132.5×2,127.3×2,126.0×2,122.5×2,121.8×2,120.3×2,120.2×2,110.6×2,105.6×2,56.4,53.2×2,45.3×2,45.0×2,35.4,26.0×2,14.2×2.ESI-MS m/z 574.2[M+H]+.
Preparation of Compound 162
Compound 8b (55mg,0.119mmol) was dissolved in 6ml of dry pyridine, hydroxylamine hydrochloride (17mg,0.238mmol) was added, and the reaction was carried out under nitrogen at 100 ℃ for 1.5 h. TLC detection till the reaction is not carried out any more, cooling to room temperature, and rotary evaporation to dryness. Separating by silica gel column chromatography, eluting with dichloromethane and methanol at ratio of 15:1(v/v) to obtain red solid N-hydroxy-2, 3-di (1-cyanopropyl-3-indole) maleimide (162)51mg, yield 89%.1H NMR(600MHz,DMSO-d6)δ10.46(s,1H,-OH),7.78(s,2H,Ar-H),7.51(d,2H,J=8.3Hz,Ar-H),7.07(t,2H,J=7.6Hz,Ar-H),6.86(d,2H,J=8.0Hz,Ar-H),6.72(t,2H,J=7.5Hz,Ar-H),4.28(t,4H,J=6.5Hz,-N-C 2H-(CH2)2CN),2.37(t,4H,J=7.1Hz,N(CH2)2-C 2H-CN),2.04-1.98(m,4H,NCH2-C 2H-CH2CN).13C NMR(150MHz,DMSO-d6)δ168.6×2,136.3×2,132.6×2,125.9×2,124.7×2,122.5×2,121.8×2,120.4×2,120.3×2,110.7×2,105.5×2,45.0×2,26.0×2,14.2×2.ESI-MS m/z 478.2[M+H]+.
Preparation of Compound 163
According to the method for synthesizing the compound 162, the compound 26e (55mg,0.13mmol) and hydroxylamine hydrochloride (25mg,0.25mmol) were synthesized and subjected to silica gel column chromatography and eluted with dichloromethane and methanol at a ratio of 20:1(v/v) to obtain 58mg of N-hydroxy-2- (1-ethyl-3-indole) -3- (6-bromo-3-indole) maleimide (162) as a red solid in a yield of 99%.1H NMR(600MHz,DMSO-d6)δ11.83(s,1H,indole-NH),10.50(brs,1H,-OH),7.84(s,1H,Ar-H),7.79(s,1H,Ar-H),7.57(s,1H,Ar-H),7.47(d,1H,J=8.2Hz,Ar-H),7.03(t,1H,J=7.6Hz,Ar-H),6.76(t,1H,J=7.6Hz,Ar-H),6.74(d,1H,J=7.1Hz,Ar-H),6.68(t,1H,J=6.2Hz,Ar-H),6.67(d,1H,J=8.1Hz,Ar-H),4.25(q,2H,J=7.0Hz,-C 2H-CH3),1.32(t,3H,J=7.1Hz,-CH2-C 3H).13C NMR(150MHz,DMSO-d6)δ168.7×2,137.3,136.0,132.3,130.7,126.1,125.2,124.7,124.3,122.9,122.7,122.3,121.6,120.2,114.9×2,110.7,106.1,105.0,41.2,15.7.HR-ESIMS m/z 450.0459[M+H]+(calcd.for C22H16N3O3Br,449.0375).
Preparation of Compound 164
According to the preparation method of compound 24, from compound 26e (30mg,0.069mmol), 4- (2-aminoethyl) morpholine (64. mu.L, 0.484mmol) and a catalytic amount of Et3N synthesis, silica gel column chromatography, dichloromethane and methanol 25:1(v/v) elution to obtain red solid N- (2- (4-morpholine) ethylYl) -2- (1-ethyl-3-indole) -3- (6-bromo-3-indole) maleimide (164)33mg, yield 88%.1H NMR(500MHz,DMSO-d6)δ11.78(s,1H,indole-NH),7.81(s,1H,Ar-H),7.76(s,1H,Ar-H),7.56(d,1H,J=1.5Hz,Ar-H),7.46(d,1H,J=8.3Hz,Ar-H),7.03(t,1H,J=7.6Hz,Ar-H),6.78(d,1H,J=7.7Hz,Ar-H),6.74(dd,1H,J=8.4Hz,1.6Hz,Ar-H),6.69(d,1H,J=8.4Hz,Ar-H),6.67(t,1H,J=8.2Hz,Ar-H),4.24(q,2H,J=7.2Hz,-C 2H-CH3),3.67(t,2H,J=6.5Hz,imide-NC 2HCH2-),3.51(t,4H,J=4.2Hz,morpholine-N(CH2-C 2H)2O),2.52(t,2H,J=6.5Hz,imide-NCH2C 2H-),2.40(t,4H,J=4.2Hz,morpholine-N(CH 2-CH2)2O),1.32(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ171.9,171.8,137.3,136.0,132.1,130.5,127.7,126.4,126.2,124.7,122.9,122.6,122.3,121.6,120.1,114.9,114.8,110.7,106.2,105.1,66.6×2,56.3,53.6×2,41.2,35.3,15.7.HR-ESIMS m/z 547.1354[M+H]+(calcd.forC28H27N4O3Br,546.1267).
Preparation of Compound 165
According to the synthesis method of compound 24, starting from compound 26e (30mg,0.069mmol), 4- (2-aminoethyl) piperazine (93. mu.L, 0.712mmol) and a catalytic amount of Et3N synthesis, silica gel column chromatography, dichloromethane/methanol 8:1(v/v) elution gave 55mg of N- (2-piperazineethyl) -2- (1-ethyl-3-indole) -3- (6-bromo-3-indole) maleimide (165) as a red solid in 99% yield.1H NMR(500MHz,DMSO-d6)δ11.78(s,1H,indole-NH),7.81(s,1H,Ar-H),7.76(d,1H,J=2.6Hz,Ar-H),7.57(d,1H,J=1.5Hz,Ar-H),7.48(d,1H,J=8.3Hz,Ar-H),7.04(t,1H,J=7.6Hz,Ar-H),6.78(d,1H,J=8.0Hz,Ar-H),6.76(dd,1H,J=8.4Hz,1.6Hz,Ar-H),6.69(d,1H,J=8.5Hz,Ar-H),6.68(t,1H,J=7.8Hz,Ar-H),4.25(q,2H,J=7.1Hz,-C 2H-CH3),3.67(d,2H,J=6.2Hz,imide-NC 2HCH2-),3.15(brs,1H,piperazine-NH),3.03(t,4H,J=4.9Hz,piperazine-N(CH 2-CH2)2NH),2.64(t,4H,J=4.9Hz,piperazine-N(CH2-CH 2)2NH),2.60(t,2H,J=5.8Hz,imide-NCH2C 2H-),1.32(t,3H,J=7.2Hz,-CH2-C 3H).13C NMR(125MHz,DMSO-d6)δ171.9,171.8,137.3,136.0,132.2,130.6,127.7,126.4,126.1,124.7,122.9,122.6,122.3,121.6,120.2,114.9,114.8,110.8,106.2,105.1,55.5×2,49.6,43.5×2,41.2,35.3,15.7.HR-ESIMS m/z 546.1515[M+H]+(calcd.for C28H28N5O2Br,545.1426).
Preparation of Compound 166
According to the synthesis of compound 64, starting from compound 8(50.0mg,0.108mmol) and I2(2.0mg,0.008mmol), silica gel column chromatography, and petroleum ether (ethyl acetate: 3:1 (v/v)) to give 12, 13-dicyanopropyl-6H-indole [2,3-a ] as a yellow powder]Pyrrole [3,4-c ]]Carbazole-5, 7-dione (166)23mg, yield 45%.1H NMR(600MHz,DMSO-d6)δ11.2(s,1H,-NH),9.14(d,2H,J=7.8Hz,Ar-H),7.89(d,2H,J=8.2Hz,Ar-H),7.66(t,2H,J=7.8Hz,Ar-H),7.44(t,2H,J=7.8Hz,Ar-H),4.81(t,4H,J=6.9Hz,N-CH 2-(CH2)2CN),2.13(t,4H,J=6.9Hz,N(CH2)2-CH 2-CN),1.71(m,4H,NCH2-CH 2-CH2CN).13C NMR(150MHz,DMSO-d6)δ171.2×2,144.3×2,133.2×2,128.1×2,125.5×2,123.9×2,122.2×2,121.6×2,120.5×2,120.2×2,113.3×2,47.5×2,24.2×2,14.2×2.HR-ESIMS m/z 458.1604[M–H]–(calcd.for C28H20N5O2,458.1617).
Preparation of Compound 167
Staurosporine (60mg,0.129mmol) was dissolved in THF (5mL) at 0 deg.C, diisopropylethylamine (64. mu.L, 0.38mmol) and triphosgene (19mg,0.064mmol) were added, stirred at room temperature for 2h, poured into ice-water, extracted with ethyl acetate (2X 30mL), washed with brine (2X 30mL), the organic phase was dried over anhydrous sodium sulfate and rotary evaporated to dryness. The crude product was dissolved in THF (3mL), diisopropylethylamine (127. mu.L, 0.77mmol), imidazole (18mg,0.25mmol) and p-dimethylaminoPhenylpyridine (31.5mg,0.258mmol), stirring at 60 ℃ for reaction for 2h, pouring into ice water, extracting with ethyl acetate (2 times X30 mL), washing with brine (2 times X30 mL), drying the organic phase with anhydrous sodium sulfate, and rotary evaporating to dryness. Silica gel column chromatography eluting with dichloromethane to methanol 50:1(v/v) afforded a light yellow solid: 56mg of 3' -N- (1-imidazolecarboxyl) staurosporine (167) was obtained in 80% yield. [ alpha ] to]D 18+176(c 0.07,CHCl3);1H NMR(500MHz,DMSO-d6)δ9.31(d,J=7.9Hz,1H,ArH),8.68(s,1H,ArH),8.61(s,1H,NH),8.07(d,J=7.8Hz,1H,ArH),8.01(d,J=8.5Hz,1H,ArH),7.79(brs,1H,ArH),7.59(d,J=8.2Hz,1H,ArH),7.51(t,J=8.2Hz,1H,ArH),7.49(t,J=8.2Hz,1H,ArH),7.37(t,J=7.7Hz,1H,ArH),7.35(brs,1H,ArH),7.31(t,J=7.5Hz,1H,ArH),7.04(dd,J=8.5,5.6Hz,1H,H-1'),5.00(s,2H,H-7),4.68(m,1H,H-3'),4.50(brs,1H,H-4'),2.94-2.99(m,1H,H-2'a),2.89(s,3H,3'-NCH3),2.61(s,3H,6'-CH3),2.36-2.43(m,1H,H-2'b),2.39(s,3H,6'-CH3).13C NMR(125MHz,DMSO-d6)δ172.0,150.8,138.6,137.2,136.3,132.6,129.5,125.9,125.8,125.5,125.5,125.3,123.9,122.8,121.7,120.6,119.7,119.6,119.5,115.2,114.3,113.2,109.0,94.7,83.2,82.1,60.2,52.3,45.5,33.2,28.9,27.0.HRESI-MS m/z 561.2242[M+H]+(calcd for C32H29N6O4,561.2245).
Preparation of Compound 168
Staurosporine (186mg,0.4mmol) was dissolved in 10mL of dichloromethane, and 1mL of triethylamine and N, N' -thiocarbonyldiimidazole (214mg,1.2mmol) were added thereto at room temperature, followed by reaction overnight at room temperature. The reaction mixture was poured into 20mL of ice water, extracted with dichloromethane, and the organic phase was dried over anhydrous sodium sulfate and concentrated, and the mixture was subjected to silica gel column chromatography and eluted with dichloromethane (methanol) ═ 20:1(v/v) to give 180mg of 3' -N- (1-imidazolylthioformyl) staurosporine (168) with a yield of 78%.1H NMR(500MHz,DMSO-d6)δ9.32(d,J=7.9Hz,1H),8.63(s,1H,NH),8.12(s,1H,ArH),8.07(d,J=7.7Hz,1H,ArH),8.03(d,J=8.5Hz,1H,ArH),7.64(d,J=7.2Hz,1H,ArH),7.59(brs,1H,ArH),7.51(t,J=7.4Hz,1H,ArH),7.50(t,J=7.7,1H,ArH),7.37(t,J=7.4Hz,1H,ArH),7.32(t,J=7.5Hz,1H,ArH),7.13(brs,1H,ArH),7.06(brs,1H,H-1'),5.47(brs,1H,H-3'),5.01(s,2H,H-7),4.79(brs,1H,H-4'),3.06(s,3H,3'-NCH3),3.02-3.09(m,1H,H-2'a),2.73(s,3H,4'-OCH3),2.44(s,3H,6'-CH3),2.41-2.47(m,1H,H-2'b);13C NMR(125MHz,DMSO-d6)δ179.3,171.9,138.8,137.7,136.2,132.7,129.3,129.0,125.8,125.4,125.2×2,123.9,122.7,121.6,120.5,119.9,119.6,119.6,115.3,114.3,113.5,108.9,94.8,81.9×2,60.4,58.1,45.5,38.2,29.4,27.1;HRESI-MS m/z 577.2031[M+H]+(calcd for C32H29N6O3S,577.2022).
Preparation of Compound 169
Compound 168(80mg,0.14mmol) was dissolved in 10mL of acetonitrile, and iodomethane (86. mu.L, 1.39mmol) was added to the solution to react at room temperature for 24 hours. Directly concentrating the reaction solution, and washing and purifying by using a mixed solution of 50mL of petroleum ether and dichloromethane 4:1(v/v) to obtain 75mg of iodomethane salt of the imidazole part of the compound 168, wherein the yield is 76%; HRESI-MS M/z 591.2164[ M-I ]]+(calcd for C33H31N6O3S, 591.2173). Dissolving tryptamine (2.0g,12.5mmol) in 20mL tetrahydrofuran, cooling to 10 ℃, adding triethylamine (3.5mL,25mmol) and tert-butoxy formic anhydride (3.03g,15.0mmol) in sequence, reacting at 10 ℃ for 1 hour, pouring the reaction liquid into 100mL ice water, extracting with ethyl acetate, drying the organic phase with anhydrous sodium sulfate, concentrating, separating by flash column chromatography, eluting with petroleum ether ethyl acetate 2:1(v/v) to obtain N- [2- (3-indole) ethyl ] ethyl]3.16g of tert-butyl carbamate, yield 97%; ESI-MS M/z 261.3[ M + H ]]+. Reacting N- [2- (3-indole) ethyl]Tert-butyl carbamate (1.8g,6.92mmol) was dissolved in 110mL THF/H2O (10:1), cooled to 0 ℃, DDQ (3.1g,13.8mmol) was added and reacted at this temperature for two hours. Pouring the reaction solution into 200mL of ethyl acetate, washing the reaction solution by using a saturated sodium bicarbonate solution until the reaction solution is colorless, drying an ethyl acetate layer by using anhydrous sodium sulfate, concentrating the dried ethyl acetate layer, separating the dried ethyl acetate layer by using a flash column chromatography, and eluting the ethyl acetate layer by using petroleum ether and ethyl acetate which is 1:1(v/v) to obtain N- [ 2-oxyl-2- (3-indole) ethyl ester]Tert-butyl carbamate 1.2g, yield 63%; ESI-MS M/z 275.4[ M + H ]]+. Reacting N- [ 2-oxylidene-2- (3-indole) ethyl]Tert-butyl carbamate (200mg,0.73mmol) was dissolved in 5mL of trifluoroacetic acid, reacted at 10 ℃ for one hour, and benzene (R) (I)5mL multiplied by 3 times) azeotropic removal of trifluoroacetic acid to obtain N- [ 2-oxoidene-2- (3-indole) ethyl]Ammonium trifluoroacetate 185mg, yield 93%. The iodomethane salt of the imidazole moiety of Compound 168 (75.0mg,0.105mmol) was dissolved in 2mL DMF and triethylamine (73.0. mu.L, 0.525mmol) and N- [ 2-oxoidene-2- (3-indole) ethyl ] were added]Ammonium trifluoroacetate (85.4mg,0.315mmol,3.0equiv) was reacted at room temperature for 24 hours. The reaction mixture was diluted with 10mL of ethyl acetate, washed with 1N hydrochloric acid, dried over anhydrous sodium sulfate, and concentrated. Semi-preparative HPLC separation, MeOH H2O9: 1(v/v) to give 3' -N- [ N- (2-oxoylidene-2- (3-indolyl) ethyl) aminothiocarbonyl]Staurosporine (169)40mg, yield 56%. [ alpha ] to]D 18+248(c 0.07,CHCl3);1H NMR(500MHz,DMSO-d6)δ12.02(d,J=2.0Hz,1H,NH),9.30(d,J=8.0Hz,1H,ArH),8.59(s,1H,NH),8.49(d,J=2.9Hz,1H,ArH),8.19(d,J=7.0Hz,1H,ArH),8.05(d,J=7.8Hz,1H,ArH),7.98(d,J=8.5Hz,1H,ArH),7.92(t,J=6.0Hz,1H,NH),7.72(d,J=8.3Hz,1H,ArH),7.52(d,J=7.2Hz,1H,ArH),7.49(t,J=7.5Hz,2H,ArH),7.36(t,J=7.4Hz,1H,ArH),7.31(t,J=7.5Hz,1H,ArH),7.25(dt,J=7.7,1.6Hz,1H,ArH),7.21(dt,J=7.6,1.5Hz,1H,ArH),7.07(t,J=7.4Hz,1H,H-1'),5.94(d,J=12.2Hz,1H,H-3'),4.97-5.09(m,2H,H-3″),5.01(s,2H,H-7),4.51(brs,1H,H-4'),2.96(s,3H,3'-NCH3),2.84(s,3H,4'-OCH3),2.72-2.76(m,1H,H-2'a),2.36(s,3H,6'-CH3),2.31(ddd,J=12.5,12.5,6.5Hz 1H,H-2'b);13C NMR(125MHz,DMSO-d6)δ190.2,182.5,172.1,139.1,136.5,136.4,133.4,132.8,129.2,125.7,125.5×2,125.1,125.1,123.9,123.0,122.7,121.9,121.5,121.3,120.4,119.6,119.4,115.4,114.3×2,113.9,112.3,109.2,95.1,83.1,82.5,60.5,54.3,52.0,45.6,32.8,29.6,27.8;HRESI-MS m/z 683.2462[M+H]+(calcd for C39H35N6O4S,683.2441).
Preparation of Compound 170
Bromoacetophenone (1.97g,10.0mmol) was dissolved in 40mL of chloroform, hexamethylenetetramine (1.47g,10.5mmol) was added, and the reaction was carried out at room temperature for 4 hours. After the reaction solution was filtered, the residue was dissolved in 80mL of methanol, and 4mL of concentrated hydrochloric acid was added to the solution to conduct a reflux reaction for 3 hours. After the reaction solution is concentrated, methanol is recombinedCrystallizing to obtain 1.5g of compound N- (2-oxoidene-2-phenylethyl) ammonium chloride with the yield of 88 percent; ESI-MS M/z 136.3[ M-Cl ]]+. The iodomethane salt of the imidazole moiety of compound 168 (49.0mg,0.068mmol) was dissolved in 2mL of DMF, and triethylamine (47.2. mu.L, 0.34mmol) and N- (2-oxoylidene-2-phenylethyl) ammonium chloride (34.9mg,0.204mmol) were added to react at room temperature for 24 hours. The reaction solution was diluted with 10mL of ethyl acetate, washed with 1N hydrochloric acid, and the organic phase was dried over anhydrous sodium sulfate and concentrated. Separating by flash column chromatography, eluting with petroleum ether and ethyl acetate 1:1(v/v) to obtain 3' -N- [ N- (2-oxylidene-2-phenylethyl) aminothiocarbonyl]Staurosporine (170)18.0mg, 41% yield. [ alpha ] to]D 18+257(c 0.07,CHCl3);1H NMR(600MHz,DMSO-d6)δ9.29(d,J=8.1Hz,1H,ArH),8.61(s,1H,NH),8.06(d,J=7.8Hz,1H,ArH),8.04(d,J=7.7Hz,2H,ArH),8.00(d,J=8.5Hz,1H,ArH),7.74(d,J=8.2Hz,1H,ArH),7.68(t,J=7.3Hz,1H,ArH),7.58(t,J=7.6Hz,2H,ArH),7.49(t,J=7.6Hz,2H,ArH),7.36(t,J=7.4Hz,1H,ArH),7.30(t,J=7.5Hz,1H,ArH),7.08(t,J=7.7Hz,1H,H-1'),5.85(m,1H,H-3'),5.02-5.15(m,2H,H-3″),5.01(s,2H,H-7),4.51(brs,1H,H-4'),2.93(s,3H,3'-NCH3),2.85(s,3H,4'-OCH3),2.70-2.74(m,1H,H-2'a),2.34(s,3H,6'-CH3),2.28(ddd,J=13.0,13.0,7.2Hz,1H,H-2'b);13CNMR(150MHz,DMSO-d6)δ195.4,182.5,171.9,139.1,136.3,135.5,133.4,132.8,129.0,128.8×2,127.8×2,125.7,125.4,125.0,124.9,123.8,122.6,121.4,120.3,119.5,119.4,115.3,114.2,114.0,109.1,94.9,82.7,82.3,60.4,54.4,51.9,45.5,32.9,29.6,27.6;HRESI-MS m/z 644.2351[M+H]+(calcd forC37H34N5O4S,644.2332).
Preparation of Compound 171
Compound 167(50mg,0.089mmol) was dissolved in 10mL of acetonitrile, and iodomethane (55. mu.L, 0.89mmol) was added and reacted at room temperature for 24 hours. Directly concentrating the reaction solution, and washing and purifying by using a mixed solution of 50mL of petroleum ether and dichloromethane (4: 1) (v/v) to obtain 48mg of the imidazole salt 167 of the compound with the yield of 77%; HRESI-MS M/z 575.2393[ M-I ]]+(calcd for C33H31N6O4,575.2401). Reacting the imidazole moiety of Compound 167The iodomethane salt (48.0mg,0.068mmol) was dissolved in 2mL of DMF, and triethylamine (47.2. mu.L, 0.34mmol) and N- [ 2-oxoidene-2- (3-indole) ethyl group were added]Ammonium trifluoroacetate (55.2mg,0.204mmol) was reacted at room temperature for 24 hours. The reaction solution was diluted with 10mL of ethyl acetate, washed with 1N hydrochloric acid, and the organic phase was dried over anhydrous sodium sulfate and concentrated. Flash column chromatography eluting with dichloromethane and ethyl acetate 1:3(v/v) to give 3' -N- [ N- (2-oxoidene-2- (3-indole) ethyl) carbamoyl]Staurosporine (171)36.0mg, yield 79%. [ alpha ] to]D 18+105(c 0.07,CHCl3);1H NMR(600MHz,DMSO-d6)δ12.08(d,J=2.5Hz,1H,NH),9.29(d,J=8.0Hz,1H,ArH),8.61(s,1H,NH),8.49(d,J=3.1Hz,1H,ArH),8.21(d,J=7.7Hz,1H,ArH),8.04(d,J=7.9Hz,1H,ArH),7.96(d,J=8.4Hz,1H,ArH),7.70(d,J=8.4Hz,2H,ArH),7.52(d,J=8.0Hz,1H,ArH),7.48(t,J=7.6Hz,2H,ArH),7.35(t,J=7.4Hz,1H,ArH),7.30(t,J=7.5Hz,1H,ArH),7.24(t,J=7.3Hz,1H,ArH),7.21(t,J=7.6Hz,1H,ArH),7.02(t,J=7.6Hz,1H,H-1'),6.84(t,J=5.3Hz,1H,NH),5.00(s,2H,H-7),4.85(d,J=12.5Hz,1H,H-3'),4.50(d,J=5.7Hz,2H,H-3″),4.24(brs,1H,H-4'),2.84(s,3H,3'-NCH3),2.75(s,3H,4'-OCH3),2.61-2.65(m,1H,H-2'a),2.30(s,3H,6'-CH3),2.22(ddd,J=12.5,12.5,7.0Hz,1H,H-2'b);13C NMR(150MHz,DMSO-d6)δ192.0,172.2,158.4,139.2,136.6,136.5,133.5,132.9,129.4,125.9,125.7,125.6,125.2×2,124.0,123.1,122.8,122.0,121.6,121.4,120.5,119.7,119.5,115.4,114.3×2,114.0,112.4,109.3,95.1,84.1,82.7,60.6,49.1,47.6,45.7,30.0,29.7,27.6;HRESI-MS m/z 667.2661[M+H]+(calcd for C39H35N6O5,667.2669).
Preparation of Compound 172
The iodomethane salt of the imidazole moiety of compound 167 (48.0mg,0.068mmol) was dissolved in 2mL of DMF, and triethylamine (47.2. mu.L, 0.34mmol) and N- (2-oxoylidene-2-phenylethyl) ammonium chloride (34.9mg,0.204mmol) were added to react at room temperature for 24 hours. The reaction solution was diluted with 10mL of ethyl acetate, washed with 1N hydrochloric acid, and the organic phase was dried over anhydrous sodium sulfate and concentrated. Flash column chromatography eluting with dichloromethane-ethyl acetate 2:1(v/v) to give 3' -N- [ N- (2-oxoylidene) acetate-2-phenylethyl) carbamoyl]Staurosporine (172)20.0mg, 47.0% yield. [ alpha ] to]D 18+174(c 0.07,CHCl3);1H NMR(600MHz,DMSO-d6)δ9.28(d,J=7.9Hz,1H,ArH),8.60(s,1H,NH),8.04(t,J=8.2Hz,1H,ArH),8.03(d,J=8.1Hz,1H,ArH),8.03(d,J=8.3Hz,1H,ArH),7.96(t,J=8.7Hz,1H,ArH),7.70(d,J=8.5Hz,1H,ArH),7.68(t,J=7.6Hz,1H,ArH),7.58(d,J=7.6Hz,1H,ArH),7.57(d,J=7.6Hz,1H,ArH),7.49(t,J=6.8Hz,2H,ArH),7.35(t,J=7.5Hz,1H,ArH),7.30(t,J=7.5Hz,1H,ArH),7.02(t,J=7.6Hz,1H,H-1'),6.90(t,J=5.3Hz,1H,NH),5.00(s,2H,H-7),4.81(d,J=12.5Hz,1H,H-3'),4.59(d,J=5.6Hz,2H,H-3″),4.20(brs,1H,H-4'),2.83(s,3H,3'-NCH3),2.72(s,3H,4'-OCH3),2.59-2.63(m,1H,H-2'a),2.29(s,3H,6'-CH3),2.20(ddd,J=12.5,12.5,6.9Hz,1H,H-2'b);13CNMR(150MHz,DMSO-d6)δ196.9,172.2,158.2,139.2,136.5,135.4,133.6,132.9,129.3,129.0×2,128.0×2,125.8,125.6,125.1×2,123.9,122.8,121.6,120.5,119.7,119.5,115.4,114.3,114.0,109.2,95.0,84.0,82.6,60.6,49.1,47.7,45.6,30.0,29.7,27.5;HRESI-MS m/z 628.2568[M+H]+(calcd for C37H34N5O5,628.2560).
Preparation of Compound 173
According to the preparation method of compound 169, the iodomethane salt (15.0mg,0.021mmol) of the imidazole moiety of compound 168 is reacted with DMF, Et3N and 4- (2-piperazineethyl) morpholine. Semi-preparative HPLC separation, MeOH H2Elution with O4: 1(v/v) gave 3' -N- [4- (2- (4-morpholin) ethyl) piperazine thiocarbonyl]Staurosporine (173)8.0mg, 47.1% yield. [ alpha ] to]D 20+101°(c 0.07,CHCl3);1H NMR(600MHz,DMSO-d6)δ9.29(d,J=7.9Hz,1H,ArH),8.52(s,1H,NH),8.03(d,J=7.8Hz,1H,ArH),7.94(d,J=8.6Hz,1H,ArH),7.56(d,J=8.2Hz,1H,ArH),7.48(t,J=7.8Hz,1H,ArH),7.45(t,J=7.8Hz,1H,ArH),7.34(t,J=7.4Hz,1H,ArH),7.27(t,J=7.5Hz,1H,ArH),7.00(dd,J=8.7,5.5Hz,1H,H-1'),5.23-5.27(m,1H,H-3'),4.98(s,2H,H-7),4.68(brs,1H,H-4'),3.91(brs,4H,morpholine-N(CH2-C 2H)2O),3.50-3.75(m,16H,-N(C 2H-C 2H)2N,piperazine-C 2H-C 2H-morpholine,-N(C 2H-CH2)2O),3.01(s,3H,3'-NCH3),2.94-2.98(m,1H,H-2'a),2.56(s,3H,4'-OCH3),2.44(s,3H,6'-CH3),2.37-2.41(m,1H,H-2'b);13C NMR(150MHz,DMSO-d6)δ193.5,172.0,138.5,136.2,132.4,129.6,125.8,125.5,125.2,125.1,123.9,122.7,121.4,120.4,119.5,119.4,115.2,114.2,113.1,108.8,94.9,83.0,82.2,63.3×2,59.9,56.3,51.6×2,51.0×2,49.8×2,49.2,47.6,45.5,37.3,29.2,27.6;ESI-MS m/z 708.4[M+H]+.
Preparation of Compound 174
According to the preparation method of compound 169, the iodomethane salt (18.0mg,0.021mmol) of the imidazole moiety of compound 168 is reacted with DMF, Et3And synthesizing N and 2, 6-difluorobenzene methylamine. Flash column chromatography eluting with dichloromethane ethyl acetate 4:1(v/v) to give 3' -N- [ N- (2, 6-difluorobenzyl) aminothiocarbonyl]Staurosporine (174)8.0mg, 48.0% yield. [ alpha ] to]D 20+128°(c 0.07,CHCl3);1H NMR(600MHz,DMSO-d6)δ9.27(d,J=7.9Hz,1H,ArH),8.60(s,1H,NH),8.04(d,J=7.8Hz,1H,ArH),7.99(d,J=8.5Hz,1H,ArH),7.93(t,J=4.2Hz,1H,NH),7.70(d,J=8.3Hz,1H,ArH),7.47(t,J=7.6Hz,2H,ArH),7.39(m,1H,ArH),7.35(t,J=7.5Hz,1H,ArH),7.29(t,J=7.5Hz,1H,ArH),7.06(t,J=7.7Hz,2H,ArH),7.03-7.06(m,1H,H-1'),5.90(d,J=12.5Hz,1H,H-3'),4.99(s,2H,H-7),4.75-4.88(m,2H,H-3″),4.47(brs,1H,H-4'),2.82(s,3H,3'-NCH3),2.74(s,3H,4'-OCH3),2.66-2.71(m,1H,H-2'a),2.35(s,3H,6'-CH3),2.20-2.27(m,1H,H-2'b);13C NMR(150MHz,DMSO-d6)δ181.6,172.0,161.3×2(dd,1JC-F=247.7Hz,3JC-F=8.2Hz),139.0,136.4,132.8,129.6(t,3JC-F=10.5Hz),129.2,125.7,125.4,125.1,125.0,123.8,122.7,121.5,120.4,119.6,119.4,115.3,114.3(t,2JC-F=18.1Hz),114.2,113.9,111.5×2(d,2JC-F=20.1Hz),109.2,95.0,83.0,82.4,60.3,54.2,45.5,38.3,32.9,29.5,27.7;ESI-MS m/z 652.3[M+H]+.
Preparation of Compound 175
According to the preparation method of compound 169, the iodomethane salt (18.0mg,0.021mmol) of the imidazole moiety of compound 168 is reacted with DMF, Et3Synthesis of N and 3-chloro-4-fluorobenzylamine. Flash column chromatography eluting with dichloromethane-ethyl acetate 4:1(v/v) to give 3' -N- [ N- (3-chloro-4-fluorophenylmethyl) aminothiocarbonyl]Staurosporine (175)8.0mg, 48.0% yield. [ alpha ] to]D 20+166°(c 0.07,CHCl3);1H NMR(600MHz,DMSO-d6)δ9.28(d,J=7.9Hz,1H,ArH),8.62(s,1H,NH),8.26(t,J=4.5Hz,1H,NH),8.05(d,J=7.8Hz,1H,ArH),8.00(d,J=8.5Hz,1H,ArH),7.71(d,J=8.2Hz,1H,ArH),7.51(d,J=7.1Hz,1H,ArH),7.48(t,J=7.7Hz,2H,ArH),7.38(t,J=7.8Hz,1H,ArH),7.32-7.37(m,2H,ArH),7.29(t,J=7.5Hz,1H,ArH),7.07(t,J=7.6Hz,1H,H-1'),5.92(d,J=12.9Hz,1H,H-3'),5.00(s,2H,H-7),4.79-4.87(m,2H,H-3″),4.50(brs,1H,H-4'),2.88(s,3H,3'-NCH3),2.79(s,3H,4'-OCH3),2.68-2.72(m,1H,H-2'a),2.36(s,3H,6'-CH3),2.26(ddd,J=12.9,12.9,6.9Hz,1H,H-2'b);13C NMR(150MHz,DMSO-d6)δ182.1,172.0,156.1(d,1JC-F=244.8Hz),139.1,137.8,136.4,132.8,129.2,129.1(d,3JC-F=7.4Hz),127.9(d,3JC-F=7.4Hz),125.7,125.4,125.1,125.0,123.8,122.7,121.5,120.4,119.6,119.4,119.0(d,2JC-F=17.8Hz),116.6(d,2JC-F=20.9Hz),115.3,114.2,113.9,109.2,95.0,83.0,82.4,60.4,54.4,45.5,35.9,33.0,29.6,27.7;ESI-MS m/z 668.4/670.4[M+H]+.
Preparation of Compound 176
According to the preparation method of compound 169, the iodomethane salt (18.0mg,0.021mmol) of the imidazole moiety of compound 168 is reacted with DMF, Et3N and 2-chloro-6-fluorophenylethylamine. Flash column chromatography eluting with dichloromethane-ethyl acetate 4:1(v/v) to give 3' -N- [ N- (2-chloro-6-fluorophenethyl) aminothiocarbonyl]Staurosporine (176)6.0mg, yield 35.0%. [ alpha ] to]D 20+96°(c 0.07,CHCl3);1H NMR(600MHz,DMSO-d6)δ9.29(d,J=8.0Hz,1H,ArH),8.60(s,1H,NH),8.06(d,J=7.7Hz,1H,ArH),8.01(d,J=8.5Hz,1H,ArH),7.75(t,J=5.4Hz,1H,NH),7.69(d,J=8.3Hz,1H,ArH),7.48(m,1H,ArH),7.36(t,J=7.5Hz,1H,ArH),7.27-7.32(m,3H,ArH),7.15-7.19(m,1H,ArH),7.06(dd,J=8.3,6.6Hz,1H,H-1'),5.98(d,J=12.1Hz,1H,H-3'),5.00(s,2H,H-7),4.39(brs,1H,H-4'),3.89-3.96(m,1H,H-3″a),3.70-3.76(m,1H,H-3″b),3.03-3.16(m,2H,H-4″),2.77(s,3H,3'-NCH3),2.68(s,3H,4'-OCH3),2.67-2.71(m,1H,H-2'a),2.40(s,3H,6'-CH3),2.25(ddd,J=12.9,12.9,6.4Hz,1H,H-2'b);13C NMR(150MHz,DMSO-d6)δ181.8,172.0,161.4(d,1JC-F=246.5Hz),138.9,136.3,134.7(d,3JC-F=6.6Hz),132.7,129.3,128.9(d,3JC-F=10.4Hz),125.7,125.4×2,125.3(d,2JC-F=25.6Hz),125.1×2,123.8,122.7,121.5,120.4,119.5,119.4,115.2,114.3(d,2JC-F=22.3Hz),114.2,113.7,109.2,95.0,83.3,82.4,60.2,53.9,45.5,43.9,32.6,29.4,27.7,26.2;ESI-MS m/z 682.4/684.4[M+H]+.
Preparation of Compound 177
According to the preparation method of compound 169, the iodomethane salt (18.0mg,0.021mmol) of the imidazole moiety of compound 168 is reacted with DMF, Et3N and 2-m-trifluoromethyl phenethylamine. Flash column chromatography eluting with dichloromethane-ethyl acetate 4:1(v/v) to give 3' -N- [ N- (2-m-trifluoromethylphenethyl) aminothiocarbonyl]Staurosporine (177)6.0mg, 35.0% yield. [ alpha ] to]D 20+132°(c 0.07,CHCl3);1HNMR(600MHz,DMSO-d6)δ9.29(d,J=8.0Hz,1H,ArH),8.61(s,1H,NH),8.05(d,J=7.8Hz,1H,ArH),7.99(d,J=8.5Hz,1H,ArH),,7.71(t,J=5.6Hz,1H,NH),7.70(d,J=8.0Hz,1H,ArH),7.52-7.58(m,4H,ArH),7.48(t,J=6.3Hz,2H,ArH),7.36(t,J=7.4Hz,1H,ArH),7.30(t,J=7.5Hz,1H,ArH),7.06(t,J=7.3Hz,1H,H-1'),5.95(d,J=12.4Hz,1H,H-3'),5.00(s,2H,H-7),4.44(brs,1H,H-4'),3.86-3.92(m,1H,H-3″a),3.74-3.80(m,1H,H-3″b),3.98-3.10(m,2H,H-4″),2.76(s,3H,3'-NCH3),2.70(s,3H,4'-OCH3),2.65-2.70(m,1H,H-2'a),2.38(s,3H,6'-CH3),2.24(ddd,J=12.9,12.9,6.8Hz,1H,H-2'b);13C NMR(150MHz,DMSO-d6)δ181.5,172.0,141.0,139.0,136.3,133.1,132.8,129.4,129.3(q,2JC-F=27.2Hz),128.9,125.7,125.4,125.2(q,3JC-F=5.0Hz),125.1,125.0,123.8,123.4(q,1JC-F=274.7Hz)122.9(q,3JC-F=5.7Hz),122.7,121.5,120.4,119.5,119.4,115.3,114.2,113.8,109.2,95.0,83.1,82.4,60.2,53.9,46.4,45.4,34.3,32.6,29.5,27.6;ESI-MS m/z 698.3[M+H]+.
Preparation of Compound 178
According to the preparation method of compound 169, the iodomethane salt (18.0mg,0.021mmol) of the imidazole moiety of compound 168 is reacted with DMF, Et3N and benzylamine. Flash column chromatography eluting with dichloromethane-ethyl acetate ═ 1:1(v/v) afforded 9.0mg of 3' -N- (N-benzylaminothiocarbonyl) staurosporine (178) in 73.2% yield. [ alpha ] to]D 20+54°(c 0.07,CHCl3);1H NMR(600MHz,DMSO-d6)δ9.28(d,J=8.0Hz,1H,ArH),8.58(s,1H,NH),8.20(brs,1H,NH),8.05(d,J=7.9Hz,1H,ArH),8.00(d,J=8.3Hz,1H,ArH),7.70(d,J=8.0Hz,1H,ArH),7.48(t,J=7.8Hz,2H,ArH),7.36(t,J=7.8Hz,1H,ArH),7.28-7.33(m,5H,ArH),7.21-7.25(m,1H,ArH),7.06(t,J=7.4Hz,H-1'),5.98(d,J=13.5Hz,1H,H-3'),5.00(s,2H,H-7),4.89(d,J=5.6Hz,2H,H-3″),4.49(s,1H,H-4'),2.89(s,3H,3'-NCH3),2.72(s,3H,4'-OCH3),2.68-2.74(m,1H,H-2'a),2.38(s,3H,6'-CH3),2.24-2.30(m,1H,H-2'b);13C NMR(150MHz,DMSO-d6)δ182.2,172.0,139.8,139.0,136.4,132.8,129.2,128.2×2,127.2×2,126.6,125.7,125.4,125.1,125.1,123.8,122.7,121.5,120.4,119.6,119.4,115.3,114.2,113.8,109.2,95.1,83.2,82.5,60.4,54.3,48.4,45.6,32.9,29.5,27.8;ESI-MS m/z 616.3[M+H]+.
Preparation of Compound 179
According to the preparation method of compound 169, the iodomethane salt (18.0mg,0.021mmol) of the imidazole moiety of compound 168 is reacted with DMF, Et3N and p-methoxybenzylamineAnd (4) synthesizing. Flash column chromatography eluting with dichloromethane and ethyl acetate 1:1(v/v) to give 3' -N- [ N- (4-methoxybenzyl) aminothiocarbonyl]Staurosporine (179)9.0mg, 69.8% yield. [ alpha ] to]D 20+40°(c 0.07,CHCl3);1H NMR(600MHz,DMSO-d6)δ9.28(d,J=7.9Hz,1H,ArH),8.58(s,1H,NH),8.13(t,J=5.4Hz,1H,NH),8.05(d,J=7.8Hz,1H,ArH),7.99(d,J=8.5Hz,1H,ArH),7.69(d,J=8.2Hz,1H,ArH),7.48(t,J=7.5Hz,2H,ArH),7.35(t,J=7.4Hz,1H,ArH),7.30(t,J=7.6Hz,1H,ArH),7.27(d,J=8.6Hz,2H,ArH),7.05(t,J=7.5Hz,1H,H-1'),6.88(d,J=8.6Hz,2H,ArH),5.00(s,2H,H-7),4.80(d,J=12.5Hz,1H,H-3'),4.47(brs,1H,H-4'),3.73(brs,2H,H-3″),2.86(s,3H,3'-NCH3),2.74(s,3H,4'-OCH3),2.67-2.73(m,1H,H-2'a),2.37(s,3H,6'-CH3),2.23-2.29(m,1H,H-2'b);13C NMR(150MHz,DMSO-d6)δ182.0,172.0,158.2,139.0,136.4,132.8,131.7,129.3,128.6×2,125.7,125.5,125.2,125.1,123.9,122.7,121.5,120.4,119.6,119.4,115.3,114.2,113.8,113.6×2,109.2,95.1,83.2,82.5,60.4,55.2,54.3,47.9,45.6,32.8,29.5,27.8;ESI-MSm/z 646.3[M+H]+.
Preparation of Compound 180
According to the preparation method of compound 171, from iodomethane salt (15.0mg,0.021mmol) of imidazole moiety of compound 167, DMF and Et3N and 4- (2-piperazineethyl) morpholine. Flash column chromatography eluting with dichloromethane-ethyl acetate 1:3(v/v) to give 3' -N- [4- (2- (4-morpholin) ethyl) piperazinecarboxyl]Staurosporine (180)8.0mg, 55.1% yield. [ alpha ] to]D 20+72°(c 0.07,CHCl3);1H NMR(600MHz,DMSO-d6)δ9.29(d,J=7.9Hz,1H,ArH),8.58(s,1H,NH),8.06(d,J=7.5Hz,1H,ArH),8.00(d,J=8.5Hz,1H,ArH),7.59(d,J=8.3Hz,1H,ArH),7.50(t,J=7.6Hz,1H,ArH),7.47(t,J=7.7Hz,1H,ArH),7.36(t,J=7.5Hz,1H,ArH),7.30(t,J=7.7Hz,1H,ArH),6.97(dd,J=8.8,5.2Hz,1H,H-1'),5.00(s,2H,H-7),4.44(ddd,J=13.0,4.9,2.2Hz,1H,H-3'),4.36(brs,1H,H-4'),3.79(brs,4H,-N(CH2-C 2H)2O),3.33(brs,8H,-N(C 2H-C 2H)2N),3.14(brs,8H,piperazine-C 2H-C 2H-morpholine,-N(C 2H-CH2)2O),2.78-2.83(m,1H,H-2'a),2.71(s,3H,3'-NCH3),2.55(s,3H,4'-OCH3),2.39(s,3H,6'-CH3),2.28-2.34(m,1H,H-2'b);13C NMR(150MHz,DMSO-d6)δ172.4,163.6,139.0,136.7,133.0,130.0,126.1,126.0,125.8,125.6,124.2,123.1,122.0,120.9,119.9,119.8,115.4,114.5,113.7,109.4,95.1,84.4,82.7,64.2×2,60.3,52.3×2,51.8×2,51.3,51.1,50.6,45.9,44.4×2,33.4,29.4,27.8;ESI-MS m/z 708.4[M+H]+.
Preparation of Compound 181
According to the preparation method of compound 171, from iodomethane salt (15.0mg,0.021mmol) of imidazole moiety of compound 167, DMF and Et3And synthesizing N and 2, 6-difluorobenzene methylamine. Flash column chromatography eluting with dichloromethane to ethyl acetate 1:2(v/v) to give 3' -N- [ N- (2, 6-difluorobenzyl) carbamoyl]Staurosporine (181)9.0mg, 67.6% yield. [ alpha ] to]D 20+48°(c 0.07,CHCl3);1H NMR(600MHz,DMSO-d6)δ9.28(d,J=7.9Hz,1H,ArH),8.60(s,1H,NH),8.04(d,J=7.7Hz,1H,ArH),7.95(d,J=8.6Hz,1H,ArH),7.65(d,J=8.2Hz,1H,ArH),7.45-7.48(m,2H,ArH),7.33-7.38(m,2H,ArH),7.29(t,J=7.5Hz,1H,ArH),7.06(t,J=7.8Hz,2H,ArH),6.98(t,J=7.6Hz,1H,H-1'),6.93(t,J=4.6Hz,1H,NH),4.99(s,2H,H-7),4.82(d,J=12.7Hz,1H,H-3'),4.34-4.44(m,2H,H-3″),4.21(brs,1H,H-4'),2.73(s,3H,3'-NCH3),2.61(s,3H,4'-OCH3),2.55-2.60(m,1H,H-2'a),2.31(s,3H,6'-CH3),2.16(ddd,J=13.0,13.0,6.7Hz,1H,H-2'b);13C NMR(150MHz,DMSO-d6)δ172.1,161.3×2(dd,1JC-F=247.5Hz,3JC-F=9.2Hz),157.7,139.1,136.4,132.8,129.5(t,3JC-F=11.0Hz),129.3,125.8,125.5,125.2,125.1,123.8,122.7,121.5,120.4,119.6,119.4,115.6(t,2JC-F=18.1Hz),115.3,114.2,113.8,111.5×2(d,2JC-F=19.9Hz),109.1,95.0,84.0,82.5,60.3,48.9,45.6,32.7,29.9,29.5,27.5;ESI-MS m/z 636.5[M+H]+.
Preparation of Compound 182
According to the preparation method of compound 169, iodomethane salt (50.0mg,0.070mmol) of imidazole moiety of compound 168 and DMF, Et3Synthesis of N and 2S-hydroxy-1-propylamine. Semi-preparative HPLC separation, MeOH H2Elution with O4: 1(v/v) gave 3' -N- [ N- (2S-hydroxypropyl) aminothiocarbonyl]Staurosporine (182)12.0mg, 28.5% yield. [ alpha ] to]D 20+31°(c 0.07,CHCl3);1H NMR(600MHz,DMSO-d6)δ9.30(d,J=8.0Hz,1H,ArH),8.59(s,1H,NH),8.05(d,J=7.8Hz,1H,ArH),8.00(d,J=8.5Hz,1H,ArH),7.69(d,J=8.2Hz,1H,ArH),7.48(t,J=7.6Hz,1H,ArH),7.47(d,J=7.6Hz,1H,ArH),7.35(t,J=7.4Hz,1H,ArH),7.30(t,J=7.5Hz,1H,ArH),7.06(t,J=7.6Hz,1H,H-1'),5.99(d,J=12.8Hz,1H,H-3'),5.01(s,2H,H-7),4.75(s,1H,OH),4.45(s,1H,H-4'),3.97(brs,1H,H-4″),3.61-3.66(m,1H,H-3″a),3.40-3.46(m,1H,H-3″b),2.85(s,3H,3'-NCH3),2.71(s,3H,4'-OCH3),2.66-2.71(m,1H,H-2'a),2.39(s,3H,6'-CH3),2.24-2.30(m,1H,H-2'b),1.07(d,J=6.2Hz,3H,H-5″);13C NMR(150MHz,DMSO-d6)δ181.7,172.0,138.9,136.3,132.7,129.3,125.7,125.4,125.1×2,123.8,122.7,121.5,120.4,119.5,119.4,115.3,114.2,113.7,109.1,95.0,83.3,82.4,64.6,60.2,54.0,53.1,45.5,32.5,29.4,27.7,21.2;ESI-MS m/z 584.7[M+H]+.
Preparation of Compound 183
Fradcarbazole C (16.0mg, 0.032mmol) was dissolved in 5mL of methanol, 100.0. mu.L of triethylamine and 100mg of hydroxylamine hydrochloride were added, and the reaction was allowed to proceed overnight at room temperature. The reaction mixture was diluted with ethyl acetate, washed with 1N hydrochloric acid, dried over anhydrous sodium sulfate and concentrated. Semi-preparative HPLC separation, MeOH H2Elution with O ═ 9:1(v/v) gave 12.0mg of 3' -N- (N-hydroxyaminoiminomethyl) staurosporine (183) in 71.8% yield. [ alpha ] to]D 20+15°(c 0.07,MeOH);1H NMR(600MHz,DMSO-d6)δ10.32(s,1H,NH),9.27(d,J=7.9Hz,1H,ArH),8.63(s,1H,NH),8.30(s,1H,NH),8.05(d,J=7.8Hz,1H,ArH),7.94(d,J=8.5Hz,1H,ArH),7.70(d,J=8.2Hz,1H,ArH),7.50(t,J=7.3Hz,2H,ArH),7.36(t,J=7.4Hz,1H,ArH),7.30(t,J=7.5Hz,1H,ArH),6.98(t,J=7.6Hz,1H,H-1'),5.00(s,2H,H-7),4.47(brs,1H,H-3'),4.18(brs,1H,H-4'),3.16(s,1H,OH),2.93(s,3H,3'-NCH3),2.73(s,3H,4'-OCH3),2.70-2.75(m,1H,H-2'a),2.35(s,3H,6'-CH3),2.27-2.32(m,1H,H-2'b);13C NMR(150MHz,DMSO-d6)δ172.0,158.6,139.4,136.4,132.9,128.9,125.8,125.5,125.1,124.9,123.9,122.7,121.5,120.5,119.7,119.5,115.4,114.4,114.3,109.1,95.0,82.5,82.0,60.6,52.0,45.6,31.6,29.4,27.2;ESI-MS m/z 525.2[M+H]+.
Preparation of Compound 184
Dissolving staurosporine (46.6mg,0.1mmol) in 5mL of dichloromethane, adding catalytic amount of DMAP, dicyclohexylcarbodiimide (24.7mg,0.12mmol) and chlorambucil (36.4mg,0.12mmol) in sequence, reacting at room temperature for 2 hours, pouring into ice water, extracting with dichloromethane, drying with anhydrous sodium sulfate, concentrating, separating by silica gel column chromatography, eluting with petroleum ether ethyl acetate ═ 1:1(v/v) to obtain 3' -N- [4- [4- (N, N-di (2-chloroethyl) amino) phenyl ] N-butyl ether]Butyryl radical]Staurosporine (184)60.1mg, 80% yield. [ alpha ] to]D 20+99°(c 0.07,CHCl3);1H NMR(CD3OD)δ9.27(d,J=8.0Hz,1H,ArH),7.85(d,J=7.7Hz,1H,ArH),7.73(d,J=8.5Hz,1H,ArH),7.40-7.44(m,2H,ArH),7.27-7.30(m,2H,ArH),7.22(d,J=8.1Hz,1H,ArH),7.03(d,J=8.5Hz,2H,ArH),6.65(dd,J=9.0,4.9Hz,1H,H-1'),6.59(d,J=8.5Hz,2H,ArH),5.10-5.14(m,1H,H-3'),4.86-4.95(m,2H,H-7),3.95(brs,1H,H-4'),3.65(t,J=6.7Hz,4H,-N(C 2H-CH2Cl)2),3.57(t,J=6.7Hz,4H,-N(CH2-C 2HCl)2),2.76(s,3H,3'-NCH3),2.56(t,J=7.9Hz,2H,H-2″),2.43(s,3H,4'-OCH3),2.43-2.49(m,1H,H-2'a),2.39(s,3H,6'-CH3),2.30-2.33(m,1H,H-2'b),1.90(t,J=7.8Hz,2H,H-4″),1.53-1.56(m,2H,H-3″);13C NMR(CD3OD)δ175.0,174.5,144.9,139.1,137.0,133.1,131.0,130.8,130.0×2,126.7,126.6,125.9,125.5,124.9,123.8,121.8,121.0,120.3,119.2,116.4,114.9,112.9,112.6×2,108.4,95.1,85.1,82.9,60.7,53.9×2,48.9,46.5,40.9×2,34.1,31.7,29.3,28.4,26.0,25.3;ESI-MS m/z752.2/754.3/756.2[M+H]+.
Preparation of Compound 185
i) Preparation of N-benzyloxymethyl-2- (3-indole) -3-bromomaleimide (185a)
2, 3-dibromomaleimide (2.55g, 10.0mmol) was placed in a 100mL three-necked flask, dissolved in 30mL dry DMF, cooled to 0 ℃ under nitrogen, and sodium hydride (480mg, 12mmol, 60% mass fraction dispersed in paraffin) was added in two portions. After 1h, 10mL dry DMF-dissolved chloromethyl benzyl methyl ether (2.08mL, 15mmol) was added and the reaction was warmed to room temperature for 2 h. Then, the reaction mixture was cooled to 0 ℃ and 20mL of a saturated ammonium chloride solution was added to terminate the reaction, the reaction mixture was extracted with ethyl acetate, the organic phase was dried over anhydrous sodium sulfate and concentrated, and petroleum ether was separated by pressure column chromatography, and the product was eluted with ethyl acetate (50: 1 (v/v)) to give 3.55g of the compound N-benzyloxymethyl-2, 3-dibromomaleimide in a yield of 94%. ESIMSm/z 395.4,397.3,399.5[ M + Na ]]+. Magnesium wire (432mg, 18.0mmol) was placed in a 100mL dry three-necked flask, 4mL dry tetrahydrofuran was added, argon was substituted, ethyl bromide (1.35mL, 18.0mmol) was introduced without water, reacted at room temperature for 15min, and then raised to 40 ℃ for 30 min. Indole (2.11g, 18.0mmol) was introduced via a catheter and reacted for 1 h. Then, N-benzyloxymethyl-2, 3-dibromomaleimide (3.29g, 8.9mmol) was added and reacted at room temperature for 4 hours. The reaction was terminated by adding 20mL of a saturated ammonium chloride solution, followed by extraction with ethyl acetate, drying of the organic phase over anhydrous sodium sulfate, concentration, and separation by pressure column chromatography, and elution with petroleum ether and ethyl acetate 4:1(v/v) gave 3.46g of compound 185a in 94% yield.1H-NMR(600MHz,DMSO-d6)δ8.93(brs,1H,NH),8.03(t,J=7.8Hz,1H,ArH),7.99(t,J=7.8Hz,1H,ArH),7.44(d,J=7.8Hz,1H,ArH),7.37(s,1H,ArH),7.27-7.36(m,5H,ArH),7.25(d,J=7.8Hz,1H,ArH),5.17(s,2H,PhCH2O 2CHN),4.67(s,2H,Ph 2CHOCH2N);13C NMR(150MHz,DMSO-d6)δ168.8,166.2,137.8,137.8,136.6,131.5,128.2×2,127.6,127.5×2,124.5,122.6,122.4,120.6,114.1,112.4,103.7,70.5,67.5;ESIMS m/z 433.0,435.0[M+Na]+.
ii) preparation of N-benzyloxymethyl-2- (1-tert-butoxycarbonyl-3-indole) -3-bromomaleimide (185b)
Will be transformed intoCompound 185a (3.15g, 8.39mmol) was dissolved in 50mL tetrahydrofuran and 3.81mL t-butoxyformic anhydride (i.e., Boc di-t-butyldicarbonate) was added2O, 16.78mmol) and 100mg of p-dimethylaminopyridine at room temperature for 4 h. Direct concentration followed by column chromatography eluting with petroleum ether and ethyl acetate 20:1(v/v) gave compound 185b 3.90g, 91% yield.1H-NMR(600MHz,CDCl3)δ8.23(s,1H,ArH),8.20(d,J=8.2Hz,1H,ArH),7.80(dd,J=7.3,8.2Hz,1H,ArH),7.41(t,J=7.3,1H,ArH),7.26(d,J=7.3Hz,1H,ArH),7.30-7.36(m,5H,ArH),5.17(s,2H,PhCH2O 2CHN),4.68(s,2H,Ph 2CHOCH2N),1.71(s,9H,-C(CH3)3);13C NMR(150MHz,CDCl3)δ168.2,165.6,148.9,137.4,136.7,135.4,130.0,128.5×2,127.9,127.6×2,126.8,125.4,123.3,122.5,120.9,115.4,108.4,85.2,71.9,67.8,28.1×3;ESIMS m/z 511.2,513.0[M+H]+.
iii) preparation of N-benzyloxymethyl-2- (1-tert-butoxycarbonyl-3-indole) -3- (3-indole) maleimide (185c)
Magnesium wire (366.7mg, 15.32mmol) was placed in a 100mL dry three-necked flask, 4mL dry tetrahydrofuran was added, argon was substituted, ethyl bromide (1.15mL, 15.32mmol) was introduced without water, reacted at room temperature for 15min, and then raised to 40 ℃ for 30 min. Indole (1.8g, 15.32mmol) was introduced via a catheter and reacted for 1 h. Then, compound 185b (3.9g, 7.66mmol) was added and reacted at room temperature for 4 h. The reaction was terminated by adding 20mL of a saturated ammonium chloride solution, followed by extraction with ethyl acetate, drying of the organic phase over anhydrous sodium sulfate, concentration, and separation by pressure column chromatography, and elution with petroleum ether and ethyl acetate 4:1(v/v) gave compound 185c (3.98g, yield 95%).1H-NMR(600MHz,CDCl3)δ8.60(brs,1H,NH),8.19(d,J=7.8Hz,1H,ArH),8.09(s,1H,ArH),8.02(s,1H,ArH);7.81(t,J=7.8Hz,1H,ArH);7.29~7.41(m,5H,ArH);7.16(dt,J=8.0,3.0Hz,1H,ArH),7.10(t,J=8.2Hz,1H,ArH),7.05(d,J=7.8,1H,ArH),6.77~6.83(m,3H,ArH),5.23(s,2H,PhCH2O 2CHN),4.72(s,2H,Ph 2CHOCH2N),1.68(s,9H,-C(CH3)3);13C NMR(150MHz,CDCl3)δ171.4,171.2,149.2,137.6,136.0,135.0,131.6,129.9,128.6,128.4×2,128.0,127.8,127.7×2,125.3,124.6,124.4,122.7,122.6,121.7,121.6,120.7,115.0,111.6,110.7,106.4,84.5,71.7,67.3,28.1×3;ESIMS m/z 546.2[M–H]–.
iv)) preparation of 6-O-triisopropylsilyl-D-glucal (185D)
0.206mL perchloric acid was slowly added to 40mL acetic anhydride, stirred at 40 ℃ for 30min, then the temperature was reduced to 30 ℃ and 10g D-glucose was slowly added and stirred for 30 min. The reaction solution is cooled to 10 ℃,3.1 g of red phosphorus, 5.8mL of liquid bromine and 3.6mL of water are slowly added in turn, and then the temperature is raised to 30 ℃ and stirring is continued for 2 h. The reaction solution was quenched with 50mL of ice water, extracted with ethyl acetate, and the ester layer was dried over anhydrous sodium sulfate and concentrated. The concentrate was dissolved in 50mL ethyl acetate, cooled to 0 deg.C and then mixed with 16.1g zinc powder and 212mg CuSO4·5H2O and 1.06g of sodium acetate were mixed with 130mL of a 60% acetic acid aqueous solution and added to the reaction mixture. Reacting at 0 deg.C for 1H, heating to room temperature, reacting for 1H, filtering the reaction solution, extracting with ethyl acetate, drying the ester layer with anhydrous sodium sulfate, concentrating, separating by pressure column chromatography, and eluting with petroleum ether ethyl acetate (3: 1 (v/v)) to obtain 10.4g of 3,4, 6-tri (O-acetyl) -D-glucal (two-step yield 68%), ESIMS M/z 273.2[ M + H273.2 ]]+. Dissolving 5.2g of 3,4, 6-tris (O-acetyl) -D-glucal (19.1mmol) in 100mL of methanol, adding 300mg of sodium methoxide, reacting at room temperature for 1h, adjusting the pH of the reaction solution to 7 with a cationic resin, filtering, concentrating, and subjecting to pressure column chromatography (eluting with ethyl acetate) to obtain 2.5g D-glucal with a yield of 90%; ESIMS M/z 147.1[ M + H ]]+. 5.6g D-glucal (38.4mmol) was dissolved in 100mL of pyridine, the temperature was reduced to 0 ℃ and 11.34mL of triisopropylchlorosilane (54.22mmol) and 15.6g of imidazole (230.4mmol) were added, the reaction was carried out at room temperature for 2 hours, the reaction was quenched with 50mL of ice water, extracted with ethyl acetate, the ester layer was dried over anhydrous sodium sulfate and concentrated, and the mixture was subjected to pressure column chromatography to obtain 5.2g of compound 185d, which was eluted with petroleum ether ethyl acetate (5: 1) (v/v) in 46% yield.1H-NMR(600MHz,CDCl3)δ6.30(d,J=6.0,1H,H-1),4.72-4.74(m,1H,H-2),4.27-4.29(m,1H,H-4),4.09(dd,J=12.0,4.8Hz,1H,H-6a),3.98(dd,J=12.0,4.8Hz,1H,H-6b),3.85(dd,J=6.0,3.6Hz,1H,H-3),3.81-3.84(1H,m,H-5),3.35(brs,1H,OH),2.35(brs,1H,OH),1.12-1.16(m,3H,-Si(CH(CH3)2)3),1.08(d,J=6.0Hz,18H,-Si(CH(CH 3)2)3).ESIMSm/z 303.2[M+H]+.
v) preparation of Compound 185e
1.43g of compound 185d (4.7mmol) is placed in a 100mL three-necked flask, dissolved by addition of 20mL of dry dichloromethane under argon, cooled to-5 ℃ and added sodium hydride (751mg,31.3mmol, 60% in paraffin) in two portions, brought to 0 ℃ for 20min and slowly brought to room temperature for 1.5 h. The temperature was again lowered to-5 ℃ and trichloroacetonitrile (5.59mL, 56.4mmol) was dissolved in 10mL of dry dichloromethane, which was introduced into the reaction solution by a catheter and allowed to warm to room temperature overnight. The reaction mixture was cooled to-78 ℃, boron trifluoride ethyl ether (17.3mL,141mmol) was added dropwise, the mixture was reacted at this temperature for 6 hours, then 20mL of a saturated sodium bicarbonate solution was added, the mixture was slowly warmed to room temperature, extracted with dichloromethane, dried over anhydrous sodium sulfate and concentrated, and subjected to pressure column chromatography to elute 1.1g of compound 185e with a yield of 52% from petroleum ether and ethyl acetate of 20:1 (v/v). [ alpha ] to]D 20+121°(c 2.02,CH2Cl2);1H-NMR(600MHz,CDCl3)δ7.02(brs,1H,NH),6.45(d,J=4.8,1H,H-1),4.92-4.94(m,1H,H-2),4.46-4.48(m,1H,H-4),4.16-4.18(m,1H,H-3),4.06(dd,J=12.0,5.4Hz,1H,H-6a),3.96(dd,J=12.0,5.4Hz,1H,H-6b),3.84-3.86(m,1H,H-5),3.17(brs,1H,OH),1.12-1.16(m,3H,-Si(CH(CH3)2)3),1.08(d,J=6.0Hz,18H,-Si(CH(CH 3)2)3);13C-NMR(150MHz,CDCl3):δ162.3,145.8,97.3,92.6,74.5,67.1,63.4,45.8,17.8×3,11.7×6;ESIMS m/z 444.0[M–H]–.
vi) preparation of Compound 185f
Dissolving 1.1g of compound 185e (2.4mmol) in 30mL of dichloromethane, cooling to 0 ℃, adding sodium hydride (244m g,10.2mmol, 60% dispersed in paraffin), slowly heating to room temperature for reaction for 3h, cooling to 0 ℃, adding water to stop the reaction, extracting with dichloromethane, drying with anhydrous sodium sulfate, concentrating, separating by pressure column chromatography, eluting with petroleum ether ethyl acetate 4:1(v/v) to obtain 595mg of compound 185f, and obtaining 595mg of compound 185fThe rate was 75%. [ alpha ] to]D 20+108°(c 3.00,CH2Cl2);1H-NMR(500MHz,CDCl3)δ6.58(d,J=7.2,1H,H-1),5.96(brs,1H,NH),4.85-4.87(m,2H,H-2and H-4),4.34(1H,dd,J=7.2,4.2Hz,H-3),4.06(dd,J=10.2,3.6Hz,1H,H-6a),3.96(dd,J=10.2,3.6Hz,1H,H-6b),3.80-3.82(m,1H,H-5),1.12-1.16(m,3H,-Si(CH(CH3)2)3),1.08(d,J=6.0Hz,18H,-Si(CH(CH 3)2)3);13C-NMR(125MHz,CDCl3):δ158.7,147.2,98.5,74.0,71.0,61.7,46.1,17.9×3,11.9×6;ESIMS m/z 326.0[M–H]-.
vii) preparation of 185g Compound
595mg of compound 185f (1.8mmol) are transferred to a two-necked flask, dissolved in 20mL of dichloromethane, cooled to-5 ℃ and added with sodium hydride (218mg,9.1mmol, 60% in paraffin), allowed to warm to room temperature for two hours, then added with dimethyl sulfate (0.87mL, 9.1mmol), reacted at room temperature for 16 hours, quenched with ice-water, extracted with dichloromethane, dried over anhydrous sodium sulfate and concentrated, separated by pressure column chromatography, and eluted with petroleum ether ethyl acetate ═ 6:1(v/v) to yield 600mg of compound 185g, 97% yield. [ alpha ] to]D 20+75°(c 1.00,CH2Cl2);1H-NMR(500MHz,CDCl3)δ6.68(d,J=7.2Hz,1H,H-1),4.93(1H,dd,J=7.2,4.8Hz,H-2),4.74-4.76(m,1H,H-4),4.09(dd,J=13.2,3.6Hz,1H,H-6a),4.07-4.10(m,1H,H-3),3.98(dd,J=13.2,3.6Hz,1H,H-6b),3.61-3.63(m,1H,H-5),2.84(s,3H,N-CH3),1.12-1.16(m,3H,-Si(CH(CH3)2)3),1.08(d,J=6.0Hz,18H,-Si(CH(CH 3)2)3);13C-NMR(125MHz,CDCl3)δ157.3,148.5,96.0,74.4,67.7,61.6,51.0,28.8,17.9×3,11.9×6.ESIMS m/z 342.2[M+H]+.
viii) preparation of mixture 185h
415mg of compound 185g (1.22mmol) are dissolved in 20mL of tetrahydrofuran, cooled to 0 ℃ and 20mL of water-soluble mercuric acetate (781mg, 2.44mmol) are added, the solution turns yellow and is allowed to warm to room temperature for reaction for 2 h. Cooling to 0 deg.C, adding 60mL of water, and slowly adding boronSodium hydride (371mg, 9.76mmol), was black in color, and carbon dioxide was added after 10min until the solution was neutral. After suction filtration, extraction with ethyl acetate, drying over anhydrous sodium sulfate, concentration, separation by pressure column chromatography, and elution with petroleum ether (ethyl acetate: 2:1 (v/v)) yielded a pair of unseparated epimers 185h (337mg, 77% yield) at the C-1 position.1H-NMR(600MHz,CDCl3)δ5.31(m,1H,H-1),5.15(dd,J=6.0,4.8Hz,1H,H-1),4.63(t,J=8.4Hz,1H,H-4),4.57(t,J=8.4Hz,1H,H-4),4.03-3.97(m,2H,H-6a),3.91-3.94(m,2H,H-6b),3.86-3.90(m,2H,H-3),3.78-3.81(m,1H,H-5),3.58-3.61(m,1H,H-5),2.86(s,3H,N-CH3),2.83(s,3H,N-CH3),2.22-2.26(m,1H,H-2a),2.04-2.08(m,1H,H-2a),1.96-2.01(m,1H,H-2b),1.81(ddd,J=13.2,8.4,6.0Hz,1H,H-2b),1.07-1.12(m,6H,-Si(CH(CH3)2)3),1.05(d,J=7.2Hz,36H,-Si(CH(CH 3)2)3);13C-NMR(150MHz,CDCl3)δ158.4,158.0,91.7,90.6,74.7,69.0,68.8,68.1,63.2,63.1,53.9,52.9,31.2,29.9,29.2,28.9,18.0×3,17.8×3,12.4×6,12.0×6;ESIMS m/z 360.2[M+H]+.
ix) preparation of Compounds 185i and 185j
712.5mg of compound 185c (1.253mmol) was placed in a 250mL three-necked flask, dissolved in 20mL of dry tetrahydrofuran, argon-protected, cooled to-78 deg.C, 10mL of dry tetrahydrofuran-dissolved triphenylphosphine (655mg,2.515mmol) was added, then 0.5mL of DIAD (2.515mmol) was dissolved in 10mL of tetrahydrofuran, the reaction solution was added dropwise, reacted at-78 deg.C for 1h, then 10mL of tetrahydrofuran-dissolved compound was added 185h (300mg,0.835mmol), reacted at-78 deg.C for 2h, and then allowed to warm to room temperature for overnight reaction. The reaction was terminated by adding a saturated ammonium chloride solution, followed by extraction with ethyl acetate, concentration and separation by pressure column chromatography and elution with petroleum ether and ethyl acetate 4:1(v/v) to give 202mg of compound 185i (yield 27%) and 210mg of compound 185j (yield 28%).
185i:[α]D 20+14.1°(c 0.59,CH2Cl2);1H NMR(600MHz,CDCl3)δ8.15(d,J=7.8Hz,1H,ArH),8.11(s,1H,ArH),7.77(s,1H,ArH),7.40-7.10(m,9H,ArH),6.86(t,J=7.8Hz,1H,ArH),6.80-6.77(m,2H,ArH),5.72(dd,J=10.8,1.8Hz,1H,H-1'),5.23(s,2H,PhCH2O 2CHN),4.59(dd,J=9.0,7.2Hz,1H,H-4'),4.72(s,2H,Ph 2CHOCH2N),4.06-4.08(m,1H,H-3'),4.01(dd,J=12.0,1.8Hz,1H,H-6'a),3.95(dd,J=12.0,2.4Hz,1H,H-6'b),3.82-3.84(m,1H,H-5'),2.87(s,3H,N-CH3),2.39-2.41(m,1H,H-2'a),2.27-2.30(m,1H,H-2'b),1.69(s,9H,-C(CH 3)3),1.04-1.10(m,3H,-Si(CH(CH3)2)3),1.02(d,J=6.0Hz,-Si(CH(CH 3)2)3);13CNMR(150MHz,CDCl3)δ171.1,171.0,158.5,149.1,137.6,135.7,135.1,130.5,129.0,128.6,128.3×2,127.7,127.6×2,126.5,125.7,124.6,123.2,122.4×2,121.7,121.5,121.0,115.1,110.6,110.4,107.0,84.6,79.4,78.3,71.7,67.3,67.0,62.9,55.7,29.5,29.3,28.1×3,17.8×3,11.8×6;ESIMS m/z 889.6[M+H]+,911.6[M+Na]+;HR-ESIMS m/z 889.4195[M+H]+(calcd for C50H61N4O9Si,889.4208).
185j:[α]D 20-9.1°(c 0.10,CH2Cl2);1H NMR(600MHz,CDCl3)δ8.15(d,J=7.2Hz,1H,ArH),8.13(s,1H,ArH),7.63(s,1H,ArH),7.39-7.42(m,3H,ArH),7.28-7.32(m,3H,ArH),7.22-7.25(m,1H,ArH),7.15-7.19(m,2H,ArH),6.95(t,J=7.2Hz,1H,ArH),6.78(t,J=7.8Hz,1H,ArH),6.70(d,J=7.8Hz,1H,ArH),6.10(dd,J=10.7,4.5Hz,1H,H-1'),5.23(s,2H,PhCH2O 2CHN),4.75(t,J=7.8Hz,1H,H-4'),4.72(s,2H,Ph 2CHOCH2N),3.99-4.03(m,1H,H-3'),3.85-3.93(m,2H,H-6'),3.80-3.83(m,1H,H-5'),2.87(s,3H,N-CH3),2.40-2.44(m,1H,H-2'a),2.06-2.11(m,1H,H-2'b),1.69(s,9H,-C(CH 3)3),1.06-1.12(m,3H,-Si(CH(CH3)2)3),1.02(d,J=6.0Hz,18H,-Si(CH(CH 3)2)3);13C NMR(150MHz,CDCl3)δ171.2,171.0,157.3,149.2,137.8,136.0,135.4,130.8,129.4,128.5×3,127.9,127.8×2,127.3,126.7,126.0,124.7,123.3,122.5×2,122.0,121.7,115.4,110.6,110.4,107.1,84.8,78.6,72.5,71.8,68.8,67.4,63.6,53.7,29.8,29.2,28.2×3,18.0×3,11.9×6.ESIMS m/z 889.5[M+H]+.
x) preparation of Compounds 185l and 188b
Compound 185i (311mg,0.350mmol) was dissolved in 40mL of toluene, 3.0g of silica gel was added, and the mixture was heated under reflux for 5 h. After cooling to room temperature, it was filtered through silica gel and eluted with ethyl acetate to give compound 185k (262mg, 95% yield); HR-ESIMS M/z 787.3499[ M-H ]]-(calcd for C45H51N4O7Si, 787.3572). 188a (180mg, 96% yield), HR-ESIMS M/z 787.3496[ M-H ] was obtained in the same manner as in the preparation of 188a (180mg, 96% yield) starting from compound 185j (210mg)]-(calcd for C45H51N4O7Si, 787.3572). 262mg of 185k (0.333mmol) was dissolved in 30mL of tetrahydrofuran, cooled to 0 ℃, deprotected by addition of tetrabutylammonium fluoride (1.0mL,1.0mmol,1.0M tetrahydrofuran solution), reacted at room temperature for 1h, diluted with ethyl acetate and washed with water, the ethyl acetate layer was dried over anhydrous sodium sulfate and concentrated, and separated by pressure column chromatography, and eluted with ethyl acetate ═ 1:2(v/v) to give 179mg of 185l, 85% yield of compound. 188b (136mg, 95% yield) was obtained in the same manner as described above, starting from 188a (179 mg).
185l:[α]D 20-2.5°(c 0.01,CH2Cl2);1H NMR(600MHz,CDCl3)δ9.40(s,1H,NH),7.67(d,J=3.0Hz,1H,ArH),7.59(s,1H,ArH),7.36-7.37(m,2H,ArH),7.27-7.32(m,4H,ArH),7.22-7.24(m,1H,ArH),7.17-7.17(m,2H,ArH),7.04(t,J=7.8Hz,1H,ArH),6.87-6.90(m,2H,ArH),6.76(t,J=7.8Hz,1H,ArH),5.67(dd,J=10.2,1.2Hz,1H,H-1'),5.14(s,2H,PhCH2O 2CHN),4.67(s,2H,Ph 2CHOCH2N),4.30(t,J=7.8Hz,1H,H-4'),3.86-3.87(m,1H,H-3'),3.81(dd,J=12.0,2.4Hz,1H,H-6'a),3.72-3.75(m,1H,H-5'),3.64(dd,J=12.0,2.4Hz,1H,H-6'b),2.77(s,3H,N-CH3),2.24-2.29(m,1H,H-2'a),2.12-2.16(m,1H,H-2'b);13C NMR(150MHz,CDCl3):δ171.7,171.6,158.6,137.7,136.3,136.0,129.7,129.2,128.5×2,128.0,127.8×2,127.7,126.6,126.5,124.9,123.3,122.9,122.6,122.2,121.5,120.4,111.8,110.0,107.6,106.5,78.9,77.6,71.7,67.2,62.1,60.5,55.7,29.6,28.8;HR-ESIMS m/z 631.2216[M-H]-(calcd forC36H31N4O7,631.2193).
188b:[α]D 20-10°(c 0.10,CH2Cl2);1H NMR(600MHz,CDCl3)δ8.90(s,1H,NH),7.80(m,1H,ArH),7.46-7.21(m,10H,ArH),7.80(d,J=3.0Hz,1H,ArH),7.45-7.46(m,2H,ArH),7.38-7.40(m,3H,ArH),7.34-7.36(m,1H,ArH),7.29-7.32(m,2H,ArH),7.20-7.25(m,2H,ArH),7.07-7.10(m,1H,ArH),7.01(t,J=7.2Hz,1H,ArH),6.72-6.74(m,2H,ArH),6.05(dd,J=10.4,5.4Hz,1H,H-1'),5.14(s,2H,PhCH2O 2CHN),4.71(s,2H,Ph 2CHOCH2N),4.60(t,J=8.4Hz,1H,H-4'),3.92-3.97(brs,1H,H-3'),3.69(dd,J=12.0,2.4Hz,1H,H-6'a),3.60(dd,J=12.0,4.2Hz,1H,H-6'b),3.52-3.54(m,1H,H-5'),2.80(s,3H,N-CH3),2.39-2.43(m,1H,H-2'a),2.25-2.30(m,1H,H-2'b);13C NMR(150MHz,CDCl3):δ171.7×2,157.3,137.8,136.4,135.8,129.7,129.1,128.5×2,127.9,127.8×2,127.7,127.0,126.8,124.3,123.3,123.0,122.7,122.3,121.6,120.4,112.0,110.1,107.6,106.5,78.4,76.5,71.8,68.9,62.1,59.2,53.2,29.8,28.9;HR-ESIMS m/z 631.2218[M-H]-(C36H31N4O7Calculated 631.2193).
xi) preparation of Compounds 185m and 188c
30mg of 185l (0.047mmol) of the compound is dissolved in 1750mL of acetone, 3mg of iodine is added for catalysis, the reaction is carried out for 12h under the irradiation of a high-pressure mercury lamp of 250w, the solution is changed from red to green fluorescence, saturated sodium thiosulfate solution is added after the concentration, ethyl acetate is used for extraction, anhydrous sodium sulfate is dried and then concentrated, and the product 185m (17mg, the yield is 57%) is obtained after the separation by pressure column chromatography and the elution of petroleum ether and ethyl acetate which are 1:1 (v/v). The same procedures used compound 188b (136mg) were repeated to give compound 188c (70mg, 51% yield).
185m:[α]D 20+71.7°(c 0.05,CH2Cl2);1H NMR(600MHz,CDCl3)δ11.0(s,1H,NH),9.23(d,J=7.8Hz,1H,ArH),8.77(d,J=7.8Hz,1H,ArH),7.54-7.57(m,1H,ArH),7.46-7.48(m,2H,ArH),7.39-7.41(m,2H,ArH),7.35-7.38(m,2H,ArH),7.28-7.31(m,3H,ArH),6.97(d,J=8.4Hz,1H,ArH),6.16(dd,J=9.0,1.8Hz,1H,H-1'),5.18(t,J=7.8Hz,1H,H-4'),5.13-5.17(m,2H,PhCH2O 2CHN),4.80(s,2H,Ph 2CHOCH2N),4.40(d,J=12.0Hz,1H,H-3'),4.10-4.13(m,2H,H-6'),3.35-3.38(m,1H,H-5'),2.91(s,3H,N-CH3),2.29-2.34(m,1H,H-2'a),1.98-2.01(m,1H,H-2'b);13C NMR(150MHz,CDCl3):δ169.5,169.0,158.7,140.7,139.7,137.5,129.7,128.6×2,128.3,128.1×3,128.0,127.6,127.2,126.2,125.0,122.7,121.7,120.7,120.5,119.5,118.4,118.1,111.2,108.6,79.3,78.3,71.9,66.8,66.2,60.9,56.2,29.7,29.0;ESIMS m/z 629.3[M-H]-.
188c:[α]D 20-25.7°(c 0.16,CH2Cl2);1H NMR(600MHz,DMSO-d6)δ11.4(s,1H,NH),9.22(d,J=7.8Hz,1H,ArH),9.10(d,J=7.8Hz,1H,ArH),7.95(d,J=8.4Hz,1H,ArH),7.79(d,J=8.4Hz,1H,ArH),7.73-7.74(m,1H,ArH),7.67-7.68(m,1H,ArH),7.61-7.64(m,2H,ArH),7.46(t,J=7.8Hz,1H,ArH),7.40(t,J=7.2Hz,1H,ArH),7.32(d,J=7.2Hz,1H,ArH),7.31(t,J=7.8Hz,1H,ArH),7.24(t,J=7.2Hz,1H,ArH),6.94(dd,J=11.4,4.8Hz,1H,H-1'),5.45(t,J=5.4Hz,1H,H-4'),5.20(s,2H,PhCH2O 2CHN),4.83-4.85(m,1H,H-3'),4.77-4.79(m,1H,OH),4.69(s,2H,Ph 2CHOCH2N),4.44-4.48(m,1H,H-5'),3.90-3.96(m,2H,H-6'),2.67(s,3H,N-CH3),2.48-2.52(m,1H,H-2'a),2.43-2.46(m,1H,H-2'b);13C NMR(150MHz,DMSO-d6)δ169.6,169.5,157.2,141.2,140.0,138.4,132.3,132.1,129.3×2,129.1,128.8×2,128.1×3,128.0,125.3,124.9,122.6,122.0,121.5 121.3,120.3,118.8,118.2,112.8,79.5,75.1,70.1,67.3,65.6,61.4,53.4,29.6,29.0;ESIMS m/z 629.2[M-H]-.
xii) preparation of Compounds 185o and 188e
307mg of triphenylphosphine (1.171mmol) and 159mg of imidazole (2.342mmol) were dissolved in 20mL of dichloromethane, the temperature was reduced to 0 ℃ and 287mg of iodine (2.342mmol) were added and the mixture was stirred for 1 h. Compound 185m (123mg,0.195mmol) was taken up in 20mL portionsDissolving methyl chloride, slowly adding the dissolved methyl chloride into the reaction solution, and heating to room temperature for reaction for 6 hours. Then, the temperature is reduced to 0 ℃, water is added for quenching, dichloromethane is used for extraction, anhydrous sodium sulfate is added for drying, concentration and pressure column chromatography separation are carried out, and petroleum ether and ethyl acetate are 2:1(v/v) for elution to obtain a compound 185n (80mg, the yield is 56%); HR-ESIMS M/z 741.1221[ M + H ]]+(C36H30N4O6I, calculated 741.1210). Using the compound 188c (70mg) as a starting material, compound 188d (54mg, yield 65%), HR-ESIMS M/z 741.1225[ M + H ] was obtained in the same manner]+(calcd forC36H30N4O6I, 741.1210). 30mg of compound 185n (0.041mmol) are dissolved in 10mL of tetrahydrofuran, cooled to 0 ℃ and 0.4mL of DBU (2.67mmol) are added, reacted at 0 ℃ for 1h and heated to 40 ℃ for 1 h. The reaction mixture was diluted with ethyl acetate, washed with water, concentrated, and subjected to pressure column chromatography and eluted with petroleum ether (ethyl acetate: 1 (v/v)) to give compound 185o (22.3mg, 89% yield). Using compound 188d (54mg) as a starting material, compound 188e (40mg, yield 90%) was obtained in the same manner.
185o:[α]D 20+141.3°(c 0.34,CH2Cl2);1H NMR(600MHz,DMSO-d6)δ12.1(s,1H,NH),9.22(d,J=7.8Hz,1H,ArH),9.08(d,J=8.4Hz,1H,ArH),7.86(d,J=8.4Hz,1H,ArH),7.71(d,J=8.4Hz,1H,ArH),7.60-7.63(m,2H,ArH),7.47(d,J=7.2Hz,1H,ArH),7.41-7.36(m,3H,ArH),7.31(t,J=7.2Hz,2H,ArH),7.24(t,J=7.2Hz,1H,ArH),7.20(dd,J=12.0,2.4Hz,1H,H-1'),5.40(d,J=9.6,1H,H-4'),5.15-5.19(m,2H,PhCH2O 2CHN),5.07-5.09(m,2H,H-6'),4.67(s,2H,Ph 2CHOCH2N),4.33-4.36(m,1H,H-3'),2.69(s,3H,N-CH3),2.44-2.51(m,1H,H-2'a),2.10-2.14(m,1H,H-2'b);13C NMR(150MHz,DMSO-d6)δ169.6,169.5,157.0,152.9,142.2,140.6,138.4,129.8,129.4,128.8×2,128.2,128.1×3,128.0,125.6,124.9,123.7,122.5,121.8,121.4,120.5,119.2,118.8,118.4,113.7,112.9,101.2,81.0,71.4,70.9,67.3,53.1,28.8,28.0;ESIMS m/z 611.3[M-H]-.
188e:[α]D 20-21.4°(c 0.7,CH2Cl2);1H NMR(600MHz,CDCl3)δ9.62(s,1H,NH),9.27(d,J=8.4Hz,1H,ArH),9.10(d,J=8.4Hz,1H,ArH),7.62-7.66(m,1H,ArH),7.51-7.56(m,2H,ArH),7.38-7.46(m,4H,ArH),7.29-7.36(m,3H,ArH),7.22(t,J=7.2Hz,1H,ArH),6.27(dd,J=11.4,2.4Hz,1H,H-1′),5.43(d,J=2.0Hz,1H,H-6′a),5.30(d,J=2.0Hz,1H,H-6′b),5.16-5.22(m,2H,PhCH2O 2CHN),5.07(d,1H,J=7.2Hz,H-4′),4.73(s,2H,Ph 2CHOCH2N),4.14-4.18(m,1H,H-3′),2.76(s,3H,N-CH3),2.47-2.53(m,1H,H-2′a),2.38-2.42(m,1H,H-2′b);13C NMR(150MHz,CDCl3)δ169.4,169.2,156.7,151.3,140.8,139.7,137.7,129.3,128.5×2,128.2,128.0×3,127.8,127.5,126.3,125.3,122.6,122.2,121.9,121.6,121.0,119.5,119.3,118.8,111.9,108.7,100.1,81.9,71.6,70.1,66.9,54.4,32.8,29.2;ESIMS m/z 611.4[M-H]-.
xiii) preparation of Compounds 185p and 188f
30mg of compound 185o (0.05mmol) was dissolved in 10mL/1mL of tetrahydrofuran/methanol, the temperature was reduced to 0 ℃ and 22mg of potassium tert-butoxide (0.2mmol) was added, the solution turned from yellow to red, the solution was slowly warmed to room temperature and stirred for 2 hours, 38mg of iodine (0.15mmol) was added, the solution was darkened, and the reaction was allowed to proceed overnight. The temperature was reduced to 0 ℃, and the mixture was poured into a saturated sodium thiosulfate solution, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and subjected to pressure column chromatography and eluted with petroleum ether and ethyl acetate (1: 2) (v/v) to give 185p (20mg, 54% yield). Using compound 188e (40mg) as a starting material, compound 188f (20mg, yield 42%) was obtained in the same manner.
185p:[α]D 20+45.9°(c 0.05,CH2Cl2);1H NMR(600MHz,DMSO-d6)δ9.28(d,J=7.8Hz,1H,ArH),9.03(d,J=7.8Hz,1H,ArH),8.11(d,J=9.0Hz,1H,ArH),8.07(d,J=8.4Hz,1H,ArH),7.70-7.66(m,2H,ArH),7.56(t,J=7.2Hz,1H,ArH),7.47(t,J=7.2Hz,1H,ArH),7.36-7.40(m,2H,ArH),7.31(t,J=7.2Hz,2H,ArH),7.24(t,J=7.2Hz,1H,ArH),7.08(dd,J=9.6,7.2Hz,1H,H-1'),5.91(d,J=12.0Hz,1H,H-4'),5.26(s,2H,PhCH2OCH 2),4.70(s,2H,PhCH 2OCH2),4.63(1H,d,J=12.6Hz,H-6′a),4.48-4.51(m,1H,H-3′),3.79(1H,d,J=12.6Hz,H-6′b),2.99(s,3H,N-CH3),2.58-2.63(m,1H,H-2′a),2.36-2.42(m,1H,H-2′b);13C NMR(150MHz,DMSO-d6)δ169.2,169.0,156.7,138.1,135.5,132.4,131.0,128.9,128.5×2,127.9,127.8×2,127.5,126.2,126.0,125.4,122.7,121.9,121.4,119.7,119.1,118.5,117.9,116.7,112.5,108.0,93.5,77.7,71.8,70.5,67.0,53.2,29.8,27.8,9.3;ESIMS m/z 761.1[M+Na]+.
188f:[α]D 20-73.4°(c 0.21,CH2Cl2);1H NMR(600MHz,CDCl3)δ9.41(d,J=8.4Hz,1H,ArH),9.23(d,J=8.4Hz,1H,ArH),8.05(d,J=8.4Hz,1H,ArH),7.61(t,J=7.2Hz,2H,ArH),7.49(t,J=7.2Hz,1H,ArH),7.43-7.46(m,4H,ArH),7.30(t,J=7.2Hz,2H,ArH),7.22(t,J=7.2Hz,1H,ArH),6.63(dd,J=10.8,6.0Hz,1H,H-1′),5.34(s,2H,PhCH2OCH 2),5.31(d,J=9.0Hz,1H,H-4′),4.73(s,2H,PhCH 2OCH2),4.52(d,J=11.4Hz,1H,H-6′a),4.27-4.32(m,1H,H-3′),3.96(1H,d,J=11.4Hz,H-6′b),2.84-2.89(m,1H,H-2′a),2.80(s,3H,N-CH3),2.41-2.48(m,1H,H-2′b);13C NMR(150MHz,CDCl3)δ169.4,169.2,155.4,141.7,137.8×2,131.8,128.7,128.4×2,128.0,127.9×2,127.8,127.6,126.6,126.1,125.1,122.8,122.3,121.7,121.3,119.7×2,115.0,114.1,107.1,92.2,79.4,73.5,71.6,67.0,53.4,29.5,29.0,14.2;ESIMS m/z 761.1[M+Na]+.
vix) preparation of Compounds 185q and 188g
25mg of compound 185p (0.034mmol) are dissolved in 20mL of benzene under argon, AIBN (3mg) and tetrabutyltin hydride (0.1mL) are added and the mixture is refluxed for 1 h. After cooling to room temperature, the mixture was concentrated and subjected to pressure column chromatography and eluted with petroleum ether and ethyl acetate (1: 2) (v/v) to give 185q (17mg, yield 80%). Using compound 188f (20mg) as a starting material, compound 188g (15mg, yield 96%) was obtained in the same manner.
185q:[α]D 20+87.3°(c 0.29,CH2Cl2);1H NMR(600MHz,CDCl3)δ9.35(d,J=7.2Hz,1H,ArH),9.10(d,J=7.8Hz,1H,ArH),7.64-7.57(m,3H,ArH),7.47-7.42(m,4H,ArH),7.35(t,J=7.2Hz,1H,ArH),7.31(t,J=7.8Hz,2H,ArH),7.23(t,J=7.2Hz,1H,ArH),6.49(dd,J=9.6,7.2Hz,1H,H-1'),5.63(d,J=9.6Hz,1H,H-4'),5.25-5.33(m,2H,PhCH2OCH 2),4.76(s,2H,PhCH 2OCH2),4.32-4.35(m,1H,H-3'),3.10(s,3H,N-CH3),2.69-2.73(m,1H,H-2'a),2.36-2.40(m,1H,H-2'b),1.94(s,3H,6'-CH3);13C NMR(150MHz,CDCl3)δ169.4,169.2,157.3,140.1,138.1,137.7,130.1,128.9,128.5×2,128.0×2,127.8,127.6,127.5,126.7,126.3,124.7,122.2,122.1,121.5,121.0,119.6,118.5,117.5,112.3,107.8,94.0,77.2,71.7,71.4,66.9,52.7,29.6,26.2,24.6;ESIMS m/z 613.5[M+H]+.
188g:[α]D 20-24.0°(c 0.19,CH2Cl2);1H NMR(600MHz,CDCl3)δ9.40(d,J=7.8Hz,1H,ArH),9.24(d,J=7.8Hz,1H,ArH),8.09(d,J=7.8Hz,1H,ArH),7.72-7.74(m,1H,ArH),7.59-7.62(m,2H,ArH),7.53-7.55(m,1H,ArH),7.43-7.47(m,3H,ArH),7.31(t,J=7.8Hz,2H,ArH),7.25(t,J=7.2Hz,1H,ArH),6.59(dd,J=9.6,6.6Hz,1H,H-1'),5.37(s,2H,PhCH2OCH 2),5.11(d,J=8.4Hz,1H,H-4'),4.77(s,2H,PhCH 2OCH2),4.26-4.31(m,1H,H-3'),2.79-2.85(m,1H,H-2'a),2.77(s,3H,N-CH3),2.42-2.48(m,1H,H-2'b),2.08(s,3H,6'-CH3);13C NMR(150MHz,CDCl3)δ169.5,169.3,155.8,142.1,137.7×2,131.0,128.9,128.7,128.4×2,127.9×2,127.8,127.7,127.6,126.6,125.8,124.6,122.3,122.2,121.6,119.7,119.5,116.4,114.1,107.5,93.3,79.0,71.9,71.6,67.0,53.0,30.0,29.7,29.5;ESIMS m/z 635.2[M+Na]+.
xx) preparation of Compounds 185 and 188
Compound 185q (10mg, 0.016mmol) was dissolved in 20mL of ethyl acetate-methanol-1: 1(v/v), replaced with argon, 5mg of 20% palladium hydroxide on carbon was added, replaced with hydrogen, and reacted overnight. Filtering with silica gel, concentrating, separating by semi-preparative HPLC, MeOH H2Eluting with O9: 1(v/v) to obtain 7mg of 4 ' -O-demethyl- (4 ' -O, 3' -N) carbonyl-7-oxoidene-3 ', 4 ' -diolepsimine (185), and obtaining the final productThe rate was 89%. Enantiomeric [4 ' -O-demethyl- (4 ' -O, 3' -N) carbonyl-7-oxoidene was prepared in the same manner using 188g (15mg) of the compound as a starting material]Staurosporine (188)11.3mg, 96% yield.
185:[α]D 20+33.5°(c 0.04,CH2Cl2);1H NMR(600MHz,DMSO-d6)δ11.2(s,1H,NH),9.22(d,J=7.8Hz,1H,ArH),9.00(d,J=7.8Hz,1H,ArH),8.08(d,J=7.8Hz,1H,ArH),7.95(d,J=7.8Hz,1H,ArH),7.65(t,J=7.8Hz,1H,ArH),7.63(t,J=7.2Hz,1H,ArH),7.49(t,J=7.8Hz,1H,ArH),7.42(t,J=7.8Hz,1H,ArH),6.99(dd,J=10.2,6.6Hz,1H,H-1'),5.76(d,J=9.6Hz,1H,H-4'),4.43-4.46(m,1H,H-3'),2.99(s,3H,N-CH3),2.80(ddd,J=9.6,6.0,2.4Hz,1H,H-2'a),2.18(ddd,J=9.6,6.0,2.4Hz,1H,H-2'b),1.80(s,3H,6'-CH3);13C NMR(150MHz,DMSO-d6)δ171.2×2,157.4,140.4,135.9,130.2,129.1,127.8,127.7,125.8,125.3,124.3,122.0×2,121.5,121.4,120.7,117.6,116.5,114.4,114.3,94.1,77.9,71.4,52.4,29.5,24.9×2;ESIMS m/z 491.3[M-H]-.
188:[a]D 20-50.2°(c 0.08,CH2Cl2);1H NMR(600MHz,DMSO-d6)δ9.23(d,J=9.0Hz,1H,ArH),9.04(d,J=10.2Hz,1H,ArH),8.09(d,J=9.6Hz,1H,ArH),7.88(d,J=10.8Hz,1H,ArH),7.64(t,J=9.0Hz,1H,ArH),7.57-7.60(m,1H,ArH),7.41-7.44(m,2H,ArH),7.01(dd,J=12.0,7.2Hz,1H,H-1'),5.33(d,J=10.8Hz,1H,H-4'),4.32-4.36(m,1H,H-3'),2.93-2.99(m,1H,H-2'a),2.57(s,3H,N-CH3),2.04-2.11(m,1H,H-2'b),2.05(s,3H,6'-CH3);13C NMR(150MHz,DMSO-d6)δ170.8,170.5,155.7,141.4,137.7,130.0,128.2,127.3,126.7,125.0,124.7,123.5,121.3,121.1×2,121.0,119.9,117.5,116.7,115.8,109.4,92.6,79.0,75.3,52.0,29.8,28.3×2;ESIMS m/z 515.2[M+Na]+.
Preparation of Compound 186,187,189,190
Dissolving compound 185(15mg, 0.030mmol) in 10mL of methanol, cooling to 0 ℃, adding sodium borohydride (7.6mg, 0.2mmol), heating to room temperature for reaction for two hours, changing the solution from yellow to colorless, diluting with ethyl acetate, adding saturated ammonium chloride solution, extracting with ethyl acetate, drying with anhydrous sodium sulfate, and evaporating to dryness. The crude product was dissolved in 5mL of glacial acetic acid, zinc powder (20mg, 0.32mmol) was added, the mixture was warmed to 40 ℃ and reacted for 1.5 hours, cooled to room temperature, diluted with ethyl acetate, washed with a saturated sodium bicarbonate solution, dried over anhydrous sodium sulfate and concentrated. Semi-preparative HPLC chromatography eluting with acetonitrile, water ═ 2:3(v/v) gave 5.2mg of 4 '-O-demethyl- (4' -O,3 '-N) carbonyl-3', 4 '-diiodiosporine (186) (yield 36%) and 5.2mg of 5-deoxy-7-oxoylidene-4' -O-demethyl- (4 '-O, 3' -N) carbonyl-3 ', 4' -diiodiosporine (187) (yield 36%). Using compound 188(11mg) as a starting material, 4.0mg of enantiomeric [4 '-O-demethyl- (4' -O,3 '-N) carbonyl ] staurosporine (189) (yield 38%) and 4.0mg of enantiomeric [ 5-deoxy-7-oxoylidene-4' -O-demethyl- (4 '-O, 3' -N) carbonyl ] staurosporine (190) (yield 38%) were obtained in the same manner.
186:[α]D 20+101.0°(c 0.10,MeOH);1H NMR(600MHz,CDCl3)δ9.32(d,J=8.0Hz,1H,ArH),7.97(d,J=7.7Hz,1H,ArH),7.68(d,J=8.3Hz,1H,ArH),7.56(m,1H,ArH),7.52-7.58(m,2H,ArH),7.43-7.48(m,2H,ArH),7.38(t,J=7.5Hz,1H,ArH),6.57(s,1H,NH),6.49(dd,J=9.6,6.8Hz,1H,H-1'),5.59(d,J=9.4Hz,1H,H-4'),5.04(d,J=16.7Hz,1H,H-7a),4.92(d,J=16.7Hz,1H,H-7b),4.28-4.30(m,1H,H-3'),3.06(s,3H,N-CH3),2.49-2.55(m,1H,H-2'a),2.22-2.28(m,1H,H-2'b),1.94(s,3H,6'-CH3);13CNMR(125MHz,CDCl3)δ172.7,157.4,139.2,137.2,133.2,129.3,127.2,126.3,125.8×2,125.5,123.5,122.1,121.8,120.8,120.3,117.8,115.8,113.0,107.5,93.9,77.2,71.7,52.9,46.1,29.6,26.2,24.7;HR-ESIMS m/z 479.1738[M+H]+(calcd for C28H23N4O4 479.1719).
187:[α]D 20+102.6°(c 0.05,MeOH);1H NMR(600MHz,CDCl3)δ9.60(d,J=7.7Hz,1H,ArH),7.98(d,J=7.7Hz,1H,ArH),7.61(d,J=8.4Hz,1H,ArH),7.56(t,J=7.7Hz,1H,ArH),7.54(t,J=8.4Hz,1H,ArH),7.51(d,J=8.4Hz,1H,ArH),7.44(t,J=7.3Hz,1H,ArH),7.40(t,J=7.4Hz,1H,ArH),6.50(dd,J=9.4,6.9Hz,1H,H-1'),6.40(s,1H,NH),5.67(d,J=9.5Hz,1H,H-4'),4.99-5.07(m,2H,H-5),4.30(d,J=9.5Hz,1H,H-3'),3.08(s,3H,N-CH3),2.59-2.64(m,1H,H-2'a),2.37-2.43(m,1H,H-2'b),1.90(s,3H,6'-CH3);13C NMR(150MHz,CDCl3)δ173.1,157.5,139.3,137.3,134.7,128.2,127.7,126.8,126.2×2,125.9,123.2,122.0,121.5,121.1,119.6,118.9,115.3,111.9,108.4,94.0,77.2,71.8,52.9,45.7,29.6,26.4,24.4;HR-ESIMS m/z 479.1706[M+H]+(calcd for C28H23N4O4,479.1719).
189:[α]D 20-72.8°(c 0.10,MeOH);1H NMR(600MHz,DMSO-d6)δ9.23(d,J=7.6Hz,1H,ArH),8.67(s,1H,NH),8.06(d,J=8.5Hz,1H,ArH),8.03(d,J=7.4Hz,1H,ArH),7.79(d,J=8.4Hz,1H,ArH),7.50-7.53(m,2H,ArH),7.37-7.40(m,1H,ArH),7.29-7.32(m,1H,ArH),6.96(dd,J=9.9,6.3Hz,1H,H-1'),5.31(d,J=8.8Hz,1H,H-4'),4.95-5.03(m,2H,H-7),4.34(ddd,J=12.1,8.8,5.1Hz,1H,H-3'),2.90-2.94(m,1H,H-2'a),2.58(s,3H,N-CH3),2.03(s,3H,6'-CH3),1.97-2.02(m,1H,H-2'b);13C NMR(150MHz,DMSO-d6)δ171.7,155.7,140.4,136.5,133.0,128.7,125.8,125.6,125.1,125.0,124.7,122.4,121.3,121.1,120.4,119.7,116.7,115.9,115.5,108.8,92.6,79.2,75.5,52.1,45.4,29.6,28.8,28.3;HR-ESIMS m/z 479.1708[M+H]+(calcd for C28H23N4O4 479.1719).
190:[α]D 20-75.6°(c 0.10,MeOH);1H NMR(600MHz,DMSO-d6)δ9.51(d,J=7.9Hz,1H,ArH),8.62(s,1H,NH),8.10(d,J=7.8Hz,1H,ArH),8.01(d,J=8.5Hz,1H,ArH),7.84(d,J=8.2Hz,1H,ArH),7.56(t,J=7.7Hz,1H,ArH),7.45-7.48(m,1H,ArH),7.38(t,J=7.4Hz,1H,ArH),7.30(t,J=7.5Hz,1H,ArH),6.96(dd,J=9.8,6.3Hz,1H,H-1'),5.29(d,J=8.7Hz,1H,H-4'),4.96-5.01(m,2H,H-5),4.34(ddd,J=12.1,8.8,5.1Hz,1H,H-3'),2.91-2.96(m,1H,H-2'a),2.59(3H,s,N-CH3),2.05-2.10(m,1H,H-2'b),1.99(s,3H,6'-CH3);13C NMR(150MHz,DMSO-d6)δ171.9,155.8,140.4,136.6,134.4,127.0,126.6,125.70,125.5,125.1×2,122.1,121.9,120.6,120.1,119.4,117.6,116.1,114.3,109.3,92.6,79.2,75.5,52.2,44.9,29.5,28.8,28.3;HR-ESIMS m/z 479.1722[M+H]+(calcd for C28H23N4O4479.1719).
Preparation of Compound 191
i) Preparation of 6-O-triisopropylsilyl-L-glucal (191a)
Slowly adding 0.041mL perchloric acid into 40mL acetic anhydride, stirring at 40 deg.C for 30min, cooling to 30 deg.C, adding 2g L-glucose, and stirring for 30 min. The reaction solution is cooled to 10 ℃,0.62 g of red phosphorus, 1.16mL of liquid bromine and 0.72mL of water are slowly added in sequence, the temperature is raised to 30 ℃, and stirring is continued for 2 hours. The reaction was quenched with 10mL of ice water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated. The concentrate was dissolved in 50mL ethyl acetate, cooled to 0 deg.C, and then mixed with 3.22g zinc powder and 42.4mg CuSO4·5H2And mixing O and 0.21g of sodium acetate uniformly with 30mL of 60% acetic acid aqueous solution by volume fraction, adding the mixture into the reaction solution, reacting at 0 ℃ for 1h, and heating to room temperature for reacting for 1 h. Filtering the reaction solution, extracting the filtrate with ethyl acetate, drying with anhydrous sodium sulfate, concentrating, separating by pressure column chromatography, eluting with petroleum ether ethyl acetate ═ 3:1(v/v) to obtain 2.5g of 3,4, 6-tri (O-acetyl) -L-glucal, with a yield of 82% in two steps; ESIMS M/z 273.3[ M + H ]]+. Dissolving 3,4, 6-tris (O-acetyl) -L-glucal (2.5g,9.19mmol) in 100mL of methanol, adding 60mg of sodium methoxide, reacting at room temperature for 1h, adjusting the pH of the reaction solution to 7 with a cationic resin, filtering, concentrating, and separating by pressure column chromatography (elution with ethyl acetate) to obtain 1.3g of L-glucal with a yield of 97%; ESIMS M/z 147.2[ M + H ]]+. The compound L-glucal (1.3g,8.9mmol) was dissolved in 30mL of pyridine, cooled to 0 ℃, added with triisopropylchlorosilane (3.78mL,17.8mmol) and imidazole (3.61g,53.4mmol), reacted at room temperature for 2 hours, quenched with 50mL of ice water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by pressure column chromatography, and eluted with ethyl acetate ═ 5:1(v/v) to give 1.41g of compound 191a in 52% yield.1H-NMR(500MHz,CDCl3)δ6.27(d,J=6.0Hz,1H,H-1),4.67-4.70(m,1H,H-2),4.26(brs,1H,H-4),4.04(dd,J=12.0,4.8Hz,1H,H-6a),3.98(dd,J=12.0,4.8Hz,1H,H-6b),3.79-3.82(m,2H,H-3and H-5),1.09-1.16(m,3H,((CH3)2CH)3Si-),1.06(d,J=6.0Hz,18H,((CH 3)2CH)3Si-).13C-NMR(125MHz,CDCl3)δ143.9,102.5,76.5,72.5,69.4,64.4,17.8×3,11.8×6;ESIMS m/z 325.1[M+Na]+.
ii) preparation of Compound 191b
1.41g of compound 191a (4.7mmol) are placed in a 100mL three-necked flask, 20mL of dry dichloromethane are added under the protection of argon and stirred to dissolve, the temperature is reduced to-5 ℃, sodium hydride (740mg,18.5mmol, 60% mass fraction is dispersed in paraffin) is added in two times, the temperature is raised to 0 ℃ for reaction for 20min, and the reaction is slowly raised to room temperature and continued for 1.5 h. The temperature was again lowered to-5 ℃ and trichloroacetonitrile (5.51mL, 55.6mmol) was dissolved in 10mL of dry dichloromethane, which was introduced into the reaction solution by a catheter and allowed to warm to room temperature overnight. The reaction mixture was cooled to-78 ℃, boron trifluoride ethyl ether (17.0mL,139mmol) was added dropwise, the reaction was carried out at this temperature for 6 hours, then 20mL of a saturated sodium bicarbonate solution was added to quench the reaction, the reaction was slowly warmed to room temperature, extracted with dichloromethane, dried over anhydrous sodium sulfate and concentrated, and subjected to pressure column chromatography, and eluted with petroleum ether and ethyl acetate 20:1(v/v) to give 0.88g of compound 191b in 42% yield. [ alpha ] to]D 20-71.6°(c 0.90,CH2Cl2);1H-NMR(500MHz,CDCl3)δ7.02(brs,1H,NH),6.45(d,J=6.0,1H,H-1),4.93(dd,J=6.0,5.0Hz,1H,H-2),4.46-4.49(m,1H,H-4),4.16-4.18(m,1H,H-3),4.06(dd,J=12.0,5.4Hz,1H,H-6a),3.96(dd,J=12.0,5.4Hz,1H,H-6b),3.82-3.86(m,1H,H-5),1.10-1.17(m,3H,((CH3)2CH)3Si-),1.07(d,J=6.0Hz,18H,((CH 3)2CH)3Si-);13C-NMR(125MHz,CDCl3)δ162.4,145.8,97.3,92.6,74.6,67.3,63.5,45.9,17.9×3,11.8×6;ESIMS m/z446.1/448.2/490.1[M+H]+.
iii) preparation of Compound 191c
Dissolving compound 191b (0.88g, 1.98mmol) in 30mL dichloromethane, cooling to 0 deg.C, adding sodium hydride (194mg,4.95mmol, 60% in paraffin), slowly heating to room temperature for reaction for 3h, cooling to 0 deg.C, adding water to terminate the reaction, extracting with dichloromethane, and adding anhydrous sulfuric acidSodium was dried, concentrated and purified by pressure column chromatography, eluting with petroleum ether and ethyl acetate 4:1(v/v) to give 537mg of 191c, 84% yield. [ alpha ] to]D 20-86.0°(c 0.50,CH2Cl2);1H-NMR(500MHz,CDCl3)δ6.59(d,J=6.0,1H,H-1),5.87(brs,1H,NH),4.85-4.88(m,2H,H-2/H-4),4.34(dd,J=7.5,4.0Hz,1H,H-3),4.04(dd,J=11.0,3.0Hz,1H,H-6a),3.99(dd,J=11.0,3.60Hz,1H,H-6b),3.82-3.84(m,1H,H-5),1.09-1.16(m,3H,((CH3)2CH)3Si-),1.06(d,J=6.0Hz,18H,((CH 3)2CH)3Si-);13C-NMR(125MHz,CDCl3)δ158.5,147.2,98.5,74.1,71.1,61.8,46.1,17.9×3,11.9×6;ESIMS m/z 326.1[M–H]–.
iv) preparation of Compound 191d
The compound 191c (537mg, 1.64mmol) was transferred to a two-necked flask, dissolved in 20mL of dichloromethane, cooled to-5 ℃, added with sodium hydride (197mg,4.92mmol, 60% dispersed in paraffin), allowed to warm to room temperature for two hours, reacted at room temperature for 16 hours with dimethyl sulfate (0.79mL, 8.21mmol), quenched with ice water, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and subjected to pressure column chromatography, petroleum ether and ethyl acetate ═ 6:1(v/v) to obtain 467mg of the compound 191d, 83% yield. [ alpha ] to]D 20-77°(c 1.00,CH2Cl2);1H-NMR(500MHz,CDCl3)δ6.67(d,J=6.0Hz,1H,H-1),4.93(dd,J=6.0,4.0Hz,1H,H-2),4.74(1H,dd,J=9.0,7.5Hz,H-4),4.05-4.07(m,1H,H-3),4.04(dd,J=12.0,2.5Hz,1H,H-6a),4.00(dd,J=12.0,2.5Hz,1H,H-6b),3.60-3.63(1H,m,H-5),2.84(s,3H,N-CH3)1.08-1.15(m,3H,((CH3)2CH)3Si-),1.06(d,J=6.0Hz,18H,((CH 3)2CH)3Si-);13C-NMR(125MHz,CDCl3)δ157.3,148.4,96.0,74.5,67.8,61.7,51.0,28.6,17.9×3,11.9×6;ESIMS m/z 342.2[M+H]+.
v) preparation of Compound 191e
Compound 191d (467mg, 1.37mmol) is dissolved in 20mL tetrahydrofuran, cooled to 0 deg.C and 20mL water is addedMercury acetate (876mg, 2.74mmol), the solution turned yellow and warmed to room temperature for 2 h. After cooling to 0 deg.C, 60mL of water was added, sodium borohydride (416mg, 11.0mmol) was added slowly and after 10min carbon dioxide was passed through until the solution was neutral. After suction filtration, extraction with ethyl acetate, drying over anhydrous sodium sulfate, concentration, separation by pressure column chromatography and elution with petroleum ether ethyl acetate ═ 2:1(v/v) gave 400mg of a mixture 191e of the 1-position epimers in 81% yield.1H-NMR(500MHz,CDCl3):δ5.30-5.33(m,1H,H-1),5.15-5.18(m,1H,H-1),4.64-4.68(m,1H,H-4),4.556-4.60(m,1H,H-4),4.04-3.86(m,6H,H-3,H-6a,H-6b,),3.77-3.82(m,1H,H-5),3.60-3.63(m,1H,H-5),2.87(s,3H,N-CH3),2.84(s,3H,N-CH3),2.22-2.27(m,1H,H-2a),2.05-2.09(m,1H,H-2a),1.97-2.02(m,1H,H-2b),1.79-1.85(m,1H,H-2b),1.08-1.15(m,6H,((CH3)2CH)3Si-),1.07(d,J=7.2Hz,36H,((CH 3)2CH)3Si-).13C-NMR(125MHz,CDCl3)δ158.2,157.8,91.6,90.6,74.5,69.0,68.7,68.1,63.2,63.0,53.7,52.8,31.1,29.9,29.1,28.8,17.9×6,12.0×12;ESIMS m/z360.2[M+H]+.
vi) preparation of Compounds 191f and 191g
870mg of compound 185c (1.59mmol) was placed in a 250mL three-necked reaction flask, dissolved in 20mL of dry tetrahydrofuran, argon-protected, cooled to-78 deg.C, 10mL of dry tetrahydrofuran-dissolved triphenylphosphine (833mg,3.18mmol) was added, then 0.62mL of DIAD (3.18mmol) was dissolved in 10mL of tetrahydrofuran, the reaction solution was added dropwise, after 1h at-78 deg.C, 10mL of tetrahydrofuran-dissolved compound 191e (380mg,1.06mmol) was added, after 2h at-78 deg.C, the reaction was allowed to warm to room temperature overnight. The reaction was terminated by adding a saturated ammonium chloride solution, followed by extraction with ethyl acetate, concentration and separation by pressure column chromatography, and elution with petroleum ether and ethyl acetate 4:1(v/v) gave 226mg of compound 191f (yield 24%) and 230mg of compound 191g (yield 25%).
191f:[α]D 20-14.2°(c 1.0,CH2Cl2);1H NMR(500MHz,CDCl3)δ8.15(d,J=7.8Hz,1H,ArH),8.11(s,1H,ArH),7.77(s,1H,ArH),7.36-7.40(m,3H,ArH),7.29-7.32(m,2H,ArH),7.23-7.25(m,1H,ArH),7.15-7.18(m,1H,ArH),7.10-7.12(m,2H,ArH),6.86(t,J=7.8Hz,1H,ArH),6.77-6.81(m,2H,ArH),5.71(dd,J=10.5,2.0Hz,1H,H-1'),5.20-5.25(m,2H,PhCH2OCH 2N),4.71(s,2H,PhCH 2OCH2N),4.69(dd,J=9.0,7.5Hz,1H,H-4'),4.05-4.09(1H,m,H-3'),4.00(dd,J=12.0,2.0Hz,1H,H-6'a),3.95(dd,J=12.0,2.0Hz,1H,H-6'b),3.82-3.85(1H,m,H-5'),2.88(s,3H,N-CH3),2.39-2.44(m,1H,H-2'a),2.27-2.30(m,1H,H-2'b),1.69(s,9H,(CH 3)3CO-),1.05-1.11(m,3H,((CH3)2CH)3Si-),1.02(d,J=6.0Hz,18H,((CH 3)2CH)3Si-).13C NMR(125MHz,CDCl3)δ171.1,171.0,158.5,149.2,137.7,135.8,135.2,130.6,129.0,128.6,128.4×2,127.7×2,127.6×2,126.6,125.8,124.6,123.2,122.5,122.2,121.8,121.6,115.1,110.6,110.5,107.1,84.6,79.5,78.4,71.7,67.4,67.1,63.0,55.8,29.6,29.4,28.2×3,17.9×3,11.9×6;ESIMS m/z 889.6[M+H]+
191g:[α]D 20+9.3°(c 0.40,CH2Cl2);1H NMR(500MHz,CDCl3)δ8.15(d,J=7.2Hz,1H,ArH),8.13(s,1H,ArH),7.64(s,1H,ArH),7.39-7.42(m,3H,ArH),7.28-7.33(m,3H,ArH),7.22-7.25(m,1H,ArH),7.15-7.20(m,2H,ArH),6.95(t,J=7.0Hz,1H,ArH),6.78(t,J=8.0Hz,1H,ArH),6.72(d,J=8.0Hz,1H,ArH),6.10(dd,J=10.0,6.0Hz,1H,H-1'),5.23(s,2H,PhCH2OCH 2N),4.76(t,J=7.8Hz,1H,H-4'),4.72(s,2H,PhCH 2OCH2N),3.99-4.04(m,1H,H-3'),3.85-3.94(m,2H,H-6'),3.80-3.83(m,1H,H-5'),2.87(s,3H,N-CH3),2.39-2.45(m,1H,H-2'a),2.05-2.13(m,1H,H-2'b),1.69(s,9H,(CH 3)3CO-),1.05-1.10(m,3H,((CH3)2CH)3Si-),1.02(d,J=6.0Hz,18H,((CH 3)2CH)3Si-).13C NMR(125MHz,CDCl3)δ171.0,170.9,157.2,149.2,137.8,136.0,135.4,130.8,129.3,128.4×3,127.7,127.6×2,127.3,126.7,126.0,124.6,123.2,122.4×2,121.9,121.6,115.3,110.5,110.3,107.1,84.7,78.6,72.4,71.8,68.8,67.4,63.5,53.6,29.7,29.2,28.2×3,17.9×3,11.9×6;ESIMS m/z 889.6[M+H]+.
vii) preparation of Compounds 191i and 194b
Compound 191f (226mg,0.254mmol) was dissolved in 40mL of toluene, 3.0g of silica gel was added, and the mixture was refluxed for 5 hours. Cooling to room temperature, filtering with silica gel, and eluting with ethyl acetate to obtain 200mg of compound 191h with a yield of 100%; ESIMS M/z 787.4[ M + H ]]+. Compound 194a (201mg, yield 100%) was obtained in the same manner as described above starting from 191g (226mg) of the compound; ESIMS M/z 787.5[ M + H ]]+. Compound 191h (200mg,0.253mmol) was dissolved in 30mL of tetrahydrofuran, cooled to 0 ℃, tetrabutylammonium fluoride (1.0mL,1.0mmol,1.0M in THF) was added, the reaction was carried out at room temperature for 1h, ethyl acetate was diluted and washed with water, the ethyl acetate layer was dried over anhydrous sodium sulfate and concentrated, and separation by pressure column chromatography and elution with petroleum ether ethyl acetate ═ 1:2(v/v) gave 158mg of compound 191i, with a yield of 98%. In the same manner as above, using 194a (201mg) as a starting material, 152mg of compound 194b was obtained in 94% yield.
191i:[α]D 20+11.6°(c 0.55,CH2Cl2);1H NMR(500MHz,CDCl3)δ8.82(brs,1H,NH),7.69(d,J=3.0Hz,1H,ArH),7.62(s,1H,ArH),7.37-7.38(m,2H,ArH),7.28-7.33(m,4H,ArH),7.23-7.26(m,1H,ArH),7.15-7.19(m,1H,ArH),7.14(d,J=7.5Hz,1H,ArH),7.07-7.10(m,1H,ArH),6.-6.92(m,2H,ArH),6.77-6.80(m,1H,ArH),5.71(dd,J=10.5,2.0Hz,1H,H-1'),5.17(s,2H,PhCH2O 2CHN),4.68(s,2H,Ph 2CHOCH2N),4.46(1H,dd,J=9.0,7.0Hz,H-4'),3.92-3.95(m,1H,H-3'),3.85-3.87(m,1H,H-6'a),3.76-3.79(m,1H,H-5'),3.66-3.69(m,1H,H-6'b),2.82(s,3H,N-CH3),2.30-2.36(m,1H,H-2'a),2.20-2.23(m,1H,H-2'b).13C NMR(125MHz,CDCl3)δ171.6,171.5,158.4,137.7,136.1,136.0,129.2,129.0,128.4×2,127.8,127.7×2,127.6,126.8,126.5,124.8,123.2,122.8,122.7,122.2,121.4,120.4,111.5,109.8,107.6,106.7,78.8,77.6,71.6,67.2,62.1,60.5,55.7,29.5,28.9;ESIMS m/z 631.3[M-H]-.
194b:[α]D 20+19.3°(c 0.25,CH2Cl2);1H NMR(500MHz,CDCl3)δ8.90(s,1H,NH),7.83(d,J=3.0Hz,1H,ArH),7.47(s,1H,ArH),7.45(d,J=7.5Hz,1H,ArH),7.38-7.41(m,3H,ArH),7.36(d,J=8.0Hz,1H,ArH),7.29-7.32(m,2H,ArH),7.20-7.25(m,2H,ArH),7.08-7.11(m,1H,ArH),7.00-7.03(t,J=7.2Hz,1H,ArH),6.73-6.76(m,2H,ArH),6.06(dd,J=10.0,5.0Hz,1H,H-1'),5.20-5.25(m,2H,PhCH2O 2CHN),4.72(s,2H,Ph 2CHOCH2N),4.62(t,J=9.5Hz,1H,H-4'),3.94-3.99(m,1H,H-3'),3.71-3.73(m,1H,H-6'a),3.61-3.63(m,1H,H-6'b),3.54-3.57(m,1H,H-5'),2.81(s,3H,N-CH3),2.42-2.47(m,1H,H-2'a),2.01-2.08(m,1H,H-2'b);13C NMR(125MHz,CDCl3)δ171.5×2,157.0,137.8,136.2,135.8,129.3,129.0,128.4×2,127.7×3,127.4,127.2,126.8,124.3,123.2,122.8,122.7,122.2,121.5,120.4,111.6,109.8,107.7,106.7,78.3,71.7,71.3,68.6,67.3,62.1,53.2,29.7,28.9;ESIMS m/z:631.3[M-H]-.
viii) preparation of Compounds 191j and 194c
10mg of compound 191i (0.016mmol) is dissolved in 1000mL of acetone, 1mg of iodine is added for catalysis, a 125w high-pressure mercury lamp is used for irradiation reaction for 12 hours, the solution changes from red to green fluorescence, saturated sodium thiosulfate solution is added after concentration, ethyl acetate is used for extraction, anhydrous sodium sulfate is used for drying and concentration, the product is separated by pressure column chromatography, and petroleum ether and ethyl acetate are 1:1(v/v) for elution to obtain 6.1mg of product 191j, wherein the yield is 61%. The same procedures used for the preparation of 5.3mg of compound 194c were repeated except for using compound 194b (10mg) as the starting material, and the yield was 53%.
191j:[α]D 20-51.7°(c 0.07,CH2Cl2);1H NMR(600MHz,CDCl3):δ11.0(s,1H,NH),9.06(d,J=7.8Hz,1H,ArH),8.64(d,J=7.8Hz,1H,ArH),7.47(t,J=7.7Hz,1H,ArH),7.39(d,J=7.5Hz,2H,ArH),7.38(d,J=7.7Hz,1H,ArH),7.31(t,J=7.8Hz,2H,ArH),7.23-7.26(m,3H,ArH),7.19(t,J=7.8Hz,1H,ArH),6.85(t,J=8.4Hz,1H,ArH),6.11(d,J=11.0Hz,1H,H-1'),5.15(t,J=7.8Hz,1H,H-4'),4.95(s,2H,PhCH2O 2CHN),4.70(s,2H,Ph 2CHOCH2N),4.28(d,J=10.8Hz,1H,H-3'),4.04-4.08(m,3H,H-5',H-6'),2.88(s,3H,N-CH3),2.21-2.26(m,1H,H-2'a),1.97-2.00(m,1H,H-2'b);13C NMR(150MHz,CDCl3):δ169.2,168.9,158.8,140.7,139.6,137.5,129.6,128.5×2,128.1,127.9×3,127.4,126.9,125.9,124.7,122.4,121.5,121.4,120.4,120.2,119.2,118.1,117.8,111.3,108.6,79.1,78.3,71.6,66.5,66.3,60.5,56.1,29.6,28.9;ESIMS m/z 629.3[M-H]-.
194c:[α]D 20+32.6°(c 0.11,CH2Cl2);1H NMR(600MHz,CDCl3):δ9.78(s,1H,NH),8.91-8.94(m,2H,ArH),7.47(d,J=8.2Hz,1H,ArH),7.39-7.41(m,3H,ArH),7.34(t,J=7.5Hz,1H,ArH),7.31(t,J=7.8Hz,2H,ArH),7.27(d,J=8.2Hz,1H,ArH),7.23-7.26(m,1H,ArH),7.21(t,J=7.8Hz,1H,ArH),7.16(t,J=7.8Hz,1H,ArH),6.62-6.64(m,1H,H-1'),5.00-5.08(m,2H,PhCH2O 2CHN),4.70(s,2H,Ph 2CHOCH2N),4.68(brs,1H,H-4'),4.49-4.50(m,1H,H-3'),4.31-4.33(m,1H,H-5'),4.04-4.09(m,2H,H-6'),2.59(s,3H,N-CH3),2.07-2.11(m,1H,H-2'a),1.97-2.03(m,1H,H-2'b);13C NMR(150MHz,CDCl3)δ169.2,169.0,157.0,140.6,139.7,137.6,129.1,128.6×2,128.1×2,128.0×2,127.7,127.1,125.8,124.9,122.2,121.6×2,121.0,123.1,118.7,118.3,118.1,111.9,109.0,77.6,75.3,70.9,66.8,64.6,60.5,54.6,29.8,28.8;ESIMS m/z 629.2[M-H]-.
ix) preparation of Compounds 191l and 194e
242mg of triphenylphosphine (0.92mmol) and imidazole (126mg,1.85mmol) were dissolved in 20mL of dichloromethane, cooled to 0 deg.C, iodine (234mg,1.85mmol) was added, and the mixture was stirred for 1 h. Compound 191j (97mg,0.15mmol) was dissolved in 20mL of dichloromethane, slowly added to the reaction solution, and allowed to warm to room temperature for 6 h. Cooling to 0 deg.C, quenching with water, extracting with dichloromethane, drying with anhydrous sodium sulfate, concentrating, separating with pressure column chromatography, and eluting with petroleum ether and ethyl acetate 2:1(v/v) to obtain 105mg of compound 191k, with a yield of 77%; ESIMSm/z 741.3[ M + H ]]+. Starting from compound 194c (80mg), compound 194d (90mg, yield 95%) was obtained in the same manner; ESIMS M/z 741.2[ M + H ]]+. Compound 191k (105mg,0.14mmol) was dissolved in 10mL of tetrahydrofuranThen, the temperature was decreased to 0 ℃ and DBU (0.4mL,2.67mmol) was added, the reaction was carried out at 0 ℃ for 1 hour, and the reaction was carried out at 40 ℃ for 1 hour. The reaction mixture was diluted with ethyl acetate, washed with water, concentrated, and subjected to pressure column chromatography and eluted with petroleum ether (ethyl acetate: 1 (v/v)) to give 80mg of 191l of the compound in 92% yield. The same procedures used compound 194d (90mg) as a starting material were repeated to give compound 194e (67mg, yield 90%).
191l:[α]D 20-96.0°(c 0.55,CH2Cl2);1H NMR(600MHz,DMSO-d6)δ12.2(s,1H,NH),9.22(d,J=7.8Hz,1H,ArH),9.08(d,J=8.4Hz,1H,ArH),7.88(d,J=8.4Hz,1H,ArH),7.75(d,J=8.4Hz,1H,ArH),7.64(m,2H,ArH),7.49(d,J=7.2Hz,1H,ArH),7.34-7.43(m,5H,ArH),7.29(m,1H,ArH),7.24(m,1H,H-1'),5.46(d,J=8.5Hz,1H,H-4'),5.13(s,2H,PhCH2O 2CHN),5.10(m,2H,H-6'),4.67(s,2H,Ph 2CHOCH2N),4.40(m,1H,H-3'),2.77(3H,s,N-CH3),2.53(m,1H,H-2'a),2.18(m,1H,H-2'b);13C NMR(150MHz,DMSO-d6)δ169.4,169.3,157.1,152.9,142.1,140.5,138.3,129.6,129.2,128.8×2,128.2,128.1×3,127.9,125.5,124.8,123.6,122.4,121.7,121.4,120.3,119.2,118.6,118.4,113.6,112.8,101.2,81.0,71.4,70.9,67.0,53.0,28.8,28.1;ESIMS m/z 611.1[M-H]-.
194e:[α]D 20+12.4°(c 0.20,CH2Cl2);1H NMR(600MHz,CDCl3)δ9.62(s,1H,NH),9.28(d,J=8.2Hz,1H,ArH),9.10(d,J=8.2Hz,1H,ArH),7.66(d,J=8.2Hz,1H,ArH),7.55-7.59(m,2H,ArH),7.42-7.47(m,4H,ArH),7.36-7.41(m,3H,ArH),7.30(t,J=7.8Hz,1H,ArH),6.30(dd,J=11.4,2.4Hz,1H,H-1′),5.52(d,J=2.0Hz,1H,H-6′a),5.36(d,J=2.0Hz,1H,H-6′b),5.11(d,1H,J=7.2Hz,H-4′),5.08-5.18(m,2H,PhCH2O 2CH),4.67(s,2H,Ph 2CHOCH2N),4.18-4.21(m,1H,H-3′),2.83(s,3H,N-CH3),2.51-2.57(m,1H,H-2′a),2.43-2.47(m,1H,H-2′b);13C NMR(150MHz,CDCl3)δ169.3,169.2,156.7,151.1,140.9,139.9,138.0,129.4,128.6×2,128.3,128.1×2,128.0,127.9,127.7,126.4,125.4,122.7,122.4,121.9,121.7,121.0,119.5,119.3,118.9,112.0,108.9,100.2,82.0,71.7,70.3,66.9,54.6,33.0,29.3;ESIMS m/z 611.4[M-H]-.
x) preparation of Compounds 191m and 194f
191l (80mg, 0.13mmol) of the compound was dissolved in 10mL/1mL of tetrahydrofuran/methanol, cooled to 0 ℃ and potassium tert-butoxide (59mg, 0.2mmol) was added, the solution turned from yellow to red, slowly warmed to room temperature and stirred for 2h, iodine (133mg, 0.15mmol) was added, the solution darkened, and the reaction was allowed to proceed overnight. Cooling to 0 ℃, pouring into a saturated sodium thiosulfate solution, extracting with ethyl acetate, drying with anhydrous sodium sulfate, concentrating, separating by pressure column chromatography, and eluting with petroleum ether and ethyl acetate (1: 2) (v/v) to obtain 191m of 60mg of the product, wherein the yield is 62%. Compound 194f (25mg, 52% yield) was obtained in the same manner as described above, starting from compound 194e (40 mg).
191m:[α]D 20-40.2°(c 0.06,CH2Cl2);1H NMR(600MHz,DMSO-d6)δ9.22(d,J=7.8Hz,1H,ArH),9.00(d,J=7.8Hz,1H,ArH),8.10(d,J=8.4Hz,1H,ArH),8.05(d,J=8.4Hz,1H,ArH),7.63-7.67(m,2H,ArH),7.49-7.54(m,1H,ArH),7.43(t,J=7.2Hz,1H,ArH),7.37-7.38(m,2H,ArH),7.29-7.32(m,2H,ArH),7.23(t,J=7.2Hz,1H,ArH),7.09(dd,J=9.6,7.2Hz,1H,H-1'),5.92(d,J=12.0Hz,1H,H-4'),5.20(s,2H,PhCH2OCH 2),4.69(s,2H,PhCH 2OCH2),4.61(1H,d,J=12.6Hz,H-6′a),4.51-4.53(m,1H,H-3′),3.80(1H,d,J=12.6Hz,H-6′b),3.01(s,3H,N-CH3),2.86-2.90(m,1H,H-2′a),2.51-2.55(m,1H,H-2′b);13C NMR(150MHz,DMSO-d6)δ169.4,169.1,156.8,139.8,138.5,138.2,137.4,132.0,129.1,128.6×2,128.1,127.9×3,125.5,125.0,124.4,122.3,121.5,121.2,120.5,119.2,117.5,116.8,113.0,110.6,93.3,78.2,70.8,70.3,65.4,52.7,29.3,28.4,11.6;ESIMS m/z 761.1[M+Na]+.
194f:[α]D 20+51.3°(c 0.12,CH2Cl2);1H NMR(600MHz,DMSO-d6)δ9.25(d,J=8.2Hz,1H,ArH),9.03(d,J=8.2Hz,1H,ArH),8.17(d,J=8.2Hz,1H,ArH),7.90(d,J=8.2Hz,1H,ArH),7.66(m,1H,ArH),7.65-7.68(m,1H,ArH),7.60-7.63(m,1H,ArH),7.44-7.50(m,2H,ArH),7.36(d,J=8.2Hz,2H,ArH),7.30(t,J=7.2Hz,2H,ArH),7.23(t,J=7.2Hz,1H,ArH),7.04-7.07(m,1H,H-1′),5.49(d,J=9.0Hz,1H,H-4′),5.13-5.18(m,2H,PhCH2OCH 2),4.93(d,J=11.4Hz,1H,H-6′a),4.67(s,2H,PhCH 2OCH2),4.34-4.38(m,1H,H-3′),3.96(1H,d,J=11.4Hz,H-6′b),2.99-3.03(m,1H,H-2′a),2.65(s,3H,N-CH3),2.51-2.55(m,1H,H-2′b);13C NMR(150MHz,DMSO-d6)δ169.6,169.3,155.9,141.6,138.4,138.3,132.2×2,132.1,128.9,128.8×2,128.1×4,125.4,125.1,124.4,122.3,121.8,121.5,120.5,119.2,118.2,116.7,116.1,110.2,92.6,80.1,73.6,71.0,65.6,53.1,30.6,29.0,14.2;ESIMS m/z 761.1[M+Na]+.
xi) preparation of Compounds 191n and 194g
191m (60mg, 0.08mmol) of compound was dissolved in 20mL of benzene under argon, AIBN (10mg) and tetrabutyltin hydride (0.2mL) were added, and the mixture was refluxed for 1 h. After cooling to room temperature, concentration and pressure column chromatography, petroleum ether and ethyl acetate 1:2(v/v) were eluted to give 42mg of 191n, 85% yield. The same procedures used for preparation of compound 194g (20mg, 96% yield) were repeated using compound 194f (25mg) as the starting material.
191n:[α]D 20-63.5°(c 0.09,CH2Cl2);1H NMR(600MHz,CDCl3)δ9.30(d,J=7.2Hz,1H,ArH),9.10(d,J=7.8Hz,1H,ArH),7.68-7.61(m,3H,ArH),7.51–7.43(m,4H,ArH),7.37(t,J=7.2Hz,3H,ArH),7.30(t,J=7.8Hz,1H,ArH),6.55(dd,J=9.6,7.2Hz,1H,H-1'),5.71(d,J=9.6Hz,1H,H-4'),5.20-5.31(m,2H,PhCH2OCH 2),4.81(s,2H,PhCH 2OCH2),4.44-4.46(m,1H,H-3'),3.18(s,3H,N-CH3),2.76-2.81(m,1H,H-2'a),2.46-2.51(m,1H,H-2'b),1.99(s,3H,6'-CH3);13C NMR(150MHz,CDCl3)δ169.3,169.1,157.3,140.1,138.1,137.7,130.1,128.9,128.5×2,127.9×2,127.8,127.6,127.4,126.5,126.2,124.6,122.1,122.0,121.4,120.9,119.4,118.4,117.4,112.3,107.8,94.0,77.2,71.7,71.4,66.8,52.7,29.6,26.2,24.6;ESIMS m/z 613.5[M+H]+.
194g:[α]D 20+33.1°(c 0.13,CH2Cl2);1H NMR(600MHz,CDCl3)δ9.38(d,J=8.0Hz,1H,ArH),9.21(d,J=7.9Hz,1H,ArH),8.08(d,J=8.6Hz,1H,ArH),7.57-5.60(m,2H,ArH),7.41-7.46(m,5H,ArH),7.31(t,J=7.6Hz,2H,ArH),7.23(t,J=7.4Hz,1H,ArH),6.58(dd,J=10.3,6.4Hz,1H,H-1'),5.30-5.35(m,2H,PhCH2OCH 2),5.09(d,J=8.9Hz,1H,H-4'),4.76(s,2H,PhCH 2OCH2),4.24-4.28(m,1H,H-3'),2.80-2.84(m,1H,H-2'a),2.76(s,3H,3'-NCH3),2.41-2.47(m,1H,H-2'b),2.07(s,3H,6'-CH3);13C NMR(150MHz,CDCl3)δ169.5,169.3,155.9,142.2,137.9,137.8,130.7,128.7,128.5×2,128.0×2,127.8,127.6,127.5,126.5,125.8,124.6,122.3,122.2,121.6,120.9,119.7,119.5,117.3,116.4,107.6,93.3,79.1,76.2,71.6,67.0,53.1,30.1,29.8,29.7;ESIMS m/z 613.6[M+H]+.
xii) preparation of Compounds 191 and 194
Compound 191n (40mg, 0.065mmol) was dissolved in 20mL of ethyl acetate/methanol (10mL/10mL), and after replacement with argon, 20mg of 20% palladium hydroxide on carbon was added, followed by replacement with hydrogen and overnight reaction. Filtering with silica gel, concentrating, separating by semi-preparative HPLC, MeOH H2Elution with O ═ 7:3(v/v) gave 28mg of 4 ' -O-demethyl- (4 ' -O, 3' -N) carbonyl-7-oxoidene-1 ', 5 ' -dioxepinine (191) in 89% yield. Using 194g (20mg) of the compound as a starting material, 15mg of 4 ' -O-desmethyl- (4 ' -O, 3' -N) carbonyl-7-oxoylidenestaurosporine (194) was obtained in the same manner, giving a yield of 96%.
191:[α]D 20-69.5°(c 2.0,CH2Cl2);1H NMR(500MHz,DMSO-d6)δ11.2(s,1H,NH),9.21(d,J=7.8Hz,1H,ArH),8.98(d,J=7.8Hz,1H,ArH),8.07(d,J=7.8Hz,1H,ArH),7.94(d,J=8.4Hz,1H,ArH),7.61-7.67(m,2H,ArH),7.48(t,J=7.8Hz,1H,ArH),7.41(t,J=7.8Hz,1H,ArH),6.98-7.01(m,1H,H-1'),5.76(d,J=10.4Hz,1H,H-4'),4.44-4.46(m,1H,H-3'),2.99(s,3H,N-CH3),2.81(ddd,J=9.6,6.0,2.4Hz,1H,H-2'a),2.18(ddd,J=9.6,6.0,2.4Hz,1H,H-2'b),1.80(s,3H,6'-CH3);13C NMR(125MHz,DMSO-d6)δ171.5,171.2,157.4,140.5,138.6,130.2,129.1,127.8,127.7,125.8,125.3,124.3,122.1,122.0,121.5,121.4,120.7,117.6,116.5,114.3,110.7,94.1,77.9,71.4,52.4,29.5,25.4,24.9;ESIMS m/z 491.3[M-H]-.
194:[α]D 20+112.9°(c 0.1,CH2Cl2);1H NMR(500MHz,DMSO-d6)δ11.2(s,1H,NH),9.23(d,J=9.0Hz,1H,ArH),9.04(d,J=9.0Hz,1H,ArH),8.09(d,J=9.5Hz,1H,ArH),7.88(d,J=9.5Hz,1H,ArH),7.65(t,J=9.0Hz,1H,ArH),7.58(t,J=9.5Hz,1H,ArH),7.43(t,J=9.0Hz,2H,ArH),7.01(dd,J=10.0,8.5Hz,1H,H-1'),5.33(d,J=8.5Hz,1H,H-4'),4.31-4.36(m,1H,H-3'),2.93-2.98(m,1H,H-2'a),2.57(s,3H,N-CH3),2.04-2.11(m,1H,H-2'b),2.05(3H,s,6'-CH3);13C NMR(125MHz,DMSO-d6)δ170.8,170.5,155.5,141.3,137.6,129.8,128.0,127.0,126.5,124.8,124.5,123.5,121.2,121.0×2,120.8,119.8,117.4,116.5,115.7,109.3,92.6,79.0,75.3,52.0,29.6,28.2×2;ESIMS m/z 491.1[M-H]-.
Preparation of Compounds 192,193,195 and 196
Dissolving compound 191(10mg, 0.020mmol) in 10mL of methanol, cooling to 0 ℃, adding sodium borohydride (7.6mg, 0.2mmol), heating to room temperature for reaction for two hours, changing the solution from yellow to colorless, diluting with ethyl acetate, adding saturated ammonium chloride solution, extracting with ethyl acetate, drying with anhydrous sodium sulfate, and evaporating to dryness. The crude product was dissolved in 5mL of glacial acetic acid, zinc powder (15mg, 0.23mmol) was added, the mixture was warmed to 40 ℃ and reacted for 1.5 hours, cooled to room temperature, diluted with ethyl acetate, washed with a saturated sodium bicarbonate solution, dried over anhydrous sodium sulfate and concentrated. Semi-preparative HPLC separation and acetonitrile elution with water ═ 7:13(v/v) gave 4 '-O-demethyl- (4' -O,3 '-N) carbonyl-1', 5 '-diteretable staurosporine (192) (3.2mg, yield 35%) and 5-deoxy-7-oxoylidene-4' -O-demethyl- (4 '-O, 3' -N) carbonyl-1 ', 5' -diteretable staurosporine (193) (3.2mg, yield 35%). 5-deoxy-7-oxoidene-4 '-O-desmethyl- (4' -O,3 '-N) carbonyl staurosporine (195) (2.7mg, 28% yield) and 2.7mg of 4' -O-desmethyl- (4 '-O, 3' -N) carbonyl staurosporine (ACT-007,196) were prepared in the same manner using compound 194(10mg) as a starting material at 28% yield.
192:[α]D 20-78.2°(c 0.05,MeOH);1H NMR(600MHz,DMSO-d6)δ9.19(d,J=7.8Hz,1H,ArH),8.65(s,1H,NH),8.10(d,J=7.6Hz,1H,ArH),7.97(d,J=8.3Hz,1H,ArH),7.91(d,J=8.3Hz,1H,ArH),7.57(t,J=7.8Hz,1H,ArH),7.48-7.51(m,1H,ArH),7.43(t,J=7.5Hz,1H,ArH),7.29(t,J=7.5Hz,1H,ArH),6.92(dd,J=9.8,6.8Hz,1H,H-1'),5.72(d,J=9.7Hz,1H,H-4'),4.94-5.03(m,2H,H-7),4.41-4.44(m,1H,H-3'),2.98(s,3H,N-CH3),2.71-2.76(m,1H,H-2'a),2.07-2.12(m,1H,H-2'b),1.79(s,3H,6'-CH3).13CNMR(150MHz,DMSO-d6)δ171.6,156.9,138.8,136.9,133.2,128.4,125.6×2,125.5,124.9,124.8,122.3,122.0,121.2,120.6,119.6,116.1,115.2,113.6,109.4,93.3,77.4,71.1,52.0,45.5,28.9,25.0,24.4;HR-ESIMS m/z 479.1710[M+H]+(calcd for C28H23N4O4 +479.1719).
193:[α]D 20-76.5°(c 0.05,MeOH);1H NMR(600MHz,DMSO-d6)δ9.49(d,J=7.8Hz,1H,ArH),8.61(s,1H,NH),8.09(d,J=7.8Hz,1H,ArH),8.03(d,J=8.2Hz,1H,ArH),7.84(d,J=8.4Hz,1H,ArH),7.52-7.55(m,2H,ArH),7.36(t,J=7.5Hz,2H,ArH),6.93(dd,J=9.7,7.0Hz,1H,H-1'),5.76(d,J=9.5Hz,1H,H-4'),4.94-5.02(m,2H,H-5),4.44-4.46(m,1H,H-3'),2.99(s,3H,N-CH3),2.78(ddd,J=10.1,6.9,2.4Hz,1H,H-2'a),2.14-2.18(m,1H,H-2'b),1.75(s,3H,6'-CH3).13C NMR(150MHz,DMSO-d6)δ171.9,156.9,138.9,137.0,134.5,127.3,126.4×2,126.2,125.7,125.5,125.2,122.0,120.5,120.4,119.6,117.2,114.5,113.0,109.9,93.3,77.4,71.1,52.0,45.1,28.9,25.1,24.1;HR-ESIMS m/z 479.1711[M+H]+(calcdfor C28H23N4O4 +479.1719).
195:[α]D 20+66°(c 0.05,MeOH);1H NMR(500MHz,DMSO-d6)δ9.51(d,J=7.9Hz,1H,ArH),8.61(s,1H,NH),8.10(d,J=7.7Hz,1H,ArH),8.01(d,J=8.5Hz,1H,ArH),7.85(d,J=8.2Hz,1H,ArH),7.56(t,J=7.6Hz,1H,ArH),7.46(t,J=7.6Hz,1H,ArH),7.37(t,J=7.4Hz,1H,ArH),7.30(t,J=7.4Hz,1H,ArH),6.96(dd,J=9.6,6.2Hz,1H,H-1'),5.30(d,J=8.7Hz,1H,H-4'),4.94-5.02(m,2H,H-5),4.32-4.37(m,1H,H-3'),2.92-2.96(m,1H,H-2'a),2.59(s,3H,N-CH3),2.05-2.10(m,1H,H-2'b),1.99(s,3H,6'-CH3).13C NMR(125MHz,DMSO-d6)δ171.8,155.6,140.3,136.5,134.2,126.9,126.5,125.6,125.4,125.0×2,122.0,121.7,120.4,119.9,119.3,117.6,115.9,114.1,109.2,92.4,79.1,75.4,52.0,44.9,29.4,28.7,28.2;HR-ESIMS m/z 479.1727[M+H]+(calcd for C28H23N4O4 +479.1719).
196:[α]D 20+73.2°(c 0.05,MeOH);1H NMR(500MHz,DMSO-d6)δ9.23(d,J=7.9Hz,1H,ArH),8.66(s,1H,NH),8.06(d,J=8.5Hz,1H,ArH),8.03(d,J=7.7Hz,1H,ArH),7.79(d,J=8.3Hz,1H,ArH),7.51(t,J=8.3Hz,1H,ArH),7.53(t,J=7.7Hz,1H,ArH),7.38(t,J=7.4Hz,1H,ArH),7.30(t,J=7.5Hz,1H,ArH),6.96(dd,J=9.7,6.3Hz,1H,H-1'),5.31(d,J=8.7Hz,1H,H-4'),4.95-5.03(m,2H,H-7),4.33-4.36(m,1H,H-3'),2.89-2.94(m,1H,H-2'a),2.59(s,3H,N-CH3),2.03(s,3H,6'-CH3),1.97-2.03(m,1H,H-2'b);13C NMR(125MHz,DMSO-d6)δ171.5,155.6,140.3,136.4,132.9,128.6,125.7,125.4,124.9,124.6×2,122.4,121.1,120.9,120.2,119.5,116.5,115.8,115.4,108.6,92.4,79.1,75.4,52.0,45.4,29.5,28.6,28.2;HR-ESIMS m/z 479.1725[M+H]+(calcd for C28H23N4O4 479.1719).
[ example 2 ] Activity assay
1. Alpha-glucosidase inhibitory Activity test
(1) Test method
The alpha-glucosidase inhibitory activity of some compounds was tested using p-nitrophenyl-alpha-D-glucopyranoside (PNPG) as substrate. PNPG is an analogue of maltose, can generate yellow p-nitrophenol after the action of alpha-glucosidase, and can be directly used for the detection of a spectrophotometer. The method comprises the following steps: first, the sample was dissolved in PBS sodium phosphate buffer (pH 6.8)Preparing 5 concentrations; then, 10. mu.L of the sample solution, 20. mu.L of the PBS solution, and 20. mu.L of a 2.5 mM-concentration glucoside solution (dissolved in a phosphate buffer solution) were added to each well of the 96-well plate, and the mixture was incubated at 37 ℃ for 5 minutes in an incubator. Alpha-glucosidase was diluted to 0.2U/mL with 0.01M PBS, 10. mu.L of each well was added to the above test solution, and after incubation at 37 ℃ for 15min in an incubator, the absorbance (OD value) at 405nm per well was measured with a microplate reader, and the inhibition (%): [ 1- (OD)Sample (I)/ODControl)]X 100%, to obtain IC50(μ M). The blank control is phosphate buffered saline solution, and the positive control is acarbose and nojirimycin.
(2) Results of the experiment
TABLE 1 inhibition Activity on alpha-glucosidase (IC)50,μM)
Compound (I) | IC50 | Compound (I) | IC50 |
8 | 11.5 | 15 | 28.8 |
28 | 2.31 | 33 | 100 |
34 | 114.8 | 35 | 100 |
36 | 19.3 | 38 | 78.0 |
39 | 7.79 | 40 | 14.8 |
49 | 42.9 | 52 | 111.3 |
58 | 38.6 | 61 | 100 |
62 | 124.3 | 63 | 86.3 |
75 | 201.5 | 76 | 92.7 |
79 | 5.09 | 88 | 45.7 |
89 | 86.6 | 91 | 168.7 |
92 | 77.1 | 93 | 98.3 |
97 | 34.3 | 100 | 109.8 |
107 | 22.0 | 108 | 8.61 |
128 | 2.11 | 135 | 125.4 |
153 | 59.67 | 184 | 1.58 |
187 | 226.2 | 188 | 162.6 |
190 | 246.1 | 196 | 253.6 |
Acarbose | 101.5 | Nojirimycin | 78.6 |
The result shows that the compound has stronger inhibitory activity to alpha-glucosidase.
2. In vivo antidiabetic nephropathy (DKD) assay
The in vivo anti-diabetic nephropathy (DKD) activity of compound 49 was evaluated using a classical db/db animal model of diabetic nephropathy.
Animal experiments are divided into 6 groups, each group is provided with 12 mice, the positive drug is selected from losartan, and each group adopts a subcutaneous injection administration mode. The administration was continued for 4 weeks, and the control group was given the same volume of physiological saline. The results show that lower injected doses of compound 49(1.0mg/kg/day and 2.0mg/kg/day) are able to significantly reduce 24 hour urine protein (24UPE) and Blood Urea Nitrogen (BUN) levels without significant change in the effect on fasting glucose (FBG); particularly, at the administration dose of 1.0mg/kg/day, the inhibition degree of 24UPE is up to 48.3 percent, which is better than that of the positive medicament Losartan (Losartan) (35.2 percent). The results are shown in Table 2.
TABLE 2 antidiabetic nephropathy (DKD) Activity of Compound 49 in mice
*p<0.05,**p<0.01vs. normal control group;#p<0.05,##p<stz control p, 0.01 vs;cp<0.05vs. losartan group;arelative kidney index (g) left kidney weight (g)/body weight (g) values are mean ± s.d. (n-12).
H & E staining results of kidney tissue sections show that the glomerular mesangial area of a diabetic nephropathy db/db mouse is obviously expanded, extracellular matrix is increased, diffuse mesangial sclerosis occurs, and a glomerular basement membrane is thickened; after the compound 49 is treated, the compound shows better treatment effect, particularly, the compound can obviously inhibit the pathological change of kidney tissues, reduce the expansion of a mesentery and inhibit the diffuse type mesentery hardening when the dose is 1.0mg/kg/day and 2.0 mg/kg/day; the treatment effect is better than that of the positive medicament of losartan (figure 1).
Claims (10)
2. the compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
the pharmaceutically acceptable salts include salts of organic or inorganic acids.
3. A compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein: the pharmaceutically acceptable salt is selected from salts of the compound with: hydrochloric acid; sulfuric acid; phosphoric acid; formic acid; acetic acid; propionic acid; lactic acid; citric acid; tartaric acid; succinic acid; fumaric acid; maleic acid; mandelic acid; malic acid; camphorsulfonic acid.
4. A process for preparing a compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein:
compounds 173-:
from compoundsWith thiocarbonyl diimidazole or triphosgene, imidazole, methyl iodide and amine compounds;
in the formulae a to VII, R4 represents ═ O, ═ S or ═ NH, R5Represents a hydroxylamino group, a 4- (2- (4-morpholino) ethyl) piperazin-1-yl group, a (2, 6-difluorophenyl) methylamino group, a (3-chloro-4-fluorophenyl) methylamino group, a 2- (2-chloro-6-fluorophenyl) -1-ethylamino group, a 2- (3-trifluoromethylphenyl) -1-ethylamino group, a phenylmethylamino group, a (4-methoxyphenyl) methylamino group, a (S) -2-hydroxy-1-propylamino group, a 4- (N, N-bis (2-chloroethyl) aminophenyl) propyl group;
alternatively, compound 183 was prepared using the following procedure: from compoundsTo obtain the compoundThen reacting with hydroxylamine hydrochloride to obtain the product;
alternatively, compound 184 was prepared using the following procedure: compound (I)Reacting with chlorambucil;
compounds 185, 187-196 were prepared as follows:
reacting a compound of a formula c1 with a compound of a formula c2 to obtain a compound of a formula c3, reacting to obtain a compound of a formula c4, reacting to obtain a compound of a formula c5, reacting to obtain a compound of a formula c6, reacting to obtain a compound of a formula c7, reacting to obtain a compound of a formula c8, reacting to obtain a compound of a formula c9, and reacting to obtain compounds 185 and 187-196;
in the above formula c1-c9, G1~G8、R3、R4、R5、R6、R7、R8As described in compounds 185, 187-196.
6. the method of claim 4, wherein the step of preparing compounds 185, 188, 191, 194 comprises: firstly, glucose is used as a raw material, and is subjected to full acetylation, 1-bit bromination, 1, 2-bit olefination reaction, deacetylation, TIPS protection of 6-bit hydroxyl, 3, 4-bit construction of oxazolyl cyclic ketone, methylation, and reduction of hydroxymercuric sodium borohydride to introduce hydroxyl at the 1-bit position, so as to obtain a sugar donor; using 2, 3-dibromomaleimide as a raw material, reacting with an indole Grignard reagent to introduce a molecule of indole through BOM protection, protecting the nitrogen and hydrogen of the indole with Boc, and reacting with the indole Grignard reagent to obtain a parent nucleus; and thirdly, glycosidating the glycosyl donor in the step I and the mother nucleus in the step II by a Mitsunobu reaction to form a first glycosidic bond, separating isomers of the glycosidic bond by silica gel column chromatography, then removing Boc and TIPS protecting groups, radiating by a high-pressure mercury lamp to perform ring closing, replacing the 6-hydroxyl with iodine, deiodinating the 5 and 6-positions to form double bonds, forming a second glycosidic bond under the catalysis of iodine, deiodinating by tetrabutyl tin hydride, and removing BOM by 20 percent of palladium hydroxide carbon.
7. The method of claim 4 or 6, wherein the step of preparing the compound 187,189,190, 192,193,195, 196 comprises:
reducing the compound 185 with sodium borohydride and zinc powder acetic acid to obtain a compound 187;
reducing the compound 188 with sodium borohydride and zinc powder acetic acid to obtain compounds 189 and 190;
reducing the compound 191 by sodium borohydride and reducing the compound by zinc powder and acetic acid to obtain compounds 192 and 193;
compound 194 is reduced with sodium borohydride and zinc dust acetic acid to produce compounds 195 and 196.
8. A composition for inhibiting α -glucosidase, anti-diabetes, or anti-diabetic complications, comprising at least one compound of any one of claims 1-3 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
9. The composition of claim 8, wherein the diabetes is alpha-glucosidase mediated diabetes.
10. The composition of claim 8, wherein the diabetic complication is diabetic nephropathy.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610382432 | 2016-06-01 | ||
CN2016103824322 | 2016-06-01 | ||
CN201610415781.XA CN106146475B (en) | 2016-06-01 | 2016-06-13 | Bisindole maleimide derivative and its preparation method and application |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610415781.XA Division CN106146475B (en) | 2016-06-01 | 2016-06-13 | Bisindole maleimide derivative and its preparation method and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110526903A CN110526903A (en) | 2019-12-03 |
CN110526903B true CN110526903B (en) | 2021-12-10 |
Family
ID=57353176
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610415781.XA Active CN106146475B (en) | 2016-06-01 | 2016-06-13 | Bisindole maleimide derivative and its preparation method and application |
CN201910489638.9A Active CN110526903B (en) | 2016-06-01 | 2016-06-13 | Bisindolylmaleimide derivative and preparation method and application thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610415781.XA Active CN106146475B (en) | 2016-06-01 | 2016-06-13 | Bisindole maleimide derivative and its preparation method and application |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN106146475B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019000224A1 (en) * | 2017-06-27 | 2019-01-03 | 中国海洋大学 | Bisindolylmaleimide derivative and preparation method and use thereof |
CN107325142A (en) * | 2017-07-21 | 2017-11-07 | 浙江大学 | A kind of staurosporine class compound and its preparation method and application |
CN112739345A (en) | 2017-11-06 | 2021-04-30 | 斯奈普生物公司 | PIM kinase inhibitor compositions, methods and uses thereof |
CN108084205B (en) * | 2017-12-26 | 2019-09-20 | 浙江大学 | A kind of indole carbazole Alkaloid and its preparation method and application |
CN108164538B (en) * | 2018-01-08 | 2019-10-15 | 浙江大学 | The indole carbazole compound and its preparation method and application that N-13 tyrosine derivative replaces |
CN108329326B (en) * | 2018-01-08 | 2020-07-10 | 浙江大学 | Indolocarbazole alkaloid derivative and preparation method and application thereof |
CN110041338B (en) * | 2018-10-30 | 2021-11-30 | 贵州省中国科学院天然产物化学重点实验室 | Bis-indole maleimide compound with anti-tumor activity and application thereof |
CN114437109B (en) * | 2022-03-08 | 2023-09-29 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | Philippine halogenated derivative and preparation method and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995017182A1 (en) * | 1993-12-23 | 1995-06-29 | Eli Lilly And Company | Protein kinase c inhibitors |
WO1995035294A1 (en) * | 1994-06-22 | 1995-12-28 | Eli Lilly And Company | Protein kinase c inhibitors |
CN101812097A (en) * | 2010-04-17 | 2010-08-25 | 中国海洋大学 | Indole carbazole and bisindole maleimide alkaloid and its production and application |
WO2011041385A2 (en) * | 2009-09-29 | 2011-04-07 | Joslin Diabetes Center, Inc. | Use of protein kinase c delta (pkcd) inhibitors to treat diabetes, obesity, and hepatic steatosis |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1298722C (en) * | 2005-03-07 | 2007-02-07 | 中国海洋大学 | Indole carbazole alkaloid and its preparing method and use |
GB0612542D0 (en) * | 2006-06-23 | 2006-08-02 | Novartis Ag | Combinations comprising staurosporines |
CN102101866A (en) * | 2010-11-04 | 2011-06-22 | 中国海洋大学 | Halogenated derivatives of staurosporine, and preparation method thereof and use thereof |
EP2670733B1 (en) * | 2011-02-01 | 2019-04-10 | The Board of Trustees of the University of Illionis | N-hydroxybenzamide derivatives as hdac inhibitors and therapeutic methods using the same |
-
2016
- 2016-06-13 CN CN201610415781.XA patent/CN106146475B/en active Active
- 2016-06-13 CN CN201910489638.9A patent/CN110526903B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995017182A1 (en) * | 1993-12-23 | 1995-06-29 | Eli Lilly And Company | Protein kinase c inhibitors |
WO1995035294A1 (en) * | 1994-06-22 | 1995-12-28 | Eli Lilly And Company | Protein kinase c inhibitors |
WO2011041385A2 (en) * | 2009-09-29 | 2011-04-07 | Joslin Diabetes Center, Inc. | Use of protein kinase c delta (pkcd) inhibitors to treat diabetes, obesity, and hepatic steatosis |
CN101812097A (en) * | 2010-04-17 | 2010-08-25 | 中国海洋大学 | Indole carbazole and bisindole maleimide alkaloid and its production and application |
Non-Patent Citations (1)
Title |
---|
双吲哚马来酰亚胺和吲哚咔唑生物碱的合成与构效关系研究;徐志红;《中国优秀硕士学位论文全文数据库(医药卫生科技辑)》;20120415;第E079-39页 * |
Also Published As
Publication number | Publication date |
---|---|
CN106146475B (en) | 2019-05-17 |
CN110526903A (en) | 2019-12-03 |
CN106146475A (en) | 2016-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110526903B (en) | Bisindolylmaleimide derivative and preparation method and application thereof | |
CN110218206B (en) | Bisindolylmaleimide derivative and preparation method and application thereof | |
CN114025844B (en) | Protein tyrosine phosphatase inhibitors and methods of use thereof | |
CN103619866B (en) | The derivant of C4-monomethyl triterpenoid and using method thereof | |
CN101374846B (en) | Cytotoxic agents containing novel tomaymycin derivatives and their therapeutic use | |
CN115667250A (en) | Heterocyclic GLP-1 agonists | |
CN102892766B (en) | Kinase inhibitors and method of treating cancer with same | |
CN111094288B (en) | Fused ring derivatives having MGAT-2 inhibitory activity | |
TW201726606A (en) | Compounds useful as immunomodulators | |
CN104812748B (en) | Pyrazoline GPR40 conditioning agents | |
CN111295372B (en) | Nitroxoline prodrugs and uses thereof | |
CN111892589A (en) | Glutaminase inhibitors | |
KR20050120773A (en) | Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists | |
CN115594734B (en) | Ketoamide derivatives and their use | |
CN103987707A (en) | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | |
CN112839944B (en) | Compounds and methods for treating rabies | |
WO2023246656A1 (en) | Sos1 proteolysis targeting chimera, and composition, preparation and use thereof | |
WO2022135546A1 (en) | Spirocyclic compound as kras-g12c inhibitor | |
CN115210247A (en) | Pyrrolobenzenediazepine derivatives and ligand-linker conjugates thereof | |
WO2023232135A1 (en) | Pde4b inhibitor and use thereof | |
TW202045487A (en) | Pd-l1 antagonist compounds | |
CN115232114A (en) | SOS1 degradation agent and preparation method and application thereof | |
CN106458987B (en) | For treating the pyrrolidines GPR40 regulator of disease such as diabetes | |
WO2019000224A1 (en) | Bisindolylmaleimide derivative and preparation method and use thereof | |
CN108239123A (en) | The eutectic of glucopyranosyl derivatives, preparation method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |